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Sickle	  cell	  disease	  (SCD)	  is	  known	  to	  be	  a	  prothrombotic	  condition;	  this	  is	  also	  true	  for	  combined	  hormonal	  contraceptives	  (HC),	  which	  increases	  the	  thrombotic	  risks	  in	  their	  users.	  Recently,	  Sickle	  Cell	  Trait	  (SCT)	  has	  been	  reported	  to	  carry	  increased	  risks	   of	   thrombosis	   Nonetheless,	   HC	   methods	   are	   efficacious	   and	   widely	   used	  while,	   pregnancy	   carries	  major	   risks	   for	   SCD	  women.	  Hence,	   there	   is	   a	   need	   for	  robust	  evidence	  about	  the	  safety	  or	  risks	  of	  HC	  in	  SCD	  and	  SCT	  to	  aid	  in	  the	  choice	  of	  contraceptive	  methods	  for	  these	  women.	  
This	   study	   aimed	   to	   test	   the	   hypothesis	   that	   there	   are	   no	   additional	   clinical	   or	  haematological	   risks	   to	   SCD	   patients	   and	   women	   with	   SCT	   using	   hormonal	  contraceptive	  methods	  that	  is	  over	  and	  above	  those	  inherent	  in	  their	  SCD	  and	  SCT	  status.	  	  
This	   is	   a	  multi-­‐centre,	   prospective	   cohort	   study,	   which	   looked	   at	   and	   compared	  clinical	  complications,	  haemostatic	  and	  haematological	  markers	  in	  68	  women	  with	  SCD,	  22	  women	  with	  SCT	  and	  27	  similar	  women	  with	  normal	  haemoglobin.	  	  
In	   conclusion	   a	   two	   year	   follow-­‐up	   of	   women	   with	   SCD	   using	   Combined	   Oral	  Contraception	   (COC)	   found	  no	   incidence	  of	  Venous	  Thrombo	  Embolism	   (VTE)	   in	  these	  women	  and	  the	  occurrence	  of	  other	  clinical	  complications,	  such	  as	  sickle-­‐cell	  crises,	   the	   need	   for	   blood	   transfusion	   and	   hospital	   admissions	   were	  minimal.	   It	  also	   demonstrated	   that	   these	   complications	   are	   comparable	   to	   women	   with	  normal	  haemoglobin	  using	  COC.	  Also	   the	  use	  of	  COC	   in	  women	  with	  SCD	  did	  not	  significantly	  alter	  the	  haemostatic	  markers	  studied,	  nor	  did	  it	  adversely	  affect	  their	  liver	   function	   or	   exacerbate	   any	   inflammatory	   changes.	   Progestogen	   only	  contraception	   (POC)	   use	   is	   associated	  with	   an	   increased	   incidence	   of	  menstrual	  irregularities	  which	  are	  not	  significantly	  different	  from	  those	  noted	  in	  women	  with	  normal	  haemoglobin	  taking	  POC.	  SCT	  women	  manifested	  increased	  prothrombotic	  tendencies,	   which	   are	   more	   marked	   in	   women	   using	   COC,	   while	   women	   with	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ADAMTS13	   A	   Disintegrin	   And	   Metalloproteinase	   with	  Thrombospondin	  Motifs	  Number	  13	  ANOVA	   Analysis	  of	  Variance	  ATP	   Adenosine	  Triphosphate	  cGMP	   cyclic	  guanosine	  monophosphate	  COC	   Combined	   (i.e.	   oestrogen	   and	   progestogen)	   oral	  contraceptives	  CRP	   C-­‐reactive	  protein	  DMPA	   Depomedroxy	  progesterone	  acetate	  DNA	   Deoxyribonucleic	  Acid	  DVT	   Deep	  vein	  thrombosis	  DVVT	   Dilute	  Viper	  Venom	  time	  EDTA	   Ethylenediaminetetraacetic	  acid	  EE	   Ethinyl	  oestradiol	  FSH	   Follicular	  stimulating	  hormone	  GnRH	   Gonadotrophin	  releasing	  hormone	  Hb	   Haemoglobin	  HbS	   sickle	  Hb	  HC	   Hormonal	  contraceptive	  HRT	   Hormone	   replacement	   therapy	   (i.e.	   	   oestrogen	   and	  progestogen	  for	  postmenopausal	  women)	  ICAM-­‐1	   intercellular	  adhesion	  molecule	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IS	   Ischaemic	  stroke	  ISC	   Irreversibly	  sickled	  cells	  IUDs	   Intra	  uterine	  contraceptive	  devices	  IUS	   Mirena®	   Intra	   Uterine	   System	   (i.e.	   slow	   release	  levonorgestrel)	  LH	   Luteinising	  hormone	  LNG	   Levonorgestrel	  MEC	   Medical	  Eligibility	  Criteria	  MI	   Myocardial	  Infarction	  MP	   Microparticles	  NETA	   Norethindrone	  acetate	  NO	   Nitric	  Oxide	  OR	   Odds	  Ratio	  PE	   Pulmonary	  embolism	  POC	   Progestogen-­‐only	  contraceptives	  POP	   Progestogen-­‐only	  pills	  PPP	   Platelet	  poor	  plasma	  PS	   Phosphatidylserine	  RBC	   Red	  blood	  cell	  RR	   Relative	  risk	  SCD	   Sickle	  cell	  disease	  (i.e.	  HbSS,	  HbSC,	  HbSβ°	  thalassaemia)	  SCD40-­‐L	   Soluble	  cell	  differentiation-­‐40	  ligand	  SCS	   Sickle	  Cell	  Society	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1.1 THE	  EPIDEMIOLOGY	  OF	  SICKLE	  CELL	  DISEASE	  




Figure	  1-­‐1	  Global	  distribution	  of	  the	  HbS	  allele,	  2012	  
The	  map	  shows	  high	  allele	   frequencies	  across	  most	  of	  sub-­‐Saharan	  Africa,	   the	  Middle	  East,	  
and	  India,	  as	  well	  as	  gene	  flow	  following	  migrations	  to	  Western	  Europe	  and	  the	  eastern	  coast	  
of	  the	  Americas.	  Reproduced	  from	  (Piel	  et	  al.,	  2013)	  
	  
1.2 THE	  PATHOPHYSIOLOGY	  OF	  SCD	  
Current	   understanding	   of	   the	   pathophysiology	   of	   sickle	   cell	   disease	   has	   evolved	  over	   many	   years,	   and	   many	   scientists	   have	   contributed	   to	   this	   (Frenette	   and	  Atweh,	   2007)	   The	   first	   scientifically	   published	   description	   of	   sickle	   cell	   disease	  was	  made	  in	  1910,	  by	  James	  B	  Herrick,	  who	  described	  the	  findings	  of	  haemolytic	  anaemia	   and	   elongated	   sickle	   (or	   crescent)-­‐	   shaped	   red	   blood	   cells	   in	   a	   dental	  student	  from	  Grenada	  (Herrick,	  2001).	  However,	   it	  was	  not	  until	  1949,	  that	  Itano	  and	   Linus	   Pauling	   described	   for	   the	   first	   time,	   the	   molecular	   abnormality	   of	  Haemoglobin	  S,	  characterised	  by	  the	  use	  of	  electrophoresis	  (Itano	  and	  Neel,	  1950;	  Itano,	   1951;	   Pauling,	   1964)	   After	   a	   further	   ten	   years,	   Ingram	   found,	   more	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specifically,	   that	   the	   abnormal	   haemoglobin	   results	   from	   the	   substitution	   of	   a	  single	  glutamic	  acid	  residue	  with	  valine	   in	   the	  β	  globin	  polypeptide	  chains	  of	   the	  molecule	   (Ingram	   et	   al.,	   1962a).	   It	   took	   the	   scientific	   world	   another	   decade	   to	  discover	  that	  haemoglobin	  S	  polymerises,	   in	  conditions	  of	   low	  oxygen	  tension,	   to	  form	   pseudo-­‐crystals,	   which	   cause	   the	   red	   blood	   cells	   to	   have	   the	   rigid	   “sickle”	  shape	   (Murayama,	   1966).	   New	   understanding	   of	   the	   pathophysiology	   of	   SCD	  continues	  to	  emerge	  in	  the	  21st	  century.	  
	  
The	   concept	   that	   the	   phospholipid	  membrane	   of	   the	   sickle	   red	   blood	   cell	   (RBC)	  also	   plays	   an	   important	   role	   in	   the	   clinical	  manifestations	   of	   the	   disease	   and	   its	  complications	   is	   relatively	  new,	  and	  has	  mainly	  unfolded	   in	   the	   last	   two	  decades	  (Frenette	  and	  Atweh,	  2007).	  With	  this	  has	  come	  an	  appreciation	  of	  the	  interaction	  of	   the	   sickle	   RBC	  membrane	  with	   other	   cellular	   and	   non-­‐cellular	   components	   of	  the	   blood,	   and	   with	   the	   endothelium	   of	   blood	   vessels	   (Embury	   et	   al.,	   2004;	  Frenette	  and	  Atweh,	  2007;	  Kaul	  et	  al.,	  2000;	  Spring	  et	  al.,	  2001;	  Stuart	  and	  Nagel,	  2004a).	  This	  feature	  is	  responsible	  for	  the	  increased	  coagulability	  of	  blood	  in	  SCD	  sufferers,	   and	   the	   related	   clinical	   complications	   of	   this,	  which	   are	   in	   addition	   to	  those	  directly	  caused	  by	  the	  sickled	  RBC’s	  themselves	  (Ataga	  and	  Key,	  2007;	  Porter	  




1.3 THE	   DIFFERENCE	   BETWEEN	   NORMAL	   HAEMOGLOBIN	   AND	   SICKLE	  
HAEMOGLOBIN	  






Figure	  1-­‐2	  Molecular	  Structure	  of	  adult	  haemoglobin	  molecule	  
The	  diagram	  shows	  the	  quaternary	  structure	  of	  a	  human	  adult	  haemoglobin	  molecule	  with	  4	  
haem	  rings	  bound	  to	  iron.	  Two	  haem	  rings	  are	  surrounded	  by	  2	  α	  chains	  and	  the	  other	  two	  
are	  surrounded	  by	  β	  globin	  chains.	  Adapted	  from(Loukopoulos,	  2001).	  
	  
In	  SCD	  there	  is	  a	  faulty	  beta	  globin	  chain.	  The	  fault	  arises	  from	  the	  substitution	  of	  the	   amino	   acid	   glutamate	   by	   a	   valine	   residue	   (Ingram	   et	   al.,	   1962a).	  Physiologically,	   glutamic	   acid	   is	   a	   polar	   residue,	   and	  hence	  normal	  Hb	   circulates	  without	   sticking	   to	   the	   endothelium,	   or	   to	   other	   blood	   components.	   Valine	   is	  hydrophobic	   and	   tends	   to	   stick	   to	   the	   adjacent	   amino	   acids	   in	   the	   globin	   chain,	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making	  HbS	  stickier,	  and	  leading	  to	  various	  clinical	  and	  pathological	  complications	  (Ataga	  and	  Key,	  2007).	  Other	  single	  amino	  acid	  substitutions	  result	   in	  a	   range	  of	  haemoglobin	  variants,	  most	  of	  which	  are	  of	  no	  clinical	  significance.	  One	  which	  does	  have	   clinical	   manifestations	   is	   known	   as	   HbC,	   in	   which	   lysine	   is	   substituted	   for	  glutamic	  acid	  at	  the	  same	  position	  in	  the	  beta	  chain	  as	  that	  affected	  in	  HbS	  (Allison,	  2009;	  Allison	  AC,	  1957;	  Takahashi	  et	  al.,	  1987).	  
	  
There	  is	  another	  category	  of	  haemoglobinopathies,	  the	  thalassaemias,	  in	  which	  the	  globin	   chains	   are	   structurally	   normal,	   but	   their	   production	   is	   not	   achieved	   in	  balanced	  quantities,	  and	  different	  tetramers	  are	  therefore	  formed.	   If	  alpha	  globin	  chain	   production	   is	   affected,	   these	   are	   known	   as	   alpha	   thalassaemias,	   and	  when	  the	  production	  of	  beta	  globins	   is	  affected,	   these	  are	  known	  as	  beta	  thalassaemias	  (Flint	  et	  al.,	  1993;	  Orkin	  et	  al.,	  1982).	  
	  
1.4 MODE	  OF	  INHERITANCE	  OF	  SCD	  
The	  production	  of	  HbS	  results	  from	  a	  single	  gene	  mutation	  affecting	  position	  six	  of	  chromosome	   11.	   It	   follows	   a	   simple	   Mendelian	   autosomal	   recessive	   mode	   of	  inheritance	   (Ingram	   et	   al.,	   1962b).	   Although	   the	   causes	   of	   these	   mutations	   are	  broadly	  unknown,	  the	  mutation	  producing	  HbS	  is	  known	  to	  confer	  some	  beneficial	  effects,	  since	  the	  heterozygous	  state	  (known	  as	  sickle	  cell	  trait)	  improves	  survival	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in	   areas	   where	   Falciparum	  malaria	   is	   endemic	   and	   thus	   has	   a	   major	   impact	   on	  population	  survival	  (Allison,	  1957a,	  1957b).	  
	  
The	   specific	   mechanism	   whereby	   the	   heterozygous	   state	   confers	   relative	  protection	  is	  unclear,	  and,	   in	  contrast,	  the	  mortality	  rate	  from	  malaria	  in	  patients	  with	   SCD	   is	   particularly	   high	   (Tan	   et	   al.,	   2011;	   Timmann	   et	   al.,	   2012).	   A	   recent	  study	  suggested	   that	   the	  malaria	  parasite	  uses	   the	  actin	  mono-­‐filaments	  beneath	  the	  RBC	  membrane	  to	  traverse	  and	  live	  inside	  the	  cell.	  In	  SCD	  these	  filaments	  are	  broken,	  as	  a	  consequence	  of	  RBC	  sickling,	  which	  may	  explain	  the	  reduced	  malaria	  parasite	  transmission	  in	  carrier	  status	  (Cyrklaff	  et	  al.,	  2011)	  However,	  it	  does	  not	  explain	   why	   the	   disease	   is	   severe	   in	   SCD.	   Whatever	   the	   mechanism,	   the	  consequence	   has	   been	   that	   the	   distribution	   of	   the	   SCD	   genes	   have	   paralleled	  malaria	   distribution	   for	   many	   years,	   until	   it	   became	   modified	   by	   population	  migration	   (Flint	   et	   al.,	   1998,	   1993;	   Lal	   and	   Vichinsky,	   2010;	   Stuart	   and	   Nagel,	  2004a).	  
	  
1.5 TYPES	  OF	  SICKLE	  CELL	  DISEASE	  
1.5.1 Genotypes	  in	  SCD	  
SCD	  comprises	  many	  genetic	  entities	  (Lal	  and	  Vichinsky,	  2010).	  All	  of	  them	  contain	  HbS.	   SCD	   occurs	   either	   with	   the	   homozygous	   inheritance	   of	   the	   HbS	   mutation	  (when	   it	   is	   designated	   as	   HbSS),	   or	   when	   the	   HbS	   mutation	   is	   inherited	   in	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combination	   with	   another	   haemoglobin	   variant	   (Lal	   and	   Vichinsky,	   2010).	   The	  most	  important	  combinations	  are	  with	  HbC,	  which	  is	  designated	  as	  HbSC	  disease,	  and	  with	  another	  variant	  known	  as	  HbO	  Arab,	  designated	  HbSO.	  Another	  clinically	  significant	   combination	   is	   that	   of	   HbS	   with	   β	   thalassaemia.	   The	   most	   severe	   β	  thalassaemia	  mutations	  result	  in	  the	  complete	  failure	  of	  beta	  chain	  production,	  and	  the	  combination	  is	  known	  as	  HbS	  β°	  thalassaemia	  (Lal	  and	  Vichinsky,	  2010).	  Other	  thalassaemia	   mutations	   result	   in	   reduction	   rather	   than	   absence	   of	   beta	   chain	  production,	  and	  combinations	  are	  designated,	  for	  example,	  as	  HbSβ+	  thalassaemia	  (Orkin	  et	  al.,	  1982;	  Stuart	  and	  Nagel,	  2004b).	  In	  this	  thesis	  the	  term	  SCD	  is	  used	  to	  encompass	  HbSS,	  HbSC	  and	  HbS	  β°	  thalassaemia.	  
	  
1.5.2 Phenotypes	  in	  SCD	  




1.6 	  PATHOPHYSIOLOGY	  OF	  SCD	  AND	  ITS	  CLINICAL	  CORRELATIONS	  
In	  conditions	  of	   low	  oxygen	  tension	  valine	  sticks	  to	  the	  adjacent	  amino	  acids	  and	  leads	   to	   haemoglobin	   S	   polymerisation,	   which	   is	   the	   first	   step	   in	   a	   cascade	   of	  abnormal	  events	  (Bookchin	  et	  al.,	  1977;	  Noguchi	  and	  Schechter,	  1985;	  Stuart	  and	  Nagel,	   2004a).	   The	   crystals	   formed	   from	   this	   process	   both	   damage	   the	   RBC	  membrane	  and	  give	  rise	   to	   the	  characteristic	   sickle	  shape	  of	   the	  RBC	  (Eaton	  and	  Hofrichter,	  1990,	  1987;	  Roth	  et	  al.,	  1979).	  Factors	  which	  increase	  the	  likelihood	  of	  HbS	  polymerisation	  are	   increased	   intracellular	  haemoglobin	  S	  concentration,	   low	  blood	  pH,	  and	  intracellular	  deoxygenation,	  whilst	  it	  is	  	  lessened	  by	  the	  presence	  of	  high	  HbF	   concentrations	   (Nagel	   et	   al.,	   1979;	  Noguchi	   et	   al.,	   1993;	   Steinberg	   and	  Brugnara,	   2003;	   Stuart	   and	   Nagel,	   2004a).	   The	   resultant	   HbS	   crystals	   impede	  normal	   RBC	   deformability,	   which	   is	   essential	   for	   the	   passage	   of	   RBC’s	   through	  capillaries.	   This	   gives	   rise	   to	   many	   adverse	   effects	   (Adachi	   and	   Asakura,	   1978;	  Adachi	  et	  al.,	  1980a,	  1980b;	  Eaton	  and	  Hofrichter,	  1990;	  Harrington	  et	  al.,	  1997).	  
	  




1.6.1 Role	  of	  RBC	  membrane	  phospholipid	  disruption	  
Initially,	  it	  was	  thought	  that	  the	  main	  problem	  in	  SCD	  was	  rheological	  in	  nature,	  as	  sickled	   RBCs	   tend	   to	  move	   slowly,	   causing	   stasis	   and	   vaso-­‐occlusion,	   because	   of	  their	  impaired	  deformability	  (Chien	  et	  al.,	  1970,	  1970).	  However	  growing	  evidence	  suggests	  that	  there	  is	  a	  more	  complex	  set	  of	  processes,	  which	  starts	  when	  repeated	  polymerisation	   of	   HbS,	   and	   its	   reversal,	   injure	   the	   RBC	  membrane	   and	   alter	   its	  normal	  phospholipid	  orientation	  (Apovo	  et	  al.,	  1989;	  Dzandu	  and	   Johnson,	  1980;	  Fathallah	  et	  al.,	  1997;	  Nagel	  et	  al.,	  1979;	  Ramachandran	  et	  al.,	  1987;	  Siciliano	  et	  al.,	  2011,	  2010;	  Stuart	  and	  Nagel,	  2004a).	  
	  
Normally,	   the	   phospholipid	   distribution	   in	   the	   RBC	   membrane	   is	   asymmetrical,	  with	  sphingomyelin	  and	  phosphatidylcholine	  being	  mainly	  on	  the	  outer	  side	  of	  the	  cell	  membrane,	  while	  phosphatidylserine	  (PS)	  is	  exclusively	  situated	  on	  the	  inner	  surface	   (An	   and	  Mohandas,	   2008;	   Boon	   and	   Smith,	   2002;	   Daleke,	   2008;	   Devaux,	  2000,	   1991;	   Traïkia	   et	   al.,	   2002).	   This	   asymmetry	   is	   usually	   maintained	   by	   an	  active	  pump	  system,	  the	  aminophospholipid	  translocase	  pump,	  which	  transfers	  PS	  consistently	  to	  the	  inner	  aspect	  of	  the	  membrane,	  thus	  keeping	  the	  phospholipids	  in	  an	  asymmetrical	  arrangement	  (Sulpice	  et	  al.,	  1994).	  The	  exposure	  of	  negatively	  charged	   phospholipids	   contributes	   to	   the	   pro-­‐inflammatory	   and	   pro-­‐thrombotic	  state	   of	   sickle	   cell	   blood	   (Frenette	   and	   Atweh,	   2007;	   Manodori	   et	   al.,	   2000).	  Manodori	   et	   al	   (2000)	   suggest	   that	   PS	   adherence	   to	   the	   endothelium	   of	   micro-­‐vessels	   is	   mediated	   through	   a	   matrix	   protein,	   thrombospondin.	   However,	   more	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recent	   evidence	   indicates	   that	   PS	   adhesion	   involves	   a	   specific	   receptor,	  which	   is	  present	   in	   the	  microvascular	  endothelial	   cells,	   identified	  as	  PSR.	  These	   receptors	  mediate	   a	   direct	   interaction	   between	   PS-­‐positive	   erythrocytes	   and	   the	   micro-­‐endothelium	   (Setty	   and	   Betal,	   2008).	   The	   same	   authors	   also	   found	   that	   these	  receptors	   can	   be	   induced	   and	   up-­‐regulated	   by	   hypoxia	   and	   inflammatory	  mediators.	  
	  




1.6.1.1 PS	  exposure	  and	  vaso-­‐occlusive	  complications	  
Hebbel	  and	  Joneckis	  (Hebbel	  et	  al.,	  1980;	  Joneckis	  et	  al.,	  1993)	  reported	  that	  sickle	  RBCs	  adhere	  to	  the	  endothelium	  of	  blood	  vessels	  in	  vitro.	  As	  previously	  discussed,	  the	  mechanism	  behind	  this	  adhesiveness	  is	  the	  presence	  of	  PS	  on	  the	  outer	  surface	  of	   the	   sickle	   RBC,	   which	   docks	   with	   the	   vessel	   endothelium	   (Setty	   et	   al.,	   2001,	  2002).	  This	  in	  turn,	  results	  in	  endothelial	  injury	  and	  RBC	  haemolysis,	  which	  results	  in	   the	   release	   of	   free	   haemoglobin	   in	   the	   plasma	   compartment.	   The	   injured	  endothelium	   suffers	   an	   oxidative	   stress,	  with	   resultant	   decreased	   levels	   of	   vaso-­‐dilators	   such	   as	   Nitric	   Oxide	   (NO),	   leading	   to	   vasoconstriction	   (Akinsheye	   and	  Klings,	  2010;	  Allen	  and	  Piantadosi,	  2006;	  Gladwin	  et	  al.,	  2001;	  Reiter	  et	  al.,	  2002).	  Normally,	   NO	   is	   produced	   in	   the	   endothelium	   from	   its	   precursor	   L-­‐arginine.	   Its	  main	   role	   is	   to	   cause	   vascular	   smooth	   muscle	   relaxation,	   by	   increasing	   cyclic	  guanosine	   monophosphate	   (cGMP)	   levels.	   The	   cGMP	   dephosphorylates	   myosin	  light	  chains,	  and	  hence	  relaxes	  the	  vascular	  smooth	  muscle,	  causing	  vaso-­‐dilatation	  (Murad,	   1986).	   The	   decrease	   in	   NO	   levels	   found	   in	   SCD	   is	   thought	   to	   be	   a	  consequence	   of	   the	   combination	   of	   decreased	   L-­‐arginine	   levels	   (Gladwin	   et	   al.,	  2001;	  Morris,	  2008;	  Morris	  et	  al.,	  2000a,	  2000b),	  increased	  NO	  scavenging	  by	  free	  haemoglobin	  (Reiter	  et	  al.,	  2002)	  and	  NO	  scavenging	  by	  oxygen	  free	  radicals	  (Aslan	  




1.6.1.2 PS	  exposure	  and	  RBC	  haemolysis	  
PS	   exposure	   on	   the	   outer	   surface	   of	   the	   RBC	  membrane	   predisposes	   the	   cell	   to	  apoptosis	  and	  phagocytosis	  by	  the	  spleen,	  leading	  to	  splenomegaly,	  hypersplenism,	  haemolytic	  anaemia	  and	  jaundice	  (Van	  Engeland	  et	  al.,	  1998).	  It	  also	  releases	  cell	  -­‐free	  haemoglobin,	  which	  plays	  a	  part	  in	  thrombosis	  (Porter	  et	  al.,	  1993).	  With	  RBC	  destruction	  and	  haemolysis,	   the	  released	  Hb	  forms	  complexes	  with	   its	  scavenger,	  haptoglobin.	   It	   is	   then	   mainly	   cleared	   by	   macrophages	   (Philippidis	   et	   al.,	   2004;	  Schaer	  et	  al.,	  2008,	  2007)	  
	  
Haptoglobin	  has	   the	   capacity	   to	  bind	  up	   to	  150	  micrograms	  of	   free	  Hb	   (Langlois	  and	  Delanghe,	  1996);Langlois	  et	  al,1996).	  The	  amount	  of	   free	  Hb	  released	  during	  the	  steady	  state	  in	  patients	  with	  Hb	  SS	  ranges	  from	  20	  to	  330	  μg/ml	  but	  can	  exceed	  410	  μg/ml	  during	  sickling	  crises	  (Naumann	  et	  al.,	  1971;	  Zhou	  et	  al.,	  2011,	  2009a).	  When	  the	  carrier	  capacity	  of	  haptoglobin	   is	  exceeded	   free	  Hb	  accumulates	   in	   the	  plasma	  (Buehler	  and	  D’Agnillo,	  2010;	  Langlois	  and	  Delanghe,	  1996).	  This	   free	  Hb	  scavenges	   NO,	   leading	   to	   vasoconstriction,	   pulmonary	   hypertension,	   cellular	  damage	  (Minneci	  et	  al.,	  2005;	  Reiter	  and	  Gladwin,	  2003;	  Reiter	  et	  al.,	  2002),	  causes	  platelet	   activation	   and	   initiates	   thrombosis	   (Brill	   et	   al.,	   2012;	   Buehler	   and	  D’Agnillo,	   2010;	   Fuchs	   et	   al.,	   2010;	   Zhou	   et	   al.,	   2011).	   Free	   Hb	   has	   been	  demonstrated	   in	  vitro	   to	   inhibit	  the	  enzyme,	  A	  Disintegrin	  And	  Metalloproteinase	  with	   Thrombospondin	   Motifs	   (ADAMTS13),	   which	   limits	   platelet	   activation	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(Sadler,	  2002;	  Studt	  et	  al.,	  2005;	  Zhou	  et	  al.,	  2011).	   It	   is	  also	  been	  suggested	  that	  free	  Hb	  can	  inhibit	  the	  cleavage	  of	  von	  Willebrand	  Factor	  (Zhou	  et	  al.,	  2009b).	   In	  addition,	   scavenging	   of	   NO	   by	   free	   Hb	   reduces	   cGMP,	   which	   inhibits	   platelet	  aggregation	  (Crawford	  et	  al.,	  2006;	  Kayanoki	  et	  al.,	  1999a;	  Radomski	  et	  al.,	  1987).	  NO	  also	  usually	  interferes	  with	  clotting	  factors	  such	  as	  Factor	  XIII	  thus	  preventing	  clot	   formation	   (Kayanoki	   et	   al.,	   1999b;	   Radomski	   et	   al.,	   1987;	   Shao	   et	   al.,	   2001;	  Zhou	  et	  al.,	  2011).	  
	  
1.6.1.3 PS	   exposure,	   endothelial	   activation	   and	   the	   SCD	   chronic	  
inflammatory	  state	  The	   increased	  endothelial	  activation	  seen	   in	  SCD,	  was	   first	  noted	  by	  Solovey	  and	  colleagues	  in	  1997,	  when	  they	  described	  the	  circulating	  endothelial	  cells	  in	  SCD	  as	  showing	   pro-­‐inflammatory,	   pro-­‐coagulant,	   and	   pro-­‐adhesive	   properties	   (Solovey	  
et	  al.,	  1997).	  It	  is	  largely	  understood	  now,	  that	  this	  endothelial	  activation	  is	  started	  by	  the	  sickle	  RBC,	  with	  exposed	  PS	  on	  its	  surface,	  adhering	  to	  the	  endothelium	  and	  injuring	  it	  (Kuypers	  et	  al.,	  1998;	  Setty	  and	  Betal,	  2008;	  Sulpice	  et	  al.,	  1994;	  Zwaal	  and	   Schroit,	   1997).	   This	   invites	   the	   adhesion	   of	   leucocytes	   to	   the	   endothelium	  (mainly	  neutrophils)	  and	  leads	  to	  the	  formation	  of	  multi-­‐cellular	  aggregates,	  from	  leucocytes	   and	   irreversibly	   sickled	   cells	   (ISC)	   (Brill	   et	   al.,	   2012;	   Frenette,	   2002;	  Fuchs	  et	  al.,	  2010;	  Turhan	  et	  al.,	  2002).	  These	  produce	   the	  chronic	   inflammatory	  state	   noted	   in	   SCD	   (Lard	   et	   al.,	   1999;	   Setty	   et	   al.,	   2008;	   Stuart	   and	   Setty,	   2001;	  Turhan	  et	  al.,	  2002).	  Studies	  conducted	   in	   transgenic	  mouse	  models	  also	  suggest	  that	  vascular	  inflammation	  and	  heterocellular	  aggregates	  contribute	  to	  the	  cascade	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of	   events	   causing	   both	   vaso-­‐occlusive	   crises	   of	   SCD	   and	   thrombosis	   (Chiang	   and	  Frenette,	  2005;	  Frenette	  and	  Atweh,	  2007;	  Frenette,	  2002;	  Turhan	  et	  al.,	  2002).	  
	  
Decreased	   NO	   levels	   also	   contribute	   to	   the	   development	   of	   the	   chronic	  inflammatory	  process	  in	  SCD	  (Aslan	  et	  al.,	  2001;	  Gladwin	  et	  al.,	  2001,	  1999;	  Morris,	  2008;	   Reiter	   and	   Gladwin,	   2003).	   Naturally,	   NO	   inhibits	   the	   formation	   of	   pro-­‐adhesive	   and	   pro-­‐inflammatory	   molecules	   such	   as	   endothelial	   Vascular	   Cell	  Adhesion	   Molecule-­‐1	   (VCAM-­‐1),	   intercellular	   adhesion	   molecule-­‐1	   (ICAM-­‐1),	   E-­‐selectin,	   P-­‐selectin,	   and	   also	   inhibits	   leucocyte	   migration	   and	   adhesion	   (Kim-­‐Shapiro	  et	  al.,	  2006;	  Stuart	  and	  Nagel,	  2004a).	  Hence,	  in	  situations	  of	  reduced	  NO	  production	   or	   abnormal	   consumption,	   there	   is	   a	   tendency	   for	   the	   circulation	   of	  higher	   levels	   of	   these	   molecules,	   and	   this	   plays	   a	   further	   role	   in	   the	   vascular	  inflammation	  characteristic	  of	  SCD	  (Bunn	  et	  al.,	  2010;	  Solovey	  et	  al.,	  2004,	  1998,	  1997,	   2001).	   Clinically,	   an	   abnormally	   increased	  white	   blood	   cell	   (WBC)	   level	   in	  SCD	   is	   an	   indicator	   of	   disease	   severity	   and	   correlates	  with	  mortality	   (Platt	  et	   al,	  1994;	  Miller	  et	  al,	  2000).	  
	  
1.6.2 The	  mechanism	  of	  thrombosis	  
Thrombi	  are	  formed	  of	  fibrin	  and	  platelets	  (Mackman,	  2008,	  2007).	  The	  initiation	  of	  a	   thrombosis	  starts	  with	  what	   is	   traditionally	  known	  as	  the	  extrinsic	  pathway,	  while	   the	   propagation	   of	   this	   process	   follows	   the	   intrinsic	   pathway	   (Mackman,	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2008,	  2007).	  In	  the	  general	  population	  thrombo-­‐embolic	  disease	  is	  multi-­‐factorial,	  caused	  by	  a	  combination	  of	  genetic	  and	  acquired	  risk	  factors	  .	  
The	  main	  physiological	  activator	  of	  haemostasis	  is	  tissue	  factor	  (TF),	  a	  cell	  surface	  glycoprotein	   with	   a	   high	   affinity	   for	   coagulation	   Factor	   VII	   (Almus	   et	   al.,	   1990;	  Moosbauer	   et	   al.,	   2007).	   Physiologically,	   TF	   is	   contained	   within	   the	   vascular	  adventitial	   cells	   (Bouchard	   et	   al.,	   1997;	   Drake	   et	   al.,	   1989a,	   1989b;	   Fleck	   et	   al.,	  1990;	  Mackman	  et	  al.,	  2007;	  Morel	  et	  al.,	  2006;	  Müller	  et	  al.,	  2003).	  In	  pathological	  conditions,	   TF	   is	   displayed	   by	   endothelial	   cells,	   monocytes,	   neutrophils	   and	  platelets,	   leading	   to	   an	   increase	   in	   total	   amount	   of	   circulating	   microparticles	  (Gregory	  et	  al.,	  1989;	  Müller	  et	  al.,	  2003;	  Siddiqui	  et	  al.,	  2002;	  Solovey	  et	  al.,	  1998;	  Zillmann	  et	  al.,	  2001).	  
Following	   injury	   or	   damage	   to	   the	   vessel	   wall	   TF	   activates	   coagulation	   FVII	   to	  FVIIa	  forming	  [TF:FVIIa]	  complex,	  which	  then	  immediately	  activates	  FX	  to	  FXa	  and	  FIX	   to	   FIXa	   (comprises	   the	   initiation	   phase	   of	   coagulation).	   As	   soon	   as	   the	  [TF:FVIIa]	  complex	  is	  formed,	  it	  is	  immediately	  inhibited	  by	  tissue	  factor	  pathway	  inhibitor	  (TFPI).	  	  The	  small	  amount	  of	  FXa	  produced	  activates	  prothrombin	  (FII)	  to	  thrombin	  (IIa)	  which	  is	  enough	  to	  activate	  FXI	  to	  FXIa	  which	  then	  further	  activates	  FIX	  to	  FIXa,	  together	  with	  cofactors	  FVIII	  and	  FV	  who	  are	  activated	  to	  FVIIIa	  and	  FVa	   respectively	   (amplification	   phase	   of	   coagualtion)	   (figure	   1.3).	   Thrombin	   is	   a	  protease	   enzyme	   which	   is	   formed	   from	   the	   cleavage	   of	   prothrombin	   by	  prothrombinase	   (Fenton,	   1986;	   Fenton	   et	   al.,	   1993,	   1991).	   Prothrombinase	   is	   a	  complex	  formed	  from	  the	  binding	  of	  activated	  Factor	  V	  (Va)	  with	  activated	  Factor	  X	  (Xa)	  (Dahlbäck,	  1997;	  Kalafatis	  and	  Mann,	  2001;	  Lawson	  et	  al.,	  1993;	  Shen	  and	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Dahlbäck,	   1994).	   Once	   thrombin	   is	   formed,	   it	   converts	   soluble	   fibrinogen	   into	  insoluble	   fibrin.	   The	   initial	   unstable	   fibrin	  mesh	   is	   converted	   to	   stable	   fibrin	   by	  Factor	  XIII	   (Coughlin	  et	  al.,	  1992;	  Fenton,	  1986;	  Vu	  et	  al.,	  1991)	  and	  at	   the	  same	  time	  	  platelets	  form	  plugs	  at	  the	  site	  of	  injury	  ,	  this	  is	  usually	  activated	  by	  collagen	  and	  thrombin.	  	  
Inorder	   for	   the	   platelets	   to	   function,	   von	  Willebrand	   Factor	   (VWF)	   is	   needed,	   a	  glycoprotein,	   which	   traps	   platelets	   and	   “glues”	   them	   together	   (Crawley	   et	   al.,	  2005).	   ADAMTS13	   is	   the	   enzyme	   responsible	   for	   cleaving	   the	  macro-­‐polymer	   of	  vWF,	   resulting	   in	   the	   disaggregation	   of	   platelets	   (Crawley	   et	   al.,	   2011).	   The	  completion	  of	  thrombus	  formation	  is	  achieved	  when	  fibrin	  is	  formed	  (Lämmle	  and	  Griffin,	  1985).	  
	  
Thrombin	  potentiates	   its	   own	   secretion	   through	   a	  positive	   feedback	  mechanism,	  by	  virtue	  of	  activating	  Factor	  V	  and	  Factor	  VIII	  (Van	  Veen	  et	  al.,	  2008).	  Conversely	  it	  exerts	  a	  negative	  feedback	  on	  the	  clotting	  system,	  by	  binding	  to	  thrombomodulin	  (an	  endothelial	  membrane	  protein)	  to	  form	  a	  compound	  which	  activates	  Protein	  C,	  giving	   rise	   to	   activated	   Protein	   C	   (APC)	   along	  with	   co-­‐factor	   Protein	   S,	  which	   in	  turn	  inhibits	  activated	  Factor	  V	  and	  activated	  Factor	  VIII	  (Va	  and	  VIIIa)	  (Bajzar	  et	  
al.,	   1996;	   Guillin,	   1998;	   Jakubowski	   and	   Owen,	   1989;	   van	   Veen	   et	   al.,	   2008).	  However,	  thrombin	  has	  some	  harmful	  effects,	  as	  it	  is	  a	  potent	  vaso-­‐constrictor,	  and	  has	  pro-­‐inflammatory	  characteristics.	  Furthermore	   it	  potentiates	  oxidative	   stress	  in	  endothelial	  cells,	  and	  promotes	  cell	  apoptosis	  (Borissoff	  et	  al.,	  2010;	  Fenton	  et	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al.,	   1993;	   Ofosu,	   2002).	   Thrombin	   is	   inactivated	   by	   another	   protease	   inhibitor	  designated	  as	  anti-­‐thrombin	  (Hatton	  et	  al.,	  1978;	  Lawson	  et	  al.,	  1993).	  
	  




	  	  Figure	  1-­‐3.	  The	  modern	  cell-­‐based	  model	  of	  haemostasis	  ,	  reproduced	  from	  Hoffman	  &	  Dargaud,	  2012.	  
1.6.3 Venous	  thrombosis	  in	  SCD	  
Though	   there	   is	  wide	   consensus	   about	   the	   increased	   risk	   of	   arterial	   thrombosis	  and	   strokes	   in	   SCD	   (Ganesan	   et	   al.,	   2002;	   Prengler	   et	   al.,	   2002),	   there	   is	   less	  agreement	   with	   regard	   to	   venous	   thrombo-­‐embolism	   (VTE)	   i.e.	   pulmonary	  embolus	   and	  deep	  vein	   thrombosis	   (PE	  and	  DVT)	   (Key	  and	  Derebail,	   2010).	  The	  incidence	  of	  clinical	  VTE	  in	  SCD	  sufferers	  in	  the	  steady	  state	  is	  not	  well	  researched	  (Key	   and	  Derebail,	   2010).	   James	   et	   al	   (2006)	   reported	   that	   pregnancy	   in	   SCD	   is	  associated	   with	   an	   increased	   incidence	   of	   VTE	   (with	   an	   Odds	   Ratio	   of	   6.7	   and	  Confidence	   intervals	   between	   4.4	   and	   10.1).	   However,	   their	   study	   did	   not	   look	  separately	   at	   the	   antenatal	   and	   postnatal	   periods,	   and	   they	   did	   not	   differentiate	  between	   PE	   and	   DVT	   (James	   et	   al.,	   2006).	   Stein	   et	   al	   (2006)	   looked	   at	   VTE	   in	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hospitalised	   SCD	   patients	   and	   found	   that	  whereas	   the	   incidence	   of	   DVT	  was	   the	  same	  in	  SCD	  patients	  as	  in	  controls	  of	  black	  African	  ethnic	  origin	  with	  normal	  Hb,	  the	  incidence	  of	  PE	  was	  higher	  in	  patients	  with	  SCD	  than	  in	  their	  control	  patients	  (Stein	  et	  al.,	  2006).	  
	  
There	  is	  an	  impression	  that,	  despite	  the	  hyper-­‐coagulable	  state	  in	  SCD,	  clinical	  VTE	  may	   not	   occur	   in	   the	   steady	   state	   without	   additional	   risk	   factors,	   such	   as	   the	  presence	   of	   other	   co-­‐morbidities,	   prolonged	   hospitalisation,	   or	   pregnancy	   (Key	  and	  Derebail,	  2010).	  
	  
1.6.3.1 Pathogenesis	  of	  thrombus	  in	  SCD	  
SCD	  creates	  a	  hyper-­‐coagulable	  state	  (Ataga	  and	  Key,	  2007;	  Francis,	  1991;	  Stuart	  and	  Nagel,	  2004a;	  Stuart	  and	  Setty,	  2001).	  There	   is	  evidence	   that	   the	  markers	  of	  thrombin	   generation	   and	   tissue	   factor	   expression	   are	   increased	   in	   SCD,	   with	   a	  reduction	   in	   the	   natural	   anti-­‐coagulant	   proteins,	   abnormal	   activation	   of	   the	  fibrinolytic	  system	  and	  activation	  of	  platelets,	  even	  in	  the	  steady	  state	  (Ataga	  and	  Key,	   2007;	   Setty	   et	   al.,	   2001;	   Stuart	   and	   Nagel,	   2004b;	   Stuart	   and	   Setty,	   2001;	  Westerman	  et	  al.,	  2008).	  The	  factors	  contributing	  to	  this	  pro-­‐thrombotic	  tendency	  are	  numerous,	  and	   the	  mechanisms	  responsible	   for	   this	  hypercoagulability	  share	  many	   similarities	   with	   the	   mechanisms	   causing	   vaso-­‐occlusive	   crises,	   described	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previously.	  In	  fact,	  it	  is	  sometimes	  not	  clear	  if	  the	  hyper-­‐coagulable	  state	  is	  a	  result	  of	  the	  vaso-­‐occlusive	  complications	  or	  the	  cause	  of	  them	  (Ataga	  and	  Key,	  2007).	  
	  
The	   core	   abnormality	   in	   the	   pro-­‐thrombotic	   cascade	   is	   the	   loss	   of	   the	   RBC	  membrane	   asymmetry,	   described	   earlier,	   leading	   to	   the	   formation	   of	   red	   cell	  membrane	  microvesicles,	  with	  PS	  exposed	  on	  the	  outer	  surface	  of	  the	  lipid	  bilayer	  (Ataga	  and	  Key,	  2007;	  Westerman	  et	  al.,	  2008).	  This	  loss	  of	  natural	  cell	  membrane	  asymmetry	  occurs	  only	   in	   the	  RBC	   in	  SCD,	  and	   there	   is	  no	  evidence	   that	  platelet	  cell	  membranes	  show	  any	  similar	  PS	  exposure	  (Ataga	  and	  Key,	  2007;	  Ataga	  et	  al.,	  2007).	  The	  exposed	  PS	  on	  SCD	  RBC’s	  increases	  the	  tendency	  to	  thrombosis	  in	  four	  ways.	   Firstly,	   directly,	   because	   exposed	   PS	   forms	   an	   attachment	   port	   for	  coagulation	  and	  anticoagulation	  enzymatic	   complexes	   (Zwaal	   and	  Schroit,	  1997).	  Secondly,	  indirectly,	  due	  to	  endothelial	  injury	  caused	  by	  adhesiveness	  of	  the	  sickle	  RBC’s	   and	   the	   subsequent	   formation	   of	   a	   multi-­‐cellular	   aggregate	   of	   WBCs	   and	  platelets.	   The	   fact	   that	   circulating	   endothelial	   cells	   with	   increased	   tissue	   factor	  (TF)	  expression	  and	  chronically	  activated	  platelets	  are	  consistently	  found	  in	  SCD,	  even	  in	  the	  steady	  state,	  signifies	  that	  this	  inflammatory	  response	  also	  plays	  a	  role	  in	   coagulation	   activation	   (Setty	   et	   al.,	   2002;	   Solovey	   et	   al.,	   2004).	   Thirdly,	   the	  presence	  of	  PS	  on	   the	  outer	   surface	  of	  RBC’s	   serves	  as	  a	  detection	   signal	   for	   cell	  apoptosis	   (Fadok	   et	   al.,	   1992)	   leading	   to	   chronic	   haemolysis,	   which	   contributes	  further	   to	   the	   pro-­‐thrombotic	   state	   by	   releasing	   free	   circulating	   haemoglobin	  (Cappellini,	  2007).	  This	  is	  evident	  by	  the	  fact	  that	  RBC’s	  with	  greater	  PS	  exposure	  cause	   a	   two-­‐fold	   increase	   in	   endothelial	   tissue	   factor	   (TF)	   expression,	   compared	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with	  RBCs	  with	  less	  PS	  exposure	  (Setty	  et	  al.,	  2008,	  2002);	  Setty	  et	  al,	  2006).	  Lastly,	  there	   is	   also	   some	   evidence	   that	   SCD	   is	   associated	   with	   increased	   levels	   of	  circulating	   cell	  membrane-­‐derived	  vesicles,	   or	  microparticles	   (Morel	   et	   al.,	   2006;	  Porter	   et	   al.,	   1993)	   .These	   microparticles	   are	   released	   by	   RBC’s,	   platelets,	  endothelial	  cells	  and	  monocytes,	  either	  following	  their	  activation	  or	  as	  a	  result	  of	  apoptosis.	   Microparticles	   thus	   play	   an	   active	   role	   in	   producing	   the	   hyper-­‐coagulable	  state	  (Westerman	  et	  al.,	  2008).	  
	  
1.6.3.2 Risk	  of	  VTE	  in	  Sickle	  Cell	  Trait	  (SCT)	  
Asymptomatic	   people	   with	   SCT	   exhibit	   a	   lesser	   degree	   of	   the	   same	   coagulation	  activation	  which	   is	  described	   in	  patients	  with	  SCD	  (Westerman	  et	  al.,	  2002).	   It	   is	  thought	  that	  the	  mechanism	  is	  similar	  to	  those	  in	  SCD,	  but	  with	  lesser	  degrees	  of	  PS	  exposure	  on	  the	  surface	  of	  RBC’s	  (Chiu	  et	  al.,	  1981).	  Dowling	  et	  al	  (2003)	  looked	  at	   the	   incidence	   of	   VTE	   in	   a	   black	   American	   population	   and	   found	   that	   the	  incidence	   of	   VTE	   is	   doubled	   in	   people	   with	   SCT	   compared	  with	   people	   with	   no	  haemoglobinopathy	  (Dowling	  et	  al.,	  2003).	  
	  
A	  recent	  study	  in	  the	  USA	  has	  also	  reported	  that	  sickle	  cell	  trait	  is	  associated	  with	  clinical	  VTE.	  Despite	  a	  prevalence	  of	  less	  than	  1%	  as	  shown	  in	  Figure	  1-­‐1,	  the	  sickle	  mutation	   contributes	   to	   approximately	   7%	   of	   clinical	   episodes	   of	   VTE	   among	  people	  of	  Afro-­‐Caribbean	  ethnic	  origin	  (Austin	  et	  al.,	  2007;	  Austin	  et	  al.,	  2009).	  The	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authors	  draw	  attention	  to	  the	  fact	  that	  this	  is	  a	  stronger	  correlation	  than	  that	  of	  the	  Factor	  V	  Leiden	  mutation	  (Austin	  et	  al.,	  2007).	  In	  addition,	  it	  has	  been	  suggested	  that	  there	  is	  potentiation	  of	  the	  risk	  of	  VTE	  in	  SCT	  women	  by	  the	  use	  of	  the	  combined	  oral	  contraceptive	  (COC)	  (Austin	  et	  al.,	  2009).	  
	  
1.7 HORMONAL	  CONTRACEPTION	  
The	   naturally	   occurring	   oestrogen,	   17	   beta	   oestrogen	   (E2)	   is	   secreted	   by	   the	  granulosa	   cells	   of	   the	   ovary.	   Secretion	   starts	   early	   in	   the	   follicular	   phase	   of	   the	  menstrual	   cycle	   and	   reaches	   its	   peak	   at	   the	   time	   of	   ovulation	   (Channing	   et	   al.,	  1980).	   Most	   of	   the	   E2	   is	   bound	   to	   the	   carrier	   protein,	   Sex	   Hormone	   Binding	  Globulin	  (SHBG),	  however	  its	  effects	  are	  exerted	  by	  the	  free	  form	  (Channing	  et	  al.,	  1980).	  There	  are	  E2	  receptors	  in	  almost	  all	  body	  organs	  and	  E2	  supports	  diverse	  physiological	  processes,	  including	  aspects	  of	  the	  cardiovascular	  system	  (Kuiper	  et	  
al.,	   1998,	   1996;	  Moriarty	   et	   al.,	   2006;	   Toran-­‐Allerand,	   2004).	   For	   example,	   E2	   is	  proven	  to	  stimulate	  nitric	  oxide	  synthase	  (NOS)	  production	  by	  vascular	  endothelial	  cells	  (Hisamoto	  and	  Bender,	  2005;	  Simoncini,	  2009).	  
	  
After	   ovulation	   the	   follicle	   transforms	   into	   the	   corpus	   luteum,	   which	   secretes	  progesterone,	   and	   thus	   progesterone	   levels	   peak	   in	   the	   mid-­‐luteal	   phase	   of	   the	  cycle	   (Channing,	   1980).	   The	   main	   actions	   of	   progesterone	   are	   confined	   to	   the	  reproductive	   system.	   Progesterone	   is	   mainly	   bound	   to	   the	   carrier	   protein,	  
48 
 
Corticosteroid	   Binding	   Globulin	   (CBG)	   (Hammond	   et	   al.,	   1984).	   Again,	   the	  physiological	   actions	   are	   exerted	   by	   the	   free	   form,	  which	   is	   rapidly	  metabolised	  (Channing	  et	  al.,	  1980).	  
	  
The	  synthetically	  derived	  oestrogen,	  ethinyl	  oestradiol	  (EE),	  has	  an	  ethinyl	  residue,	  which	  has	  a	  higher	  receptor	  affinity,	  and	  it	  is	  more	  durable	  during	  transport,	  giving	  it	  a	   longer	  half-­‐life	  than	  E2	  (Djerassi,	  2006;	  Djerassi	  et	  al.,	  2006).	  Because	  of	  this,	  EE	   is	   the	  most	  commonly	  used	  oestrogen	  in	  contraceptive	  medication.	  Unlike	  E2,	  progesterone	   has	  many	   synthetic	   analogues,	   known	   collectively	   as	   progestogens	  (Hammond	   et	   al.,	   2001;	   Raynaud	   and	   Bercovici,	   1979).	   The	   first	   manufactured	  progestogens	  are	   identified	   in	   clinical	  practice	  as	   “first	   generation”	  progestogens	  and	   include	   preparations	   such	   as	  Norethindrone	   acetate	   (NETA)	   and	   Ethynodiol	  diacetate	  (Hammond	  et	  al.,	  2001).	  These	  first	  generation	  preparations	  are	  derived	  from	  19	  nor-­‐testerone	  and	  they	  exhibit	  low	  to	  medium	  progestogenic	  activity	  and	  slight	   oestrogenic	   effects	   (Hammond	   et	   al.,	   2001).	   The	   so	   called	   “second	  generation”	   progestogens	   are	   now	   the	   most	   commonly	   used	   in	   contraceptive	  medications.	   They	   are	   derived	   from	   17-­‐α-­‐hydroxy-­‐progesterone	   and	   include	  Levonorgestrel	  (LNG)	  and	  Norgestrel.	  They	  have	  progestotogenic	  and	  androgenic	  effects;	   hence	  Levonorgestrel	   adversely	   affects	   serum	   lipoproteins	   (Hammond	  et	  al.,	   2001;	   Blumenthal	   and	   Edelman,	   2008).	   However,	   in	   combinations	   with	  oestrogen,	  both	  NETA	  and	  LNG	  reduce	  androgen	  production	  (Thorneycroft	  et	  al.,	  1999).	  The	  “third	  generation”	  progestogens	  (e.g.	  desogestrel,	  gestodene)	  have	  less	  androgenic	   and	   oestrogenic	   effects	   compared	  with	   the	   older	   progestogens.	   Thus	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they	  show	  less	  negative	  impact	  on	  serum	  lipids,	  body	  metabolism	  and	  weight	  gain,	  and	  they	  have	  positive	  effects	  on	  acne	  (Hammond	  et	  al.,	  2001;	  Practice	  Committee	  of	  American	  Society	  for	  Reproductive	  Medicine,	  2008).	  
	  
Hormonal	   contraceptives	   (HC)	   can	   be	   divided	   into	   the	   combined	   hormonal	  contraceptives	  (CHC)	  containing	  oestrogen	  and	  progestogens,	  and	  the	  progestogen	  only	   contraceptive	   (POC)	   (Practice	   Committee	   of	   American	   Society	   for	  Reproductive	  Medicine,	  2008).	  
	  
	  
1.7.1 Combined	  Hormonal	  Contraceptives	  (CHC)	  




COC’s	   are	   known	   to	   be	   well	   tolerated	   and	   highly	   effective	   (Foidart	   et	   al.,	   2000;	  Huber	  et	  al.,	   2000).	   It	   has	  been	   reported	   that	   approximately	  100	  million	  women	  worldwide	   are	   using	   COC’s	   (WHO	   Scientific	   Group,	   1998).	   COC’s	   are	   extensively	  used	  worldwide,	  in	  the	  USA	  it	  is	  estimated	  that	  25%	  of	  women	  of	  reproductive	  age	  have	   used	   them	   (Practice	   Committee	   of	   American	   Society	   for	   Reproductive	  Medicine,	  2008;	  Odlind	  et	  al.,	  2002).	  In	  the	  UK,	  it	  has	  been	  estimated	  that	  a	  similar	  percentage	  of	  women	  have	  used	  COC	  (Lader,	  2009).	  It	   is	  the	  preferred	  method	  of	  young	  women	  in	  the	  UK,	  in	  particular.	  53%	  of	  women	  aged	  20-­‐24	  years	  have	  used	  the	   combined	   oral	   contraceptive	   pills	   in	   their	   life	   time	   (Lader,	   2009).	   COC’s	   are	  popular	  with	  women	  because	  of	   their	   ease	   of	   use,	   effectiveness,	   low	   rate	   of	   side	  effects,	   and	   the	   predictable	   return	   of	   subsequent	   fertility	   (within	   three	  months)	  (Cerel-­‐Suhl	  and	  Yeager,	  1999;	  Blumenthal	  and	  Edelman,	  2008).	  
	  
COCs	  are	  also	  known	  to	  reduce	  the	  incidence	  of	  endometrial	  and	  ovarian	  cancer,	  to	  reduce	   chronic	   pelvic	   pain,	   ovarian	   cysts,	   and	   to	   reduce	   menstrual	   blood	   loss	  (Practice	  Committee	  of	  American	  Society	  for	  Reproductive	  Medicine,	  2008).	  There	  is	  also	  a	  considerable	  role	   for	  COC	   in	   the	  control	   	  of	   symptoms	  of	  dysmenorrhea	  and	  endometriosis	  (Harada	  et	  al.,	  2008).	  
However	  COC’s	   are	   found	   to	   increase	   the	   risk	  of	   venous	   and	   arterial	   thrombosis	  (Van	   Hylckama	   Vlieg	   and	   Middeldorp,	   2011).	   The	   increased	   VTE	   risk	   is	   noted	  mainly	  with	  the	  preparations	  containing	  third	  generation	  progestogens,	  especially	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gestodene	   (Bloemenkamp	   et	   al.,	   1995;	   	  WHO	   Scientific	   Group,”	   1998;	   Jick	   et	   al.,	  1995;	  Kemmeren	  et	  al.,	  2001a,	  2001b;	  Spitzer,	  1996).	  However,	  the	  VTE	  risk	  with	  norgestimate-­‐containing	   pills	   is	   considered	   similar	   to	   that	   of	   users	   of	  levonorgestrel-­‐containing	  OCs.(Jick	  et	  al.,	  2006)	  
Recently,	  drospirenone,	  a	  progestogen	  derived	  from	  17α-­‐spironolactone	  has	  been	  used	   in	   COC	   medications.	   It	   exerts	   progestogenic	   and	   anti-­‐androgenic	   effects	  (Krattenmacher,	  2000).	  





1.7.1.1 COC	  and	  VTE	  risk	  
Only	   two	   years	   after	   COC’s	   were	   approved	   for	   use	   in	   the	   USA,	   Jordan	   wrote	  “because	   Enavid	   may	   produce	   uncontrollable	   vomiting	   and	   provoke	   pulmonary	  embolism	   and	   infarction,	   I	   would	   counsel	   caution	   in	   the	   use	   of	   this	   widely	  advertised	   drug”	   (Jordan	   and	   Anand,	   1961).	   Later,	   Inman	   wrote	   about	   the	  increased	   occurrence	   of	   VTE	   in	   COC	   users,	   and	   attributed	   this	   increase	   to	   the	  oestrogen	  component	  of	  COC	  (Inman	  and	  Vessey,	  1968;	  Inman,	  1970).	  
	  
Five	  decades	  have	  passed	  since	  those	  initial	  reports	  and,	  despite	  the	  reduction	  in	  the	  EE	  dose	  in	  COC	  medication,	  from	  50	  μg	  to	  30	  and	  to	  20	  μg,	  and	  changes	  in	  the	  progestogen	  components	  used,	  still	  the	  evidence	  is	  that	  COC’s	  are	  associated	  with	  significantly	   increased	   rates	   of	   VTE	   (WHO	   Scientific	   Group,”	   1998,	   	  WHO,	   1995;	  Jick	  et	  al.,	  1995;	  Kemmeren	  et	  al.,	  2001a,	  2001b;	  van	  Hylckama	  Vlieg	  et	  al.,	  2009).	  1995,	   the	   “pill	   scare	   year”,	  was	   an	   important	  mile	   stone	   in	   the	   history	   of	   COC’s,	  when	  initial	  reports	  were	  published	  suggesting	  that	  third	  generation	  progestogens	  (desogestrel	   and	  gestodene)	   in	  COC’s	   increase	   the	   risk	  of	  VTE	  more	   than	   second	  generation	  progestogens	  such	  as	   levonorgestrel	  and	  norgestrel	  (Bloemenkamp	  et	  
al.,	  1995;	   Jick	  et	  al.,	  1995;	  Spitzer,	  1996;	  WHO,	  1995).	  These	  studies	  stimulated	  a	  series	   of	   further	   studies	   looking	   at	   VTE	   risk	   in	   COC	   in	   more	   detail.	   All	   of	   them	  reached	  the	  conclusion	  that	  there	  is	  an	  increased	  risk	  of	  VTE,	  which	  is	  greater	  with	  those	   containing	   third	   generation	   progestogens	   (except	   norgestimate)	   than	   first	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generation	   (ie	   norethindrone	   acetate	   and	   ethynodiol	   diacetate)	   or	   second	  generation	  progestogens	  (Kemmeren	  et	  al.,	  2001a,	  2001b).	  
	  
The	  Royal	  College	  of	  General	  Practitioners’	  (“New	  oral	  contraception	  study,”	  1986)	  Oral	   Contraception	   Study,	  which	   has	   been	   an	   ongoing	   study	   since	   1968,	   initially	  suggested	   an	   increased	   risk	   of	   adverse	   vascular	   events	   among	  women	  who	   had	  ever	   used	   COC’s.	   This	   was	   noted	   mainly	   among	   older	   women	   and	   those	   who	  smoked	   (“New	   oral	   contraception	   study,”	   1986).	   A	   twenty	   five	   year	   follow	   up	  report	  from	  the	  same	  study,	  however,	  suggested	  that	  all	  the	  adverse	  effects	  of	  oral	  contraceptives	   occurred	   in	   current	   or	   recent	   users,	   with	   few	   effects	   persisting	  beyond	  10	  years	   after	   stopping	  use	   (Hannaford	  and	  Kay,	  1998;	  Hannaford	  et	   al.,	  1994).	  The	  most	  recent	  reports	  from	  this	  study	  indicate	  that	  long	  term	  use	  of	  COC	  is	  not	  associated	  with	  increased	  mortality	  in	  the	  studied	  cohort	  (Hannaford	  et	  al.,	  2010).	   Further	   epidemiological	   studies	   have	   confirmed	   this	   finding,	   and,	   the	  current	  consensus	  is	  that	  vascular	  risks	  are	  maximal	  within	  the	  first	  three	  months	  of	  starting	  COC’s	  (Van	  Hylckama	  Vlieg	  et	  al.,	  2009;	  Vessey	  et	  al.,	  1989).	  Currently	  the	  estimate	  of	  absolute	  VTE	  risk	  in	  COC	  users	  is	  6.29	  per	  10,000	  woman-­‐years,	  for	  users	  of	  COC’s	  containing	  less	  than	  50μg	  EE,	  which	  compares	  with	  the	  background	  risk	  in	  non-­‐users	  of	  3	  per	  10,000	  woman-­‐years	  (Lidegaard	  et	  al.,	  2009).	  
	  
Further	   studies	   have	   stratified	   the	   VTE	   risk	   according	   to	   the	   progestogen	  component	   of	   the	   pills.	   It	   is	   estimated	   that	   the	   risk	   associated	   with	   the	   third	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generation	   progestogens	   is	   1.5	   to	   3	   times	   the	   risk	   with	   second	   generation	   COC	  preparations	   (Jick	   et	   al.,	   1995;	   WHO,	   1995).	   Lidegaard	   (2011)	   found	   that	   the	  relative	  risk	  (RR)	  of	  VTE	  in	  users	  of	  COC	  preparations	  containing	   less	  than	  50	  µg	  EE	  was	  2.9	  with	   levonorgestrel	  use,	  6.6	  with	  desogestrel,	  6.2	  with	  gestodene	  and	  6.4	  with	  drospirenone	  use	  (95%	  CI	  of	  2.2	  to	  3.85,	  5.6	  to	  7.8;	  5.6	  to	  7.0	  and	  4	  to	  7.5,	  respectively)	  (Lidegaard	  et	  al.,	  2011).	  
	  
COC	  formulations	  containing	  drospirenone	  are	  found	  by	  some	  studies	  to	  increase	  VTE	  risk	  more	  than	  COC’s	  containing	  third	  generation	  progestogens	  (Parkin	  et	  al.,	  2011),	  whilst	  other	  studies	  have	  not	  found	  this	  (Dinger	  et	  al.,	  2007).	  Parkin	  et	  al,	  (2011)	  in	  data	  derived	  from	  the	  RCGP	  study,	  concluded	  that	  the	  incidence	  of	  VTE	  is	  23.0	  per	  100	  000	  woman	  years	  (95%	  confidence	  interval	  13.4	  to	  36.9)	  in	  current	  users	  of	  COC’s	  containing	  drospirenone,	  and	  9.1	  per	  100	  000	  woman	  years	  (6.6	  to	  12.2)	   in	   current	   users	   of	   COC’s	   containing	   levonorgestrel	   (Parkin	   et	   al.,	   2011).	  Similar	  findings	  are	  derived	  from	  a	  study	  conducted	  by	  Sidney	  et	  al	  (Sidney	  et	  al.,	  2012).	  
	  
1.7.1.1.1 Mechanisms	  for	  increased	  VTE	  risk	  in	  COC	  use	  
It	  is	  evident	  now	  that	  COCs	  interfere	  with	  all	  haemostatic	  parameters	  (Tchaikovski	  and	   Rosing,	   2010).	   Firstly,	   COCs	   increase	   the	   pro-­‐coagulant	   factors.	   They	  consistently	  elevate	  prothrombin,	  fibrinogen	  and	  FVII,	  while	  factors	  such	  as	  FVIII,	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FX	  and	  FV	  may	  or	  may	  not	  be	   increased	  (Kluft	  and	  Lansink,	  1997;	  Middeldorp	  et	  al.,	  2000;	  van	  Rooijen	  et	  al.,	  2002).	  Secondly,	  COC	  use	  is	  associated	  with	  a	  decrease	  in	  natural	  anti	  coagulants.	  Several	  studies	  suggest	  that	  there	  is	  a	  decrease	  in	  anti-­‐thrombin,	   protein	   S	   and	   Tissue	   Factor	   Inhibitor	   (TFPI).	   This	   in	   turn	   leads	   to	  activated	  protein	  C	  resistance	  (APCR).	  The	  APCR	  noted	  in	  COC	  users	  is	  both	  APTT	  assay	   based	   and	   the	   endogenous	   thrombin	   potential	   based	   (Mackie	   et	   al.,	   2001;	  Rosing	  et	  al.,	  1999;	  van	  Rooijen	  et	  al.,	  2002).	  The	  resistance	  to	  APC	  is	  mainly	  due	  to	  decreases	  in	  protein	  S	  and	  TFPI	  levels,	  with	  a	  small	  effect	  from	  the	  decrease	  in	  anti	  thrombin	  levels	  (Rosendaal	  and	  Reitsma,	  2009).	  Thirdly,	  there	  is	  activation	  of	  the	  fibrinolytic	   system	   in	   COC	   users	   with	   increased	   Plasminogen,	   and	   tissue	  plasminogen	   (tPA)	   activity	   (Kluft	   and	   Lansink,	   1997;	   Meijers	   et	   al.,	   2000).	   Van	  Rooijen	   et	   al	   (2006)	   suggested	   that	   SHBG	   is	   a	   surrogate	   marker	   for	   the	  prothrombotic	   risk	   of	   COC	   and	   the	   greater	   the	   increase	   in	   SHBG	   the	   greater	   the	  VTE	  risk	  (Van	  Rooijen	  et	  al.,	  2006).	  All	  these	  thrombotic	  tendencies	  are	  seen	  even	  with	  the	  low	  dose	  EE	  pills,	  but	  are	  more	  noticeable	  with	  COCs	  containing	  higher	  EE	  doses	  and	  “third	  generation	  progestogens”	  (Rosing	  et	  al.,	  1999;	  Tans	  et	  al.,	  2000;	  van	  Rooijen	  et	  al.,	  2002).	  
	  
1.7.1.2 COC	  and	  arterial	  disease	  
While,	   there	   is	  a	  general	  consensus	  that	  COC	   increases	  VTE	  risks	   in	   its	  users,	   the	  risk	  of	  arterial	  disease,	  i.e.	  myocardial	  infarction	  (MI)	  and	  ischaemic	  stroke	  (IS)	  is	  less	  agreed	  upon,	  with	  some	  studies	  suggesting	  that	  there	  no	  increased	  risk	  at	  all	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(Petitti	   et	   al.,	   1996;	   Rosenberg	   et	   al.,	   1990;	   Schwartz	   et	   al.,	   1998;	   Siritho	   et	   al.,	  2003).	  However,	  other	  studies	  suggest	  that	  COC	  does	  indeed	  increase	  the	  risks	  of	  IS	  and	  MI	  (Baillargeon	  et	  al.,	  2005;	  Croft	  and	  Hannaford,	  1989;	  Gillum	  et	  al.,	  2000;	  La	  Vecchia,	  1992;	  Lidegaard	  and	  Kreiner,	  2002).	  
	  
Recently	   Lidegaard	   et	   al,(2012),	   in	   an	   epidemiological	   study,	   with	   1.7	   million	  participants,	  concluded	  that	  COC	  use	  increases	  the	  risks	  of	  thrombotic	  stroke	  and	  myocardial	   infarction.	   Furthermore,	   they	   found	   that	   the	   risk	   increases	   with	  increase	  in	  the	  EE	  dose,	  with	  the	  risk	  increased	  by	  a	  factor	  of	  0.9	  to	  1.7	  with	  COC	  preparations	   that	   contain	  20	  μg	  of	  EE	  and	  by	  a	   factor	  of	  1.3	   to	  2.3	   if	   the	  dose	   is	  30μg	  or	  more	  (Lidegaard	  et	  al.,	  2012).	  
	  
In	  contrast	   to	  VTE	  risk,	  most	  of	   the	  studies	   that	   looked	  at	   IS	  and	  MI	  risk	  suggest	  that	  there	  is	  no	  difference	  in	  the	  incidence	  of	  these	  complications	  according	  to	  the	  type	   of	   progestogen	   used,	   with	   second	   generation	   progestogen	   preparations	  carrying	   the	   same	   risk	   as	   the	   third	   generation	   progestogens	   (Kemmeren	   et	   al.,	  2002;	   Lidegaard	   et	   al.,	   2012).	   There	   is	   also	   no	   reported	   added	   risk	   of	   IS	   and	  cardiovascular	  disease	  in	  users	  of	  drospirenone-­‐containing	  COC’s,	  compared	  with	  those	   containing	   second-­‐	   and	   third-­‐generation	   progestogens,	   as	   is	   the	   case	  with	  regard	  to	  VTE	  risk	  (Gronich	  et	  al.,	  2011).	  When	  comparing	  risk	  of	  IS	  to	  the	  risk	  of	  MI,	  Lidegaard	  et	  al	  (	  2012)	  found	  that	  the	  IS	  risk	  was	  higher	  than	  MI	  risk,	  quoting	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this	  risk	  to	  be	  21.4	  per	  100,000	  person-­‐years	  for	  IS	  and	  10.1	  per	  100,000	  person-­‐years	  for	  MI	  (Lidegaard	  et	  al.,	  2012).	  
	  
Some	  studies	  have	  attempted	   to	  explore	  whether	   the	   increased	  arterial	   risks	  are	  due	   to	   confounding	   factors,	   or	   arise	   de	   novo.	   They	   have	   reached	   different	  conclusions,	   with	   some	   suggesting	   that	   conditions	   such	   as	   cigarette	   smoking,	  migraine,	   obesity,	   and	   hypertension	   are	   the	   pertinent	   causes	   of	   MI	   or	   IS	  development	  in	  COC	  users	  (Curtis	  et	  al.,	  2002;	  Petitti,	  2003).	  However,	  Baillargeon	  et	  al,	  (2005)	  found	  that	  even	  after	  correcting	  for	  these	  confounding	  factors,	  there	  is	  still	  an	  increased	  incidence	  of	  IS	  and	  MI	  with	  COC	  use	  (Baillargeon	  et	  al.,	  2005).	  
	  
Finally,	  the	  issue	  of	  the	  increased	  risk	  in	  current	  COC	  users	  versus	  ever	  users,	  has	  also	  stimulated	  some	  studies,	  which	  agree	  that	  the	  risk	  is	  higher	  in	  current	  users.	  (Baillargeon	  et	  al.,	  2005)	  have	  indicated	  an	  overall	  adjusted	  odds	  ratio	  (OR)	  for	  IS	  in	  current	  COC	  users,	  to	  be	  approximately	  2.08	  (95%	  CI	  of	  1.55	  to	  2.80)	  compared	  with	  past	   users.	  Nonetheless,	   despite	   these	  proven	   risks,	   the	   incidence	   is	   so	   low	  that	  even	  if	  a	  small	  increase	  is	  there,	  it	  is	  likely	  to	  have	  no	  impact	  in	  young	  women.	  Hence,	  the	  contraceptive	  benefits	  of	  COC	  are	  calculated	  as	  	  outweighing	  these	  risks,	  in	  numerical	  terms,	  except	  in	  women	  with	  co	  morbidities	  (Baillargeon	  et	  al.,	  2005;	  Kemmeren	  et	  al.,	  2002;	  Lidegaard	  and	  Kreiner,	  2002).	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1.7.2 Progestogen	  Only	  Contraception	  (POC)	  
POCs	  comprise	  the	  oral	  preparations,	  progestogen	  only	  pills	  (POP),	  and	  the	   long-­‐acting	  parenteral	  reversible	  progestogen-­‐only	  contraceptive	  medications	  (LARC)	  ie	  injectable	   Depot	   medroxyprogesterone	   acetate	   (DMPA),	   the	   subcutaneous	  contraceptive	  implants	  and	  the	  levonorgestrel	  intra-­‐uterine	  system	  (IUS).	  	  
1.7.2.1 Progesteron	  Only	  	  Pills	  
The	  current	  evidence	  is	  that	  POC	  carries	  negligible	  risk	  of	  VTE	  (Kuhl,	  1996;	  Mantha	  et	  al.,	  2012;	  Vasilakis	  et	  al.,	  1999).	  However,	  the	  number	  of	  studies	  in	  this	  area	  is	  quite	  small.	  A	  recent	  meta	  analysis	  found	  only	  eight	  studies	  looking	  at	  VTE	  risk	  in	  POP	   users	   (Mantha	   et	   al.,	   2012).	   Five	   of	   these	   studies	  were	   case-­‐control	   studies	  (Vasilakis	   et	   al	   ,	   1995;	  WHO,	   1998;	   Heinemann	   et	   al,1999;	   Barsoum,	   2010;	   Van	  Hylckama	   Vlieg	   et	   al,	   2010),	   while	   three	   were	   retrospective	   cohort	   studies.	  (Conard	  et	  al.,	  2004a;	  Lidegaard	  and	  Kreiner,	  2002;	  Vaillant-­‐Roussel	  et	  al.,	  2011).	  These	  studies	  reported	  a	  RR	  of	  VTE	  of	  1.03,	  with	  POP	  use	  (95%	  CI	  of	  0.76	  to	  1.39)	  (Mantha	  et	  al.,	  2012).	  Kemmeren	  et	  al,	  (2004)	  even	  suggested	  that	  POCs	  containing	  Levonorgestrel	  confer	  anti	  thrombotic	  effects	  (Kemmeren	  et	  al.,	  2004).	  
	  
1.7.2.2 Long	  Acting	  Reversible	  Contraceptives	  (LARC)	  
Depo	  Medroxyprogesterone	  Acetate	   (DMPA)	  acts	  mainly	  by	  preventing	  ovulation	  (Bhathena,	  2001;	  Power	  and	  Guillebaud,	  2002).	  However,	  it	  acts	  also	  by	  increasing	  the	   thickness	   of	   cervical	   mucus,	   and	   changing	   the	   quality	   of	   the	   endometrium,	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hence	   hindering	   fertilisation	   and	   implantation	   (Bhathena,	   2001;	   Fraser	   and	  Weisberg,	   1981;	   Hickey	   and	   Fraser,	   2000).	   In	   2004	   sub-­‐cutaneous	   injection	   of	  104mg	   of	  medroxy-­‐progesterone	   acetate	   was	   approved	   for	   contraceptive	   use	   in	  the	   USA,	   however,	   the	   most	   widely	   used	   preparation	   currently	   is	   the	   intra-­‐muscular	   injection	   of	   150mg	   of	   medroxy-­‐progesterone	   acetate.	   The	   main	   side	  effects	   of	   DMPA	   are	   amenorrhoea	   and	   irregular	   bleeding	   (Arias	   et	   al.,	   2006;	  Bhathena,	   2001).	   DMPA	   is	   recommended	   to	   be	   given	   every	   12	   weeks	   (FSRH,	  2008).	  DMPA	  is	  also	  associated	  with	  a	  delay	  in	  return	  of	  fertility	  after	  cessation	  of	  use,	   with	   an	   average	   delay	   of	   10	  months	   (Arias	   et	   al.,	   2006;	   Garza-­‐Flores	   et	   al.,	  1985;	  Jain	  et	  al.,	  2004;	  Pardthaisong,	  1984).	  
	  
1.7.2.3 Levonorgestrel	  intra	  uterine	  system	  (Mirena®)	  




1.7.2.4 Contraceptive	  implants	  




1.8 REPRODUCTIVE	  HEALTH	  IN	  SCD	  
The	   essence	   of	   this	   study	   is	   to	   explore	   the	   safety	   of	   effective	   and	   reversible	  methods	   of	   contraception,	   which	   would	   enable	   women	   with	   SCD	   to	   plan	   their	  pregnancies	  optimally.	  
	  
1.8.1 Pregnancy	  in	  SCD	  
Worldwide,	   the	  prevalence	  of	   sickle	   cell	   disease	  has	   increased	  over	   the	  past	   few	  decades,	  and	  this	  is	  also	  the	  case	  in	  the	  UK.	  The	  number	  of	  people	  with	  SCD	  in	  the	  UK,	   albeit	   low,	   has	   doubled	   in	   two	   decades,	   from	   estimates	   of	   5,000	   in	   1986	   to	  12,000	   in	   2009	   (Streetly	   et	   al.,	   2009).	   Pregnancies	   in	   SCD	   in	   the	   UK	   number	  approximately	  60	  per	  year	  (Author’s	  unpublished	  data,	  Appendix	  1).	  Nonetheless,	  it	   is	  difficult	   for	  many	  doctors	   in	  areas	  of	  particularly	   low	  prevalence	   to	  develop	  expertise	  in	  treating	  patients	  with	  SCD,	  and	  this	  may	  be	  a	  confounding	  factor	  in	  the	  outcome	   of	   some	   SCD	   pregnancies.	   Great	   developments	   in	   the	   paediatric	   and	  haematological	  care	  of	  SCD	  patients	  mean	  that	  the	  majority	  of	  affected	  individuals	  now	  live	  into	  adulthood.	  If	  it	  is	  presumed	  that	  fertility	  is	  normal	  in	  SCD,	  many	  adult	  women	  with	  SCD	  potentially	  could	  experience	  pregnancy.	  However,	  because	  SCD	  is	  an	   incurable	   condition,	   with	   multiple	   chronic	   complications,	   pregnancies	   in	  women	  with	  SCD	  are	  particularly	  complex.	  The	  haematological	  and	  cardiovascular	  nature	  of	  the	  disease	  makes	  SCD	  complications	  particularly	  relevant	  to	  pregnancy,	  because	   pregnancy	   imposes	   significant	   strains	   on	   these	   two	   important	   body	  systems.	  Maternal	  sickle	  cell	  disease	  is	  consistently	  reported	  to	  be	  associated	  with	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an	  increased	  complication	  rate	  compared	  to	  pregnant	  women	  without	  this	  disease	  (Howard	  and	  Oteng-­‐Ntim,	  2012;	  Howard	  et	  al.,	  1995;	  Rahimy	  et	  al.,	  2000;	  Serjeant	  et	  al.,	  2004a;	  Tuck	  et	  al.,	  1983;	  Villers	  et	  al.,	  2008).	  Despite	  some	  studies	  suggesting	  that	   SCD	   pregnancy-­‐associated	   complications	   have	   fallen	   over	   recent	   decades	  (Chase	   et	   al.,	   2010;	   Smith	   et	   al.,	   1996;	   Yu	   et	   al.,	   2009)	   still	   substantial	  maternal	  mortality	  occurs:	  2·1%	  in	  Jamaica,	  1.6%	  in	  the	  U.K	  and	  0.07%	  to	  1.7%	  in	  the	  USA	  (Serjeant	  et	  al.,	  2004a;	  Villers	  et	  al.,	  2008).	  There	  is	  also	  a	  high	  perinatal	  mortality	  rate	  in	  these	  pregnancies,	  i.e.	  still	  births	  and	  deaths	  in	  the	  first	  week	  of	  life.	  In	  the	  UK	   this	   is	   reported	   for	   the	   years	   2000	   to	   2004,	   to	   be	   53/1000	   (Author’s	  unpublished	  data,	  Appendix	  1),	  which	  compares	  with	  the	  overall	  contemporaneous	  perinatal	   mortality	   rate	   in	   the	   UK	   of	   7.9/1000	   (NOS,	   2010).	   Morbidity	   is	   also	  increased,	  with	  severe	  sickle	  crises	  occurring	  in	  about	  40%	  of	  pregnancies,	  severe	  pre	  eclampsia	  and	  deliveries	  by	  emergency	  caesarean	  section,	  being	  amongst	   the	  most	  significant	   (Howard	  et	  al.,	  1995;	  Rahimy	  et	  al.,	  2000;	  Serjeant	  et	  al.,	  2004b;	  Tuck	   et	   al.,	   1983;	   Villers	   et	   al.,	   2008).	   Recently,	   the	   UK	   Obstetric	   Survellance	  System	  Sixth	  Annual	  Report	   found	  no	  reporting	  of	  maternal	  mortality,	  but	  a	  high	  morbidity	   rate,	  with	  52%	  of	  women	  experiencing	  antenatal	  painful	   crises,	  6%	  of	  them	  having	  acute	  chest	  syndrome	  and	  24%	  of	   these	  women	  receiving	  antenatal	  blood	  transfusion	  (UKOSS,	  2012).	  
	  
It	   is	   therefore	   particularly	   important	   that	   pregnancies	   in	   women	   with	   SCD	   are	  planned,	   as	  much	   as	   is	   possible,	   so	   that	   their	   health	   and	   care	   can	   be	   optimised	  prior	   to	  conception,	  and	  plans	   for	   their	  care	   in	  pregnancy	   in	  place,	   since	   there	   is	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evidence	   that	   this	   can	   improve	   the	   outcomes	   (Biermann	   et	   al.,	   2006).	   Effective	  planning	   of	   pregnancies	   would	   give	   women	   and	   their	   doctors	   a	   chance	   to	   time	  pregnancy	  when	  they	  are	  in	  optimal	  health	  and	  their	  medication	  has	  been	  adjusted	  appropriately,	   for	   example,	   stopping	   Hydroxycarbamide	   (previously	   known	   as	  Hydroxyurea).	  This	  medication	  has	  the	  beneficial	  effect	  of	  increasing	  the	  levels	  of	  HbF,	  which	  mitigates	  the	  adverse	  effects	  of	  HbS.	  However,	   it	   is	  an	  anti-­‐neoplastic	  agent,	  inhibits	  the	  enzyme	  ribonucleotide	  reductase,	  thus	  leading	  to	  DNA	  synthesis	  inhibition.	   Hence,	   it	   is	   potentially	   teratogenic	   and	   the	   USA’s	   Food	   and	   Drug	  Administration	  (FDA)	  advises	  that	  women	  contemplating	  pregnancy	  should	  avoid	  its	  use	  (USA	  FDA,	  2012).	  
	  
1.8.2 Contraception	  in	  SCD	  
Although	   women	   with	   SCD	   attain	   menarche	   late,	   compared	   with	   women	   with	  normal	  haemoglobin,	  once	  they	  start	  menstruating	  there	  is	  no	  further	  reduction	  in	  fertility	   (Serjeant	   et	   al.,	   2005).	   Their	   need	   for	   good	   contraceptive	   advice	   is	  generally	   met	   with	   a	   lack	   of	   knowledge	   and	   understanding	   about	   appropriate	  contraceptive	  methods	   for	   SCD	  women	   from	   the	  majority	   of	   doctors	   and	   nurses	  they	  are	  likely	  to	  encounter	  (Howard	  and	  Tuck,	  1994;	  Howard	  et	  al.,	  1993).	  
Widely	   held	   instinctive	   concerns	   about	   the	   prescription	   of	   combined	   hormonal	  contraceptives	   for	  women	  with	  SCD	  arise	   from	  the	   fact	   that	  SCD	  alone	  has	  many	  haemostatic	   complications,	   as	   described	   earlier,	   with	   proven	   prothrombotic	  tendencies,	   whilst	   the	   combined	   contraceptive	   pills	   are	   also	   known	   to	   carry	  
64 
 
thrombotic	   and	   cardiovascular	   risks.	   Hence,	   there	   is	   an	   understandable	   concern	  that	   the	   two	   together	   will	   bring	   particularly	   deleterious	   risks	   for	   these	   women,	  with	  regard	  to	  VTE,	  strokes	  and	  acute	  sickling	  crises.	  There	   is	  however,	  a	   lack	  of	  scientific	   evidence	   for	   this	   assumption.	   In	   consequence	   SCD	   women	   may	  potentially	  be	  deprived	  of	  the	  most	  commonly	  used	  and	  efficacious	  contraceptive	  methods	  available,	  which	  is	  the	  issue	  being	  pursued	  in	  this	  thesis.	  
	  
In	  practice,	  in	  the	  SCD	  population,	  DMPA	  use	  is	  ten	  times	  the	  rate	  in	  the	  general	  population,	  with	  approximately	  38%	  of	  women	  with	  SCD	  using	  it,	  compared	  with	  3%	  for	  both	  DMPA	  and	  implants	  in	  the	  general	  population	  (FSRH,	  2008).	  
	  
There	  has	  also	  been	  a	  marked	  increase	  in	  the	  use	  of	  POP	  in	  women	  with	  SCD,	  which	  is	  used	  by	  15%	  of	  them,	  compared	  with	  5%	  of	  the	  general	  population	  and	  in	  the	  levonorgestrel-­‐releasing	  intra	  uterine	  system	  (Mirena®),	  used	  by	  9%	  of	  SCD	  women	  compared	  with	  1%	  of	  the	  general	  population.	  This	  increase	  in	  use	  is	  probably	  understandable,	  on	  the	  basis	  that	  POC	  carries	  negligible	  added	  risk	  of	  thrombosis	  (Conard	  et	  al.,	  2004b).	  In	  addition,	  DMPA	  has	  been	  reported	  in	  two	  small	  studies	  to	  be	  beneficial	  to	  SCD	  women,	  with	  a	  reduced	  frequency	  of	  painful	  crises	  (De	  Abood	  et	  al.,	  1997;	  De	  Ceulaer	  et	  al.,	  1982).	  This	  has	  led	  to	  wide	  recommendation	  in	  haematology	  circles,	  of	  this	  method	  of	  contraception	  for	  women	  with	  SCD.	  It	  should	  be	  noted,	  however,	  that	  DMPA	  and	  other	  POPs	  are	  associated	  with	  more	  side	  effects	  than	  COC’s,	  and	  are	  not	  particularly	  liked	  by	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young	  women,	  as	  is	  reflected	  by	  their	  relatively	  low	  rate	  of	  use	  in	  the	  general	  population	  (FSRH,	  2008).	  	  
	  
The	  unplanned	  pregnancy	  rate	   in	  SCD	  women	   is	  approximately	  60%	  (Howard	  et	  al.,	  1993)	  and	  53%	  in	  2010	  (Author’s	  unpublished	  data,	  Appendix	  2).	  This	  clearly	  implies	  that	  these	  women	  are	  not	  being	  given	  effective	  advice.	  
	  
1.8.2.1 COC	  and	  SCD	  
In	   contrast	   to	   the	  general	  population,	   the	  use	  of	  COC	   in	  women	  with	  SCD	   is	   low,	  despite	   the	   World	   Health	   Organisation’s	   guidelines	   for	   contraceptive	   use	   now	  acknowledging	   that	   the	   use	   of	   COC	   in	   women	  with	   SCD	   has	  more	   benefits	   than	  risks	  (UKMEC,	  2009).	  A	  recent	  study	  conducted	  by	  the	  author	   found	  a	  significant	  decline	  in	  the	  use	  of	  COC	  by	  women	  with	  SCD	  from	  1993	  to	  2010,	  from	  45%	  to	  31	  %	  with	  a	  marked	  increase	  in	  POC	  use	  from	  37%	  to	  67.	  %	  (Appendix	  2).	  
	  
COC	  use	  requires	  careful	  consideration	  in	  women	  with	  SCD	  because	  of	  three	  main	  issues.	  Firstly,	  COC’s	  are	  known	  to	  increase	  the	  thrombotic	  risk	  in	  its	  users	  and	  this	  thrombotic	   risk	   may	   be	   considered	   to	   be	   potentially	   additive	   to	   the	   increased	  thrombotic	   risk	   conferred	   by	   SCD	   itself.	   Secondly,	   women	   with	   SCD	   are	   at	  increased	   risk	   of	   arterial	   disease	   and	   COC	   is	   also	   proven	   to	   increase	   the	   risk	   of	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ischaemic	   strokes	   (IS)	   and	  myocardial	   infarctions.	   Yet	   on	   the	   other	   hand,	   SCD	   is	  characterised	   by	   painful	   occlusive	   crises	   and	   there	   are	   some	   studies	   suggesting	  that	   hormonal	   steroids	   decrease	   the	   risk	   of	   sickle	   crises.	   In	   addition,	   the	   non	  contraceptive	  effects	  of	  COC,	  such	  as	  the	  decrease	  in	  menstrual	  blood	  loss	  could	  be	  beneficial	   for	   SCD	   patients.	   COC	   use	   also	   is	   known	   to	   relieve	   dysmenorrhoea,	  which	  is	  especially	  beneficial	  for	  women	  with	  SCD,	  as	  it	  is	  reported	  there	  is	  greater	  incidence	  of	  dysmenorrhoea	   in	  SCD,	  and	  some	  women	  experience	  a	  clustering	  of	  sickling	  crises	  with	  menstruation	  (Samuels-­‐Reid	  and	  Scott,	  1985).	  
	  
COC	  use	   in	  SCD,	  has	  attracted	  much	   less	   research	  compared	  with	  COC	  use	   in	   the	  general	  population.	  The	  assumption	  that	  COC	  would	  definitely	  be	  harmful	  for	  SCD	  patients	  and	  the	  fact	  that	  there	  is	  a	  small	  minority	  of	  SCD	  women	  using	  COCs	  could	  have	  contributed	  to	  this.	  The	  author	  identified	  only	  four	  studies	  looking	  at	  COC	  use	  in	   SCD.	   These	   studies	   found	   no	  major	   adverse	   side	   effects.	   Howard	   et	   al	   (1993)	  reporting	   on	   67	   SCD	  women	   using	   COC,	   noted	   irregular	   bleeding	   in	   three	   of	   his	  participants,	  increased	  crises	  in	  four,	  and	  eight	  who	  discontinued	  their	  COC	  use.	  De	  Abood	   et	   al.(1997)	   compared	   the	   effects	  of	   COC	   (Microgynon,	  with	   30µg	   ethinyl	  oestradiol	   and	   levonorgestrel	   150µg)	   on	   the	   intensity	   and	   frequency	   of	   painful	  crises,	  with	  DMPA	   and	   a	   control	   group	   of	   sterilised	   SCD	  women.	   They	   found	   no	  adverse	  effects	  from	  any	  contraceptive	  method	  in	  the	  study	  and	  no	  change	  in	  the	  haematological	   parameters	   that	   they	   studied.	   Yoong	   et	   al	   (2003)	   compared	  changes	  in	  red	  cell	  deformability	  in	  COC	  users	  with	  a	  group	  using	  POC	  and	  with	  a	  third	  group	  of	  non	  contraceptive	  users.	  No	  changes	  in	  red	  blood	  cell	  deformability	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were	  found	  in	  his	  in	  vitro	  studies.	  Yoong	  et	  al	  (2003)	  also	  looked	  at	  the	  markers	  of	  thrombin	  generation,	  platelet	  activation	  and	  fibrinolysis	  in	  women	  with	  sickle	  cell	  disease	   on	   the	   COC,	   POC	   and	   in	  women	   not	   on	   any	   hormonal	   preparations,	   and	  found	  no	  significant	  variations	  in	  these	  haematologic	  markers	  studied.	  
	  
1.8.2.2 Progestogen	  only	  Contraception	  and	  SCD	  
Despite	   the	   fact	   that	   POCs	   are	   used	   by	   a	   greater	   proportion	   of	   SCD	   women	  compared	   to	   COC	   medications,	   still	   the	   studies	   which	   have	   looked	   at	   them	   are	  scarce	   and	   many	   of	   them	   have	   involved	   only	   small	   numbers	   of	   participants	  (Haddad	  et	  al.,	  2012).	  
	  
Adadevoh	  and	  Isaacs	  (1973)	  measured	  the	  effects	  of	  oral	  megestrol	  acetate	  on	  the	  numbers	  of	  irreversible	  sickled	  cells	  (ISC)	  and	  of	  sickle	  crises	  in	  seven	  women	  and	  one	  man	  with	  SCD	   in	  a	  randomised	  controlled	  cross	  over	  study.	  Each	  participant	  received	   megestrol	   acetate	   and	   the	   placebo	   (vitamins)	   in	   succession	   over	   a	   six	  week	   period.	   The	   researchers	   did	   not	   report	   the	   wash	   out	   period,	   nor	   the	  randomisation	  process	  they	  had	  followed	  and	  used	  different	  progestogen	  doses	  for	  the	   individuals	   studied	   They	   found	   higher	   overall	   sickle	   crisis	   rates	   among	   the	  group	  whilst	   they	  were	  taking	  megestrol	  acetate,	  although	  the	   individual	  sickling	  rates	  were	  the	  same	  in	  the	  two	  groups	  and	  there	  was	  no	  effect	  on	  the	  number	  of	  ISCs.	  Extrapolation	  of	  this	  study	  to	  clinical	  contraceptive	  use	  should	  be	  made	  with	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caution,	   because	   of	   the	   very	   small	   sample	   size,	   and	   the	   fact	   that	   the	   doses	  administered	  here	  were	  not	  those	  relevant	  to	  normal	  contraceptive	  use	  (Adadevoh	  and	   Isaacs,	   1973).	   In	   another	   study	   30	   SCD	   women	   who	   had	   used	   POP	   were	  interviewed	   and	   none	   of	   them	   reported	   serious	   side	   effects	   nor	   increased	   sickle	  crises,	  although	  six	  reported	  irregular	  bleeding	  and	  two	  discontinued	  use	  because	  of	  side	  effects	  (Howard	  et	  al.,	  1993).	  
	  
1.8.2.2.1 Depot	  MedroxyProgesterone	  Acetate	  (DMPA)	  and	  SCD	  




DMPA	  was	   one	   of	   the	   first	   contraceptive	  methods	   to	   be	   studied	   in	   SCD	  women,	  however,	  there	  are,	  to	  date,	  only	  five	  studies	  of	  its	  use,	  and	  the	  number	  of	  subjects	  in	  each	  has	  been	  small.	  There	  are	  also	  considerable	  differences	  in	  the	  study	  designs	  and	  in	  their	  measured	  outcomes,	  both	  clinical	  and	  haematological.	  
	  
The	  first	  study	  by	  De	  Ceulaer	  et	  al,	  1982,	  compared	  the	  use	  of	  DMPA	  with	  placebo	  injections	  in	  a	  randomised	  cross-­‐over	  study,	  which	  involved	  25	  women	  with	  Hb	  SS	  disease.	  Each	  participant	  received	  both	  the	  DMPA	  and	  the	  placebo	  injections.	  The	  women	  who	  initially	  received	  DMPA	  for	  nine	  months,	  had	  a	  six	  month	  “wash	  out”	  period	  before	  receiving	  the	  placebo	  injection	  for	  a	  further	  9	  months,	  and	  vice	  versa	  for	   the	   other	   group.	   The	  main	   outcome	  measures	  were	   painful	   crises	   and	   some	  haematological	  markers	  i.e.	   total	  Hb,	  HbF%,	  reticulocyte	  count	  and	  total	  bilirubin	  concentration.	   They	   found	   a	   statistically	   significant	   reduction	   in	   the	   incidence	   of	  painful	   crises,	   and	   a	   concurrent	   improvement	   in	   most	   of	   the	   haematological	  indices.	  Although	  this	  study	  design	  has	  been	  appraised	  to	  be	  level	  I	   	  (Mohllajee	  et	  
al.,	   2005)	  with	  a	   fair	   internal	  validity	   (Haddad	  et	  al,	   2012),	   however,	   the	   sample	  size	  was	   small,	   and	   the	   six	  month	   ”wash	  out”	  period	  after	  DMPA	  might	  not	  have	  been	   enough	   to	   clear	   its	   effects,	   which	   can	   last	   up	   to	   18	   months	   after	   the	   last	  injection.	   (Garza-­‐Flores	   et	   al.,	   1985).	   The	   time	   periods	   involved	  might	   also	   raise	  concerns	  regarding	  the	  tendency	  to	  seasonal	  variation	  in	  the	  frequency	  of	  sickling	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crises,	  although	  this	  study	  was	  conducted	  in	  Jamaica,	  where	  this	  is	  unlikely	  to	  be	  a	  significant	  factor.	  	  
	  
The	  second	  study	   including	  DMPA	  was	  carried	  out	   in	  1993	  by	  Howard	  et	  al	  who	  interviewed	  a	   total	   of	  164	  women	  with	   sickle	   cell	  disease	   in	  North	  London.	  This	  was	  a	  cross	  sectional,	  questionnaire-­‐based	  study,	  which	  looked	  at	  whether	  women	  with	  SCD	  experience	  complications	   from	  different	   contraceptive	  methods.	   In	   this	  study,	  26	  women	  reported	  DMPA	  use.	  Approximately	  a	  third	  of	  them	  experienced	  irregular	   bleeding,	   11.5	  %	   had	   stopped	   DMPA	   because	   of	   side	   effects,	   but	   none	  experienced	  any	  increase	  in	  sickle	  crises,	  or	  any	  episode	  of	  VTE.	  This	  study	  relied	  on	  self	  reporting	  and	  there	  were	  no	  laboratory	  or	  objective	  clinical	  data	  included	  in	  the	  analysis.	  
	  
The	  third	  study	  was	  a	  non	  randomised	  controlled	  study	  done	  by	  De	  Abood	  et	  al,	  in	  1997.	  They	  compared	  DMPA	  use	  in	  13	  SCD	  women	  with	  Microgynon	  (30	  µg	  ethinyl	  estradiol	  with	  150	  µg	  levonorgestrel)	  in	  14	  SCD	  women,	  with	  a	  third	  group	  acting	  as	   a	   control	   comprising	   16	   women	   who	   had	   had	   surgical	   sterilisation.	   The	  researchers	  were	   interested	   in	   the	  occurrence	  and	  severity	  of	  painful	   crises,	   and	  haematological	   parameters	   such	   as	   haemoglobin	   and	   haematocrit	   levels,	  reticulocyte	   count,	   and	   coagulation	   markers	   including	   prothrombin	   time	   and	  thromboplastin	   time.	   Their	   study	   found	   that	   the	   DMPA	   group	   reported	   a	  significant	   decrease	   in	   painful	   episodes	   over	   the	   period	   of	   the	   study	   (50%	   at	   3	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months,	  70%	  at	  one	  year;	  p=.014)	  compared	  to	  a	   lesser	  decrease	   in	   the	  COC	  and	  the	   sterilisation	   groups	   at	   one	   year	   follow	   up.	   No	   adverse	   side	   effects	   were	  reported	  in	  either	  group	  and	  no	  change	  in	  the	  studied	  blood	  parameters	  occurred	  at	  anytime	  during	  the	  follow-­‐up	  period.	  This	  is	  also	  a	  small	  sized	  study,	  which	  used	  DMPA	  in	  non-­‐	  contraceptive	  regimens,	  (DMPA	  was	  given	  every	  month	  for	  a	  total	  of	  three	   months	   in	   contrast	   to	   the	   normal	   three	   months	   interval	   used	   in	  contraception);	   hence	   the	   extrapolation	   to	   contraceptive	   use	   again	   requires	  caution	  (De	  Abood	  et	  al	  1997).	  
	  
The	  fourth	  and	  fifth	  studies	  were	  performed	  by	  Yoong	  et	  al,	  1999	  and	  2003.	  Both	  these	  studies	  were	  laboratory	  based,	  and	  cross-­‐sectional,	  which	  looked	  at	  various	  haematological	  parameters,	  and	  included	  30	  and	  44	  participants,	  respectively.	  The	  first	   study	   principally	   compared	   red	   cell	   deformability,	   in	   three	   groups:	   SCD	  women	   using	   progestogen-­‐only	   contraceptives,	   SCD	   women	   using	   COC	   a	   third	  group	  of	  SCD	  women	  not	  taking	  any	  exogenous	  hormones.	  The	  2003	  study	  looked	  at	  platelet	  activation	  and	  thrombin	  generation	  in	  three	  similar	  groups.	  Both	  studies	  concluded	   that	   there	  were	   no	   significant	   differences	   in	   these	   parameters	   among	  the	  three	  groups	  (Yoong	  et	  al.,	  1999).	  
	  
O’Brien	  et	  al.	  (2011)	  conducted	  a	  cross	  sectional	  study	  to	  look	  at	  rates	  of	  use,	  types	  of	   contraception	   used	   and	   the	   frequency	   of	   pregnancy,	   VTE	   and	   osteopenia	   in	  women	   aged	   13-­‐21	   years	   in	   Michigan,	   USA.	   They	   used	   the	   International	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Classification	   of	  Diseases,	  Ninth	  Revision,	   Clinical	  Modification	   (ICD-­‐9-­‐CM)	   codes	  to	  collect	  information	  from	  the	  Michigan	  Medicaid	  program	  between	  2000-­‐	  2003.	  They	   identified	   250	   women	   with	   SCD,	   of	   whom	   only	   20	   were	   hormonal	  contraceptive	  users	  (8%),	  with	  12	  using	  DMPA.	  The	  authors	  did	  not	  state	  what	  the	  contraceptive	  methods	  used	  by	   the	  other	  eight	  women	  were.	  The	  study	  reported	  that	  VTE	  and	  osteopenia	  were	  infrequently	  recognised;	  however,	  the	  exact	  number	  is	  not	  specified.	  Within	  the	  inherent	  limitations	  of	  this	  study	  design,	  still	  one	  would	  comment	  that	  the	  rate	  of	  hormonal	  contraceptive	  use	  in	  this	  population	  of	  women	  with	  SCD	  was	  small.	  
	  
1.8.2.2.2 Contraceptive	  implants	  and	  SCD	  
Studies	  looking	  at	  contraceptive	  implants	  in	  SCD	  are	  few,	  small	  in	  size,	  and	  look	  at	  different	   outcome	  measures.	  However,	   all	   have	   found	  no	   adverse	   effects.	  Firstly,	  Ladipo	   et	   al.	   (1993)	   carried	   out	   an	   observational	   study	   looking	   at	   the	   safety	   of	  Norplant	   in	   25	   SCD	   women.	   They	   looked	   at	   adverse	   clinical	   outcomes,	  haematological	  parameters,	  including	  reticulocyte	  counts,	  HbF	  and	  total	  bilirubin,	  and	   biochemical	   markers	   including	   serum	   albumin	   and	   serum	   creatinine	  concentrations,	  HDL	  cholesterol,	  and	  aspartate	  transaminase	  (AST).	  They	  found	  no	  unexpected	  or	  serious	  side	  effects,	  haematological	  or	  biochemical	  changes	  after	  the	  use	  of	  Norplant.	  This	  was	  again	  a	  small	  size	  study	  which	  did	  not	  look	  specifically	  at	  the	  incidence	  of	  sickle	  crises,	  and	  its	  practical	  relevance	  is	  limited,	  since	  Norplant	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was	  withdrawn	  from	  use	  in	  the	  UK	  in	  1999	  (Gbolade,	  1999)	  and	  in	  the	  USA	  in	  2002	  (Wysowski,	  2005).	  
The	   second	   study	   was	   conducted	   by	   Nascimento	   et	   al.	   (1998).	   This	   was	   a	   non-­‐randomised,	   controlled	   study	   intended	   to	   assess	   safety,	   clinical,	   haematological,	  and	  biochemical	  outcomes	  in	  30	  women	  with	  SCD.	  They	  compared	  Uniplant	  use	  in	  20	   SCD	   participants	   with	   a	   control	   group	   of	   ten	   non-­‐users	   of	   hormonal	  contraceptives.	   Clinically,	   they	   found	   a	   significant	   decrease	   in	   the	   incidence	   of	  painful	   crises	   and	   other	   symptoms,	   e.g.	   headache	   and	   body	   weakness,	   in	   the	  Uniplant	  group.	  They	  also	  found	  no	  serious	  side	  effects	  during	  one	  year	  of	   follow	  up,	   and	   all	   participants	   chose	   to	   continue	   with	   Uniplant	   use	   after	   the	   study.	  Haematologically,	   the	   study	   also	   found	   significant	   increases	   in	   HbF	   levels	   in	   the	  study	   group.	   Yet	   again,	   the	   sample	   size	   was	   not	   powered	   enough	   to	   detect	   any	  clinical	  change	  and	  there	  were	  no	  paired	  statistical	  tests	  done.	  
	  
The	  third	  study	  was	  done	  by	  Barbosa	  et	  al.	  (2001),	  who	  carried	  out	  uncontrolled	  descriptive	  study	  included	  ten	  SCD	  women	  and	  looked	  at	  unintended	  pregnancies,	  abnormal	   weight	   gain	   and	   increase	   in	   blood	   pressure	   values	   associated	   with	  Uniplant	  use.	  They	  also	  studied	  biochemical	  changes	  in	  carbohydrate	  metabolism	  by	   undertaking	   Glucose	   Tolerance	   Tests	   (GTTs),	   measuring	   fasting	   insulin	   and	  glycosylated	   haemoglobin	   levels.	   There	   were	   no	   pregnancies	   during	   the	   study	  period.	  In	  addition,	  there	  were	  no	  significant	  changes	  in	  weight	  or	  blood	  pressure,	  glycosylated	  hemoglobin	  and	  serum	  insulin	  levels	  before	  and	  after	  insertion	  of	  the	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Uniplants.	  As	  with	  the	  previous	  studies	  the	  small	  sample	  size	  is	  a	  drawback,	  as	  well	  as	   the	   lack	   of	   a	   comparison	   group.	   The	   biochemical	   markers	   studied	   in	   this	  research	  (i.e.	  of	  carbohydrate	  metabolism)	  are	  not	  known	  to	  change	  with	  SCD	  or	  with	  progestogen	  implant	  use,	  hence	  their	  significance	  in	  this	  study	  is	  unclear	  	  
	  
1.8.2.2.3 Mirena	  Intra	  Uterine	  System	  (IUS)	  use	  in	  SCD	  
The	   author	   believes	   that	   the	   use	   of	   the	  Mirena	   IUS	   use	   has	   not	   been	   studied	   in	  women	  with	  SCD	  as	  yet.	  
	  
1.8.2.3 SCD	  and	  Intra	  uterine	  devices	  (IUDs)	  





1.9 SICKLE	  CELL	  TRAIT	  AND	  HORMONAL	  CONTRACEPTION	  
The	   evidence	   that	   SCT	   is	   a	   prothrombotic	   condition	   has	   already	   been	   discussed	  (Austin	  et	  al,	  2007).	  The	  increased	  risk	  of	  VTE	  with	  the	  use	  of	  COCs	  has	  also	  been	  discussed	  previously.	  There	  has	  been	  only	  one	   study	  attempting	   to	   to	   assess	   the	  combined	  effects	  of	  these	  two	  factors	  on	  the	  incidence	  of	  VTE	  (Austin	  et	  al.	  2009).	  This	   was	   a	   case	   controlled	   study	   of	   60	   African-­‐American	   women	   with	   a	   first	  episode	   of	   otherwise	   unprovoked	   VTE	   and	   the	   control	   group	  were	   196	   African-­‐American	  women	  without	  VTE.	  The	  OR	  of	  being	  a	  current	  HC	  user	  in	  the	  VTE	  cases	  was	   3.8	   (95%	   CI	   1.7-­‐8.1),	   which	   was	   statistically	   significant.	   The	   OR	   of	   being	   a	  current	  HC	  user	  and	  having	  SCT	   in	   the	  VTE	  cases	  was	  apparently	  doubled	  at	  6.7,	  although	  the	  confidence	  interval	  here	  was	  very	  wide	  ,	  1-­‐43,	  and	  the	  calculation	  did	  not	  reach	  statistical	  significance.	  No	  conclusion	  can	  therefore	  be	  drawn	  from	  this	  as	   to	   whether	   the	   VTE	   risk	   of	   SCT	   and	   the	   HC	   use	   is	   multiplicative	   or	   simply	  additive,	  and	  there	  has	  been	  no	  study	  published	  to	  date	  looking	  at	  arterial	  events	  (MI	  and	  IS)	  with	  this	  combination	  of	  SCT	  and	  HC	  use.	  
	  
1.10 Summary	  of	  literature	  review	  
Hadad	   et	   al,	   in	   2012,	   carried	   out	   a	   systematic	   review	   to	   examine	   the	   safety	   of	  hormonal	  contraceptives	  and	  intrauterine	  contraceptive	  device	  use	  among	  women	  with	  sickle	  cell	  disease,	  and	  concluded	  that	  the	  lack	  of	  evidence	  on	  the	  risk	  of	  VTE	  among	   COC	   users	   with	   sickle	   cell	   disease,	   and	   on	   IUD	   use	   among	   women	   with	  sickle	  cell	  disease,	  represented	  major	  gaps	  in	  the	  research	  literature.	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At	   the	   same	   time,	   many	   authors	   identify	   sickle	   cell	   disease	   as	   a	   condition	   that	  exposes	   women	   to	   increased	   risk	   of	   unintended	   pregnancy,	   with	   38-­‐63%	   of	  pregnancies	  being	  unplanned.	  There	  has	  been	  a	  tendency	  to	  be	  less	  cautious	  with	  the	   prescription	   of	   HCs	   for	   women	   with	   sickle	   cell	   disease,	   solid	   evidence	   to	  underpin	   this	   remains	   lacking.	   Furthermore,	   no	   research	   has	   concluded	   clearly	  that	  any	  one	  hormonal	  contraceptive	  method	  poses	  lesser	  or	  higher	  risks	  for	  SCD	  women	  than	  any	  other.	  Recommendations	  from	  official	  bodies	  have	  been	  relaxed,	  but	   this	   is	  mainly	   based	   on	   the	   fact	   that	   the	   risks	   of	   pregnancy	   are	   so	   high	   (UK	  MEC,	  2009).	  
	  














While	   the	   haematological	   tests	   used	   in	   this	   study	   are	   intended	   to	   improve	   the	  understanding	  of	  the	  factors	  which	  are	  known	  to	  influence	  the	  risk	  of	  thrombosis,	  this	  project	  also	  studies	  the	  clinical	  effects	  of	  hormonal	  contraceptives	  on	  women	  with	  sickle	  cell	  disease	  and	  sickle	  cell	   trait	  and	  their	  relationships.	   	  The	  practical	  importance	  of	   	  being	  able	  to	  give	  complete	  and	  well	   founded	  guidance	  to	  women	  with	  SCD	   is	   to	  enable	   them	  to	  achieve	   their	   family	  planning	  aims	  optimally,	  with	  the	  minimum	  of	   unplanned	   (as	   opposed	   to	   planned)	   pregnancies.	   The	   benefit	   of	  this	  should	  permit	  improved	  pregnancy	  outcomes.	  
	  
2.2 STUDY	  HYPOTHESIS	  
There	   are	   no	   additional	   clinical	   or	   haematological	   risks	   to	   Sickle	   Cell	   Disease	  patients	  and	  women	  with	  Sickle	  Cell	  Trait	  using	  hormonal	  contraceptive	  methods,	  over	  and	  above	  those	  inherent	  in	  their	  SCD	  and	  SCT.	  
	  
2.3 AIMS	  OF	  THE	  STUDY	  
1. To	  characterise	  any	  differences	   in	   the	  occurrence	  of	  clinical	  complications	  i.e.	  sickle	  crises,	  the	  need	  for	  blood	  transfusion,	  episodes	  of	  VTE,	  menstrual	  irregularities,	  and	  hospital	  admissions.	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2. To	  explore	  the	  differences	  in	  the	  contraceptive	  side	  effects,	  discontinuation	  of	   contraceptive	   method,	   accidental	   interruptions	   and	   the	   number	   of	  planned	  and	  unplanned	  pregnancies	  in	  women	  with	  SCD	  and	  SCT.	  3. To	   evaluate	   any	   differences	   in	   haemostatic	   markers	   i.e.	   pro-­‐	   and	   anti-­‐coagulant	   markers,	   haematological	   parameters,	   coagulation	   activation	  markers,	   platelet	   activation	   markers,	   markers	   of	   endothelial	   activation,	  markers	   of	   tissue	   damage,	   markers	   of	   thrombin	   generation,	   markers	   of	  haemolysis	  and	  liver	  function,	  both	  metabolic	  and	  synthetic.	  
	  
These	  features	  are	  assessed	  in	  the	  following	  groups	  
• Women	  with	  SCD	  using	  different	  methods	  of	  hormonal	  contraception	  
• Women	  with	  SCT	  using	  different	  methods	  of	  hormonal	  contraception	  
• Women	  with	  normal	  Hb	  using	  different	  methods	  of	  hormonal	  contraception	  
• Women	  with	  SCD,	  women	  with	  SCT	  and	  women	  with	  normal	  haemoglobin	  using	  Combined	  (oestrogen	  and	  progestogen)	  Oral	  Contraceptives	  
• Women	  with	  SCD,	  women	  with	  SCT	  and	  women	  with	  normal	  haemoglobin	  using	  Progestogen-­‐Only	  Contraception	  










3.1 STUDY	  DESIGN	  
This	  was	  a	  multi-­‐centre,	  prospective	  cohort	  study	  involving	  six	  different	  hospitals	  in	  London.	  The	  study	  was	  set	  up	  to	  investigate	  the	  possibility	  of	  additional	  clinical	  or	  haematological	  risks	  of	  hormonal	  contraceptive	  methods	  in	  women	  with	  Sickle	  Cell	   Disease	   (SCD)	   and	   Sickle	   Cell	   Trait	   (SCT),	   over	   and	   above	   those	   risks	  associated	  with	  the	  haematological	  disorders	  themselves.	  
	  





3.2 STUDY	  GROUPS	  
Study	   participants	  were	   recruited	   from	   the	   Sickle	   Cell	   Society	   (SCS)	   activities	   or	  were	   past	   obstetric	   patients	   at	   the	   RFH.	   Interviews	   were	   conducted	   and	   blood	  samples	  collected	  either	  at	  the	  Royal	  Free	  Hospital	  (RFH)	  or	  their	   local	  hospitals.	  All	  women	  had	  their	  travel	  expenses	  reimbursed.	  
Women	   were	   divided	   into	   three	   main	   groups	   according	   to	   their	   chosen	  contraception	  method	  or	  if	  they	  were	  not	  using	  any	  hormonal	  contraception.	  They	  were	   also	   divided	   into	   a	   further	   three	   main	   categories,	   depending	   on	   their	  haemoglobin	  type,	  giving	  a	  total	  of	  nine	  subgroups,	  shown	  in	  Table	  .3-­‐1.	  The	  study	  comparisons	  were	  made	  across	  each	  column	  and	  down	  each	  row	  of	  the	  table.	  
	   Type	  of	  contraception	   	  Type	  of	  haemoglobin	   	   SCD	   SCT	   AA	  	   COC	   SCD+	  COC	   SCT+	  COC	   AA	  +	  COC	  POC	   SCD+	  POC	   SCT	  +POC	   AA	  +	  POC	  No	  hormonal	  contraception	   SCD	  +	  No	  HC	   SCT	  +	  No	  HC	   AA	  +	  No	  HC	  
Table	  .3-­‐1	  Study	  groups	  
Nine	   study	  groups	  emerged	   from	  dividing	   the	  women	  by	   type	  of	  haemoglobin	   (normal	   i.e.	  
AA,	  SCD	  and	  SCT)	  and	  type	  of	  contraception	  (COC,	  POC	  and	  no	  hormonal	  contraception).	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3.3 ETHICAL	  APPROVAL	  
Ethical	  approval	  was	  obtained	  from	  the	  Cambridge	  4	  Ethics	  Committee,	  reference	  number:	   06/MRE05/59	   (Appendix	   3).	   I	   also	   obtained	   site	   specific	   assessment	  (SSA)	  approvals	  from	  the	  local	  Research	  Ethics	  Committees	  of	  all	  the	  participating	  centres,	   in	   addition	   to	   separate	   approvals	   from	   the	   Research	   and	   Development	  offices	   of	   the	   participating	   centres.	   All	   women	   participating	   in	   the	   study	   gave	  informed	  written	  consent	  prior	  to	  their	  enrolment	  in	  the	  study	  (the	  consent	  form	  is	  shown	  in	  Appendix	  9).	  
	  
3.4 POWER	  CALCULATION	  
Dr	   Richard	  Morris	   (Reader	   in	  Medical	   Statistics	   &	   Epidemiology,	   Department	   of	  Primary	  Care	  &	  Population	  Sciences,	  UCL)	  has	  calculated	  the	  required	  sample	  size	  in	   this	   study	   to	   be	   55	   women	   in	   each	   group.	   	   This	   was	   calculated	   using	   the	  standard	  deviation	  (SD)	  of	  the	  thrombin	  generation	  (which	  is	  the	  main	  test	  in	  my	  study).	  This	  SD	  	  is	  calculated	  by	  reference	  to	  a	  previous	  study	  carried	  out	  by	  Yoong	  et	  al,	  2003	  which	  looked	  at	  the	  coagulation	  markers	  in	  SCD	  and	  found	  a	  thrombin	  generation	  SD	  (TGSD)	  of	  10	  units.	  
The	  TGSD	  between	  the	  women	  in	  my	  study	  	  is	  likely	  to	  be	  smaller	  than	  that	  quoted	  by	  Yoong	  et	  al	  (9)	  since	  Yoong	  used	  only	  one	  measurement	  per	  woman.	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Assuming	   a	   SD	   of	   7	   for	  Beta	   –TG	   it	  will	   be	   possible	   to	   detect	   a	   difference	   of	   4.3	  units	  between	  the	  hormonal	  contraceptive	  users	  and	  non	  users,	  with	  90%	  power	  at	  a	  5%	  significance	  level.	  	  
The	  formula	  below	  is	  used	  to	  calculate	  the	  sample	  size:	  
n=	  2x	  (z	  α/2	  +	  zβ)	  ²σ²	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  δ²	   	  (	  σ	  =	  standard	  deviation	  of	  the	  TG	  in	  both	  groups,	  α	  =	  type	  1	  error	  (False	  positive),	  β	  =	   type	  2	  error	  (False	  negative)	  and	  δ	  =	   the	  difference	  between	  the	  mean	  of	  TG	  parameters	  in	  the	  HC	  users	  and	  non-­‐users).	  
	  
3.5 DATA	  	  
3.5.1 Interviews	  
All	  women	  who	  consented	  to	  take	  part	  in	  the	  study	  were	  interviewed	  by	  me	  during	  their	   first	   visit.	   Information	   about	   the	   woman’s	   demographic	   and	   clinical	  characteristics,	  past	  medical	  history,	  previous	  and	  current	  contraceptive	  use,	  and	  haemoglobin	   type	   was	   obtained	   during	   the	   interview.	   Full	   details	   of	   the	  information	  collected	  during	  the	  interview	  are	  given	  in	  Appendix	  2.	  All	  the	  women	  were	   given	   a	   diary	   to	   note	   prospectively	   any	   relevant	   events,	   such	   as	   hospital	  admission,	   sickle	   crisis	   or	   other	   complications,	   blood	   transfusion,	   contraceptive	  problems	  or	   failures	  and	  any	  medication	  changes.	  These	  were	  the	  clinical	  events,	  side	   effects	   and	   complications	   used	   in	   the	   study	   analysis.	   Some	   retrospective	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information	  given	  by	  the	  women	  at	  their	  enrolment	  interview	  will	  be	  mentioned	  in	  Chapter	  7,	  but	  none	  of	  this	  information	  is	  included	  in	  the	  study	  results.	  
	  
3.5.2 Contraceptives	  used	  
Oral	   contraceptive	   preparations	   used	   in	   all	   women	   except	   two	   are	   monophasic	  preparations	  containing	  E2	  and	  levonoregestrel	  or	  norethisterone.	  	  The	  other	  two	  women	  used	  preparations	  containing	  E2	  and	  Drospirenone	  (one	  woman	  has	  SCT	  and	  the	  other	  woman	  has	  normal	  Hb).	  
	  
The	  Progestogen	  only	  contraception	  methods	  used	  were	  DMPA	  in	  one	  woman,	  POP	  in	  11	  women,	   implants	   in	   seven	  women,	  and	  eight	  women	  used	  Mirena	   IUS.	  The	  distribution	  of	  the	  Mirena	  IUS	  is	  even	  between	  women	  with	  SCD,	  SCT	  and	  normal	  Hb.	  
	  
3.5.3 Physical	  examination	  	  
A	  physical	  assessment	  was	  undertaken	  at	  each	  visit,	  namely	  blood	  pressure	  check,	  weight	  and	  BMI	  calculation.	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3.5.4 Data	  collection	  schedule	  
The	  schedule	  of	  data	  collection	  during	  the	  study	  is	  shown	  in	  the	  Table	  3-­‐2	  below.	  The	  women	  with	  SCD	  were	  studied	   for	  a	  period	  of	  22	   to	  26	  months.	  The	  women	  with	   SCT	  and	   the	  women	  with	  normal	  Hb	  were	   studied	   for	   a	  period	  of	   20	   to	  25	  months.	  
	   INITIAL	  INTERVIEW	   3	   MONTHS	  AFTER	  ENROLLMENT	  
END	  OF	  STUDY	  
DEMOGRAPHIC	  CHARACTERISTICS	   	   	   	  AGE	   P	   	   	  ETHNICITY	   P	   	   	  SMOKING	  HISTORY	   P	   	   	  HAEMOGLOBIN	  TYPE	   P	   	   	  CLINICAL	  CHARACTERISTICS	   	   	   	  HEIGHT	   P	   	   	  WEIGHT	   P	   P	   P	  BMI	   P	   P	   P	  BP	   P	   P	   P	  CLINICAL	  EVENTS	   P	   P	   P	  SICKLE	  CRISIS	   P	   P	   P	  BLOOD	  TRANSFUSION	   P	   P	   P	  HOSPITAL	  ADMISSION	   P	   P	   P	  STROKES	   P	   P	   P	  VTE	  (PEs	  AND	  DVTs)	   P	   P	   P	  CONTRACEPTIVE	  DATA	   	   	   	  SIDE	  EFFECTS,	  COMPLICATIONS	   	   P	   P	  DISCONTINUATION,	  ACCIDENTAL	  	  INTERRUPTIONS	   	   P	   P	  PLANNED	  AND	  UNPLANNED	  pprePREGNANCIES	   	   P	   P	  BLOOD	  SAMPLES	   	   P	   	  
Table	  3-­‐2	  Data	  collection	  schedule	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3.6 BLOOD	  COLLECTION	  
3.6.1 Timing	  of	  blood	  collection	  
The	  first	  blood	  collection	  took	  place	  at	  least	  3	  months	  after	  the	  enrolment	  process	  to	  ensure	  that	  the	  contraceptive	  methods	  used	  were	  well	  established,	  and	  a	  steady	  state	  was	   reached.	   It	   is	   acknowledged	   that	   	   this	   delay	   between	   recruitment	   and	  drawing	  of	   blood	   samples,	   does	   carry	   the	  disadvantage	   	   that	   	   any	   intial	   surge	  of	  	  hyper-­‐coagulability	  	  will	  be	  missed.	  In	  the	  general	  population	  the	  highest	  incidence	  of	  VTEs	  is	  in	  the	  first	  three	  months	  of	  use.	  My	  current	  study	  is	  unable	  to	  investigate	  whether	  this	  is	  the	  case	  in	  women	  with	  SCD.	  
Blood	   collection	   was	   planned	   to	   be	   at	   least	   four	   weeks	   after	   the	   last	   sickle	   cell	  crisis	   or	   six	   weeks	   after	   an	   exchange	   transfusion,	   or	   any	   blood	   transfusion.	  Collections	  were	   carried	   out	   during	   the	   luteal	   phase	   of	   each	  woman’s	  menstrual	  cycle.	  However,	   this	  aspect	  of	   timing	  was	  not	   relevant	   in	  women	  with	  prolonged	  use	   of	   Medroxy	   progesterone	   Acetate	   (Depo-­‐Provera	   injections)	   who	   were	  amenorrhoeic	  and	  also	  not	  applicable	  in	  some	  of	  the	  Mirena	  IUS	  users	  and	  in	  the	  women	   using	   contraceptive	   implants.	   Thus,	   blood	   samples	   were	   obtained	   from	  these	  women	  without	  reference	  to	  previous	  cycles.	  
3.6.2 Precautions	  for	  blood	  collections	  
Physical	   factors	   that	   could	   lead	   to	   sample	   discrepancies	   such	   as	   smoking,	   eating	  and	  drinking,	  as	  well	  as	  general	  stress,	  were	  taken	  into	  account	  during	  the	  blood	  taking	   process.	   For	   these	   reasons,	   the	   women	   did	   not	   undertake	   any	   vigorous	  physical	   activity	   (including	   rushing	   up	   the	   stairs),	   and	  were	   asked	   to	   rest	   in	   the	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waiting	   area	   for	   a	   minimum	   of	   30	   minutes	   prior	   to	   venesection.	   Furthermore,	  haemostasis	   from	  prolonged	  tourniquet	   induced	  pressure	   is	  known	  to	  contribute	  to	  haemoconcentration.	  Thus,	  wherever	  possible,	  the	  use	  of	  a	  tourniquet	  was	  kept	  to	   a	  minimum.	  When	   deemed	   necessary,	   a	   tourniquet	   was	   used	   to	   aid	   with	   the	  identification	   of	   vein	   location,	   and	  was	   released	   promptly	  when	   the	   needle	  was	  inserted	  into	  the	  vein.	  Due	  to	  the	  frequent	  thrombosis	  of	  peripheral	  veins	  in	  sickle	  cell	   patients,	   as	   a	   result	   of	   their	   repeated	   use	   for	   blood	   transfusions	   and	   blood	  taking,	  veins	  other	  than	  those	  in	  the	  ante-­‐cubital	  fossa	  were	  also	  used.	  Occasionally	  these	  involved	  peripheral	  veins	  in	  the	  anterior	  aspect	  of	  the	  arm	  or	  dorsum	  of	  the	  hand.	   A	   (green)	  wide	   needle	   (size	   21	   gauge)	  was	   preferred;	   however	   in	   limited	  cases,	  when	   veins	  were	   particularly	   fibrosed,	   a	   smaller	   gauge	   (blue)	   needle	  was	  used.	  
	  
Specimen	   collection,	   storage	   and	   transmission	   of	   the	   samples	   to	   the	   laboratory	  were	   all	   carried	   out	   according	   to	   the	   International	  WHO	   guidelines	   on	   drawing	  blood:	  best	  practices	   in	  phlebotomy,	   in	  order	  to	  minimise	   flaws	   in	  the	  specimens	  (WHO,	  2010).	  All	  patients	  were	  identified	  appropriately,	  associated	  request	  forms	  were	  completed	  and	  specific	  precautions	  were	  taken	  for	  any	  hazardous	  specimens.	  All	   samples	   were	   transported	   by	   me	   to	   the	   appropriate	   laboratory	   within	   four	  hours	   of	   collection,	   in	   specially	   supplied	   containers,	   at	   room	   temperature.	  Appropriately	  validated	  training	  was	  undertaken	  to	  allow	  for	  this	  process.	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3.7 LABORATORY	  INVESTIGATIONS	  
3.7.1 Laboratory	  markers	  studied	  
Pro	  and	  anti	  coagulant	  markers	   Coagulation	  activation	  markers	   Platelet	  activation	  markers	  
Endothelial	  activation	  markers	  
Markers	  of	  tissue	  damage	  
PT/INR	   TAT	   sP	  selectin	   sVCAM	   Microparticles	  
INR	   Prothrombin	  Fragments	  1+2	   sCD40	  ligand	   slCAM-­‐1	   Tissue	  Factor	  APTT	   D	  dimer	   PF4	   sEselectin	   	  Thrombin	  Time	   	   	   	   	  Fibrinogen	   	   	   	   	  
VWF	  Ag	   	   	   	   	  
Lupus	   Screen	  (DRVVT)	   	   	   	   	  Antithrombin	  acrivity	  Protein	  C	  activity,	  Protein	  S	  free	  &	  APCR	  with	  FV	  deficient	  plasma	  
	   	   	   	  
Factors	   ΙΙ,	   V,VII,	   X,	  VIII,	  IX,	  XI,	  XII	  &	  XIIIa	   	   	   	   	  LT	  	  (5pM)	   Free	  Hb	   ALT	   CRP	   Hb	  ETP	  (5pM)	   Haptoglobin	   AST	   WBC	   Platelets	  PH	  (5pM)	   LDH	   Bilirubin	   Neutrophils	   HCT	  TP	  (5pM)	   	   Albumin	   Lymphocytes	   	  Slope	   	   ALP	   Monocytes	   	  ST	  (5pM)	   	   	   Eosinophil	   	  	   	   	   Basophils	   	  




PT:	   Prothrombin	   time,	   INR:	   international	   normalised	   ratio,	   APTT:	   Activated	   Partial	  Thrombopastin	   Time,	   TT:	   Thrombin	   Time,	   Fib:	   Fibrinogen,	   VWFAg:	   von	   Willebrand	  Factor	  Antigen,	  DRVVT:	  Dilute	  Russell	  Viper	  Venom	  time,	   	  AT:AC:	  anti-­‐thrombinactivity,	  
PC:AC:	  Protein	  C	  activity,	  APCR	  V:	  Activated	  Protein	  C	  resistance,	  	  Factors	  ΙΙ,	  V,VII,	  VIIIC,	  
IX,	   X,	   XI,	   XII,	   XIIIa:	   Clotting	   factors,	   TAT:	   Thrombin	   Anti-­‐thrombin	   complexes,	   F1+2:	  Prothrombin	   fragments	   1	   and	   2,	   sP	   selectin:	   Soluble	   Platelet	   selectin,	   sCD40	   ligand:	  Soluble	   Cell	   Differentiation	   molecule	   40	   ligand,	   PF4:	   platelet	   factor	   4,	   sVCAM:	   soluble	  vascular	   cell	   adhesion	   molecule-­‐1,	   slCAM:	   soluble	   intercellular	   adhesion	   molecule-­‐1,	  
sEselectin:	   soluble	   Endothelial-­‐leukocyte	   adhesion	  molecule-­‐1,	  Mp:	  Micro	   particles,	  TF:	  Tissue	   Factor.	   LT	   (5pM):	   lag	   time	   (initiated	   with	   5	   pMol	   tissue	   factor),	   ETP	   (5pM):	  endogenous	   thrombin	   potential	   (initiated	   with	   5	   pMol	   tissue	   factor),	   PH	   (5pM):Peak	  height	  (initiated	  with	  5	  pMol	  tissue	  factor),	  TP	  (5pM):	  time	  to	  peak	  (initiated	  with	  5	  pMol	  tissue	  factor),	  Slope:	  thrombin	  generation	  slope,	  ST	  (5pM):	  Starting	  time	  (initiated	  with	  5	  pMol	  Tissue	   factor),	  LDH:	  Lactate	  dehydrogenase,	  ALT	   :	  Alanine	  aminotransferase,	  AST:	  Aspartate	   aminotransferase,	   ALP:	   Alkaline	   phosphatase,	   CRP:	   Complement-­‐Reactive	  Protein,	  WBC:	  White	  Blood	  Cells,	  HCT:	  Haematocrit.	  
(Table	  of	  Abbreviations)	  
As	  alluded	  to	  previously	  (Chapter	  1)	  all	  the	  pro-­‐	  and	  anti-­‐coagulant	  markers	  listed	  above,	  are	  known	  to	  be	  abnormal	  in	  SCD	  in	  the	  steady	  state,	  showing	  a	  change	  of	  the	   order	   of	   5	   to	   30%.	  Most	   of	   these	  markers	   are	   known	   also	   to	   be	   changed	   by	  taking	  hormonal	   contraception,	   although	  by	   a	  much	   smaller	   order	  of	  magnitude,	  and	   are	   strongly	   correlated	   with	   the	   incidence	   of	   clinical	   VTE	   (Auerbach	   et	  
al.,2004;	   Heijboer	   et	   al.,1990)	   The	   markers	   of	   coagulation	   activation,	   platelet	  activation	  and	  tissue	  damage,	  which	  I	  have	  chosen	  to	  study,	  are	  also	  recognised	  as	  significant	   indicators	   of	   the	   pathological	   features	   of	   sickle	   cell	   disease	   and	   to	  correlate	   with	   the	   incidence	   of	   VTE	   in	   the	   general	   population.	   Furthermore,	   D	  dimer	   levels	   are	   known	   to	   correlate	   strongly	  with	   arterial	   thrombosis,	   although	  they	  are	  also	  known	  to	  rise	  markedly	   in	  any	  condition	   involving	   inflammation	  or	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malignancy(Gershlick,1999)	  The	  validity	  of	   the	  endothelial	  activation	  molecules	   I	  have	  chosen	  to	  measure	  in	  my	  study,	  as	  markers	  of	  clinically	  significant	  endothelial	  damage,	   and	   hence	   correlating	   with	   arterial	   and	   venous	   thrombosis,	   will	   be	  discussed	  further	  in	  Chapter	  7.	  The	  markers	  of	  thrombin	  generation	  which	  I	  have	  studied	   are	   less	   well	   established	   as	   predictors	   of	   clinical	   VTE,	   and	   the	   value	   of	  these	   will	   also	   be	   discussed	   further	   in	   Chapter	   7.	   The	   markers	   of	   haemolysis	  measured	  are	  chosen	  as	   indicators	  of	  erythrocyte	  damage,	  and	  are	  thus	  expected	  to	  be	  relevant	  to	  sickle	  cell	  disease	  only.	  
3.8 SAMPLE	  HANDLING	  
3.8.1 Samples	   for	   free	   Haemoglobin	   (Hb),	   full	   blood	   count	   (FBC),	  
Lactate	  dehydrogenase	  (LDH),	  and	  bilirubin	  




3.8.2 Sample	  collection	  for	  haemostatic	  markers	  




All	   blood	   samples	   were	   kept	   and	   centrifuged	   at	   room	   temperature	   within	   four	  hours	  of	  collection.	  All	  sample	  analyses	  was	  carried	  out	  at	  the	  Royal	  Free	  Hospital	  laboratories:	   in	   the	  Katharine	  Dormandy	  Haemophilia	  Centre	  &	  Thrombosis	  Unit	  Laboratory,	   Special	   Haematology	   laboratory	   and	   the	   Clinical	   Biochemistry	  laboratory.	  
	  
3.8.3 Blood	  sample	  preparation	  and	  analysis	  
3.8.3.1 Free	  Hb	  sample	  analysis	  
These	  samples	  were	  processed	  in	  the	  Special	  Haematology	  laboratory	  at	  the	  Royal	  Free	   Hospital.	   The	   analysis	   followed	   a	   standard	   protocol	   (given	   in	   Appendix	   4)	  This	  protocol	  was	  prepared	  by	  Dr	  S	  Sulkar,	  and	  the	  actual	  analysis	  was	  done	  by	  the	  Special	  Haematology	  staff.	  
	  
3.8.3.2 Thrombin	  Generation	  Tests:	  sample	  analyses	  
The	   thrombin	   generation	   test	   (TGT)	   is	   an	   in-­‐vitro	   global	   function	   test	   of	   the	  haemostatic	  system.	  All	  patients	  in	  this	  study	  had	  	  TGT	  measurement	  	  using	  triple	  spun	   platelet	   poor	   plasma	   (PPP)	   triggered	   with	   PPP	   reagent	   	   that	   containing	   5	  pMol	   tissue	   factor	   (TF)	   and	   4µMphospholipid,	   using	   the	   Calibrated	   Automated	  Thrombinoscope	   (CAT)	   method	   (Thrombinoscope	   B.V.	   Maastricht,	   The	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Netherlands).	  	  Briefly,	  20µL	  of	  5	  pM	  reagent	  (activator)	  was	  added	  to	  three	  wells	  of	  an	   ELISA	   plate	   (Immunolon	   2HB™,	   VWR	   UK,	   East	   Grinstead).	   	   Then	   20µL	   of	  Thrombin	  Calibrator	  reagent	  with	  a	  known	  thrombin	  concentration,	  was	  added	  to	  the	  two	  other	  wells,	  to	  take	  into	  account	  the	  inter	  filter	  effect	  from	  the	  colour	  of	  the	  patient’s	   sample	   (Hemker	   et	   al,	   2003).	   	   80µL	   of	   PPP	   derived	   from	   the	   subject’s	  blood	  sample	  is	  then	  added	  to	  all	  five	  wells	  followed	  by	  20µL	  of	  FluCa	  substrate	  (a	  fresh	  fluorogenic	  substrate	  containing	  2.5	  mMol	  Z-­‐Gly-­‐Gly-­‐Arg-­‐AMC	  and	  100	  mMol	  CaCl²).	   	   Fluorescence	   was	   measured	   using	   a	   Fluoroskan	   Ascent	   fluorimeter	  (Thermolab	  Systems,	  Helsinki,	  Finland).	  The	  endogenous	  thrombin	  potential	  (ETP)	  was	   generated	   by	   dedicated	   software	   (Thrombinoscope™	   B.V.,	   Maastricht,	   The	  Netherlands)	   (Hemker	   et	   al,	   2003).	   	   Thrombinoscope	   BV,	   the	   developer	   of	   the	  Calibrated	   Automated	   Thrombinoscope	   (CAT)	   was	   founded	   in	   2004	   by	   the	  University	  of	  Maastricht.	  
	  
3.8.4 Other	  haemostatic	  markers	  
3.8.4.1 Techniques	  to	  assay	  platelet	  and	  endothelial	  activation	  markers	  
Plasma	   levels	   of	   the	   following	   adhesion	  molecules	  were	  determined	  by	  Enzyme-­‐linked	   Immunosorbent	   Assay	   (ELISA	   )	   techniques,	   as	   per	   the	   manufacturers’	  inserts:	   soluble	   CD40	   ligand	   (Bender	   Med	   Systems,	   Vienna,	   Austria),	   soluble	  Intercellular	  adhesion	  molecule-­‐1	  (s	  ICAM)	  (Bender	  Med	  Systems,	  Vienna,	  Austria),	  Soluble	   Vascular	   cell	   adhesion	   molecule-­‐1	   (sVCAM-­‐1)	   (Bender	   Med	   Systems,	  Vienna,	   Austria),	   	   Soluble	   Endothelial-­‐leukocytes	   adhesion	   molecule-­‐1	   (s	   E-­‐
96 
 
selectin)	   (Bender	  Med	  Systems,	  Vienna,	  Austria)	  and	  Soluble	  Platelet	   selectin	   (sP	  Selectin)	  (Bender	  Med	  Systems,	  Vienna,	  Austria).	  Laboratary	  reference	  ranges	  are	  given	  in	  Appendix	  4.	  
	  
3.8.4.2 Techniques	  to	  assay	  clotting	  factors	  and	  pro-­‐coagulant	  markers	  
Frozen	   double	   spun	   platelet-­‐poor	   plasma	   (PPP)	   was	   used	   to	   measure	   clotting	  factors	  VIII,	  IX,	  XI	  and	  XII	  by	  a	  one	  stage	  APTT-­‐based	  clotting	  assay,	  using	  an	  APTT	  lyophilized	  silica	  reagent.	   (Instrumentation	  Laboratory,	  (IL)	  Warrington,	  UK)	  and	  deficient	  plasma	  from	  Pathway	  Diagnostics,	  (Epsom,	  UK)	  on	  an	  ACL	  3000	  analyser.	  Clotting	   factors	  FII,	  VII,	  V	  and	  X	  were	  measured	  by	  a	  one	  stage	  PT-­‐based	  clotting	  assay	  on	  an	  ACL	  TOP	  700	  analyser	   (IL,	  Warrington,	  UK)	  with	  Recombiplastin	  2G	  reagent	  and	  deficient	  plasmas	  all	  from	  IL.	  
	  




von	  Willebrand	   factor	   antigen	   (VWF:Ag)	   was	   determined	   by	   an	   in-­‐house	   ELISA	  (Riddell	   et	   al.,	   2002).	   Thrombin	   anti-­‐thrombin	   (TAT)	   complexes	   (Siemens,	  Marburg,	   Germany),	   prothrombin	   fragment	   1+2	   (F1+2)	   (Siemens,	   Marburg,	  Germany),	  D-­‐dimers	  (IL,	  Warrington,	  UK),	  and	  FXIII:A	  measurements	  were	  also	  by	  ELISA,	  using	  paired	  matched	  antibody	  sets	  (Affinity	  Biologicals,	  Ancaster,	  Ontario,	  Canada).	   Protein	   C	   (PC)	   and	   Protein	   S	   (PS)	   were	   measured	   on	   an	   ACL	   TOP	  coagulometer	   using	   the	   Prochrom	   ™	   protein	   C	   chromogenic	   activity	   kit	   (IL,	  Warrington,	  United	  Kingdom)	   and	   the	   Free	  protein	   S	   kit	   (IL,	  Warrington,	  United	  Kingdom).	   Antithrombin	   activity	   levels	   (AT:Ac)	   were	   measured	   on	   a	   CS2000i	  (Sysmex,	   Milton	   Keynes,	   UK)	   using	   the	   AT	   activity	   assay	   (Siemens,	   United	  Kingdom).	  	  Tissue	  factor	  (TF)	  levels	  were	  measured	  using	  the	  Actichrome	  TF	  assay	  (American	  Diagnostica,	  US),	  Platelet	  Factor	  4	  was	  measured	  by	  ELISA	   (American	  Diagnostica	   Inc,	   Stamford,	   USA),	   	   and	   Microparticles	   were	   measured	   in	   PPP	  samples	  using	  the	  Zyumphen	  ELISA	  (Hypen	  Bio	  Med,	  Quadratech,	  UK)	  according	  to	  the	  manufacturers’	  instructions.	  
	  
3.8.4.3 Haptoglobin	  assay	  
The	   Haptoglobin	   assay	   was	   from	   Siemens,	   Marburg,	   Germany,	   using	   the	   No-­‐Partigen	   Haptoglobin	   measurement	   by	   radial	   diffusion.	  	   The	   method	   of	  measurement	  was	  according	  to	  the	  manufacturer’s	  instructions,	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3.8.4.4 C-­‐Reactive	  protein	  (CRP)	  assay	  
The	  CRP-­‐HS	  assay	  (Hyphen	  Biomed,	  Neuville-­‐Sur-­‐Oise,	  France)	  was	  used,	  which	  is	  a	   highly	   sensitive	   ELISA	  method	   for	   the	  measurement	   of	   human	   CRP	   in	   plasma.	  The	   method	   used	   was	   again	   by	   the	   manufacturer’s	   instructions,	   which	   give	   a	  reference	  range	  of	  0.2	  -­‐10	  ug/mL.	  	  	  
	  
The	   thrombin	   generation	   tests,	   haemostatic	   and	   thrombotic	   marker	   assays,	   and	  the	   CRP	   and	   haptoglobin	   measurements	   were	   done	   by	   Ms	   A	   Riddell,	   Chief	  Biomedical	   Scientist,	   Dr	   William	   Pickering,	   Tejas	   Gandhi,	   Saravanan	   Vinayagam	  and	   Saman	   Aghighi	   (Biomedical	   Scientists)	   in	   the	   laboratories	   of	   the	   Katherine	  Dormandy	   Haemophilia	   and	   Thrombosis	   Unit	   at	   the	   Royal	   Free	   Hospital.	   I	  undertook	  the	  sample	  collection	  and	  transport	  and	  	  was	  trained	  in	  the	  laboratory	  techniques.	  	  
	  
3.8.4.5 Techniques	  to	  assay	  FBC,	  Bilirubin,	  LDH,	  AST,	  ALT,	  ALP,	  albumin	  




3.9 STATISTICAL	  ANALYSIS	  
Numerical	  variables	  were	  summarised	  using	  the	  mean	  and	  standard	  deviation	  or	  the	  median	   and	   range,	   depending	  on	   the	  data	  distribution	   i.e.	   normal	   or	   skewed	  distributions.	   Categorical	   variables	   were	   summarised	   using	   counts	   and	  percentages.	  
	  
One-­‐way	   analysis	   of	   variance	   (anova)	   was	   used	   to	   investigate	   differences	   in	  numerical	   biomarkers	   by	   type	   of	   contraception	   in	   the	   study	   subjects	   and	  differences	  in	  numerical	  biomarkers	  by	  haemoglobin	  type.	  
	  
Two-­‐way	   analysis	   of	   variance	   was	   used	   to	   investigate	   differences	   in	   numerical	  biomarkers	  by	  type	  of	  contraception	  and	  haemoglobin	  type.	  
	  
All	   the	  assumptions	  for	  the	  tests	  were	  checked,	  and,	  where	  appropriate,	   the	  non-­‐parametric	  equivalent	  test	  was	  also	  used.	  	  
	  
Linear	  Regression	  testing	  (LRT)	  was	  used	  as	  the	  main	  statistical	  test	  to	  examine	  all	  the	  results	  in	  this	  thesis.	  .Logistic	  regression	  analysis	  was	  also	  undertaken,	  to	  see	  if	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CHAPTER	  4 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  




4.1 THE	  STUDY	  GROUPS	  
This	   chapter	   describes	   the	   characteristics	   of	   the	   nine	   study	   groups,	   defined	   by	  their	   types	   of	   haemoglobin	   and	   by	   their	   method	   of	   contraception	   used.	   The	  recruitment	  process	  and	  sequence	  of	  assessments	  will	  also	  be	  described.	  
	  
4.1.1 Recruitment	  and	  selection	  of	  sickle	  cell	  women	  
Firstly,	   I	   obtained	   the	   lists	   of	   haematologists	   and	   sickle	   cell	   counsellors	   in	   the	  Greater	  London	  area	  with	   the	  help	  of	   the	  UK	  Forum	   for	  Haemoglobin	  Disorders.	  Subsequently,	   I	   contacted	   these	  haematologists	  and	  counsellors	  and	  most	  agreed	  to	   be	   named	   as	   “principal	   investigators”	  with	  me	   in	   the	   project.	   Hence,	   a	  Multi-­‐Centre	  Research	  Ethics	   (MREC)	  approval	  was	   required	  and	  was	  obtained	   for	   the	  study	  (as	  described	  in	  Chapter	  3).	  
	  
In	   some	   of	   the	   relevant	   hospitals,	   I	  was	   able	   to	   gain	   registration	   for	   the	   project	  with	   the	   hospital’s	   Research	   and	   Development	   (R&D)	   offices.	   However	   in	   the	  remaining	  hospitals	  this	  process	  was	  not	  successful,	  despite	  investing	  considerable	  time	  and	  effort	  in	  negotiating	  with	  the	  relevant	  staff.	  The	  processes	  from	  applying	  for	  MREC	   approval	   to	   the	   completion	   of	   study	   registration	  with	   the	   final	   centre	  successfully	  recruited	  took	  more	  than	  two	  years	  (from	  September	  2006	  to	  October	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2008).	  There	  was	  also	  a	   further	  delay	   in	  some	  of	   the	  hospitals	   involved,	  before	   I	  was	   able	   to	   arrange	   appointments	   to	   attend	   the	   relevant	   haematology	   clinics	   in	  order	   to	   recruit	   potential	   participants	   for	   the	   study.	   The	   initial	   intention	  was	   to	  include	  all	  hospitals	  with	  known	  sickle	  cell	  patients	  in	  the	  Greater	  London	  area	  in	  the	   study,	   however	   due	   to	   either	   difficulties	   in	   securing	   an	   identified	   “principal	  investigator”	   for	   the	   project	   at	   some	   hospitals,	   or,	   as	   mentioned	   earlier,	   due	   to	  failure	  to	  obtain	  Site	  Specific	  Assessment	  (SSA)	  and	  local	  R&D	  approvals,	   this	  did	  not	  materialise.	  This	  was	  not	  because	  of	  any	  actual	  objection	  to	  my	  study,	  but	  due	  to	  slow	  and	  unresponsive	  bureaucratic	  procedures	  at	  some	  hospitals.	  
	  




I	  attended	  several	  meetings	  of	  the	  Sickle	  Cell	  Society	  (SCS)	  and	  distributed	  PIS’s	  to	  women	  with	  sickle	  cell	  disease,	  and	  talked	  to	  them	  in	  person	  to	  explain	  the	  study	  further,	  if	  they	  wished.	  I	  also	  gave	  a	  formal	  presentation	  about	  the	  study	  at	  the	  SCS	  30th	   anniversary	   meeting	   which	   was	   attended	   by	   many	   SCD	   women,	   and	   the	  response	  and	  interest	  they	  showed	  was	  very	  positive	  and	  encouraging.	  Many	  of	  the	  women	   I	   met	   in	   this	   context	   told	   me	   about	   their	   own	   personal	   difficulties	   in	  obtaining	  clear	  contraceptive	  advice	   from	  their	  own	  doctors,	  which	  reinforced	   to	  me	  the	  relevance	  of	  what	  I	  was	  attempting	  to	  achieve	  with	  my	  project	  
	  
In	  addition,	  I	  sat	  repeatedly	  in	  haematology	  clinics	  at	  the	  participating	  hospitals	  to	  talk	   to	   potentially	   eligible	  women	   on	   a	   one-­‐to-­‐one	   basis.	   All	   these	  women	  were	  given	  the	  PIS	  to	  read	  and	  I	  answered	  their	  questions.	  Some	  of	  them	  discussed	  the	  project	   with	   their	   haematologist	   and	   haemoglobinopathy	   counsellor	   before	  deciding	   to	   participate.	   Interested	   women	   were	   then	   asked	   to	   sign	   the	   consent	  form	  	  
	  
4.1.2 Recruitment	  and	  selection	  of	  women	  with	  sickle	  cell	  trait	  
I	  obtained	  a	  list	  of	  all	  women	  who	  were	  found	  to	  have	  SCT	  as	  part	  of	  their	  antenatal	  screening	  from	  the	  Haemoglobinopathy	  midwife	  at	  the	  Royal	  Free	  Hospital	  (RFH).	  Women	  who	  delivered	  during	  the	  three	  year	  period	  2007-­‐	  2009	  where	  contacted	  by	   letter	  and	  I	  asked	  them	  to	  state	  their	  current	  method	  of	  contraception,	   if	   they	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were	  pregnant	  at	  the	  time	  of	  contact	  or	  if	  they	  were	  intending	  to	  become	  pregnant	  during	  the	  proposed	  time	  of	  the	  study.	  I	  also	  invited	  the	  NHS	  staff	  at	  the	  different	  participating	  hospitals	  and	  colleagues	  at	  the	  RFH	  with	  SCT	  to	  participate.	  In	  total	  I	  made	   initial	   contact	  with	  80	  women.	  Women	  who	  responded	  positively	  and	  who	  fitted	   the	   inclusion	   criteria	   for	   the	   study	  were	   then	   interviewed	   individually	   and	  their	   informed	   consent	   obtained.	   These	  women	  were	   given	   the	   PIS	   intended	   for	  SCD	  (Appendix	  6)	  as	  well	  as	  the	  PIS	  and	  consent	  forms	  designed	  by	  the	  Katherine	  Dormandy	  Haemophilia	  Centre	  at	  the	  RFH	  for	  their	  Plasma	  Bank	  (Appendix	  7	  &	  8).	  All	   the	  participating	  SCT	  women	  were	  seen	  and	  their	  blood	  samples	   taken	  at	   the	  RFH	  except	  for	  three	  of	  them,	  who	  were	  seen	  at	  their	  own	  local	  hospitals.	  
	  
4.1.3 Recruitment	  and	  selection	  of	  women	  with	  normal	  Haemoglobin	  




4.2 PARTICIPATION	  OF	  RECRUITED	  WOMEN	  
A	  total	  of	  130	  women	  consented	  to	  take	  part	  in	  this	  study,	  of	  whom	  thirteen	  didnot	  complete	  all	  aspects	  of	  the	  study.	  One	  died	  during	  a	  visit	  to	  Nigeria,	  one	  emigrated	  to	  the	  United	  States	  of	  America,	  one	  became	  pregnant	  during	  the	  time	  of	  the	  study,	  and	  ten	  women	  were	  lost	  to	  follow	  up.	  	  
	  
















Figure	   4‑3	   summarises	   the	   recruitment	   process	   for	   women	  with	   SCD	  with	   each	  type	  of	   contraceptive	  method,	   Figure	  4‑4	   for	  women	  with	   SCT	  with	   each	   type	  of	  contraceptive	  method	  and	  Figure	  4‑5	  for	  women	  with	  normal	  Hb.	  
	  
	  


















Figure	  4‑6	  summarises	  the	  recruitment	  process	  for	  women	  on	  the	  combined	  oral	  contraceptive	   pills	   (COC),	   Figure	   4‑7	   for	   women	   on	   progesterone	   only	  contraception	   (POC)	   and	   Figure	   4‑8	   for	   women	   not	   using	   any	   hormonal	  contraception.	  
	  
	  



























Camden	  and	  Islington	  
Sickle	  cell	  and	  
Thalassaemia	  Centre	  
3(4.41)	   0	   0	   2.56	  
Central	  Middlesex	  
Hospital	  and	  Brent	  Sickle	  
and	  Thalassaemia	  Centre.	  
21(30.88)	   0	   4	   21.36	  
Homerton	  University	  
Hospital	  
7(10.29)	   2	   0	   9.40	  
Royal	  Free	  Hospital	  
(including	  women	  
recruited	  from	  the	  SCS	  
membership)	  
17(25.00)	   20	   23	   51.28	  
University	  College	  
Hospital	  
7(10.29)	   0	   0	   5.98	  
Whittington	  Hospital	   13(19.11)	   0	   0	   11.11	  
Table	  4-­‐1	  Number	  of	  study	  participants	  from	  each	  centre	  for	  each	  haemoglobin	  type	  
4.3 DEMOGRAPHIC	  ANALYSIS	  ACROSS	  SCD	  WOMEN	  





No	  HC	  (n	  =	  30)	   POC	  (n	  =	  29)	   COC	  (n	  =9)	   P	  value	  
Mean	  age	  in	  
years	  (SD)	  
37.56(9.75)	   35.62(7.18)	   25.33(5.65)	   0.005	  
Difference	  (95%	  
CI)	  
	   -­‐1.94	  (-­‐6.25	  to	  2.37)	   -­‐12.23	  (-­‐17.72	  to	  -­‐1.6.73)	   	  
BMI	  mean	  (SD)	   25.62(4.42)	   24.34(4.36)	   24.23(4.79)	   0.942	  
Difference	  (95%	  
CI)	  
	   -­‐1.28(-­‐6.76	  to	  4.20)	   -­‐1.39	  (-­‐5.5	  to	  2.72)	   	  
Smoking	  (%)	   2	  (6.66)	   6	  (20.68)	   1	  (11.11%)	   	  
Difference	  (95%	  
CI)	  
	   4(-­‐0.11	  to8.31)	   -­‐1(-­‐5.11	  to	  3.11)	   	  
No	  of	  cigarettes	  
mean	  (SD)	  
0.46(1.94)	   1.89(4.83)	   0.44(1.33)	   0.876	  
Difference	  (95%	  
CI)	  
	   1.43	  (-­‐2.68	  to	  5.53)	   -­‐0,02(-­‐4.33	  to	  4.29)	   	  
Table	  4-­‐2	  Demographics	  of	  the	  women	  with	  SCD	  
Using	   Bonferroni	   adujsment,	   there	   is	   a	   significant	   difference	   in	   age	   between	   the	  group	  of	  women	  using	  COC	  s	  and	  the	  others.	  




4.4 DEMOGRAPHIC	  ANALYSIS	  ACROSS	  SCT	  WOMEN	  
As	   for	   women	   with	   SCD,	   population	   demographics	   for	   the	   3	   groups	   of	  contraception	   for	   women	  with	   SCT	  were	   compared	   to	   each	   other	   in,	   where	   the	  non-­‐hormonal	   contraceptive	   group	   served	   as	   the	   reference	   population	   in	   Table	  4-­‐3.	   The	   same	   variables	  were	   compared	   between	   the	   groups:	   age,	   BMI,	   smoking	  status	   and	   cigarettes	   smoked	   per	   day,	   although	   none	   of	   the	   women	   with	   SCT	  smoked.	  There	  were	  no	  statistical	  differences	  between	  COC	  users,	  POC	  users	  and	  the	  reference	  group,	  non-­‐hormonal	  contraceptive	  users.	  
	  
Demographic	  variables	   No	  HC	  (n	  =	  30)	   POC	  (n	  =	  29)	   COC	  (n	  =9)	   P	  	  
Mean	  age	  in	  years	  (SD)	   32.28	  (8.03)	   36.57(4.54)	   32.12(4.38)	   0.232	  
Difference	  between	  
means	  (95%	  CI)	  
	   4.29	  (1.74	  to	  6.83)	   -­‐0.16	  (-­‐2.7	  to	  2.38)	   	  
BMI	  mean	  (SD)	   32.28(8.03)	   25.07(2.38)	   24.62(3.02)	   0.747	  
Difference	  (95%	  CI)	   	   -­‐7.21(-­‐11.13	  to	  -­‐3.29)	   -­‐7.66	  (-­‐11.58	  to	  -­‐3.74)	   	  
Smoking	  (%)	   0	   0	   0	   	  
Table	  4-­‐3	  Demographics	  of	  the	  women	  with	  SCT	  
ANOVA	   analysis,	   comparing	   the	   demographics	   of	   SCT	   POC	   and	   COC	   users	   to	   the	   SCT	   non-­‐




4.5 DEMOGRAPHIC	  ANALYSIS	  ACROSS	  NORMAL	  HB	  WOMEN	  




No	  HC	  (n	  =	  9)	   POC	  (n	  =	  8)	   COC	  (n	  =10)	   P	  	  
Mean	  age	  in	  
years	  (SD)	  




	   0.5	  (-­‐2.04	  to	  2.85)	   -­‐5.2	  (-­‐7.74	  to	  -­‐2.84)	   	  
BMI	  mean	  (SD)	   26.11(3.29)	   27.62(2.77)	   26.6(3.47)	   0.829	  
Difference	  (95%	  
CI)	  
	   1.51(-­‐1.03	  to	  4.05)	   -­‐1.02	  (-­‐3.56	  to	  1.52)	   	  
Smoking	   1	  	   0	   0	   	  
No	  of	  cigarettes	  
mean	  (SD)	  
0.55(1.66)	   n/a	   n/a	   	  
Table	  4-­‐4	  Demographics	  of	  the	  women	  with	  Hb	  AA	  
ANOVA	  analysis,	  comparing	  the	  demographics	  of	  Hb	  AA	  POC	  and	  COC	  users	  to	  the	  Hb	  AA	  non-­‐




4.6 DEMOGRAPHIC	  ANALYSIS	  OF	  COC	  USERS	  




Hb	  AA	  (n	  =	  10)	   SCT	  (n	  =	  8)	   SCD	  (n	  =9)	   P	  	  
Mean	  age	  in	  
years	  (SD)	  
31.8(9.41)	   32.12(4.38)	   25.33(5.65)	   0.100	  
Difference	  (95%	  
CI)	  
Reference	   0.32	  (-­‐2.42	  to	  3.06)	   -­‐6.47	  (-­‐8.82	  to	  -­‐4.11)	   	  
BMI	  mean	  (SD)	   26.6	  (3.47)	   24.62	  (3.02)	   24.23(4.79)	   00.428	  
Difference	  (95%	  
CI)	  
Reference	   -­‐1.98	  (-­‐6.09	  to	  2.13)	   -­‐2.37	  (-­‐4.72	  to	  -­‐0.018)	   	  
Smoking	  (%)	   0	   0	   1	  (11.11%)	   	  
No	  of	  cigarettes	  
mean	  (SD)	  
0	   0	   0.44(1.33)	   	  
Table	  4-­‐5	  Demographic	  characteristics	  of	  COC	  users	  
	  
4.7 DEMOGRAPHIC	  ANALYSIS	  OF	  POC	  USERS	  
Similarly	  the	  POC	  users	  recruited	  to	  the	  study	  were	  also	  grouped	  according	  to	  their	  haemoglobin	   type	   into	   SCD,	   SCT	   and	   normal	   haemoglobin.	   The	   demographics	   of	  these	  3	  groups	  were	  compared,	  using	  the	  normal	  haemoglobin	  group,	  Hb	  AA	  as	  the	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Hb	  AA	  (n	  =	  8)	   SCT	  (n	  =	  7)	   SCD	  (n	  =29)	   P	  	  
Mean	  age	  in	  
years	  (SD)	  
37.5(10.75)	   36.57(4.54)	   35.62(5.65)	   0.110	  
Difference	  	  (95%	  
CI)	  
Reference	   -­‐0.93	  (-­‐3.67	  to	  1.61)	   -­‐0.95	  (-­‐3.69	  to	  1.79)	   	  
BMI	  mean	  (SD)	   27.62	  (2.77)	   25.07	  (2.38)	   24.34(4.35)	   0.137	  
Difference	  (95%	  
CI)	  
Reference	   -­‐2.55	  (-­‐5.87	  to	  1.37)	   -­‐0.73	  (-­‐3.27	  to	  1.81)	   	  
Smoking	  (%)	   1(12.50)	   1(14.28)	   6	  (20.68%)	   	  
Difference	  (95%	  
CI)	  
Reference	   0.06	  (-­‐2.09	  to	  2.21)	   -­‐0.02	  (-­‐2.33	  to	  2.37)	   0.691	  
No	  of	  cigarettes	  
mean	  (SD)	  
0	   0	   0.44(1.33)	   	  
Table	  4-­‐6	  Demographic	  characteristics	  of	  POC	  users	  
	  
4.8 DEMOGRAPHIC	   ANALYSIS	   OF	   USERS	   OF	   NON-­‐HORMONAL	  
CONTRACEPTIVES	  







Hb	  AA	  (n	  =	  9)	   SCT	  (n	  =	  7)	   SCD	  (n	  =30)	   P	  	  
Mean	  age	  in	  
years	  (SD)	  




	   4.72	  (0.60	  to	  8.40)	   5.28	  (2.92	  to	  7.63)	   	  




	   -­‐1.97	  (-­‐5.10	  to	  0.57)	   1.48	  (-­‐0.87	  to	  -­‐4.02)	   	  
Smoking	  (%)	   1	  (10)	   0	   2	  (22.22%)	   	  
No	  of	  cigarettes	  
mean	  (SD)	  
0.55	  (1.66)	   0	   0.466	  (1.94)	   	  




CHAPTER	  5 	  	  	  	  	  	  	  







Figure	  5-­‐1:	  This	  is	  a	  picture	  of	  a	  twenty	  two	  year	  old	  patient	  with	  SCD	  (	  inserted	  with	  full	  


















5.2 CLINICAL	  EVENTS	  IN	  SCD	  WOMEN	  
Clinical	  variables	   No	   HC	   (n	   =	   30)	  
Mean	  (SD)	  
POC	   (n	   =	   29)	  
Mean	  (SD)	  
COC	   (n	   =	   9)	  
Mean	  (SD)	  
P	  	  
Number	  of	  previous	  pregnancies	   1.2	  (1.09)	   1.79	  (1.47)	   0.77	  (0.83)	   0.104	  95%	  C.I.	   Reference	   0.59	  (-­‐0.06	  to	  1.24)	   -­‐0.42	  (-­‐1.37	  to	  .052)	   	  Duration	  of	  use	  of	  contraceptive	  method	  prior	  to	  enrolment	  (months)	  mean	  (SD)	  
18	  (4.72)	   33.44	  (7.53)	   14.7	  (3.65)	   0.005	  
95%	  C.I.	   Reference	   15.54	  (11.03	  to	  21.08)	   -­‐3.3	  (-­‐7.80	  to	  -­‐1.20)	   	  
Type	  of	  SCD	  Hb	  SS	   19	   24	   4	   	  Hb	  SC	   9	   2	   5	   	  Hb	  S	  βThalassaemia	   2	   3	   0	   	  
Table	  5-­‐1	  The	  obstetric	  history	  and	  duration	  of	  use	  of	   their	  contraceptive	  method	  prior	   to	  







Clinical	  events	   No	  HC	  (n=30)	   POC	  (n=29)	   COC	  (n=9)	  
	  Severe	  sickle	  crises	  (total)	   14	   12	   2	  Number	   of	   women	   with	   severe	  sickle	  crises	   10	   5	   1	  Hospital	  admissions	  (total)	   16	   13	   3	  Number	  of	  women	  with	  hospital	  admission.	   11	   7	   2	  Blood	  transfusions	  (total	  number	  of	  sessions)	   5	   3	   0	  Number	  of	  women	  receiving	  transfusion	   3	   3	   0	  VTE	  (DVT	  &	  PE)	   0	   0	   0	  Strokes	  &	  heart	  attacks	   0	   0	   0	  Arterial	  thrombosis	   0	   0	   0	  
Table	  5-­‐2	  Clinical	  events	  during	  the	  study	  in	  the	  SCD	  women	  
Clinical	  events	   No	  HC	  (n=30)	   POC	  (n=29)	   COC	  (n=9)	  
	  Side	  effects	  (i.e.	  headaches,	  nausea,	  mood	  swings,	  bloatedness,	  breast	  tenderness)	  
0	   4	   1	  
Discontinuation	   0	   0	   0	  Unintended	  interruptions	   0	   1	   1	  Planned	  pregnancies	   1	   0	   0	  Unplanned	  pregnancies	   1	   0	   0	  Amenorrhoea	   0	   11	   0	  Menstrual	  irregularities	   4	   8	   2	  
Table	  5-­‐3:	  Contraceptive	  side	  effects	  and	  problems	  during	  the	  study	  in	  the	  SCD	  women	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5.3 LABORATORY	  RESULTS	  FOR	  SCD	  WOMEN	  
Laboratory	  marker	  
(reference	  values)	  	  




COC	  (n=9)	  	  	  	  
Mean	  (SD)	  
P	  	  Prothrombin	  time	  (12	  –	  15	  secs)	   14.93	  (1.57)	   15.35	  (1.77)	   14.83	  (1.65)	   0.814	  Difference	  (95%	  CI)	   Reference	   0.42	  	  (	  -­‐0.44	  to	  1.29)	   0.1	  	  (-­‐1.37	  to	  1.16)	   	  International	  normalised	  ratio	  (INR)(0.8-­‐1.2)	   1.16	  (0.134)	   1.19	  (0.147)	   1.15	  (0.11)	   0.652	  Difference	  (95%	  CI)	   Reference	   0.03	  (-­‐0.04	  to	  .1)	   0	  (-­‐0.11	  to	  .1)	   	  Activated	  partial	  thromboplastin	  time	  (25-­‐35	  seconds)	   27.98	  (2.35)	   29.24	  (3.55)	   29.41	  (2.68)	   0.090	  Difference	  (95%	  CI)	   Reference	   1.26	  (-­‐0.28	  to	  2.81)	   1.43	  (-­‐0.82	  to	  3.68)	   	  Thrombin	  Time	  (12-­‐14	  seconds)	   13.8	  (1.00)	   13.12	  (1.28)	   12.85	  (0.67)	   0.099	  Difference	  (95%	  CI)	   Reference	   -­‐0.68	  (-­‐1.25	  to	  -­‐0.1)	   -­‐	  0.95	  (-­‐1.79	  to	  -­‐0.12)	   	  Fibrinogen	  (2.14-­‐3.51	  g/dL)	  	   3.09	  (0.61)	   3.33	  (0.56)	   3.46	  (0.80)	   0.423	  Difference	  (95%	  CI)	   Reference	   0.24	  (-­‐0.08	  to	  0.56)	   0.37	  (-­‐0.1	  to	  .84)	   	  Factor	  VIII	  Coagulant	  (50-­‐150	  iu/dL)	  	   168.93	  (51.58)	   154.14	  (41.74)	   149.11	  (38.16)	   0.418	  Difference	  (95%	  CI)	   Reference	   -­‐14.79	  (-­‐38.98	  to	  9.4)	   -­‐19.82	  (-­‐54.81	  to	  15.16)	   	  von	  Willebrand	  Factor	  antigen	  (46	  –	  153	  (iu/dL)	   181.96	  (68.43)	   171.33	  (64.39)	   164.22	  (66.28)	   0.950	  Difference	  (95%	  CI)	   Reference	   -­‐10.64	  (-­‐45.2	  to	  =23.93)	   -­‐17.74	  (-­‐68.19	  to	  -­‐32.7)	   	  Dilute	  Viper	  Venom	  Time	  (ratio)	  (<1.16)	   0.92	  (0.17)	   0.92	  (0.12)	   0.91	  (0.07)	   0.025	  Difference	  (95%	  CI)	   Reference	   -­‐0.01	  (-­‐0.08	  to	  -­‐0.07)	   -­‐0.01	  (-­‐0.12	  to	  -­‐0.09)	   	  





(reference	  values)	  	  
No	  HC	  (n=30)	  
Mean	  (SD)	  
POC	  (n=29)	  	  
Mean	  (SD)	  
COC	  (n=9)	  	  	  	  
Mean	  (SD)	  
P	  	  
Anti-­‐thrombin	  activity	  (85-­‐113	  iu/dL)	   98.56	  (10.89)	   95.58	  (9.18)	   92.02	  (13.40)	   0.356	  
Difference	  (95%	  CI)	   Reference	   -­‐2.98	  (-­‐8.47	  to	  2.51)	   -­‐6.54	  (-­‐14.55	  to	  1.47)	   	  
Protein	  C	  activity	  (70-­‐135	  iu/dL)	   85.03	  (15.49)	   82.00	  (12.53)	   75.53	  (20.23)	   0.188	  Difference	  (95%	  CI)	   Reference	   -­‐3.03	  (-­‐10.84	  to	  4.77)	   -­‐9.5	  (-­‐20.89	  to	  1.89)	   	  Free	  Protein	  S	  	  (75-­‐125	  iu/dL)	   56.3	  (13.30)	   59.06	  (14.95)	   59.20	  (16.87)	   0.655	  Difference	  (95%	  CI)	   Reference	   2.77	  (-­‐4.78	  to	  10.31)	   2.9	  (-­‐8.11	  to	  13.91)	   	  Activated	  Protein	  C	  Resistance	  (Factor	  V	  Leiden)	  (>2.0)	   2.84	  (0.35)	   2.87	  (0.31)	   2.80	  (0.14)	   0.030	  Difference	  (95%	  CI)	   Reference	   0.04	  (-­‐0.14	  to	  0.21)	   -­‐0.04	  (-­‐0.28	  to	  -­‐0.2)	   	  Factor	  II	  	  (84.3-­‐120.0	  iu/dL)	   90.33	  (14.27)	   91.27	  (9.99)	   91.00	  (11.93)	   0.179	  Difference	  (95%	  CI)	   Reference	   0.94	  (-­‐5.46	  to	  7.34)	   0.67	  (-­‐8.68	  to	  10.01)	   	  Factor	  V	  	  (63.85-­‐120.5	  iu/dL)	   100.30	  (18.62)	   95.93	  (16.33)	   98.88	  (12.46)	   0.404	  Difference	  (95%	  CI)	   Reference	   -­‐4.37	  (-­‐13.21	  to	  4.47)	   -­‐1.41	  (-­‐14.31	  to	  11.49)	   	  Factor	  VII	  (77.5-­‐150.5	  iu/dL)	   92.40	  (22.70)	   78.17	  (22.40)	   83.11	  (21.30)	   0.976	  Difference	  (95%	  CI)	   Reference	   -­‐14.23	  (-­‐25.88	  to	  -­‐2.57)	   -­‐9.29	  (-­‐26.3	  to	  7.72)	   	  








(reference	  values)	  	  




COC	  (n=9)	  	  	  
Mean	  (SD)	  
P	  	  Factor	  IX	  (77.7-­‐130.0	  iu/dL)	   121.16	  (29.69)	   120.65	  (41.70)	   121.88	  (22.28)	   0.060	  Difference	  (95%	  CI)	   Reference	   -­‐0.51	  (-­‐18.56	  to	  17.53)	   0.72	  (-­‐25.61	  to	  27.06)	   	  Factor	  X	  (71.8-­‐130.0	  iu/dL)	   94.83	  (22.96)	   89.62	  (16.62)	   102.55	  (19.63)	   0.243	  Difference	  (95%	  CI)	   Reference	   -­‐5.21	  (-­‐15.64	  to	  5.21)	   7.72	  (-­‐7.49	  to	  22.94)	   	  Factor	  XI	  (68-­‐144	  iu/dL)	   92.36	  (20.84)	   86.03	  (15.95)	   89.44	  (14.58)	   0.265	  Difference	  (95%	  CI)	   Reference	   -­‐6.33	  (-­‐15.78	  to	  3.11)	   -­‐2.92	  (-­‐16.7	  to	  10.86)	   	  Factor	  XII	  (46.7-­‐181.0	  iu/dL)	   99.76	  (24.16)	   83.68	  (30.19)	   97.77	  (32.82)	   0.392	  Difference	  (95%	  CI)	   Reference	   -­‐16.08	  (-­‐30.66	  to	  -­‐1.5)	   -­‐1.99	  (-­‐23.27	  to	  19.29)	   	  Factor	  XIIIa	  (97.4-­‐179.0	  iu/dL)	   66.10	  (29.90)	   66.39	  (18.26)	   67.55	  (26.06)	   0.391	  Difference	  (95%	  CI)	   Reference	   0.29	  (-­‐10.76	  to	  11.34)	   1.46	  (-­‐14.52	  to	  17.44)	   	  
Table	  5-­‐6	  Pro	  and	  anti-­‐thrombotic	  biochemical	  markers	  in	  SCD	  (3)	  






Laboratory	  marker	  	  
(reference	  ranges)	  	  
No	  HC	  (n	  =	  30)	  
Mean	  (SD)	  
POC	  (n	  =	  29)	  
Mean	  (SD)	  
COC	  (n	  =	  9)	  
Mean	  (SD)	  
P	  	  
Thrombin:anti-­‐thrombin	  III	  complex	  (2	  -­‐	  4.2	  mcg/l)	   19.70	  (40.28)	   5.45	  (3.06)	   8.15	  (4.29)	   <0.001	  Difference	  (95%	  CI)	   Reference	   -­‐14.24	  (-­‐28.89	  to	  -­‐0.41)	   -­‐11.55	  (-­‐33.43	  to	  -­‐10.33)	   	  Prothrombin	  fragment	  1	  +	  2	  (69	  –	  229	  pmol/L)	  	   492.72	  (380.72)	   374.37	  (277.51)	   244.62	  (114.91)	   0.005	  Difference	  (95%	  CI)	   Reference	   -­‐118.35	  (-­‐288.2	  to	  51.49)	   -­‐248.1	  (-­‐501.73	  to	  -­‐5.53)	   	  D	  dimer	  (<130	  ng/ml)	   943.76	  (1019.4)	   762.17	  (728.76)	   614.44	  (283.46)	   0.001	  Difference	  (95%	  CI)	   Reference	   -­‐181.59	  (-­‐617.44	  to	  -­‐254.26)	   -­‐329.32	  (-­‐965.42	  to	  -­‐306.77)	   	  





No	  HC	  (n	  =	  30)	  
Mean	  (SD)	  
POC	  (n	  =	  29)	  
Mean	  (SD)	  
COC	  (n	  =	  9)	  
Mean	  (SD)	  
P	  	  
Soluble	  Platelet	  selectin(92-­‐212	  ng/ml)	   84.89	  (32.91)	   81.77	  (26.71)	   72.00	  (20.47)	   0.249	  Difference	  (95%	  CI)	   Reference	   -­‐3.12	  (-­‐18.64	  to	  12.4)	   -­‐12.9	  (-­‐35.04	  to	  9.25)	   	  Soluble	  Cell	  Differentiation	  40	  ligand(0.03-­‐3.98	  ng/ml)	   1.32	  (3.19)	   1.52	  (1.69)	   1.06	  (0.92)	   <0.001	  Difference	  (95%	  CI)	   Reference	   0.19	  (-­‐1.11	  to	  -­‐1.49)	   -­‐0.26	  (-­‐2.12	  to	  -­‐1.59)	   	  Platelet	  factor	  4	  (<10I.U./ml)	   140.62	  (74.09)	   147.51	  (67.63)	   150.38	  (66.90)	   0.884	  Difference	  (95%	  CI)	   Reference	   6.89	  (-­‐31.89	  to	  45.68)	   9.76	  (-­‐47.06	  to	  66.59)	   	  











COC	  (n=9)	  	  	  	  
Mean	  (SD)	  
P	  	  
Soluble	  vascular	  cell	  adhesion	  molecule	  (131-­‐1223	  ng/ml))	   1095.10	  (563.89)	   1162.03	  (917.68)	   1003.22	  (604.20)	   0.036	  Difference	  (95%	  CI)	   Reference	   66.93	  (-­‐327.32	  to	  461.18)	   -­‐91.88	  (-­‐654.39	  to	  470.62)	   	  Soluble	  inter-­‐cellular	  adhesion	  molecule-­‐1	  (41-­‐669	  ng/ml)	   555.06	  (162.63)	   528.03	  (128.44)	   445.06	  (119.85)	   0.377	  Difference	  (95%	  CI)	   Reference	   -­‐27.03	  (-­‐103.98	  to	  49.91)	   -­‐110	  (-­‐219.78	  to	  -­‐.21)	   	  Soluble	  endothelial-­‐leucocyte	  adhesion	  molecule-­‐1	  (1.5	  –	  88.1ng/ml))	  
86.86	  (34.49)	   52.66	  (29.58)	   89.77	  (52.84)	   0.091	  
Difference	  (95%	  CI)	   Reference	   -­‐16.2	  (-­‐36.18	  to	  -­‐3.78)	   20.92	  (-­‐7.59	  to	  -­‐49.42)	   	  
Table	  5-­‐9:	  Endothelial	  activation	  markers	  in	  the	  SCD	  women	  
Laboratory	  marker	  
(reference	  values)	  	  




COC	  (n=9)	  	  	  
Mean	  (SD)	  
P	  	  
Micro	  particles	  (<10nMol/ml)	  	   34.94	  (20.36)	   39.03	  (27.10)	   25.41	  (13.46)	   0.061	  Difference	  (95%	  CI)	   Reference	   4.09	  (-­‐7.94	  to	  16.12)	   -­‐9.53	  (-­‐27.01	  to	  7.94)	   	  Tissue	  Factor(<2pMol/ml)	  	   12.07	  (5.96)	   8.83	  (6.94)	   13.72	  (5.40)	   0.626	  Difference	  (95%	  CI)	   Reference	   -­‐3.24	  (-­‐6.75	  to	  .27)	   1.65	  (-­‐3.19	  to	  6.48)	   	  








(reference	  values)	  	  
	  




COC	  (n=9)	  	  	  	  
Mean	  (SD)	  
P	  	  
Lag	  Time	  (initiated	  with	  5pMol	  Tissue	  Factor)(2.0	  -­‐	  3.2	  minutes)	  
1.66	  (0.66)	   1.59	  (0.53)	   1.36	  (0.34)	   0.095	  
Difference	  (95%	  CI)	   Reference	  	   -­‐0.06	  (-­‐0.37	  to	  0.24)	   -­‐0.29	  (-­‐0.73	  to	  0.15)	   	  Endogenous	  Thrombin	  Potential	  (initiated	  with	  5pMol	  Tissue	  Factor)(1159	  –	  2168	  nMol)	  
1345.43	  (245.32)	   1480.67(269.79)	  	   1482.88	  (348.20)	   0.431	  
Difference	  (95%	  CI)	   Reference	   135.25	  (-­‐6.72	  to	  277.21)	   137.46	  (-­‐67.87	  to	  342.78)	   	  Peak	  Height	  (initiated	  with	  5pMol	  Tissue	  Factor)(	  147	  –	  359	  nM)	  
305.64	  (85.92)	   319.07	  (52.31)	   342.66	  (51.52)	   0.792	  
Difference	  (95%	  CI)	   Reference	   13.43	  (-­‐15.61	  to	  42.46)	   37.02	  (-­‐4.98	  to	  79.02)	   	  Time	  to	  Peak	  (initiated	  with	  5pMol	  Tissue	  Factor)(4.6	  –	  7.4	  min)	   3.90	  (0.96)	   3.91	  (0.82)	   3.43	  (0.38)	   0.028	  Difference	  (95%	  CI)	   Reference	   0.02	  (-­‐0.43	  to	  0.47)	   -­‐0.47	  (-­‐1.12	  to	  -­‐0.18)	   	  Slope	  (33	  –	  142	  nM/min)	   142.72	  (40.36)	   143.25	  (39.32)	   168.51	  (35.63)	   0.914	  Difference	  (95%	  CI)	   Reference	   0.53	  (-­‐20.13	  to	  21.19)	   25.79	  (-­‐4.1	  to	  55.67)	   	  Start	  Time	  (initiated	  with	  5pMol	  Tissue	  Factor)(19	  28.3	  min)	   17.48	  (2.01)	   18.57	  (2.75)	   17.50	  (2.29)	   0.263	  Difference	  (95%	  CI)	   Reference	   1.09	  (-­‐0.16	  to	  2.34)	   0.02	  (-­‐1.79	  to	  1.83)	   	  






(reference	  values)	  	  




COC	  (n=9)	  	  	  	  Mean	  
(SD)	  
P	  	  
Free	  Hb	  (0-­‐	  1/l)	   0.10	  (0.09)	   0.09	  (0.10)	   0.10	  (0.05)	   0.120	  Difference	  (95%	  CI)	   Reference	   -­‐0.01	  (-­‐0.06	  to	  .03)	   0	  (-­‐0.07	  to	  .07)	   	  Haptoglobin	  (<	  1.22	  g/l)	   1.54	  (0.46)	   1.56	  (0.66)	   1.58	  (0.70)	   0.154	  Difference	  (95%	  CI)	   Reference	   0.02	  (-­‐0.31	  to	  0.35)	   0.05	  (-­‐0.4	  to	  0.49)	   	  Lactate	  dehydrogenase	  (240-­‐480	  units/l)	   734.17	  (321.20)	   637.23	  (227.28)	   555.50	  (210.22)	   0.148	  Difference	  (95%	  CI)	   Reference	   -­‐96.94	  (244.73	  to	  50.84)	   -­‐178.67	  (397.19	  to	  39.85)	   	  Bilirubin	  (<	  21	  μMol/l)	   39.74	  (27.72)	   38.11	  (32.63)	   32.00	  (20.80)	   0.326	  Difference	  (95%	  CI)	   Reference	   -­‐1.63	  (-­‐17.52	  to	  14.26)	   -­‐7.74	  (-­‐30.22	  to	  14.74)	   	  
Table	  5-­‐12:	  Markers	  of	  haemolysis	  in	  the	  SCD	  women	  
Laboratory	  marker	  
(reference	  values)	  	  




COC	  (n=9)	  	  	  	  
Mean	  (SD)	  
P	  	  
Alanine	  amino	  transferase	  (<33	  units/l)	   22.07	  (9.240	   19.96	  (11.89)	   23.11	  (12.46)	   0.364	  Difference	  (95%	  CI)	   Reference	   -­‐2.11	  (-­‐7.89	  to	  3.68)	   1.04	  (-­‐7.32	  to	  9.4)	   	  Aspartate	  amino	  transferase	  (	  <31	  units/l)	   35.19	  (19.55)	   29.78	  (11.91)	   34.00	  (14.26)	   0.045	  Difference	  (95%	  CI)	   Reference	   -­‐5.41	  (-­‐14.03	  to	  3.21)	   -­‐1.19	  (-­‐13.43	  to	  -­‐0.11)	   	  Alkaline	  phosphatase	  (<	  129	  units/l)	  	   88.13	  (36.43)	   86.86	  (48.12)	   89.66	  (65.29)	   0.078	  Difference	  (95%	  CI)	   Reference	   1.28	  (-­‐25.47	  to	  22.92)	   1.53	  (-­‐33.62	  to	  36.68)	   	  Serum	  albumin	  (35-­‐50g/l)	   45.82	  (2.91)	   45.79	  (3.56)	   44.66	  (5.83)	   0.028	  Difference	  (95%	  CI)	   Reference	   -­‐.03	  (-­‐1.97	  to	  1.9)	   -­‐1.16	  (-­‐3.97	  to	  -­‐0.164)	   	  









COC	  (n=9)	  	  	  	  
Mean	  (SD)	  
P	  	  Haemoglobin	  (11.5-­‐15-­‐5	  g/dl)	   9.07	  (1.44)	   9.22	  (1.55)	   10.37	  (1.73)	   0.788	  Difference	  (95%	  CI)	   Reference	   0.16	  [-­‐.64	  to	  .95]	   1.31	  [.14	  to	  2.47]	   	  Platelet	  count	  (140-­‐400	  10^9/l)	   331.40	  (144.39)	   323.39	  (134.12)	   310.77	  (109.49)	   0.652	  Difference	  (95%	  CI)	   Reference	   -­‐8.01	  [-­‐79.48	  to	  63.46]	   -­‐20.62	  [-­‐123.99	  to	  82.75]	   	  Haematocrit	  (0.35-­‐0.47	  l/l)	   0.26	  (0.03)	   0.26	  (0.04)	   0.27	  (0.05)	   0.305	  Difference	  (95%	  CI)	   Reference	   0.01	  [-­‐.02	  to	  .03]	   0.02	  [-­‐.02	  to	  .05]	   	  
Table	  5-­‐14:	  Blood	  count	  values	  in	  the	  SCD	  women	  
Laboratory	  marker	  
(reference	  values)	  	  




COC	  (n=9)	  	  	  	  
Mean	  (SD)	  
P	  	  Complement	  reactive	  protein	  (0.2-­‐10.0	  mcg/ml)	   35.39	  (22.07)	   35.58	  (19.20)	   42.11	  (31.31)	   0.205	  Difference	  (95%	  CI)	   Reference	   0.23	  (-­‐1.34	  to	  1.79)	   1.67	  (-­‐0.57	  to	  3.91)	   	  White	  blood	  cells	  	  (3.5-­‐11.0	  10^9/l)	   8.22	  (2.69)	   8.45	  (3.42)	   9.89	  (2.04)	   0.190	  Difference	  (95%	  CI)	   Reference	   0.28	  	  (-­‐0.86	  to	  1.43)	   1.32	  (-­‐0.27	  to	  2.91)	   	  Neutrophils	  (1.7-­‐8.0	  10^9/l)	   4.22	  (1.70)	   4.50	  (2.38)	   5.54	  (2.06)	   0.261	  Difference	  (95%	  CI)	   Reference	   0.27	  (-­‐0.27	  to	  0.8)	   0.18	  (-­‐0.56	  to	  0.92)	   	  Lymphocytes	  (1.0-­‐3.510^9/l)	   2.57	  (1.07)	   2.83	  (0.89)	   2.75	  (0.86)	   0.686	  Difference	  (95%	  CI)	   Reference	   0	  (-­‐0.13	  to	  0.12)	   0.11	  (-­‐0.07	  to	  0.28)	   	  Monocytes	  (0.1-­‐1.010^9/l)	   0.70	  (0.37)	   0.82	  (0.36)	   0.91	  (0.55)	   0.271	  Difference	  (95%	  CI)	   Reference	   0.12	  (-­‐0.1	  to	  0.34)	   0.21	  (-­‐0.1	  to	  0.52)	   	  Eosinophils	  (0.0-­‐0.46	  10^9/l))	   0.23	  (0.22)	   0.22	  (0.19)	   0.33	  (0.31)	   0.210	  Difference	  (95%	  CI)	   Reference	   0	  (-­‐0.13	  to	  0	  .12)	   0.11	  (-­‐0.07	  to	  0.28)	   	  Basophils	  (0.0-­‐0.20	  10^9/l)	   0.04	  (0.03)	   0.04	  (0.04)	   0.04	  (0.02)	   0.036	  	   Reference	   0	  (-­‐0.02	  to	  .02)	   0	  (0.03	  to	  .03)	   	  
Table	  5-­‐15:	  Inflammatory	  markers	  in	  the	  SCD	  women	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5.4 SUMMARY	  OF	  RESULTS	  FOR	  THE	  SCD	  WOMEN	  
It	   is	  noticeable	  that	  SCD	  women	  who	  are	  using	  POC	  had	  been	  using	  their	  method	  for	  a	  significantly	  longer	  time	  period	  of	  time	  prior	  to	  enrollment	  in	  the	  study.	  This	  partly	  results	  from	  the	  women	  using	  Mirena	  IUS®	  ,	  which	  is	  usually	  	  regarded	  as	  a	  longer	  time	  scale	  method	  (5	  years	  between	  changes).Of	  the	  women	  who	  are	  using	  any	   hormonal	   contraception	  method,	   those	   using	   POC	  were	   3	   times	   as	  many	   as	  those	  	  using	  COC.	  
	  
In	  terms	  of	  serious	  clinical	  events	  there	  were	  fewer	  severe	  sickle	  cell	  crises	  in	  the	  women	   on	   COC,	   who	   also	   had	   fewer	   hospital	   admissions	   and	   fewer	   episodes	   of	  blood	   transfusion.The	  woman	  who	   suffered	  VTE	  during	   the	   study	  was	  not	   using	  hormonal	  contraception.	  There	  were	  no	  episodes	  of	  stroke	  and	  heart	  attack	  during	  the	  study	  period.	  	  
	  
The	  women	  most	   frequently	  experiencing	  method	  specific	  side	  effects	  during	  the	  study	  were	  those	  on	  POC,	  in	  whom	  the	  main	  issues	  were	  menstrual	  irregularities	  and	  amenorrhea.	  
	  
In	  the	  pro	  and	  anti-­‐	  coagulant	  markers	  studied,	  the	  only	  abnormally	  high	  marker	  was	  VWF	  which	  showed	  mild	  elevation	  in	  all	  three	  groups	  without	  any	  statistically	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significant	   difference.	  On	   the	   other	   hand	   although,	   the	  mean	   values	   for	  APCR	   lie	  within	  the	  reference	  range	  the	  differences	  between	  the	  groups	  did	  reach	  statistical	  significance.	  
	  
All	   the	   coagulation	   activation	   markers	   studied	   show	   levels	   higher	   than	   the	  reference	   range,	   which	   is	   an	   adverse	   result.	   However,	   these	   levels	   are	   also	  significantly	   increased	   in	   the	   group	   of	   SCD	   women,	   who	   are	   not	   using	   any	  hormonal	  contraception.	  
	  
The	   platelet	   activation	   marker	   PF4	   is	   markedly	   increased	   (an	   adverse	   result)	  without	   any	   statistically	   significant	   difference	   between	   the	   three	   groups.	   The	  sCD40	   ligand	  mean	   level	   is	   increased	   in	   the	  group	  using	  POC	  compared	   to	  other	  SCD	  women	  and	  this	   increase	  reached	  statistical	  significance,	  although	  the	  actual	  levels	  are	  still	  within	  the	  reference	  range.	  
Endothelial	   activation	   markers	   showed	   no	   marked	   differences	   between	   SCD	  women	   on	   different	  methods	   of	   contraception,	   except	   the	   level	   of	   sVCAM	  which	  was	  increased	  in	  the	  group	  using	  POC.	  
	  
Markers	   of	   tissue	   damage	   showed	  marked	   elevation.	  MP	   is	   about	   2.5	   to	   3	   times	  higher	  than	  the	  reference	  range,	  while	  TF	  4	  was	  2	  to	  6	  times	  higher	  in	  all	  the	  three	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groups.	  There	  is	  no	  statistically	  significant	  difference	  between	  the	  groups	  though.	  Thrombin	  generation	  tests	  are	  all	  within	  the	  reference	  range	  in	  all	  three	  groups.	  
	  
LDH	  and	  bilirubin	  showed	  marked	  elevation	  compared	  to	  the	  reference	  range	  in	  all	  three	  groups.	  
	  
Liver	   function	   tests	   showed	   abnormal	   results,	   with	   AST	   levels	   higher	   in	   SCD	  women	   not	   using	   any	   hormonal	   contraception	   and	   in	   women	   using	   COC	   The	  difference	   in	   its	  mean	  values	   reached	   statistical	   significance	   and	  CRP	  was	  3	   to	  4	  times	   higher	   than	   the	   reference	   range.	   This	   elevation	   occurred	   in	   all	   the	   three	  groups.	   The	   blood	   count	   values	   are	   not	   markedly	   different	   between	   the	   three	  groups.	  The	  interpretation	  of	  these	  results	  will	  be	  discussed	  in	  detail	  in	  Chapter	  7.	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Figure	  5-­‐2	  This	  is	  a	  picture	  of	  a	  thirty	  two	  year	  old	  woman	  with	  SCT	  (inserted	  with	  full	  permission	  of	  the	  participant).	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The	  study	  results	  for	  women	  with	  SCT	  will	  be	  presented	  in	  this	  section	  first	  in	  the	  form	  of	   tables	  and	  the	  most	   important	   findings	  will	  be	  summarised	  at	   the	  end	  of	  these	  tables,	  as	  mentioned	  previously.	  
5.5 CLINICAL	  EVENTS	  IN	  SCT	  WOMEN	  







Number	  of	  previous	  pregnancies	  (mean+/-­‐SD)	   1.42	  (1.13)	   1.71	  (0.95)	   1.12	  (0.640)	   0.904	  Difference	  (95%	  CI)	   Reference	   0.29	  (-­‐0.74	  to	  1.31)	   -­‐0.3	  (-­‐1.3	  to	  0.69)	   	  Duration	  of	  use	  of	  contraceptive	  method	  prior	  to	  enrolment	  (months)	  (mean+/-­‐SD)	  
16	  (5.12)	   12	  (6.80)	   11.5	  (6.48)	   0.781	  
Difference	  (95%	  CI)	   Reference	   -­‐0.4	  (-­‐9.48	  to	  1.49)	   -­‐4.5	  (-­‐10.8	  to	  1.18)	   	  
Table	  5-­‐16	  The	  obstetric	  history	  and	  duration	  of	  use	  of	  their	  contraceptive	  method	  prior	  to	  
the	  enrolment	  interview	  in	  the	  SCT	  women	  
Clinical	  variables	  	   No	  HC	  (n=7)	  	  	   POC	  (n=7)	  	  	   COC	  (n=8)	  	  	  
Severe	  sickle	  crises	  (total)	   0	   0	   0	  Hospital	  admissions	  (total)	   2	   1	   0	  Blood	  transfusions	  (total	  number	  of	  sessions)	   0	   0	   0	  VTE	  (DVT	  &	  PE)	   0	   0	   0	  Strokes	  &	  heart	  attacks	  	   0	   0	   0	  Arterial	  thrombosis	   0	   0	   0	  




Clinical	  variables	  	   No	  HC	  (n=7)	   POC	  (n=7)	   COC	  (n=8)	  	  Side	  effects	  (i.e.	  headaches,	  nausea,	  mood	  swings,	  bloatedness,	  breast	  tenderness)	   0	   1	   2	  Discontinuation	   0	   0	   0	  Unintended	  interruptions	   2	   0	   0	  Planned	  pregnancies	   0	   0	   0	  Unplanned	  pregnancies	   0	   0	   0	  Amenorrhoea	   0	   1	   0	  Menstrual	  irregularities	   2	   1	   0	  










5.6 LABORATORY	  RESULTS	  FOR	  SCT	  WOMEN	  
Laboratory	  marker	  
(Reference	  values)	   No	  HC	  (n=7)	  Mean	  (SD)	   POC	  (n=7)	  Mean	  (SD)	   COC	  (n=8)	  Mean	  (SD)	   P	  	  Prothrombin	  time	  (12	  –	  15	  secs)	   11.02	  (0.77)	   11.51	  (0.94)	   11.73	  (1.28)	   0.459	  Difference	  	  (95%	  CI)	   Reference	   0.49	  (-­‐0.68	  to	  1.65)	   0.71	  (-­‐0.42	  to	  1.84)	   	  International	  normalised	  ratio	  (INR)(0.8-­‐1.2)	   1.03	  (0.07)	   1.03	  (0.02)	   1.06	  (0.04)	   0.106	  Difference	  	  (95%	  CI)	   Reference	   0	  (-­‐0.06	  to	  0.05)	   0.02	  (-­‐0.03	  to	  .08)	   	  Activated	  partial	  thromboplastin	  time	  (25-­‐35	  seconds)	   32.05	  (4.44)	   30.27	  (1.30)	   29.53	  (1.78)	   0.009	  Difference	  	  (95%	  CI)	   Reference	   -­‐1.79	  (-­‐4.94	  to	  1.37)	   -­‐2.52	   (-­‐5.57	  to	  -­‐0.53)	   	  Thrombin	  Time	  (seconds)(12-­‐14)	   15.38	  (1.88)	   14.22	  (0.83)	   14.02	  (1.22)	  	   0.163	  Difference	  	  (95%	  CI)	   Reference	   -­‐1.16	  (-­‐2.7	  to	  0.38)	   -­‐1.36	   (-­‐2.85	  to	  0.13)	   	  Fibrinogen	  (2.14-­‐3.51	  g/dL)	  	   4.93	  (3.59)	   3.25	  (0.09)	   2.94	  (0.66)	   <0.001	  Difference	  	  (95%	  CI)	   Reference	   -­‐1.68	  (-­‐4.06	  to	  0.7)	   -­‐1.99	   (-­‐4.29	  to	  -­‐0.31)	   	  Factor	  VIII	  Coagulant	  (50-­‐150	  iu/dL)	  	   148.00	  (19.00)	   154.57	  (80.06)	   121.00	  (34.05)	   0.004	  Difference	  	  (95%	  CI)	   Reference	   6.57	  (-­‐50.1	  to	  63.24)	   -­‐27	  (-­‐81.87	  to	  -­‐27.87)	   	  von	  Willebrand	  Factor	  antigen	  (46	  –	  153	  iu/dL)	   124.32	  (36.75)	   86.92	  (32.00)	   105.87	  (33.40)	   0.944	  Difference	  	  (95%	  CI)	   Reference	   -­‐37.4	  (-­‐75.52	  to	  0.72)	   -­‐18.45	   (-­‐55.37	   to	   -­‐18.46)	   	  Dilute	  Viper	  Venom	  Time	  (ratio)	  (<1.16)	   0.94	  (0.21)	   1.13	  (027)	   0.99	  (0.16)	   0.466	  Difference	  	  (95%	  CI)	   Reference	   0.19	  (-­‐0.06	  to	  0.43)	   0.04	  (-­‐0.19	  to	  0.28)	   	  





(Reference	  values)	  	   No	  HC	  (n=7)	  Mean	  (SD)	  	   POC	  (n=7)	  Mean	  (SD)	  	   COC	  (n=8)	  Mean	  (SD)	  	   P	  	  Anti-­‐thrombin	  :	  Anti-­‐coagulant	  ratio	  (85-­‐113)	   108.08	  (8.74)	   108.26	  (6.43)	   100.45	  (9.39)	   0.648	  Difference	  	  (95%	  CI)	   Reference	   0.17	  (-­‐9.17	  to	  9.52)	   -­‐7.63	  (-­‐16.67	  to	  1.42)	   	  Protein	  C	  :	  Activity	  (70-­‐135	  iu/dL)	   100.28	  (21.62)	   102.80	  (28.03)	   99.80	  (15.46)	   0.368	  Difference	  	  (95%	  CI)	   Reference	   -­‐0.49	  (-­‐25.82	  to	  24.85)	   2.51	  9-­‐22.02	  to	  27.04)	   	  Free	  Protein	  S	  	  (75-­‐125	  iu/dL)	   70.28	  (14.63)	   74.94	  (11.78)	   87.12	  (38.13)	   0.009	  Difference	  	  (95%	  CI)	   Reference	   4.66	  (-­‐23.81	  to	  33.12)	   16.84	  (10.72	  to	  44.4)	   	  Activated	  Protein	  C	  Resistance	  (Factor	  V	  Leiden)	  (>2.0)	   2.71	  (0.12)	   2.85	  (0.11)	   2.75	  (0.24)	   0.087	  Difference	  	  (95%	  CI)	   Reference	   0.14	  (-­‐0.06	  to	  0.34)	   0.01	  (0.18	  to	  0.2)	   	  Factor	  II	  	  (84.3-­‐120.0	  iu/dL)	   95.71	  (20.87)	   104.71	  (7.34)	   107.12	  (8.32)	   0.018	  Difference	  	  (95%	  CI)	   Reference	   9	  (-­‐6.02	  to	  24.02)	   11.41	  (3.13	  to	  25.95)	   	  Factor	  V	  	  (63.85-­‐120.5	  iu/dL)	   81.71	  (23.02)	   97.00	  (17.22)	   98.00	  (28.33)	   0.493	  Difference	  	  (95%	  CI)	   Reference	   15.29	  (-­‐11.12	  to	  41.69)	   16.29	  (9.28	  to	  41.85)	   	  Factor	  VII	  	  (77.5-­‐150.5	  iu/dL)	   83.14	  (21.11)	   93.42	  (16.68)	   76.75	  (12.18)	   0.409	  Difference	  	  (95%	  CI)	   Reference	   10.29	  (-­‐8.55	  to	  29.12)	   -­‐6.39	  (-­‐24.63	  to	  -­‐11.84)	   	  









(Reference	  values)	   No	  HC	  (n=7)	  Mean	  (SD)	   POC	  (n=7)	  Mean	  (SD)	   COC	  (n=8)	  Mean	  (SD)	   P	  	  Factor	  IX	  (77.7-­‐130.0	  iu/dL)	   101.14	  (16.75)	   108.57	  (28.40)	   95.75	  (23.11)	   0.474	  Difference	  	  (95%	  CI)	   Reference	   7.43	  (-­‐18.58	  to	  33.43)	   -­‐5.39	  (-­‐30.57	  to	  -­‐19.79)	   	  Factor	  X	  (71.8-­‐130.0	  iu/dL)	   91.71	  (10.64)	   102.57	  (21.43)	   98.25	  (14.20)	   0.247	  Difference	  	  (95%	  CI)	   Reference	   10.86	  (-­‐7.01	  to	  28.73)	   6.54	  (-­‐10.77	  to	  -­‐23.84)	   	  Factor	  XI	  (68-­‐144	  iu/dL)	   91.42	  (21.46)	   102.42	  (13.95)	   100.87	  (18.31)	   0.603	  Difference	  	  (95%	  CI)	   Reference	   11	  (-­‐9.34	  to	  31.34)	   9.45	  (-­‐10.24	  to	  -­‐29.14)	   	  Factor	  XII	  (46.7-­‐181.0	  iu/dL)	   85.71	  (36.11)	   103.14	  (23.51)	   95.87	  (20.37)	   0.329	  Difference	  	  (95%	  CI)	   Reference	   17.43	  (-­‐13	  to	  47.85)	   10.16	  (-­‐19.3	  to	  -­‐39.62)	   	  Factor	  XIIIa	  (97.4-­‐179.0	  iu/dL)	   97.85	  (14.62)	   81.57	  (30.50)	   78.37	  (27.80)	   0.225	  Difference	  	  (95%	  CI)	   Reference	   -­‐16.29	  (-­‐44.73	  to	  12.15)	   -­‐19.48	  (-­‐47.02	  -­‐to	  8.06)	   	  








(Reference	  range)	   No	  HC	  (n	  =	  7)	  Mean	  (SD)	   POC	  (n	  =	  7)	  Mean	  (SD)	   COC	  (n	  =	  8)	  Mean	  (SD)	   P	  	  Thrombin:anti-­‐thrombin	  III	  complex	  (2-­‐4.2	  mcg/l)	   3.12	  (0.57)	   4.04	  (1.49)	   10.61	  (19.97)	   <0.007	  Difference	  	  (95%	  CI)	   Reference	   0.92(	  -­‐18.68	  to	  20.52)	   7.49(04.15	  to	  25.13)	   	  Prothrombin	  fragment	  1	  +	  2	  (69	  –	  229	  pmol/L)	   142.71	  (109.00)	   139.00	  (51.36)	   210.00	  (219.45)	   0.005	  Difference	  	  (95%	  CI)	   Reference	   -­‐3.71(-­‐101.71	  to	  -­‐94.29)	   67.29	  (34.32	  to	  95.39	  to	  	   	  D	  dimer	  (	  <130	  ng/ml)	  	   126.20	  (70.58)	   196.00	  (106.69)	   184.37	  (200.72)	   0.079	  Difference	  	  (95%	  CI)	   Reference	   69.8	  (89.55	  to	  143.55)	   58.16	  (33.55	  to	  143.55)	   	  
Table	  5-­‐22:	  Coagulation	  activation	  markers	  in	  	  SCT	  women	  
Laboratory	  marker	  
(Reference	  values)	  	   No	  HC	  (n=7)	  Mean	  (SD)	   POC	  (n=7)	  Mean	  (SD)	   COC	  (n=8)	  Mean	  (SD)	   P	  	  Soluble	  Platelet	  selectin(92-­‐212	  ng/ml)	   52.57	  (14.05)	   47.14	  (20.60)	   63.50	  (16.22)	   0.652	  Difference	  	  (95%	  CI)	   Reference	   -­‐5.43	  (-­‐24.59	  to	  13.73)	   10.93	  (-­‐7.63	  to	  29.48)	   	  Soluble	  Cell	  Differentiation	  40	  ligand(0.03-­‐3.98	  ng/ml)	   0.48	  (0.32)	   1.25	  (1.36)	   1.24	  (1.05)	   0.011	  Difference	  	  (95%	  CI)	   Reference	   0.77	  (-­‐0.37	  to	  1.9)	   0.76	  (-­‐0.35	  to	  1.86)	   	  Platelet	  factor	  4	  (<10	  I.U./ml)	   77.00	  (6.28)	   78.50	  (17.67)	   137.00	  (97.58)	   0.004	  Difference	  	  (95%	  CI)	   Reference	   1.5	  (-­‐82.05	  to	  85.05)	   60	  (23.55	  to	  143.55)	   	  





Table	  5-­‐24:	  Endothelial	  activation	  markers	  in	  SCT	  women	  
Laboratory	  marker	  
(Reference	  values)	  	   No	  HC	  (n=7)	  Mean	  (SD)	  	   POC	  (n=7)	  Mean	  (SD)	  	   COC	  (n=8)	  Mean	  (SD)	  	   P	  	  Micro	  particles	  (nMol/ml)	  (<	  10)	   8.34	  (5.15)	   8.32	  (4.02)	   9.96	  (5.36)	   0.769	  Difference	  	  (95%	  CI)	   Reference	   -­‐0.01	  (-­‐5.5	  to	  5.48)	   1.62	  (-­‐3.7	  to	  6.94)	   	  Tissue	  Factor(<	  2	  pMol/ml)	  	   5.48	  (7.54)	   2.12	  (1.89)	   5.67	  (5.43)	   0.015	  Difference	  	  (95%	  CI)	   Reference	   -­‐3.36	  (-­‐9.49	  to	  2.77)	   0.19	  (0.05	  to	  6.12)	   	  





(Reference	  values)	   No	  HC	  (n=7)	  Mean	  (SD)	   POC	  (n=7)	  Mean	  (SD)	   COC	  (n=8)	  Mean	  (SD)	   P	  value	  Soluble	  vascular	  cell	  adhesion	  molecule	  (131-­‐1223	  ng/ml))	   486.42	  (206.99)	   606.42	  (505.56)	   419.75	  (178.04)	   0.018	  Difference	  	  (95%	  CI)	   Reference	   120	  (-­‐244.11	  to	  484.11)	   -­‐66.68	  (-­‐419.23	  to	  285.87)	   	  Soluble	  inter-­‐cellular	  adhesion	  molecule-­‐1	  (41-­‐669	  ng/ml)	   281.44	  (70.19)	   271.87	  (41.29)	   281.62	  (69.55)	   0.404	  Difference	  	  (95%	  CI)	   Reference	   -­‐9.57	  (-­‐79.23	  to	  60.09)	   0.18	  (-­‐67.27	  to	  67.63)	   	  Soluble	  endothelial-­‐leucocyte	  adhesion	  molecule-­‐1	  	  (1.5	  –	  88.1ng/ml))	  
51.14	  (22.98)	   81.00	  (35.18)	   136.12	  (138.41)	   <0.001	  




(Reference	  values)	   No	  HC	  (n=7)	  Mean	  (SD)	   POC	  (n=7)	  Mean	  (SD)	   COC	  (n=8)	  Mean	  (SD)	   P	  	  
Lag	  Time	  (initiated	  with	  5pMol	  Tissue	  Factor)	  (2.0	  -­‐	  3.2	  minutes)	   2.38	  (1.38)	   2.24	  (0.56)	   1.76	  (0.26)	   0.001	  Difference	  	  (95%	  CI)	   Reference	   -­‐0.14	  (-­‐1.13	  to	  0.85)	   -­‐0.62	  (-­‐1.61	  to	  -­‐0.37)	   	  Endogenous	  Thrombin	  Potential	  (initiated	  with	  5pMol	  Tissue	  Factor)	  (1159	  –	  2168	  nMol)	  
1484.71	  (332.92)	   1303.00	  (230.56)	   1608.14	  (282.05)	   0.691	  
Difference	  	  (95%	  CI)	   Reference	   -­‐181.71	  (-­‐501.69	  to	  138.26)	   123.43	  (-­‐196.54	  to	  443.4)	   	  Peak	  Height	  (initiated	  with	  5pMol	  Tissue	  Factor)(	  147	  –	  359	  nM)	   283.85	  (59.41)	   233.85	  (86.88)	   272.51	  (23.38)	   0.021	  Difference	  	  (95%	  CI)	   Reference	   -­‐50	  (-­‐119.91	  to	  19.91)	   -11.34 (-81.25 to -5.85)	   	  Time	  to	  Peak	  (initiated	  with	  5pMol	  Tissue	  Factor)(4.6	  –	  7.4	  min)	   4.93	  (1.63)	   4.12	  (0.80)	   4.40	  (0.95)	   0.198	  Difference	  	  (95%	  CI)	   Reference	   -­‐0.8	  (-­‐2.14	  to	  .53]	   -­‐0.52	  (-­‐1.86	  to	  0.81)	   	  Slope	  (33	  –	  142	  nM/min)	   114.90	  (33.82)	   132.41	  (63.94)	   114.57	  (39.86)	   0.278	  Difference	  	  (95%	  CI)	   Reference	   17.51	  (-­‐36.04	  to	  71.07)	   -­‐0.33	  (-­‐53.88	  to	  53.22)	   	  Start	  Time	  (initiated	  with	  5pMol	  Tissue	  Factor)(19	  -­‐	  28.3	  min)	   20.92	  (2.22)	   24.21	  (5.50)	   23.14	  (3.91)	   0.128	  Difference	  	  (95%	  CI)	   Reference	   3.29	  (-­‐1.33	  to	  7.9)	   2.21	  (-­‐2.4	  to	  6.83)	   	  








(Reference	  values)	   No	  HC	  (n=7)	  Mean	  (SD)	   POC	  (n=7)	  Mean	  (SD)	   COC	  (n=8)	  Mean	  (SD)	   P	  	  
Free	  Hb	  (0-­‐1/l)	   0.14	  (0.19)	   0.12	  (0.09)	   0.05	  (0.05)	   0.194	  Difference	  	  (95%	  CI)	   Reference	   -­‐0.02	  (-­‐0.16	  to	  0.13)	   0.09	  (-­‐0.23	  to	  0.05)	   	  Haptoglobin	  (<	  1.22	  g/l)	   1.11	  (0.43)	   1.15	  (0.44)	   0.88	  (0.34)	   0.776	  Difference	  	  (95%	  CI)	   Reference	   0.03	  (-­‐0.42	  to	  0.49)	   -­‐0.23	  (-­‐0.68	  to	  0.21)	   	  Lactate	  dehydrogenase	  (240-­‐480	  units/l)	   417.83	  (76.16)	   467.28	  (57.29)	   406.71	  (62.45)	   0.803	  Difference	  	  (95%	  CI)	   Reference	   49.45	  (-­‐26.99	  to	  125.9)	   -­‐11.12	  (-­‐87.56	  to	  65.33)	   	  Bilirubin	  (<	  21	  μMol/l)	   5.28	  (1.70)	   7.00	  (3.46)	   9.62	  (5.620	   0.028	  Difference	  	  (95%	  CI)	   Reference	   1.71	  (-­‐2.81	  to	  6.24)	   4.34	  (0.05	  to	  8.72)	   	  





(Reference	  values)	   No	  HC	  (n=7)	  Mean	  (SD)	   POC	  (n=7)	  	  	  Mean	  (SD)	   COC	  (n=8)	  Mean	  (SD)	   P	  	  Alanine	  amino	  transferase	  (<33	  units/l)	  	   20.14	  (13.35)	   14.71	  (3.90)	   19.12	  (5.61)	   0.820	  Difference	  	  (95%	  CI)	   Reference	   -­‐5.43	  (-­‐14.97	  to	  4.12)	   -­‐1.02	  (-­‐10.26	  to	  8.22)	   	  Aspartate	  amino	  transferase	  (	  <31	  units/l)	   23.71	  (9.17)	   23.14	  (4.87)	   19.75	  (2.49)	   0.219	  Difference	  	  (95%	  CI)	   Reference	   -­‐0.57	  (-­‐7.32	  to	  6.18)	   -­‐3.96	  (-­‐10.5	  to	  2.57)	   	  Alkaline	  phosphatase	  (<	  129	  units/l)	  	   54.57	  (22.99)	   64.14	  (17.78)	   56.62	  (18.89)	   0.844	  Difference	  	  (95%	  CI)	   Reference	   9.57	  (-­‐12.76	  to	  31.9)	   2.05	  (-­‐19.57	  to	  23.68)	   	  Serum	  albumin	  (35-­‐50g/l)	   42.42	  (1.61)	   43.71	  (2.13)	   45.12	  (6.08)	   0.206	  Difference	  	  (95%	  CI)	   Reference	   1.29	  (-­‐3.17	  to	  5.75)	   2.7	  (-­‐1.62	  to	  7.02)	   	  
Table:	  5-­‐28	  Biochemical	  markers	  of	  liver	  function	  in	  SCT	  women	  
Laboratory	  marker	  
(Reference	  values)	  	   No	  HC	  (n=7)	  Mean	  (SD)	  	   POC	  (n=7)	  Mean	  (SD)	  	   COC	  (n=8)	  Mean	  (SD)	  	   P	  	  Haemoglobin	   (11.5-­‐15-­‐5	  g/dl)	   11.65	  (0.54)	   12.47	  (1.03)	   11.75	  (1.17)	   0.265	  Difference	  	  (95%	  CI)	   Reference	   -­‐0.62	  (-­‐93.31	  to	  92.07)	   26.38	  (-­‐66.31	  to	  119.07)	   	  Platelet	   count	   (140-­‐400	  10^9/l)	   252.33	  (84.91)	   251.71	  (70.91)	   278.71	  (81.43)	   0.913	  Difference	  	  (95%	  CI)	   Reference	   0.92	  (-­‐0.22	  to	  2.06)	   0.21	  (-­‐0.94	  to	  1.35)	   	  Haematocrit	   (0.35-­‐0.47	  l/l)	   0.35	  (0.02)	   0.38	  (0.03)	   0.36	  (0.03)	   0.514	  Difference	  	  (95%	  CI)	   Reference	   0.03	  (-­‐0.02	  to	  .07)	   0.01	  (-­‐0.03	  to	  -­‐0.05)	   	  





(Reference	  values)	   No	  HC	  (n=7)	  Mean	  (SD)	   POC	  (n=7)	  Mean	  (SD)	   COC	  (n=8)	  Mean	  (SD)	  	   P	  value	  Complement	  reactive	   protein	  (0.2-­‐10.0	  mcg/ml)	   13.28	  (10.79)	   13.57	  (16.29)	   11.12	  (8.55)	   0.270	  Difference	  	  (95%	  CI)	   Reference	   0.29	  (-­‐13.31	  to	  13.88)	   -­‐2.16	  (-­‐15.32	  to	  11)	   	  White	   blood	   cells	  	  (3.5-­‐11.0	  10^9/l))	   5.78	  (2.59)	   4.16	  (1.26)	   6.90	  (1.99)	   0.724	  Difference	  	  (95%	  CI)	   Reference	   -­‐1.62	  (-­‐5.73	  to	  2.5)	   1.13	  (-­‐1.92	  to	  4.18)	   	  Neutrophils	   (1.7-­‐8.0	  10^9/l))	   3.21	  (1.62)	   1.90	  (0.94)	   3.99	  (1.79)	   0.813	  Difference	  	  (95%	  CI)	   Reference	   -­‐1.3	  (-­‐4.29	  to	  1.68)	   0.79	  (-­‐1.42	  to	  3)	   	  Lymphocytes	   (1.0-­‐3.510^9/l))	   1.93	  (1.28)	   1.75	  (0.07)	   2.29	  (0.37)	   0.023	  Difference	  	  (95%	  CI)	   Reference	   -­‐0.18	  (-­‐1.89	  to	  1.53)	   0.36	  (0.19	  to	  1.63)	   	  Monocytes	   (0.1-­‐1.010^9/l)	   0.31	  (0.15)	   0.42	  (0.13)	   0.34	  (0.08)	   0.827	  Difference	  	  (95%	  CI)	   Reference	   0.03	  (-­‐0.23	  to	  0.28)	   0.11	  (-­‐0.08	  to	  0.3)	   	  Eosinophils	   (0.0-­‐0.46	  10^9/l))	   0.22	  (0.17)	   0.15	  (0.15)	   0.17	  (0.10)	   0.637	  Difference	  	  (95%	  CI)	   Reference	   -­‐0.07	  (-­‐0.35	  to	  0.2)	   -­‐0.04	  (-­‐0.25	  to	  0.16)	   	  Basophils	   (0.0-­‐0.20	  10^9/l))	   0.02	  (0.19)	   0.01	  (0.00)	   0.03	  (0.02)	   0.609	  Difference	  	  (95%	  CI)	   Reference	   -­‐0.01	  (-­‐0.05	  to	  0.02]	   0	  (-­‐0.02	  to	  0.03)	   	  
Table	  5-­‐30:	  Inflammatory	  markers	  in	  SCT	  women	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5.7 SUMMARY	  OF	  RESULTS	  FOR	  THE	  SCT	  WOMEN	  
The	  prior	  enrollment	  contraception	  period	  is	  more	  evenly	  distributed	  between	  the	  three	  groups	  of	  SCT	  women.	  There	  are	  minimal	  serious	  clinical	  events	  noted	  in	  SCT	  women.	  
	  
The	   pro	   and	   anti-­‐	   coagulant	  markers	   showed	   some	   interesting	   differences:	   Free	  protein	  S	  level	  is	  lower	  than	  the	  reference	  range	  in	  the	  group	  of	  women	  using	  POC	  and	   women	   not	   using	   any	   HC	   methods.	   This	   adverse	   result	   is	   statistically	  significantly	  different	  from	  the	  levels	  in	  women	  using	  COC.	  There	  was	  an	  increase	  in	   Factor	   VIII	   levels	   in	   SCT	   women	   using	   POC,	   with	   again	   the	   group	   using	   COC	  showing	   the	   best	   results	   in	   this	   comparison.	   The	   SCT	  women	   not	   using	   any	   HC	  have	  APTT	  and	  Fibrinogen	   levels	  which	  are	  higher	   than	   the	   reference	   range	  and	  this	  was	  statistically	  significantly	  different	  from	  the	  levels	  in	  the	  other	  two	  groups.	  FII	   levels	   were	   	   higher	   than	   the	   reference	   range	   in	   SCT	  women	   using	   COC.	   The	  difference	  is	  statistically	  significant.	  	  
Coagulation	  activation	  markers	  showed	  also	  were	  found	  to	  have	  some	  interesting	  values	   and	   differences.	   TAT	   levels	   weremore	   than	   2.5	   times	   higher	   than	   the	  reference	  range	  in	  the	  women	  using	  COC.	  The	  differenece	  between	  the	  groups	  was	  statistically	   signficant.	   Prothrombin	   fragment	   F1+2	   level	   were	   statistically	  significantly	   high	   in	   the	   COC	   group,	   although	   the	   level	   itself	  was	  well	  within	   the	  reference	  range.	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Similar	   to	   the	   coagulation	   activation	   markers,	   two	   of	   the	   platelet	   activation	  markers,	  sCD40	  and	  PF4,	  were	  statistically	  significantly	  higher	  than	  the	  reference	  group	   in	  women	  using	  COC.	  However,	  whilst,	  PF4	   is	  elevated	   in	  all	   three	  groups,	  the	  elevation	  in	  women	  using	  COC	  is	  twice	  as	  high	  as	  in	  the	  other	  two	  groups	  (	  13	  times	   higher	   than	   the	   normal	   range).	   SCD40	   ligand	   is	   increased	   in	   the	   women	  using	  POC	  in	  addition	  to	  the	  women	  using	  COC,	  but	  still	  in	  the	  normal	  range.	  
All	   the	   endothelial	   activation	   marker	   levels,	   except	   sE	   selectin	   were	   within	   the	  reference	  range	  (however,	  it	  should	  be	  noted	  that	  the	  reference	  range	  is	  wide).	  SE	  selectin	   was	   elevated	   in	   women	   using	   COC	   and	   this	   increase	   was	   statistically	  significant.	  The	  differences	  in	  sVCAM	  levels	  were	  also	  statistically	  significant,	  with	  the	  group	  taking	  POC	  showing	  the	  highest	  levels.	  	  
	  
Markers	  of	   tissue	  damage	   in	  SCT	  women	  showed	  two	  different	  directions.	  While,	  MPs	  were	  within	  the	  reference	  range	  in	  all	  three	  groups.	  TF,	  in	  contrast	  was	  	  raised	  two	  above	   the	   reference	   range	   in	  women	   taking	  COC	  and	  women	  not	   taking	  any	  contraception.	   The	   difference	   in	   TF	   values	   between	   the	   three	   groups	   was	  statistically	  significant.	  
Two	  of	   the	   thrombin	   generation	   test	   parameter	   (PH	   (5pM)	   and	  LT	   (5pM))	  were	  statistically	  significantly	  higher	  in	  women	  not	  using	  HC.	  




Figure	  5-­‐3:	  This	  is	  a	  twenty	  six	  year	  old	  woman	  with	  normal	  haemoglobin	  type	  (This	  picture	  
is	  inserted	  with	  full	  permission	  of	  the	  participant)	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5.8 CLINICAL	  EVENTS	  IN	  WOMEN	  WITH	  NORMAL	  HAEMOGLOBIN	  




COC	  	  (n=10)	  
Mean	  (SD)	  
P	  	  Number	  of	  previous	  pregnancies	  Mean	  (SD)	   1.40	  (0.88)	   1.75	  (1.16)	   1.10(0.87)	   0.670	  Difference	  	  (95%	  CI)	   Reference	   0.35(-­‐2.0	  to-­‐2.89)	   -­‐0.3(-­‐6.18	  to	  -­‐3.64)	   	  Duration	  of	  use	  of	  contraceptive	  method	  prior	  to	  enrolment	  (months)	  Mean(SD)	  
20	  (7.68)	   14	  (16.36)	   15.2	  (10.07)	   0.543	  
Difference	  	  (95%	  CI)	   Reference	   -­‐6(-­‐8.54	  to-­‐3.45)	   -­‐4.8(-­‐7.15	  to	  -­‐2.25)	   	  
Table	  5-­‐31:	  Obstetric	  history	  and	  duration	  of	  use	  of	  their	  contraceptive	  method	  prior	  to	  the	  
enrolment	  interview	  in	  women	  with	  normal	  Hb	  
Clinical	  variables	   No	  HC	  (n=9)	  
Mean	  (SD)	  
POC	  (n=8)	  	  	  	  
Mean	  (SD)	  
COC	  (n=10)	  	  	  
Mean	  (SD)	  Severe	  sickle	  crises	  (total)	   0	   0	   0	  Hospital	  admissions	  (total)	   3	   1	   2	  Blood	  transfusions	  (total	  number	  of	  sessions)	   0	   0	   0	  VTE	  (DVT	  &	  PE)	   0	   0	   0	  Strokes	  &	  heart	  attacks	  	   0	   0	   0	  Arterial	  thromboses	   0	   0	   0	  




Clinical	  variables	   No	  HC	  (n=9)	  
Mean	  (SD)	   POC	  (n=8)	  	  Mean	  (SD)	   COC	  (n=10)	  Mean	  (SD)	  Side	  effects	  (i.e.	  headaches,	  nausea,	  mood	  swings,	  bloatedness,	  breast	  tenderness)	  
0	   3	   1	  
Discontinuation	   0	   1	   0	  Unintended	  interruptions	   0	   2	   0	  Planned	  pregnancies	   0	   1	   0	  Unplanned	  pregnancies	   1	   0	   0	  Amenorrhoea	   0	   2	   0	  Menstrual	  irregularities	   2	   3	   0	  




5.9 LABORATORY	  RESULTS	  FOR	  WOMEN	  WITH	  NORMAL	  HAEHOGLOBIN	  
Laboratory	  marker	  
(reference	  values)	  	   No	  HC	  (n=9)	  Mean	  (SD)	   POC	  (n=8)	  Mean	  (SD)	   COC	  (n=10)	  Mean	  (SD)	   P	  	  Prothrombin	  time	  (12	  –	  15	  seconds)	   10.77	  (0.72)	   11.23	  (0.57)	   11.16	  (0.97)	   0.346	  Difference	  	  (95%	  CI)	   Reference	   0.47	  (-­‐0.5	  to	  1.44)	   -­‐0.97	  (-­‐2.09	  to	  .14)	   	  International	  normalised	  ratio	  (INR)(0.8-­‐1.2)	   1.00	  (0.06)	   1.04	  (0.05)	   1.03	  (0.08)	   0.398	  Difference	  	  (95%	  CI)	   Reference	   0.03	  (-­‐0.02	  to	  .08)	   -­‐0.03	  (-­‐0.09	  to	  .04)	   	  Activated	  partial	  thromboplastin	  time	  (25-­‐35	  seconds)	   31.08	  (2.18)	   30.15	  (2.13)	   30.00	  (2.62)	   0.810	  Difference	  	  (95%	  CI)	   Reference	   0.36	  (-­‐0.87	  to	  1.6)	   0.46	  (-­‐0.96	  to	  1.88)	   	  Thrombin	  Time	  	  (12-­‐14	  seconds)	   15.01	  (0.76)	   14.05	  (1.29)	   14.19	  (1.07)	   0.384	  Difference	  	  (95%	  CI)	   Reference	   -­‐0.8	  (-­‐1.33	  to	  -­‐0.27)	   -­‐0.59	  (-­‐1.19	  to	  0.02)	   	  Fibrinogen	  	  (2.14-­‐3.51	  g/dL)	  	   2.82	  (0.51)	   3.14	  (0.63)	   3.11	  (0.52)	   0.813	  Difference	  	  (95%	  CI)	   Reference	   -­‐0.04	  (-­‐0.5	  to	  0.43)	   -­‐0.14	  (-­‐0.68	  to	  0.39)	   	  Factor	  VIII:C	  	  (50-­‐150	  iu/dL)	  	   143.55	  (42.86)	   152.37	  (62.81)	   155.10	  (39.99)	   0.400	  Difference	  	  (95%	  CI)	   Reference	   -­‐6.9	  (-­‐26.78	  to	  12.98)	   -­‐17.78	  (-­‐40.5	  to	  4.94)	   	  von	  Willebrand	  Factor	  antigen	  (46	  –	  153	  iu/dL)	   143.13	  (45.89)	   129.66	  (53.53)	   109.77	  (35.18)	   0.512	  Difference	  	  (95%	  CI)	   Reference	   -­‐15.27	  (-­‐41.37	  to	  10.83)	   -­‐38.83	  (-­‐68.84	  to	  -­‐8.82)	   	  Dilute	  Viper	  Venom	  Time	  (ratio)	  (<1.16)	   0.91	  (0.04)	   1.09	  (0.24)	   1.16	  (0.19)	   <0.001	  Difference	  	  (95%	  CI)	   Reference	   0.06	  (-­‐0.02	  to	  0.14)	   0.1	  (0.01	  to	  0.19)	   	  





(reference	  values)	  	   No	  HC	  (n=9)	  Mean	  (SD)	   POC	  (n=8)	  Mean	  (SD)	   COC	  (n=10)	  Mean	  (SD)	   P	  	  Anti-­‐thrombin	  :	  Activity	  (85-­‐113	  iu/dL)	   105.87	  (5.82)	   109.07	  (9.34)	   102.33	  (7.64)	   0.458	  Difference	  	  (95%	  CI)	   Reference	   -­‐1.39	  (-­‐5.85	  to	  3.06)	   -­‐3.1	  (-­‐8.23	  to	  2.02)	   	  Protein	  C	  :	  Activity	  (70-­‐135	  iu/dL)	   100.38	  (23.48)	   105.20	  (19.57)	   98.10	  (23.52)	   0.861	  Difference	  	  (95%	  CI)	   Reference	   -­‐1.31	  (-­‐9.79	  to	  7.17)	   1.61	  (-­‐8.14	  to	  11.36)	   	  Free	  Protein	  S	  	  (75-­‐125	  iu/dL)	   73.22	  (10.60)	   66.87	  (20.15)	   78.60	  (25.60)	   0.067	  Difference	  	  (95%	  CI)	   Reference	   1.27	  (-­‐6.87	  to	  9.42)	   12.92	  (3.56	  to	  22.28)	   	  Activated	  Protein	  C	  Resistance	  (Factor	  V	  Leiden)	  (>2.0)	   2.71	  (0.03)	   2.71	  (0.09)	   2.78	  (0.07)	   0.024	  Difference	  	  (95%	  CI)	   Reference	   0.05	  (-­‐0.07	  to	  0.16)	   -­‐0.03	  (-­‐0.01	  to	  -­‐0.15)	   	  Factor	  II	  (84.3-­‐120.0	  iu/dL)	   101.66	  (26.41)	   107	  75	  (16.85)	   117.80	  (18.74)	   0.429	  Difference	  	  (95%	  CI)	   Reference	   3.04	  (-­‐3.81	  to	  9.89)	   12.33	  (4.46	  to	  20.21)	   	  Factor	  V	  (63.85-­‐120.5	  iu/dL)	   80.55	  (8.88)	   94.87	  (10.77)	   97.70	  (17.07)	   0.160	  Difference	  	  (95%	  CI)	   Reference	   2.3	  (-­‐5.26	  to	  9.86)	   4.58	  (-­‐4.11	  to	  13.27)	   	  Factor	  VII	  (77.5-­‐150.5	  iu/dL)	   86.88	  (24.79)	   83.62	  (11.81)	   95.50	  (20.30)	   0.176	  Difference	  	  (95%	  CI)	   Reference	   -­‐8.32	  (-­‐17.18	  to	  0.53)	   -­‐4.1	  (-­‐14.28	  to	  6.08)	   	  








No	  HC	  (n=9)	  Mean	  
(SD)	   POC	  (n=8)	  Mean	  (SD)	   COC	  (n=10)	  Mean	  (SD)	  	   P	  	  Factor	  IX	  	  (77.7-­‐130.0	  iu/dL)	   96.22	  (16.70)	   102.00	  (14.11)	   127	  90	  (44.03)	   0.003	  Difference	  	  (95%	  CI)	   Reference	   2.1	  (-­‐11.6	  to	  15.81)	   3.13	  (2.62	  to	  18.89)	   	  Factor	  X	  (71.8-­‐130.0	  iu/dL)	   93.66	  (17.72)	   92.37	  (16.30)	   105.30	  (21.45)	   0.733	  Difference	  	  (95%	  CI)	   Reference	   -­‐1.95	  (-­‐9.84	  to	  5.95)	   8.17	  (-­‐0.91	  to	  17.24)	   	  Factor	  XI	  (68-­‐144	  iu/dL)	   94.44	  (9.55)	   103.37	  (22.28)	   99.80	  (14.05)	   0.081	  Difference	  	  (95%	  CI)	   Reference	   -­‐0.83	  (-­‐8.39	  to	  6.72)	   4.04	  (-­‐4.65	  to	  12.72)	   	  Factor	  XII	  (46.7-­‐181.0	  iu/dL)	   83.77	  (24.05)	   120.25	  (40.14)	   116.80	  (49.13)	   0.158	  Difference	  	  (95%	  CI)	   Reference	   -­‐1.07	  (-­‐14.44	  to	  12.31)	   9.76	  (-­‐5.62	  to	  25.14)	   	  Factor	  XIIIa	  (97.4-­‐179.0	  iu/dL)	   97.77	  (20.18)	   87.12	  (29.14)	   68.70	  (19.79)	   0.482	  Difference	  	  (95%	  CI)	   Reference	   -­‐4.41	  (-­‐14.7	  to	  5.88)	   -­‐5.95	  (-­‐17.71	  to	  5.82)	   	  











(reference	  values)	  	   No	  HC	  (n=9)	  Mean	  (SD)	   POC	  (n=8)	  Mean	  (SD)	   COC	  (n=10)	  Mean	  (SD)	   P	  	  Thrombin:anti-­‐thrombin	  III	  complex	  	  (2	  -­‐	  4.2	  mcg/l)	   4.90	  (1.91)	   4.21	  (1.80)	   3.53	  (0.70)	   0.020	  Difference	  	  (95%	  CI)	   Reference	   -­‐9.18	  (-­‐18.37	  to	  0.02)	   -­‐7.03	  (-­‐17.59	  to	  -­‐3.52)	   	  Prothrombin	  fragment	  1	  +	  2	  (69	  –	  229	  pmol/L)	   144.11	  (78.38)	   120.12	  (46.96)	   156.80	  (60.94)	   0.407	  Difference	  	  (95%	  CI)	   Reference	   -­‐81.84	  (-­‐200.39	  to	  36.7)	   -­‐168.36	  (-­‐304.47	  to	  -­‐32.25)	   	  D	  dimer	  (ng/ml)	  (<130)	   107.00	  (48.24)	   137.12	  (103.39)	   107.00	  (54.82)	   0.096	  Difference	  	  (95%	  CI)	   Reference	   -­‐148.52	  (-­‐456.1	  to	  159.05)	   -­‐407.9	  (-­‐759.6	  to	  -­‐56.2)	   	  
Table	  5-­‐37	  :	  Coagulation	  activation	  markers	  in	  the	  women	  with	  normal	  Hb	  
Laboratory	  marker	  
(reference	  values)	  	   No	  HC	  (n=9)	  Mean	  (SD)	   POC	  (n=8)	  Mean	  (SD)	   COC	  (n=10)	  Mean	  (SD)	   P	  	  Soluble	  Platelet	  selectin(92-­‐212	  ng/ml)	   53.55	  (12.99)	   53.25	  (11.56)	   52.30	  (17.45)	   0.491	  Difference	  	  (95%	  CI)	   Reference	   -­‐3.03	  (-­‐14.78	  to	  8.72)	   -­‐11.41	  (-­‐24.74	  to	  1.92)	   	  Soluble	  Cell	  Differentiation	  40	  ligand	  (0.03-­‐3.98	  ng/ml)	  
0.59	  (0.18)	   2.27	  (2.36)	   5.49	  (0.83)	   <0.001	  
Difference	  	  (95%	  CI)	   Reference	   0.57	  (0.42	  to	  1.96)	   1.71	  (0.13	  to	  3.28)	   	  Platelet	  factor	  4	  (<10	  I.U./ml)	   82.33	  (19.29)	   105.00	  (16.30)	   79.50	  (19.09)	   0.992	  Difference	  	  (95%	  CI)	   Reference	   14.75	  (-­‐19.47	  to	  48.97)	   9.8	  (-­‐35.79	  to	  55.39)	   	  




(reference	  values)	  	   No	  HC	  (n=9)	  Mean	  (SD)	   POC	  (n=8)	  Mean	  (SD)	   COC	  (n=10)	  Mean	  (SD)	  	   P	  	  Soluble	  vascular	  cell	  adhesion	  molecule	  (131-­‐1223	  ng/ml))	   507.66	  (260.05)	   396.00	  (154.43)	   608.90	  (298.83)	   <0.001	  Difference	  	  (95%	  CI)	   Reference	   40.59	  (-­‐251.27	  to	  332.44)	   -­‐198.64	  (-­‐529.78	  to	  -­‐132.5)	   	  Soluble	  inter-­‐cellular	  adhesion	  molecule-­‐1	  (41-­‐669	  ng/ml)	   354.33	  (102.25)	   270.31	  (42.35)	   279.97	  (56.34)	   0.051	  Difference	  	  (95%	  CI)	   Reference	   -­‐36.11	  (-­‐104.36	  to	  32.15)	   -­‐136.86	  (-­‐214.3	  to	  -­‐-­‐59.42)	   	  Soluble	  endothelial-­‐leucocyte	  adhesion	  molecule-­‐1	  	  (1.5	  –	  88.1ng/ml))	  
66.55	  (13.15)	   69.87	  (31.30)	   72.90	  (27.85)	   0.073	  
Difference	  	  (95%	  CI)	   Reference	   -­‐4.98	  (-­‐26.03	  to	  16.07)	   31.61	  (7.73	  to	  55.5)	   	  
Table	  5-­‐39	  Endothelial	  activation	  markers	  in	  the	  women	  with	  normal	  Hb	  
Laboratory	  marker	  
(reference	  values)	  	   No	  HC	  (n=9)	  Mean	  (SD)	   POC	  (n=8)	  Mean	  (SD)	   COC	  (n=10)	  Mean	  (SD)	   P	  	  Micro	  particles	  (nMol/ml)	  (<	  10)	   8.95	  (4.03)	   6.70	  (2.27)	   9.58	  (1.11)	   <0.001	  Difference	  	  (95%	  CI)	   Reference	   2.66	  (-­‐6.51	  to	  11.83)	   -­‐10.64	  (-­‐21.16	  to	  -­‐0.11)	   	  Tissue	  Factor(<2	  pMol/ml)	  	   5.60	  (5.90)	   6.12	  (6.10)	   6.12	  (6.37)	   0.926	  Difference	  	  (95%	  CI)	   Reference	   -­‐2.63	  (5.57	  to	  0.32)	   -­‐1.18	  (-­‐4.45	  to	  2.09)	   	  







(reference	  values)	  	   No	  HC	  (n=9)	  Mean	  (SD)	   POC	  (n=8)	  Mean	  (SD)	   COC	  (n=10)	  Mean	  (SD)	   P	  	  Lag	  Time	  (initiated	  with	  5pMol	  Tissue	  Factor)	  (2.0	  -­‐	  3.2	  minutes)	  
1.87	  (0.40)	   2.42	  (0.90)	   2.22	  (0.40)	   0.032	  
Difference	  	  (95%	  CI)	   Reference	   0.04	  (-­‐0.25	  to	  0.34)	   -­‐0.01	  (-­‐0.35	  to	  0.34)	   	  Endogenous	  Thrombin	  Potential	  (initiated	  with	  5pMol	  Tissue	  Factor)	  (1159	  –	  2168	  nM)	  
1637.88	  (284.27)	   1636.87	  (364.16)	   1837.60	  (337.35)	   0.798	  
Difference	  	  (95%	  CI)	   Reference	   56.97	  (-­‐71.08	  to	  185.01)	   229.19	  (81.08	  to	  377.3)	   	  Peak	  Height	  (initiated	  with	  5pMol	  Tissue	  Factor)	  (	  147	  –	  359	  nM)	  
322.00	  (37.80)	   320.75	  (84.72)	   310.30	  (72.63)	   0.106	  
Difference	  	  (95%	  CI)	   Reference	   -­‐0.02	  (-­‐26.45	  to	  26.41)	   5.8	  (-­‐24.77	  to	  36.37)	   	  Time	  to	  Peak	  (initiated	  with	  5pMol	  Tissue	  Factor)	  (4.6	  –	  7.4	  min)	  
4.27	  (0.47)	   4.40	  (0.69)	   4.60	  (0.81)	   0.354	  
Difference	  	  (95%	  CI)	   Reference	   -­‐0.09	  (-­‐0.48	  to	  0.3)	   0.01	  (-­‐0.44	  to	  0.47)	   	  Slope	  (33	  –	  142	  nM/min)	   134.62	  (17.37)	   187.55	  (101.15)	   138.00	  (53.60)	   <0.001	  Difference	  	  (95%	  CI)	   Reference	   12.83	  (-­‐7.84	  to	  33.5)	   5.35	  (1.85	  to	  29.26)	   	  Start	  Time	  (initiated	  with	  5pMol	  Tissue	  Factor)	  (19	  28.3	  min)	   20.22	  (1.71)	   21.37	  (2.86)	   24.45	  (3.37)	   0.187	  Difference	  	  (95%	  CI)	   Reference	   1.47	  (-­‐0.01	  to	  2.95)	   3.15	  (1.43	  to	  4.86)	   	  







(reference	  values)	  	   No	  HC	  (n=9)	  Mean	  (SD)	   POC	  (n=8)	  Mean	  (SD)	   COC	  (n=10)	  Mean	  (SD)	   P	  	  Free	  Hb	  (0.0	  –	  0.5.mg/l)	   0.05	  (0.08)	   0.06	  (0.05)	   0.06	  (0.06)	   0.520	  Difference	  	  (95%	  CI)	   Reference	   -­‐0.01	  (-­‐0.05	  to	  0.03)	   -­‐0.03	  (-­‐0.07	  to	  0.02)	   	  Haptoglobin	  (<	  1.22	  g/l)	   1.28	  (0.69)	   1.19	  (0.54)	   1.13	  (0.44)	   0.497	  Difference	  	  (95%	  CI)	   Reference	   -­‐0.01	  (-­‐0.26	  to	  0.24)	   -­‐0.21	  (-­‐0.49	  to	  0.08)	   	  Lactate	  dehydrogenase	  (240-­‐480	  units/l)	   379.14	  (70.03)	   371.00	  (134.91)	   432.75	  (134.38)	   0.262	  Difference	  	  (95%	  CI)	   Reference	   -­‐68.91	  (-­‐178.81	  to	  40.99)	   -­‐162.29	  (-­‐291.32	  to	  -­‐33.26)	   	  Bilirubin	  	  (<	  21	  μMol/l)	   6.37	  (2.13	   8.12	  (6.24	   6.50	  (2.07)	   0.004	  Difference	  	  (95%	  CI)	   Reference	   -­‐0.43	  (-­‐11.95	  to	  11.09)	   -­‐10.96	  (-­‐24.3	  to	  -­‐2.37)	   	  










(reference	  values)	  	   No	  HC	  (n=9)	  Mean	  (SD)	   POC	  (n=8)	  Mean	  (SD)	   COC	  (n=10)	  Mean	  (SD)	   P	  	  Alanine	  amino	  transferase	  (<33	  units/l)	  	   11.37	  (2.61)	   25.00	  (20.88)	   15.44	  (4.69)	   <0.001	  Difference	  	  (95%	  CI)	   Reference	   0.28	  (-­‐4.44	  to	  4.99)	   0.54	  (0.16	  to	  4.93)	   	  Aspartate	  amino	  transferase	  (<31	  units/l)	   20.87	  (4.58)	   22.31	  (6.39)	   25.62	  (6.20)	   0.661	  Difference	  	  (95%	  CI)	   Reference	   -­‐3.13	  (-­‐8.98	  to	  2.73)	   -­‐3.68	  (-­‐10.49	  to	  3.13)	   	  Alkaline	  phosphatase	  (<	  129	  units/l)	  	   69.62	  (17.48)	   96.00	  (77.63)	   69.66	  (27.69)	   0.001	  Difference	  	  (95%	  CI)	   Reference	   5.48	  (-­‐12.91	  to	  23.87)	   -­‐6.85	  (-­‐28.19	  to	  -­‐1.48)	   	  Serum	  albumin	  (35-­‐50g/l)	   45.37	  (1.84)	   42.61	  (5.60)	   43.88	  (2.26)	   0.007	  Difference	  	  (95%	  CI)	   Reference	   -­‐0.32	  (-­‐1.92	  to	  1.28)	   -­‐0.67	  (-­‐2.53	  to	  -­‐0.12)	   	  
Table	  5-­‐43:	  Biochemical	  markers	  of	  liver	  function	  in	  the	  women	  with	  normal	  Hb	  
Laboratory	  marker	  
(reference	  values)	  	   No	  HC	  (n=9)	  Mean	  (SD)	   POC	  (n=8)	  Mean	  (SD)	   COC	  (n=10)	  Mean	  (SD)	   P	  	  Haemoglobin	  (11.5-­‐15-­‐5	  g/dl)	   12.18	  (0.49)	   11.95	  (1.07)	   12.04	  (0.97)	   0.110	  Difference	  	  (95%	  CI)	   Reference	   0.21	  (-­‐0.55	  to	  0.98)	   1.36	  (0.47	  to	  2.25)	   	  Platelet	  count	  (140-­‐400	  10^9/l)	   261.44	  (54.42)	   228.00	  (46.01)	   233.50	  (70.88)	   0.486	  Difference	  	  (95%	  CI)	   Reference	   -­‐12.89	  (-­‐62.51	  to	  36.74)	   -­‐34.44	  (-­‐91.77	  to	  22.88)	   	  Haematocrit	  (0.35-­‐0.47	  l/l)	   0.37	  (0.02)	   0.37	  (0.04)	   0.37	  (0.02)	   0.183	  Difference	  	  (95%	  CI)	   Reference	   0	  (-­‐0.02	  to	  0.03)	   0.04	  (0.01	  to	  0.07)	   	  





(reference	  values)	  	   No	  HC	  (n=9)	  Mean	  (SD)	   POC	  (n=8)	  Mean	  (SD)	   COC	  (n=10)	  Mean	  (SD)	   P	  	  
Complement	  reactive	  protein	  (0.2-­‐10.0	  mcg/ml)	   17.66	  (20.63)	   13.00	  (9.98)	   16.22	  (9.70)	   0.139	  Difference	  	  (95%	  CI)	   Reference	   -­‐1.25	  (-­‐10.89	  to	  8.39)	   -­‐4.98	  (-­‐15.82	  to	  5.86)	   	  White	  blood	  cells	  	  (3.5-­‐11.0	  10^9/l))	   5.33	  (0.93)	   6.41	  (2.84)	   6.99	  (2.02)	   0.030	  Difference	  	  (95%	  CI)	   Reference	   0.54	  (-­‐0.77	  to	  1.85)	   0.89	  (-­‐0.64	  to	  2.43)	   	  Neutrophils	  (1.7-­‐8.0	  10^9/l))	   2.49	  (0.44)	   2.95	  (0.82)	   3.32	  (1.20)	   0.054	  Difference	  	  (95%	  CI)	   Reference	   0.36	  (-­‐0.54	  to	  1.26)	   0.73	  (-­‐0.3	  to	  1.76)	   	  Lymphocytes	  (1.0-­‐3.510^9/l))	   2.23	  (0.48)	   1.80	  (0.78)	   2.35	  (0.98)	   0.203	  Difference	  	  (95%	  CI)	   Reference	   0.18	  (-­‐0.26	  to	  0.61)	   0.1	  (-­‐0.4	  to	  0.6)	   	  Monocytes	  (0.1-­‐1.010^9/l)	   0.45	  (0.10)	   0.45	  (0.09)	   0.45	  (0.21)	   0.101	  Difference	  	  (95%	  CI)	   Reference	   0.13	  (-­‐0.04	  to	  0.31)	   0.05	  (-­‐0.15	  to	  0.25)	   	  Eosinophils	  (0.0-­‐0.46	  10^9/l))	   0.13	  (0.79)	   0.14	  (0.10)	   0.21	  (0.26)	   0.007	  Difference	  	  (95%	  CI)	   Reference	   0	  (-­‐0.1	  to	  0.09)	   0.05	  (0.01	  to	  0.16)	   	  Basophils	  (0.0-­‐0.20	  10^9/l))	   0.02	  (0.008)	   0.01	  (0.01)	   0.02	  (0.01)	   0.518	  Difference	  	  (95%	  CI)	   Reference	   0	  (-­‐0.01	  to	  0.02)	   0	  (-­‐0.02	  to	  0.01)	   	  





5.10 SUMMARY	  OF	  RESULTS	  FOR	  WOMEN	  WITH	  NORMAL	  HB	  	  
There	  is	  even	  distribution	  of	  the	  duration	  of	  contraception	  use	  between	  the	  three	  groups.	  As	  expected,	  serious	  clinical	  events	  were	  minimal	  during	  the	  study	  period.	  
Contraceptive	   side	   effects	   are	   relatively	   uncommon	   and	   evenly	   distributed	  between	  all	  the	  women	  with	  normal	  haemoglobin.	  
All	   the	  pro	   and	   anti-­‐coagulant	  markers	   in	  women	  with	  normal	  Hb	   lie	  within	   the	  reference	   range	   however,	   there	   is	   a	   tendency	   for	   the	   APCR	   mean	   value	   to	   be	  statistically	   significantly	   higher	   in	   the	   group	   using	   COC.	   Factor	   VIIIC	   levels	  were	  high	   in	  women	  using	  POC	  and	  COC	  compared	  with	   levels	   in	  women	  using	  no	  HC.	  Though	   DRVVT	   values	   remained	  within	   the	   reference	   range	   however,	   there	   is	   a	  statistically	  significant	  difference	  between	  the	  groups,	  with	  women	  using	  COC	  and	  POC	  having	  the	  higher	  levels.	  Factor	  IX	  levels	  werestatistically	  significantly	  higher	  in	  women	  using	  COC	  but	  the	  values	  were	  within	  the	  reference	  range.	  
	  
Rather	  strangely,	  TAT	   levels	  were	  higher	   than	  the	  reference	  range	   in	  women	  not	  receiving	  any	  hormonal	  contraception.	  
D	  dimer	  levels	  were	  high	  in	  women	  using	  POC,	  while	  PF4	  is	  worse	  in	  those	  women	  who	   use	   POC.	   MPs	   levels	   fell	   within	   the	   reference	   range	   in	   all	   three	   groups	  however	  COC	  women	  showed	  statistically	   significantly	   raised	   levels	   compared	   to	  other	  women.	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SD40	   ligand	   levels	  varied	  significantly	  between	   the	   three	  groups,	  being	  higher	   in	  women	  using	  COC.	  	  
	  
While	  TF	  levels	  were	  2-­‐3	  times	  higher	  than	  the	  reference	  range	  in	  all	  three	  groups,	  there	  was	  no	  statistically	  significant	  difference	  between	  the	  women	  using	  COC	  and	  other	  two	  groups.	  
	  
TG	  results	  were	  within	  the	  range	  in	  all	  the	  three	  groups	  except	  the	  results	  for	  the	  Slope	  which	  showed	  a	  significant	  increase	  in	  women	  using	  POC.	  	  
	  
Full	  blood	  counts	  were	  within	  the	  reference	  range	  in	  all	  the	  three	  groups	  although	  	  some	  values	  of	  liver	  function	  tests	  were	  raised	  abnormally.	  
	  




CHAPTER	  6 	  	  	  	  	  	  	  








The	  study	  results	  for	  women	  using	  combined	  oral	  contraceptive	  pills	  (COC)	  will	  be	  presented	   first	   in	   the	   form	   of	   tables	   and	   the	   most	   important	   findings	   will	   be	  summarised	   at	   the	   end	   of	   these	   tables.	   This	   will	   be	   followed	   by	   tables	   and	   a	  summary	   of	   the	   results	   for	   the	   women	   using	   Progestogen	   only	   contraception	  (POC).	   Finally,	   the	   findings	   in	   the	   women	   who	   are	   not	   using	   any	   hormonal	  contraception	  will	  be	  presented,	  again	  in	  the	  forms	  of	  tables	  and	  the	  key	  findings	  will	  be	  summarized.	  In	  all	  the	  tables,	  the	  reference	  group	  for	  comparisons	  is	  that	  of	  the	  women	  with	  normal	  Hb.	  
6.2 CLINICAL	  EVENTS	  IN	  WOMEN	  USING	  COC	  
Clinical	  variables	  	   SCD	  (n	  =9)	  
Mean	  (SD)	  
SCT	  (n	  =8)	  
Mean	  (SD)	  
Hb	  AA	  (n=10)	  	  	  	  	  	  	  
Mean	  (SD)	  
P	  	  
Number	  of	  previous	  pregnancies	  	   0.77	  (0.83)	   1.125	  (0.64)	   1.1	  (0.87)	   0.691	  Difference	  (95%	  CI)	   -­‐0.35(-­‐2.0	  to	  .19)	   .01	  (-­‐0.53	  to	  0.51]	   Reference	   	  Duration	  of	  use	  of	  contraceptive	  method	  prior	  to	  enrolment	  (months)	  	  
14.77	  (13.65)	   11.5	  (6.48)	   15.2	  (10.07)	   0.168	  
Difference	  (95%	  CI)	   3.27(0.91	  to	  .62)	   -­‐3.7(-­‐6.44	  to	  -­‐0.97)	   Reference	   	  
Table	  6-­‐1:	  The	  obstetric	  history	  and	  duration	  of	  use	  of	  their	  contraceptive	  method	  prior	  to	  








SCD	  (n	  =9)	  
	  
SCT	  (n	  =	  8)	  
	  
Hb	  AA	  (n=10)	  
	  Severe	  sickle	  crises	  (total)	   2	   0	   0	  Number	  of	  women	  with	  severe	  sickle	  crises	   1	   0	   0	  Hospital	  admissions	  (total)	   3	   0	   2	  Number	  of	  women	  with	  hospital	  admission	   2	   0	   2	  Blood	  transfusions	  (total	  number	  of	  sessions)	   0	   0	   0	  Number	  of	  women	  receiving	  transfusion	   0	   0	   0	  VTE	  (DVT	  &	  PE)	   0	   0	   0	  Strokes	  &	  heart	  attacks	   0	   0	   0	  




SCD	  (n	  =9)	  
	  
SCT	  (n	  =	  8)	  
	  
Hb	  AA	  (n=10)	  
	  Side	  effects	  (i.e.	  headaches,	  nausea,	  mood	  swings,	  bloatedness,	  breast	  tenderness)	   1	   2	   1	  Discontinuation	   0	   0	   0	  Unintended	  interruptions	   1	   0	   2	  Planned	  pregnancies	   0	   0	   0	  Unplanned	  pregnancies	   0	   0	   0	  Amenorrhoea	   0	   0	   0	  
Table	  6-­‐3:	  Contraceptive	  side	  effects	  and	  problems	  during	  the	  study	  in	  women	  using	  COC	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6.3 LABORATORY	  RESULTS	  FOR	  WOMEN	  USING	  COC	  
Laboratory	  marker	  	  
(reference	  values)	  
SCD	  (n=	  9)	  
Mean	  (SD)	  




P	  	  Prothrombin	  time	  	  (12	  –	  15	  seconds)	   14.83	  (1.65)	  	   11.73	  (1.28)	  	   11.16	  (0.97)	  	   0.337	  Difference	  (95%	  CI)	   0.68(0.06	  to	  1.30)	   0.31(-­‐0.31	  to	  0.93)	   Reference	   	  International	  normalised	  ratio	  (INR)(0.8-­‐1.2)	   1.16	  (0.11)	   1.06	  (0.05)	   1.04	  (0.08)	   0.086	  Difference	  (95%	  CI)	   0.03	  (-­‐0.05	  to	  0.08)	   -­‐0.03	  (-­‐0.08	  to	  0.02)	   Reference	   	  Activated	  partial	  thromboplastin	  time	  (25-­‐35	  seconds)	   29.41	  (2.68)	   29.54	  (1.78)	   30.00(2.63)	   0.519	  Difference	  (95%	  CI)	   0.05	  (-­‐1.21	  to	  1.31)	   -­‐0.89	  (-­‐2.15	  to	  0.37)	   Reference	   	  Thrombin	  Time	  	  (12-­‐14	  seconds)	   12.86	  (0.67)	   14.03	  (1.23)	   14.19(1.08)	   0.266	  Difference	  (95%	  CI)	   -­‐0.41	  (-­‐0.95	  to	  0.13)	   0.15	  (-­‐0,02	  to	  0.08)	   Reference	   	  Fibrinogen	  	  (2.14-­‐3.51	  g/dL)	   3.47	  (0.80)	   2.95	  (0.66)	   3.12	  (0.52)	   0.488	  Difference	  (95%	  CI)	   0.28	  (-­‐0.21	  to	  0.77)	   0.14	  (-­‐0.35	  to	  0.63)	   Reference	   	  Factor	  VIII	  Coagulant	  (I.U./ml)	  	   149.11(38.17)	   121.00(34.05)	   155.10	  (40.00)	   0.908	  Difference	  (95%	  CI)	   -­‐1.83	  (-­‐22.88	  to	  19.22)	   -­‐5.95	  (-­‐27	  to	  -­‐125.25)	   Reference	   	  von	  Willebrand	  Factor	  antigen	  	  (46	  –	  153	  iu/dL)	   164.22(66.28)	   105.87	  (33.40)	   109.77(35.18)	   0.095	  Difference	  (95%	  CI)	   31.1	  (-­‐5.70	  to	  56.50)	   -­‐1.78	  (-­‐27.18	  to	  23.62)	   Reference	   	  Dilute	  Viper	  Venom	  Time	  (ratio)	  (<1.16)	   0.91(0.07)	   0.99(0.16)	   1.16	  (0.19)	   0.039	  Difference	  (95%	  CI)	   -­‐0.09	  (-­‐0.01	  to	  -­‐0.17)	   0.03	  (0.01	  to	  0.11)	   Reference	   	  




Laboratory	  marker	  	  
(reference	  values)	  
SCD	  (n=	  9)	  Mean	  
(SD)	  




P	  	  Anti-­‐thrombin	  :	  Activity	  (85-­‐113	  iu/dL)	   92.03	  (13.40)	   100.46(9.40)	   102.33	  (7.64)	   0.270	  Difference	  (95%	  CI)	   5.76	  (1.43	  to	  10.09)	   1.76	  (-­‐2.57	  to	  6.09)	   Reference	   	  Protein	  C	  :	  Activity	  (70-­‐135	  iu/dL)	   75.53(20.24)	   102.80(28.04)	   98.10(23.53)	   0.685	  Difference	  (95%	  CI)	   -­‐3.29	  (-­‐11.35	  to	  4.77)	   4.51	  (3.55	  to	  12.57)	   Reference	   	  Free	  Protein	  S	  (75-­‐125	  iu/dL)	   59.20(16.88)	   87.13	  (38.14)	   78.60(25.61)	   0.103	  Difference	  (95%	  CI)	   -­‐8.73	  (-­‐0.65	  to	  -­‐16.81)	   12.53	  (2.45	  to	  20.61)	   Reference	   	  Activated	  Protein	  C	  Resistance	  (Factor	  V	  Leiden)	  (>2.0)	   2.80(0.14)	   2.73(0.25)	   2.78(0.08)	   0.009	  Difference	  (95%	  CI)	   0.06	  (-­‐0.04	  to	  0.16)	   0.17	  (0.07	  to	  0.27)	   Reference	   	  Factor	  II	  	  (84.3-­‐120.0	  iu/dL)	   91.00(11.94)	   107.13(8.32)	   117.80(18.75)	   0.094	  Difference	  (95%	  CI)	   -­‐6.81(-­‐0.11	  to	  -­‐13.51	  )	   -­‐10.43(-­‐17.13	  to	  -­‐3.73)	   Reference	   	  Factor	  V	  	  (63.85-­‐120.5	  iu/dL)	   98.89(12.46)	   98.00(28.33)	   97.70(17.08)	   0.083	  Difference	  (95%	  CI)	   -­‐4.62	  (-­‐12.58	  to	  3.34)	   11.25	  (3.29	  to	  19.21)	   Reference	   	  Factor	  VII	  	  (77.5-­‐150.5	  iu/dL)	   83.11(21.31)	   76.75(12.19)	   95.50(20.30)	   0.322	  Difference	  (95%	  CI)	   1.01(-­‐8.39	  to	  10.42)	   -­‐8.11(-­‐11.63	  to	  1.29)	   Reference	   	  




Laboratory	  marker	  	  
(reference	  values)	  
SCD	  (n=	  9)	  
Mean	  (SD)	  




P	  	  Factor	  IX	  (77.7-­‐130.0	  iu/dL)	   121.89(22.28)	   95.75(23.11)	   127.90(44.04)	   0.087	  Difference	  (95%	  CI)	   -­‐21.76(-­‐35.95	  to	  -­‐7.56)	   -­‐20.93(-­‐29.49	  to	  -­‐12.36)	   Reference	   	  Factor	  X	  (71.8-­‐130.0	  iu/dL)	   102.56(19.63)	   98.25(14.20)	   105.30(21.45)	   0.542	  Difference	  (95%	  CI)	   -­‐1.82(-­‐9.64	  to	  6)	   -­‐7.25(-­‐17.48	  to	  2.96)	   Reference	   	  Factor	  XI	  (68-­‐144	  iu/dL)	   89.44(14.59)	   100.88(18.31)	   99.80(14.05)	   0.734	  Difference	  (95%	  CI)	   0.54	  (-­‐7.28	  to	  8.36)	   4.26	  (-­‐3.56	  to	  12.08)	   Reference	   	  Factor	  XII	  (46.7-­‐181.0	  iu/dL)	   97.78(32.82)	   95.88(20.38)	   116.80(49.13)	   0.076	  Difference	  (95%	  CI)	   -­‐16.31	  (-­‐30.46	  to	  -­‐2.15)to	  	   -­‐28.75(42.90	  to	  -­‐14.60)	   Reference	   	  Factor	  XIIIa	  (97.4-­‐179.0	  iu/dL)	   67.56(26.06)	   78.38(27.81)	   68.70(19.80)	   0.617	  Difference	  (95%	  CI)	   6.26(-­‐3.95	  to	  16.47)	   8.01(-­‐2.20	  to	  18.22)	   Reference	   	  




Laboratory	  marker	  	  
(reference	  values)	  
SCD	  (n=	  9)	  
Mean	  (SD)	  




P	  	  Thrombin:anti-­‐thrombin	  III	  complex	  (2	  -­‐	  4.2	  mcg/l)	   8.15	  (4.29)	   10.61(19.98)	   3.53(0.70)	   <0.001	  Difference	  (95%	  CI)	   3.59	  (-­‐6.17	  to	  13.35)	   19.28	  (9.52	  to	  29.04)	   Reference	   	  Prothrombin	  fragment	  1	  +	  2	  (69	  –	  229	  pmol/L)	   244.63(114.91)	   210.00(219.45)	   156.80(60.95)	   0.003	  Difference	  (95%	  CI)	   53.96	  (-­‐60.76	  to	  168.68)	   158.5	  (-­‐141.44	  to	  458.44)	   Reference	   	  D	  dimer	  (ng/ml)	  (<130)	   614.44	  (283.46)	   184.38	  (200.72)	   107.00(54.82)	   <	  0.001	  Difference	  (95%	  CI)	   228.64	  (217.78	  to	  239.49)	   145.9	  (135.04	  to	  156.76)	   Reference	   	  
Table	  6-­‐7:	  Coagulation	  activation	  markers	  in	  women	  using	  COC	  
Laboratory	  marker	  	  
(reference	  values)	  
SCD	  (n=	  9)	  
Mean	  (SD)	  





Soluble	  Platelet	  selectin	  (92-­‐212	  ng/ml)	   72.00(20.48)	   63.50(16.22)	   52.30(17.46)	   0.811	  Difference	  (95%	  CI)	   3.02	  (-­‐7.84	  to	  13.88)	   -­‐1.24	  (-­‐12.09	  to	  9.62)	   Reference	   	  Soluble	  Cell	  Differentiation	  40	  ligand	  (0.03-­‐3.98	  ng/ml)	   1.07(0.92)	   1.24(1.05)	   5.49(8.33)	   <0.001	  Difference	  (95%	  CI)	   -­‐7.41(-­‐8.86	  to	  -­‐5.96)	   -­‐7.28	  (-­‐8.73	  to	  -­‐5.83)	   Reference	   	  Platelet	  factor	  4	  (<10	  I.U./ml)	  	   150.39(66.91)	   137.00(97.58)	   79.50(19.09)	   0.481	  Difference	  (95%	  CI) 47.82	  (-­‐6.51	  to	  102.15)	   78.49	  (24.16	  to	  132.82)	   Reference	    





Laboratory	  marker	  	  
(reference	  values)	  
SCD	  (n=	  9)	  
Mean	  (SD)	  





Soluble	  vascular	  cell	  adhesion	  molecule	  (ng/ml)	  (131-­‐1223)	   1003.22(604.21)	   419.75(178.05)	   608.90(829.84)	   0.002	  Difference	  (95%	  CI)	   -­‐225.63(-­‐282.35	  to	  54.16)	   -­‐651.79	  (-­‐931.52	  to	  -­‐372)	   Reference	   	  Soluble	  inter-­‐cellular	  adhesion	  molecule-­‐1(ng/ml)	  (41-­‐669)	   445.07(119.85)	   281.63(69.56)	   279.97(56.34)	   0.083	  Difference	  (95%	  CI)	   63.51	  (9.57	  to	  117.45)	   13.22	  (-­‐40.22	  to	  67.16)	   Reference	   	  Soluble	  endothelial-­‐leucocyte	  adhesion	  molecule-­‐1	  (ng/ml)	  (1.5	  –	  88.1)	  
89.78(52.84)	   136.13	  (138.42)	   72.90(27.85)	   <0.001	  
Difference	  (95%	  CI)	   24.99(2.27	  to	  47.71)	   110.57	  (87.89	  to	  133.29)	   Reference	   	  
Table	  6-­‐9:	  Endothelial	  activation	  markers	  in	  women	  using	  COC	  
	  	  
Laboratory	  marker	  	  
(reference	  values)	  
SCD	  (n=	  9)	  
Mean	  (SD)	  





Micro	  particles	  (<10	  nMol/ml)	  	   25.41(13.46)	   9.96(5.36)	   9.58(11.10)	   0.005	  Difference	  (95%	  CI)	   2.36(-­‐10.39	  to	  10.39)	   -­‐5.74	  (-­‐13.78	  to	  -­‐2.29)	   Reference	   	  Tissue	  Factor(<2pMol/ml)	  	   13.72(5.40)	   5.67(5.43)	   6.12(6.74)	   0.770	  Difference	  (95%	  CI)	   -­‐1.34	  (-­‐4.12	  to	  1.44)	   -­‐1.31	  (-­‐4.09	  to	  1.47)	   Reference	   	  





Laboratory	  marker	  	  
(reference	  values)	  
SCD	  (n=	  9)	  
Mean	  (SD)	  





Lag	  Time	  (initiated	  with	  5pMol	  Tissue	  Factor)	  (2.0	  -­‐	  3.2	  minutes)	  
1.37(0.34)	   1.76(0.27)	   2.23(0.41)	   0.568	  
Difference	  (95%	  CI)	   -­‐0.07(-­‐0.34	  to	  0.20)	   -­‐0.14(-­‐0.41	  to	  0.13)	   Reference	   	  Endogenous	  Thrombin	  Potential	  (initiated	  with	  5pMol	  Tissue	  Factor)	  (1159	  –	  2168	  nM)	  
1482.89(348.20)	   1608.14(282.05)	   1837.60(337.36)	   0.859	  
Difference	  (95%	  CI)	   10.84	  (-­‐120.15	  to	  141.83)	   -­‐55.31(-­‐186.29	  to	  75.68)	   Reference	   	  Peak	  Height	  (initiated	  with	  5pMol	  Tissue	  Factor)(	  147	  –	  359	  nM)	  	   342.67(51.52)	   272.52(23.39)	   310.30(72.62)	   0.035	  Difference	  (95%	  CI)	   -­‐21.1	  (-­‐47.62	  to	  -­‐5.42)	   49.23	  (22.71	  to	  172.24)	   Reference	   	  Time	  to	  Peak	  (initiated	  with	  5pMol	  Tissue	  Factor)(4.6	  –	  7.4	  min)	   3.43(0.39)	   4.41(0.95)	   4.61(0.81)	   0.069	  Difference	  (95%	  CI)	   -­‐0.81	  (-­‐1.20	  to	  -­‐0.42)	   0.14	  (-­‐0.25	  to	  0.53)	   Reference	   	  Slope	  	  (33	  –	  142	  nM/min)	   168.51(35.64)	   114.57(39.87)	   138.00(53.60)	   0.486	  	   -­‐17.96	  (-­‐39.52	  to	  3.6)	   -­‐13.73	  (-­‐35.29	  to	  7.83)	   Reference	   	  Start	  Time	  (initiated	  with	  5pMol	  Tissue	  Factor)(19	  28.3	  min)	   17.50(2.29)	   23.14(3.91)	   24.45(3.37)	   0.380	  Difference	  (95%	  CI)	   -­‐1.08	  (-­‐2.41	  to	  0.25)	   0.54	  (-­‐0.79	  to	  1.87)	   Reference	   	  






Laboratory	  marker	  	  
(reference	  values)	  
SCD	  (n=	  9)	  
Mean	  (SD)	  





Free	  Hb	  (11-­‐15.5mg/l)	   0.1	  (0.05)	   0.05(0.05)	   0.06(0.07)	   0.604	  Difference	  (95%	  CI)	   -­‐0.02(-­‐0.95	  to	  0.02)	   -­‐0.02(-­‐0.059	  to	  0.02)	   Reference	   	  Haptoglobin	  (<	  1.22	  g/l)	   1.59(0.70)	   0.88(0.34)	   1.14(0.45)	   0.151	  Difference	  (95%	  CI)	   0.25(0.015	  to	  0.74)	   -­‐0.11(-­‐0.35	  to	  0.13)	   Reference	   	  Lactate	  dehydrogenase	  (240-­‐480	  units/l)	   555.50(210.23)	   406.71(62.45)	   432.75(134.39)	   0.027	  Difference	  (95%	  CI)	   75.84(22.80	  to	  43.04)	   -­‐71.94(-­‐398.36	  to	  -­‐36.70)	   Reference	   	  Bilirubin	  (<	  21	  μMol/l)	   32.00(20.81)	   9.63(5.63)	   6.50(2.07)	   <0.001	  Difference	  (95%	  CI)	   18.74(8.35	  to	  29.13)	   3.56(1.83	  to	  13.95)	   Reference	   	  




Laboratory	  marker	  	  
(reference	  ranges)	  
SCD	  (n=	  9)	  
Mean	  	  (SD)	  
SCT	  (n=	  8)	  
Mean	  	  (SD)	  
Hb	  AA	  (n=10)	  
Mean	  	  (SD)	  
P	  	  
Alanine	  amino	  transferase	  (<33	  units/l)	  	   45.13(6.08)	   19.13(5.62)	   15.44(4.69)	   0.015	  Difference	  (95%	  CI)	   1.39(-­‐3.65	  to	  6.53)	   0.93(0.11	  to	  5.97)	   Reference	   	  Aspartate	  amino	  transferase	  (	  <31	  units/l)	   34.00(14.27)	   19.75(2.49)	   25.63(6.21)	   <0.001	  Difference	  (95%	  CI)	   8.06(2.12	  to	  13.99)	   -­‐3.72(-­‐9.66	  to	  -­‐1.50)	   Reference	   	  Alkaline	  phosphatase	  (<	  129	  units/l)	  	   89.67(65.29)	   56.63(18.90)	   69.67(27.69)	   0.003	  Difference	  (95%	  CI)	   37.6(18.19	  to	  57.00)	   -­‐8.79(-­‐28.19	  to	  -­‐10.61)	   Reference	   	  Serum	  albumin	  (35-­‐50g/l)	   44.67(5.83)	   45.13(6.08)	   43.89(2.26)	   0.031	  Difference	  (95%	  CI)	   3.57(1.88	  to	  5.26)	   3.82(2.13	  to	  5.50)	   Reference	   	  
Table	  6-­‐13:	  Biochemical	  markers	  of	  liver	  function	  in	  women	  using	  COC	  
Laboratory	  marker	  	  
(reference	  values)	  
	  
SCD	  (n=	  9)	  
Mean	  (SD)	  
	  







Haemoglobin	  (11.5-­‐15-­‐5	  g/dl)	   10.38(1.74)	   11.76(1.17)	   12.04(0.98)	   0.249	  Difference	  (95%	  CI)	   0.76(0.17	  to	  1.35)	   0.19(-­‐0.77	  to	  0.77)	   Reference	   	  Platelet	  count	  (140-­‐400	  10^9/l)	   310.78(109.49)	   278.71(81.43)	   233.50(70.88)	   0.451	  Difference	  (95%	  CI)	   38.61(-­‐11.37	  to	  88.59)	   10.55(-­‐39.43	  to	  60.53)	   Reference	   	  Haematocrit	  (0.35-­‐0.47	  l/l)	   0.28(0.05)	   0.36(0.04)	   0.37(0.231)	   0.081	  Difference	  (95%	  CI)	   -­‐0.18(-­‐0.18	  to	  -­‐0.34)	   -­‐0.191(-­‐0.21	  to	  -­‐0.37)	   Reference	   	  




Laboratory	  marker	  	  
(reference	  values)	  
SCD	  (n=	  9)	  
Mean	  (SD)	  





Complement	  reactive	  protein	  (0.2-­‐10.0	  mcg/ml)	   42.11(31.31)	   11.13(8.56)	   15.22(9.71)	   0.001	  Difference	  (95%	  CI)	   21.6(12.78	  to	  30.42)	   1.15(0.97	  to	  85.9)	   Reference	   	  White	  blood	  cells	  	  (3.5-­‐11.0	  10^9/l))	   9.90(2.05)	   6.91(2.00)	   6.99(2.03)	   0.998	  Difference	  (95%	  CI)	   0.02(-­‐1.27	  to	  1.31)	   -­‐0.03(-­‐1.32	  to	  1.23)	   Reference	   	  Neutrophils	  (1.7-­‐8.0	  10^9/l))	   5.55(2.07)	   4.00(1.79)	   3.33(1.20)	   0.426	  Difference	  (95%	  CI)	   0.87(-­‐0.01	  to	  1.75)	   1.59(0.71	  to	  2.47)	   Reference	   	  Lymphocytes	  (1.0-­‐3.510^9/l))	   2.75(0.86)	   2.30(0.37)	   2.35(0.98)	   0.185	  Difference	  (95%	  CI)	   -­‐0.12(-­‐0.55	  to	  0.31)	   -­‐0.61(-­‐1.04	  to	  -­‐0.18)	   Reference	   	  Monocytes	  (0.1-­‐1.010^9/l)	   0.92(0.55)	   0.43(0.13)	   0.46(0.21)	   0.008	  Difference	  (95%	  CI)	   0.34(0.18	  to	  0.49)	   -­‐0.08(-­‐0.24	  to	  -­‐0.00)	   Reference	   	  Eosinophils	  (0.0-­‐0.46	  10^9/l))	   0.34(0.31)	   0.18(0.11)	   0.21(0.26)	   0.131	  Difference	  (95%	  CI)	   0.05(-­‐0.04	  to	  0.15)	   -­‐0.15(-­‐0.25	  to	  -­‐0.05)	   Reference	   	  Basophils	  (0.0-­‐0.20	  10^9/l))	   0.04(0.02)	   0.03(0.02)	   0.02(0.01)	   0.426	  Difference	  (95%	  CI)	   0.01(-­‐0.00	  to	  0.02)	   0.01(-­‐0.00	  to	  0.02)	   Reference	   	  





6.4 SUMMARY	  OF	  RESULTS	  FOR	  THE	  WOMEN	  USING	  COC	  
All	   women	   using	   COC	   are	   well	   established	   on	   their	   method,	   and	   there	   were	   no	  major	   clinical	   events	   among	   them.	   There	  were	   also	   no	  major	   contraceptive	   side	  effects	  in	  any	  of	  the	  three	  groups.	  	  
	  




Coagulation	  activation	  markers	  behaved	  independently.	  While,	  TAT	  complex	  and	  D	  Dimer	   mean	   values	   were	   markedly	   increased	   in	   SCD	   and	   SCT	   COC	   users,	  Prothrombin	  fragments	  1+2	  levels	  remained	  within	  the	  reference	  range	  for	  all	  the	  3	   groups.	   However,	   the	   differences	   in	   all	   of	   these	   markers	   between	   the	   groups	  reached	  statistical	  significance	  	  
	  
Platelet	   activation	  markers	   i.e.	   soluble	  platelet	   selectin	   and	  Soluble	  CD	  40	   ligand	  and	  platelet	   factor	  4	   also	   varied	   in	   trend.	   SP	   selectin	   levels	  were	   lower	   than	   the	  reference	  range	  in	  all	  the	  three	  groups,	  but	  with	  a	  trend	  of	  highest	  in	  SCD,	  next	  in	  SCT	   and	   lowest	   in	   normal	   Hb,	   but	   the	   difference	   did	   not	   reach	   statistical	  significance.	  Soluble	  CD	  40	  ligand	  was	  raised	  above	  the	  reference	  range	  in	  women	  with	  normal	  Hb,	  while	  being	  normal	  in	  women	  with	  SCD	  and	  SCT	  (although	  the	  SD	  is	   wide)	   and	   this	   difference	   was	   statistically	   significant.	   Platelet	   factor	   4	   was	  markedly	  elevated	  in	  all	  COC	  users	  with	  a	  gradation	  from	  normal	  Hb	  to	  SCT	  to	  SCD,	  although	  differences	  between	  the	  Hb	  types	  did	  not	  reach	  statistical	  significance.	  	  
	  
Endothelial	  activation	  markers	  differed	  in	  trend	  as	  well.	  SVCAM	  levels	  were	  within	  the	  reference	  range	  (which	  itself	  is	  wide)	  for	  all	  women	  using	  COC	  but	  showing	  a	  counter-­‐intuitive	  trend	  lowest	  in	  SCT,	  with	  normal	  Hb	  in	  the	  middle	  and	  highest	  in	  SCD.	  SICAM-­‐1	   levels	  were	  also	   in	   the	  reference	  range	  but	  highest	   in	  SCD	  women.	  
179 
 
SELAM-­‐1	   was	   significantly	   highest	   in	   SCT	   women,	   with	   mean	   levels	   above	   the	  reference	  range	  (although	  there	  is	  a	  wide	  SD).	  	  
	  
Markers	  of	  tissue	  damage:	  microparticle	  levels	  were	  doubled	  in	  SCD	  women	  using	  COC	  .Tissue	  factor	  levels	  were	  elevated	  in	  all	  COC	  users,	  with	  a	  particularly	  marked	  effect	  in	  SCD	  women.	  
	  
Parameters	  of	  thrombin	  generation:	  The	  lag	  time	  was	  reduced	  below	  the	  reference	  range	  in	  SCD	  and	  SCT	  women,	  more	  so	  in	  the	  SCD	  women.	  Time	  to	  peak	  and	  start	  time	  were	  also	  shortest	  in	  SCD	  women.	  
	  






6.5 CLINICAL	  EVENTS	  IN	  WOMEN	  USING	  POC	  
Clinical	  variables	  	   SCD	  (n	  =29)	  
Mean	  (SD)	  
SCT(n	  =	  7)	  
Mean	  (SD)	  




Number	  of	  previous	  pregnancies	  (mean+/-­‐SD)	   1.79	  (1.4)	   1.71	  (0.95)	   1.75	  (1.16)	   0.405	  Difference	  (95%	  CI)	   0.24(-­‐1.21	  to	  1.69)	   -­‐0.21(-­‐1.66	  to	  1.24)	   Reference	   	  Duration	  of	  use	  of	  contraceptive	  method	  prior	  to	  enrolment	  (months)	  (mean+/-­‐SD)	  
33.44	  (27.53)	   12	  (6.80)	   14	  (16.36)	   0.003	  
Difference	  (95%	  CI)	   20.73(18.9	  to	  22.55)	   -­‐9.56	  (-­‐14.06	  to	  -­‐5.05)	   Reference	   	  
Table	  6-­‐16:	  The	  obstetric	  history	  and	  duration	  of	  use	  of	  their	  contraceptive	  method	  prior	  to	  
the	  enrolment	  interview	  in	  women	  using	  POC	  
	  
Clinical	  events	   SCD	  (n	  =29)	   SCT	  (n	  =	  7)	   Hb	  AA	  (n	  =	  8)	  Severe	  sickle	  crises	  (total)	   12	   0	   0	  Number	  of	  women	  with	  severe	  sickle	  crises	   5	   1	   0	  Hospital	  admissions	  (total)	   13	   0	   1	  Number	  of	  women	  with	  hospital	  admission	   7	   0	   1	  Blood	  transfusions	  (total	  number	  of	  sessions)	   3	   0	   0	  Number	  of	  women	  receiving	  transfusion	   3	   0	   0	  VTE	  (DVT	  &	  PE)	   0	   0	   0	  Strokes	  &	  heart	  attacks	  	   0	   0	   0	  Arterial	  thrombosis	   0	   0	   0	  







SCD	  (n	  =29)	  
	  
SCT	  (n	  =	  7)	  
	  
Hb	  AA	  (n	  =	  8)	  
	  Side	  effects	  (i.e.	  headaches,	  nausea,	  mood	  swings,	  bloatedness,	  breast	  tenderness)	   4	   1	   3	  Discontinuation	   0	   0	   1	  Unintended	  interruptions	   1	   0	   2	  Planned	  pregnancies	   0	   0	   1	  Unplanned	  pregnancies	   0	   0	   0	  Amenorrhoea	   11	   1	   2	  Menstrual	  irregularities	   8	   1	   3	  





6.6 LABORATORY	  RESULTS	  FOR	  WOMEN	  USING	  POC	  
Laboratory	  marker	  
(reference	  values)	  	  
SCD	  (n=	  29)	  
Mean	  (SD)	  
SCT	  (n=	  7)	  
Mean	  (SD)	  
Hb	  A+A	  (n=8)	  	  	  	  	  	  
Mean	  (SD)	  
P	  	  
Prothrombin	  time	  (12	  –	  15	  seconds)	   15.36	  (1.77)	   11.51	  (0.95)	   11.24	  (0.57)	   0.005	  Difference	  (95%	  CI)	   4.12	  (2.89	  to	  5.35)	   0.28	  (0.13	  to	  1.87)	   Reference	   	  International	  normalised	  ratio	  (INR)(0.8-­‐1.2)	   1.19	  (0.15)	   1.03	  (0.03)	   1.05	  (0.05)	   <0.001	  Difference	  (95%	  CI)	   0.14	  (0.04	  to	  0.24)	   -­‐0.02	  (-­‐0.19	  to	  -­‐0.01)	   Reference	   	  Activated	  partial	  thromboplastin	  time	  (25-­‐35	  seconds)	   29.24	  (3.56)	   30.27	  (1.30)	   30.15	  (2.13)	   0.020	  Difference	  (95%	  CI)	   -­‐0.91	  (-­‐3.41	  to	  1.6)	   0.12	  (0.01	  to	  3.37)	   Reference	   	  Thrombin	  Time	  (12-­‐14	  seconds	   13.13	  (1.28)	   14.23	  (0.83)	   14.05	  (1.29)	   0.471	  Difference	  (95%	  CI)	   -­‐0.92	  (-­‐1.92	  to	  .07)	   0.18	  (-­‐1.11	  to	  1.46)	   Reference	   	  Fibrinogen	  (2.14-­‐3.51	  g/dL)	  	   3.33	  (0.56)	   3.26	  (0.90)	   3.14	  (0.64)	   0.280	  Difference	  (95%	  CI)	   0.19	  (-­‐0.32	  to	  0.7)	   0.12	  (-­‐0.55	  to	  0.78)	   Reference	   	  Factor	  VIII:C	  (50	  –	  150	  iu/dL)	  	   154.14	  (41.75)	   154.57	  (80.07)	   152.38	  (62.82)	   0.063	  Difference	  (95%	  CI)	   1.77	  (-­‐41.32	  to	  44.86)	   2.2	  (-­‐53.43	  to	  57.83)	   Reference	   	  von	  willebrand	  Factor	  antigen	  (46	  –	  153	  (iu/dL)	   171.33	  (64.39)	   86.93	  (32.00)	   129.66	  (53.54)	   0.174	  Difference	  (95%	  CI)	   41.67	  (-­‐5.85	  to	  89.18)	   -­‐42.73	  (-­‐104.31	  to	  18.84)	   Reference	   	  Dilute	  Viper	  Venom	  Time	  (ratio)	  (<1.16)	   0.92	  (0.13)	   0.14	  (0.27)	   1.10	  (0.25)	   0.010	  Difference	  (95%	  CI)	   -­‐0.18	  (-­‐0.32	  to	  -­‐0.03)	   0.04	  (0.01	  to	  0.23)	   Reference	   	  





(reference	  values)	  	  
SCD	  (n=	  29)	  
Mean	  (SD)	  
SCT	  (n=	  7)	  
Mean	  (SD)	  
Hb	  A+A	  (n=8)	  
Mean	  	  (SD)	  
P	  	  
Anti-­‐thrombin	  :	  Activity	  	  (85-­‐113	  iu/dL)	   95.58	  (9.18)	   108.26	  (6.43)	   109.07	  (9.35)	   0.588	  Difference	  (95%	  CI)	   -­‐13.49	  (-­‐20.64	  to	  -­‐6.34)	   -­‐0.81	  (-­‐10.08	  to	  8.45)	   Reference	   	  Protein	  C	  :	  Antivity	  (70-­‐135	  iu/dL)	   82.00	  (12.53)	   99.80	  (15.47)	   105.20	  (19.57)	   0.280	  Difference	  (95%	  CI)	   -­‐23.2	  (-­‐34.82	  to	  -­‐11.58)	   -­‐5.4	  (-­‐20.46	  to	  9.66)	   Reference	   	  Free	  Protein	  S	  	  (75-­‐125	  iu/dL)	   59.07	  (14.96)	   74.94	  (11.78)	   66.88	  (20.15)	   0.390	  Difference	  (95%	  CI)	   -­‐7.81	  (-­‐20.37	  to	  4.75)	   8.07	  (-­‐8.21	  to	  24.34)	   Reference	   	  Activated	  Protein	  C	  Resistance	  	  (Factor	  V	  Leiden)	  (>2.0)	   2.88	  (0.32)	   2.86	  (0.11)	   2.71	  (0.10)	   0.001	  Difference	  (95%	  CI)	   0.17	  (-­‐0.05	  to	  0.38)	   0.14	  (0.11	  to	  0.42)	   Reference	   	  Factor	  II	  	  (84.3-­‐120.0	  iu/dL)	   91.28	  (10.00)	   104.71	  (7.34)	   107.75	  (16.85)	   0.076	  Difference	  (95%	  CI)	   -­‐16.47	  (-­‐25.48	  to	  -­‐7.47)	   -­‐3.04	  (-­‐14.71	  to	  8.63)	   Reference	   	  Factor	  V	  	  (63.85-­‐120.5	  iu/dL)	   95.93	  (16.34)	   97.00	  (17.22)	   94.88	  (10.78)	   0.432	  Difference	  (95%	  CI)	   1.06	  (-­‐11.58	  to	  13.69)	   2.13	  (-­‐14.25	  to	  18.5)	   Reference	   	  Factor	  VII	  	  (77.5-­‐150.5	  iu/dL)	   78.17	  (22.40)	   93.43	  (16.68)	   83.63	  (11.82)	   0.155	  Difference	  (95%	  CI)	   -­‐5.45	  (-­‐21.73	  to	  10.82)	   9.8	  (-­‐11.29	  to	  30.9)	   Reference	   	  






(reference	  values)	  	  
SCD	  (n=	  29)	  
Mean	  (SD)	  
SCT	  (n=	  7)	  
Mean	  (SD)	  
Hb	  A+A	  (n=8)	  	  	  	  	  	  
Mean	  	  (SD)	  
P	  	  
Factor	  IX	  (77.7-­‐130.0	  iu/dL)	   89.62	  (16.63)	   92.38	  (16.31)	   102.57	  (21.43)	   0.694	  Difference	  (95%	  CI)	   18.66	  (-­‐10.87	  to	  48.18)	   6.57	  (-­‐31.69	  to	  44.83)	   Reference	   	  Factor	  X	  	  (71.8-­‐130.0	  iu/dL)	   120.66	  (41.71)	   108.57	  (28.41)	   102.00	  (14.11)	   0.013	  Difference	  (95%	  CI)	   -­‐2.75	  (-­‐16.76	  to	  11.25)	   10.2	  (-­‐7.95	  to	  28.34)	   Reference	   	  Factor	  XI	  	  (68-­‐144	  iu/dL)	   86.03	  (15.96)	   102.43	  (13.95)	   103.38	  (22.29)	   0.412	  Difference	  (95%	  CI)	   -­‐17.34	  (-­‐31.01	  to	  -­‐3.67)	   -­‐0.95	  (-­‐18.66	  to	  16.77)	   Reference	   	  Factor	  XII	  	  (46.7-­‐181.0	  iu/dL)	   83.69(30.20)	   103.14(23.52)	   120.25(40.15)	   0.402	  Difference	  (95%	  CI)	   -­‐36.56	  (-­‐61.8	  to	  -­‐11.33)	   -­‐17.11	  (-­‐49.81	  to	  15.6)	   Reference	   	  Factor	  XIIIa	  	  (97.4-­‐179.0	  iu/dL)	   66.39(18.26)	   81.57(30.51)	   87.13(29.14)	   0.115	  Difference	  (95%	  CI)	   -­‐20.73	  (-­‐39.09	  to	  -­‐2.38)	   -­‐5.55	  (-­‐29.25	  to	  18.14)	   Reference	   	  
Table	  6-­‐21:	  Pro	  and	  anti-­‐coagulant	  markers	  in	  the	  women	  using	  POC	  (3)	  
Laboratory	  marker	  
(reference	  values)	  	  
SCD	  (n=	  29)	  
Mean	  (SD)	  
SCT	  (n=	  7)	  
Mean	  (SD)	  
Hb	  A+A	  (n=8)	  
Mean	  	  (SD)	  
	  
P	  
Thrombin:anti-­‐thrombin	  III	  complex	  (2	  -­‐	  4.2	  mcg/L)	   5.46	  (3.06)	   4.04	  (1.49)	   4.21(1.81)	   0.070	  Difference	  (95%	  CI)	   1.25	  (-­‐0.94	  to	  3.43)	   -­‐0.17	  [-­‐2.98	  to	  2.64)	   Reference	   	  Prothrombin	  fragment	  1	  +	  2	  (69	  –	  229	  pmol/L)	  	   374.37	  (277.51)	   139.00	  (51.36)	   120.13	  (46.96)	   <0.001	  Difference	  (95%	  CI)	   254.25	  (68.32	  to	  440.17)	   18.88	  (12.17	  to	  257.92)	   Reference	   	  D	  dimer	  (<130	  ng/ml)	   762.17	  (728.77)	   196.00	  (106.70)	   137.13	  (103.39)	   <0.001	  Difference	  (95%	  CI)	   625.05	  (137	  to	  1113.1)	   58.88	  (	  45.62	  to	  691.37)	   Reference	   	  









Hb	  A+A	  (n=8)	  
Mean	  	  (SD)	  
P	  	  
Soluble	  Platelet	  selectin	  (92-­‐212	  ng/ml)	   81.78	  (26.72)	   47.14	  (20.60)	   53.25	  (11.56)	   0.066	  Difference	  (95%	  CI)	   28.53	  (9.17	  to	  47.88)	   -­‐6.11	  (-­‐30.99	  to	  18.78)	   Reference	   	  Soluble	  Cell	  Differentiation	  40	  ligand	  (0.03-­‐3.98	  ng/ml)	  
1.52	  (1.69)	   1.25	  (1.37)	   2.28	  (2.37)	   0.351	  
Difference	  (95%	  CI)	   -­‐0.76	  (-­‐2.21	  to	  0.7)	   -­‐1.03	  (-­‐2.9	  to	  0.85)	   Reference	   	  Platelet	  factor	  4	  (I.U./ml)	  (<	  10)	   147.52	  (67.63)	   78.50	  (17.68)	   105.00	  (10.23)	   0.254	  Difference	  (95%	  CI)	   42.52	  (-­‐96.59	  to	  181.63]	   -­‐26.5	  (-­‐193.69	  to	  140.69)	   Reference	   	  
Table	  6-­‐23:	  Platelet	  activation	  markers	  in	  women	  using	  POC	  
Laboratory	  marker	  
(reference	  values)	  	  
SCD	  (n=	  29)	  
Mean	  (SD)	  






Soluble	  vascular	  cell	  adhesion	  molecule	  (ng/ml)	  (131-­‐1223)	   1162.04	  (917.68)	   606.43	  (505.56)	   396.00	  (154.44)	   <0.001	  Difference	  (95%	  CI)	   766.04	  [132.71	  to	  1399.36]	   210.43	  [60.85	  to	  1024.7]	   Reference	   	  Soluble	  inter-­‐cellular	  adhesion	  molecule-­‐1(ng/ml)	  (41-­‐669)	   528.03	  (128.45)	   271.87	  (41.29)	   270.31	  (42.36)	   0.001	  Difference	  (95%	  CI)	   257.72	  [170.09	  to	  345.35]	   1.56	  [	  1.11	  to	  14.23]	   Reference	   	  Soluble	  endothelial-­‐leucocyte	  adhesion	  molecule-­‐1	  (ng/ml)	  (1.5	  –	  88.1)	  
52.67	  (29.59)	   81.00	  (35.19)	   69.88	  (31.30)	   0.860	  
Difference	  (95%	  CI)	   -­‐17.21	  [-­‐42.3	  to	  -­‐7.89]	   11.13	  [2.14	  to	  43.39]	   Reference	   	  




(reference	  values)	  	  
SCD	  (n=	  29)	  
Mean	  (SD)	  
SCT	  (n=	  7)	  
Mean	  (SD)	  
Hb	  A+A	  (n=8)	  
Mean	  (SD)	  
P	  	  
Micro	  particles	  (<10nMol/ml)	  	   39.03	  (27.11)	   8.33	  (4.02)	   6.70	  (2.28)	   <0.001	  Difference	  (95%	  CI)	   32.33	  (14.21	  to	  50.46)	   1.63	  (0.21	  to	  25.12)	   Reference	   	  Tissue	  Factor(<2pMol/ml)	  	   8.84	  (6.95)	   2.13	  (1.89)	   6.13	  (6.11)	   0.011	  Difference	  (95%	  CI)	   2.71	  (2.44	  to	  7.86)	   -­‐4	  (-­‐10.53	  to	  -­‐2.53)	   Reference	   	  
Table	  6-­‐25:	  Markers	  of	  tissue	  damage	  in	  women	  using	  POC	  
Laboratory	  marker	  (reference	  
values)	  	  
SCD	  (n=	  29)	  Mean	  
(SD)	  
SCT	  (n=	  7)	  	  	  
Mean	  (SD)	  




Lag	  Time	  (initiated	  with	  5pMol	  Tissue	  Factor)	  (2.0	  -­‐	  3.2	  minutes)	   1.60	  (0.53)	   0.160	   2.42	  (0.91)	   0.002	  Difference	  (95%	  CI)	   -­‐0.82	  (-­‐1.33	  to	  -­‐0.32)	   0.18	  (0.083	  to	  0.47)	   Reference	   	  Endogenous	  Thrombin	  Potential	  (initiated	  with	  5pMol	  Tissue	  Factor)	  (1159	  –	  2168	  nMol)	   1480.68	  (269.80)	   0.463	   1636.88(364.17)	   0.176	  Difference	  (95%	  CI)	   -­‐156.2	  (-­‐385.82	  to	  73.42)	   -­‐333.87	  (-­‐630.31	  to	  -­‐37.44)	   Reference	   	  Peak	  Height	  (initiated	  with	  5pMol	  Tissue	  Factor)(	  147	  –	  359	  nM)	  	   319.07	  (52.31)	   0.111	   320.75	  (84.73)	   0.949	  Difference	  (95%	  CI)	   -­‐1.68	  (-­‐54.41	  to	  51.06)	   -­‐86.89	  (-­‐154.97	  to	  -­‐18.81)	   Reference	   	  Time	  to	  Peak	  (initiated	  with	  5pMol	  Tissue	  Factor)	  (4.6	  –	  7.4	  min)	   3.92	  (0.83)	   0.868	   4.40	  (0.70)	   0.141	  Difference	  (95%	  CI)	   -­‐0.48	  (-­‐1.13	  to	  0.17)	   -­‐0.28	  (-­‐1.12	  to	  0.56)	   Reference	   	  Slope	  (33	  –	  142	  nM/min)	   143.25	  (39.33)	   0.002	   187.55	  (101.15)	   0.067	  Difference	  (95%	  CI)	   -­‐44.3	  (-­‐91.87	  to	  3.28)	   -­‐55.14	  (-­‐116.56	  to	  6.28)	   Reference	   	  Start	  Time	  (initiated	  with	  5pMol	  Tissue	  Factor)	  (19	  28.3	  min)	   18.57	  (2.75)	   0.048	   21.38	  (2.86)	   0.042	  Difference	  (95%	  CI)	   -­‐2.8	  (-­‐5.5	  to	  -­‐0.11)	   2.84	  (-­‐0.64	  to	  6.32)	   Reference	   	  





(reference	  values)	  	  
SCD	  (n=	  29)	  
Mean	  (SD)	  
SCT	  (n=	  7)	  
Mean	  (SD)	  




Free	  Hb	  	  (11-­‐15.5mg/l)	   0.09(	  0.10	   0.12(	  0.10	   0.06(	  0.05	   0.177	  Difference	  (95%	  CI)	   0.02	  (-­‐0.05	  to	  0.1)	   0.06	  (-­‐0.04	  to	  0.16)	   Reference	   	  Haptoglobin	  	  (<	  1.22	  g/l)	   1.56	  (0.66)	   1.15	  (0.45)	   1.19	  (0.55)	   0.510	  Difference	  (95%	  CI)	   0.37	  (-­‐0.13	  to	  0.88)	   -­‐0.04	  (-­‐0.68	  to	  0.6)	   Reference	   	  Lactate	  dehydrogenase	  (240-­‐480	  units/l)	   637.23	  (227.29)	   467.29	  (57.30)	   371.00	  (134.91)	   0.004	  Difference	  (95%	  CI)	   266.23	  (97.18	  to	  435.28)	   96.29	  (-­‐115.92	  to	  308.49)	   Reference	   	  Bilirubin	  (<	  21	  μMol/l)	   38.11	  (32.64)	   7.00	  (3.46)	   8.13	  (6.24)	   <0.001	  Difference	  (95%	  CI)	   29.99	  (8.15	  to	  51.82)	   -­‐1.12	  (-­‐29.2	  to	  -­‐0.26)	   Reference	   	  











(reference	  values)	  	  
SCD	  (n=	  29)	  
Mean	  (SD)	  
SCT	  (n=	  7)	  
Mean	  (SD)	  
Hb	  A+A	  (n=8)	  
Mean	  (SD)	  
P	  	  
Alanine	  amino	  transferase	  	  (<33	  units/l)	  	   19.97(11.89)	   14.71(	  3.90)	   25.00(20.89)	   0.001	  Difference	  (95%	  CI)	   -­‐5.03	  (-­‐15.65	  to	  5.58)	   -­‐10.29	  (-­‐24.05	  to	  3.47)	   Reference	   	  Aspartate	  amino	  transferase	  (	  <31	  units/l)	  	  	   29.79(11.91)	   23.14(	  4.88)	   22.31(	  6.40)	   0.023	  Difference	  (95%	  CI)	   7.47	  (-­‐0.89	  to	  15.84)	   0.83	  (-­‐9.97	  to	  11.63)	   Reference	   	  Alkaline	  phosphatase	  	  (<	  129	  units/l)	  	   86.86(48.12)	   64.14(17.78)	   96.00(77.64)	   0.023	  Difference	  (95%	  CI)	   -­‐9.14	  (-­‐50.71	  to	  32.43)	   -­‐31.86	  (-­‐85.73	  to	  -­‐22.0)	   Reference	   	  Serum	  albumin	  (35-­‐50g/l)	   45.79(	  3.57)	   43.71(	  2.14)	   42.61(5.60)	   0.064	  Difference	  (95%	  CI)	   3.18	  (0.09	  to	  6.28)	   1.1	  (-­‐2.91	  to	  5.11)	   Reference	   	  





(reference	  values)	  	  
SCD	  (n=	  29)	  
Mean	  (SD)	  
SCT	  (n=	  7)	  
Mean	  (SD)	  
Hb	  A+A	  (n=8)	  
Mean	  (SD)	  
P	  	  
Haemoglobin	  (11.5-­‐15-­‐5	  g/dl)	   9.23	  (1.56)	   12.47(1.03)	   11.95	  (1.07)	   0.310	  Difference	  (95%	  CI)	   -­‐2.72	  (-­‐3.87	  to	  -­‐1.58)	   0.52	  (-­‐0.96	  to	  2)	   Reference	   	  Platelet	  count	  (140-­‐400	  10^9/l)	   323.39	  (134.13)	   251.71	  (70.91)	   228.00	  (46.02)	   0.007	  Difference	  (95%	  CI)	   95.39	  (2.06	  to	  188.72)	   23.71	  (9.67	  to	  144.2)	   Reference	   	  Haematocrit	  (0.35-­‐0.47	  l/l)	   0.27(	  0.05)	   0.38	  (0.03)	   0.37	  (0.04)	   0.779	  Difference	  (95%	  CI)	   -­‐0.1	  (-­‐0.14	  to	  -­‐0.07)	   0.01	  -­‐0.05	  to	  0.07)	   Reference	   	  





(reference	  values)	  	  
SCD	  (n=	  29)	  
Mean	  (SD)	  
SCT	  (n=	  7)	  
Mean	  (SD)	  
	   	  
Complement	  reactive	  protein	  (0.2-­‐10.0	  mcg/ml)	   35.58	  (19.20)	   13.57	  (16.30)	   13.00	  (15.98)	   0.793	  Difference	  (95%	  CI)	   22.58	  (7.55	  to	  37.61)	   0.57	  (-­‐18.48	  to	  19.63)	   Reference	   	  White	  blood	  cells	  	  (3.5-­‐11.0	  10^9/l))	   8.46	  (3.43)	   4.17	  (1.27)	   6.42	  (2.85)	   0.573	  Difference	  (95%	  CI)	   2.04	  (-­‐0.99	  to	  5.07)	   -­‐2.25	  (-­‐7.73	  to	  3.23)	   Reference	   	  Neutrophils	  (1.7-­‐8.0	  10^9/l))	   4.50	  (2.39)	   1.90	  (0.94)	   2.95	  (0.83)	   0.061	  Difference	  (95%	  CI)	   1.55	  (-­‐0.46	  to	  3.56)	   -­‐1.05	  (-­‐4.66	  to	  2.57)	   Reference	   	  Lymphocytes	  (1.0-­‐3.510^9/l))	   2.84	  (0.90)	   1.75	  (0.08)	   1.80	  (0.79)	   0.191	  Difference	  (95%	  CI)	   1.03	  (0.23	  to	  1.84)	   -­‐0.05	  (-­‐1.49	  to	  1.4)	   Reference	   	  Monocytes	  (0.1-­‐1.010^9/l)	   0.83	  (0.36)	   0.34	  (0.08)	   0.45	  (0.10)	   0.018	  Difference	  (95%	  CI)	   0.38	  (0.07	  to	  0.68)	   -­‐0.11	  (-­‐0.65	  to	  0.43)	   Reference	   	  Eosinophils	  (0.0-­‐0.46	  10^9/l))	   0.23	  (0.19)	   0.15	  (0.16)	   0.14	  (0.11)	   0.396	  Difference	  (95%	  CI)	   0.08	  (-­‐0.08	  to	  0.25)	   0	  (-­‐0.29	  to	  0.3)	   Reference	   	  Basophils	  (0.0-­‐0.20	  10^9/l))	   0.05	  (0.05)	   0.01	  (0.01)	   0.02	  (0.01)	   0.396	  Difference	  (95%	  CI)	   0.03	  (-­‐0.01	  to	  0.07)	   0	  (-­‐0.07	  to	  0.07)	   Reference	   	  





6.7 SUMMARY	  OF	  RESULTS	  FOR	  THE	  WOMEN	  USING	  POC	  
As	  already	  observed	  in	  Chapter	  5,	  the	  SCD	  women	  using	  POC	  had	  been	  using	  that	  method	   significantly	   longer	   than	   the	   SCT	   and	   normal	   Hb	   women.	   Clinically	  significant	  events	  were	  much	  higher	  in	  the	  SCD	  women	  on	  POC,	  but	  seemed	  to	  be	  related	  to	  their	  SCD	  itself,	  and	  no	  POC	  users	  had	  clinically	  recognised	  episodes	  of	  VTE	  or	  arterial	  thrombosis.	  
The	  occurrence	  of	  contraceptive	  side	  effects	  with	  women	  using	  POCs	  was	  similar	  in	   all	   the	   three	   groups.	   These	   were	   mainly	   amenorrhoea	   and	   menstrual	  irregularities,	  and	  it	  should	  be	  noted	  that	  the	  SCD	  women	  were	  the	  largest	  group	  on	  POC,	  as	  has	  been	  previously	  highlighted	  (Chapter	  5).	  
Looking	   at	   the	   pro	   and	   anti-­‐coagulant	   markers,	   PT	   and	   INR	   levels	   were	   at	   the	  upper	   limit	  of	   the	  reference	  range	   in	   the	  SCD	  women	  and	   the	  difference	  reached	  statistical	  significance.	  The	  DRVVT,	  AT:activity	  and	  PC:	  activity	  levels	  all	  fell	  within	  the	   reference	   ranges,	   with	   values	   lowest	   in	   SCD	   women.	   However	   only	   the	  difference	   in	  DRVVT	  reached	  statistical	  significance.	  Although	  activated	  protein	  C	  resistance	   levels	   lie	  within	   the	   reference	   range,	   the	  difference	  between	   the	   three	  groups	   is	   statistically	   significant,	  with	   levels	   being	   lower	   in	  women	  with	   normal	  Hb.	   Protein	   S	   levels	   were	   lower	   than	   the	   reference	   range	   (i.e.	   adverse)	   in	   all	  women	  using	  POC,	  but	  most	  markedly	  so	  with	  SCD	  women.	  
Factors	  II,	  VII,	  XI,	  and	  XII	  mean	  values	  lie	  within	  the	  reference	  range,	  being	  lowest	  in	  SCD	  women.	  Factor	  X	  was	  highest	  in	  SCD	  women	  but	  again	  all	  the	  mean	  values	  were	  within	  the	  reference	  range.	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Factor	  XIIIa	  levels	  were	  lower	  than	  the	  reference	  range	  in	  all	  POC	  users	  but	  lowest	  in	  those	  with	  SCD.	  
With	   regard	   to	   coagulation	   activation	   markers,	   TAT	   complex	   and	   Prothrombin	  F1+2	  were	  normal	   in	  women	  using	  POC,	  except	   in	  SCD	  women,	  where	   the	   levels	  were	  markedly	  raised.	  




6.8 	  CLINICAL	  EVENTS	  IN	  WOMEN	  NOT	  USING	  HC	  








Number	  of	  previous	  pregnancies	  (mean+/-­‐SD)	   1.2	  (1.09)	   1.42	  (1.13)	   1.44	  (0.88)	   0.752	  Difference	  (95%	  CI)	   0.21(-­‐6.06	  to	  6.48)	   0.25(-­‐6.02	  to	  6.52)	   Reference	   	  Duration	  of	  use	  of	  contraceptive	  method	  prior	  to	  enrolment	  (months)	  (mean+/-­‐SD)	  
18(4.72)	   16(5.12)	   20(7.68)	   0.271	  
Difference	  (95%	  CI)	   -­‐0.4	  (-­‐7.26	  to	  5.87)	   -­‐2.56(-­‐9.36	  to	  4.3)	   Reference	   	  
Table	  6-­‐31:	  The	  obstetric	  history	  and	  duration	  of	  use	  of	  their	  contraceptive	  method	  prior	  to	  
the	  enrolment	  interview	  in	  women	  not	  using	  HC	  
Clinical	  events	   SCD	  (n=30)	   SCT	  (n=7)	   Hb	  AA	  (n	  =9)	  
	  Severe	  sickle	  crises	  (total)	   14	   0	   0	  Number	  of	  women	  with	  severe	  sickle	  crises	   10	   2	   0	  Hospital	  admissions	  (total)	   16	   0	   3	  Number	  of	  women	  with	  hospital	  admission	   11	   0	   3	  Blood	  transfusions	  (total	  number	  of	  sessions)	   5	   0	   0	  Number	  of	  women	  receiving	  transfusion	   3	   0	   0	  VTE	  (DVT	  &	  PE)	   1	   0	   0	  	  Strokes	  &	  heart	  attacks	  	   0	   0	   0	  	  Arterial	  thrombosis	   0	   0	   0	  	  





Contraceptive	  problems	   SCD	  (n=30)	   SCT	  (n=7)	   Hb	  AA	  (n=9)	  
Side	  effects	  (i.e.	  headaches,	  nausea,	  mood	  swings,	  bloatedness,	  breast	  tenderness)	  
0	   0	   0	  
Discontinuation	   0	   0	   0	  	  Unintended	  interruptions	   0	   0	   0	  	  Planned	  pregnancies	   1	   0	   0	  	  Unplanned	  pregnancies	   1	   0	   1	  	  Amenorrhoea	   0	   1	   0	  	  Menstrual	  irregularities	   4	   2	   2	  	  
Table	  6-­‐33:	  Contraceptive	  side	  effects	  and	  problems	  during	  the	  study	  in	  women	  not	  using	  HC	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6.9 LABORATORY	  RESULTS	  FOR	  WOMEN	  NOT	  USING	  HC	  
Laboratory	  marker	  
(reference	  values)	  	  
SCD	  (n=30)	  
Mean	  	  (	  SD)	  
SCT	  (n=7)	  
Mean	  	  (	  SD)	  
Hb	  AA	  (n=9)	  
Mean	  	  (	  SD)	  
P	  	  
Prothrombin	  time	  	  (12	  –	  15	  seconds)	   14.94	  (1.57)	   11.03	  (0.78)	   10.77	  (0.72)	   0.019	  Difference	  (95%	  CI)	   4.16	  (3.12	  to	  5.2)	   0.25	  (-­‐1.13	  to	  1.63)	   Reference	   	  International	  normalised	  ratio	  (INR)(0.8-­‐1.2)	   1.00	  (0.06)	   1.04	  (0.07)	   1.16	  (0.13)	   0.024	  Difference	  (95%	  CI)	   0.16	  (0.07	  to	  0.25)	   0.04	  (-­‐0.08	  to	  0.15)	   Reference	   	  Activated	  partial	  thromboplastin	  time	  (25-­‐35	  seconds)	   27.98	  (2.35)	   32.06	  (4.44)	   31.09	  (2.19)	   0.060	  Difference	  (95%	  CI)	   -­‐3.11	  (-­‐5.19	  to	  -­‐1.03)	   0.97	  (-­‐1.79	  to	  3.73)	   Reference	   	  Thrombin	  Time	  	  (12-­‐14	  seconds)	   13.80(1.00)	   15.38(1.80)	   15.011(0.76)	   0.033	  Difference	  (95%	  CI)	   -­‐1.2	  (-­‐2.07	  to	  -­‐0.34)	   0.37	  (-­‐0.78	  to	  1.53)	   Reference	   	  Fibrinogen	  (2.14-­‐3.51	  g/dL)	  	   3.10	  (0.62)	   4.94	  (3.60)	   2.82	  (0.51)	   <0.001	  Difference	  (95%	  CI)	   0.27	  (-­‐0.84	  to	  1.39)	   2.11	  (0.64	  to	  3.59)	   Reference	   	  Factor	  VIII:C	  (50	  –	  150	  iu/dL)	  	   168.93	  (51.59)	   148.00	  (19.00)	   143.56	  (42.87)	   0.045	  Difference	  (95%	  CI)	   25.38	  (-­‐10.47	  to	  61.22)	   4.44	  (-­‐43.09	  to	  51.98)	   Reference	   	  von	  willebrand	  factor	  antigen	  (46	  –	  153	  iu/dL)	   181.96	  (68.43)	   124.32	  (36.75)	   143.13	  (45.89)	   0.138	  Difference	  (95%	  CI)	   38.83	  (-­‐8.03	  to	  85.7)	   -­‐18.8	  (-­‐80.95	  to	  43.34)	   Reference	   	  Dilute	  Viper	  Venom	  Time	  (ratio)	  (<1.16)	   0.92	  (0.17)	   0.94(0.21)	   0.91(0.04)	   0.001	  Difference	  (95%	  CI)	   0.01	  (-­‐0.11	  to	  0.14)	   0.03	  (0.01	  to	  0.2)	   Reference	   	  





(reference	  values)	  	  
SCD	  (n=30)	  
Mean	  	  (	  SD)	  
SCT	  (n=7)	  
Mean	  	  (	  SD)	  
Hb	  AA	  (n=9)	  
Mean	  	  (	  SD)	  
P	  	  
Anti-­‐thrombin	  :	  Antivity	  (85-­‐113	  iu/dL)	   98.57	  (10.90)	   108.09	  (8.74)	   105.88	  (5.82)	   0.149	  Difference	  (95%	  CI)	   -­‐7.31	  (-­‐14.86	  to	  .24)	   2.21	  (-­‐7.81	  to	  12.22)	   Reference	   	  Protein	  C	  :	  Activity	  (70-­‐135	  iu/dL)	   85.03	  (15.50)	   100.29(21.62)	   100.39	  (23.49)	   0.241	  Difference	  (95%	  CI)	   -­‐15.36	  (-­‐29.28	  to	  -­‐1.44)	   -­‐0.1	  (-­‐18.56	  to	  18.35)	   Reference	   	  Free	  Protein	  S	  (75-­‐125	  iu/dL)	   56.30	  (13.30)	   70.28	  (14.63)	   73.22	  (10.60)	   0.685	  Difference	  (95%	  CI)	   -­‐16.92	  (-­‐26.92	  to	  -­‐6.92)	   -­‐2.94	  (-­‐16.19	  to	  10.32)	   Reference	   	  Activated	  Protein	  C	  Resistance	  (Factor	  V	  Leiden)	  (>2.0)	   2.84	  (0.35)	   2.71	  (0.12)	   2.71	  (0.03)	   <0.001	  Difference	  (95%	  CI)	   0.13	  (0.1	  to	  0.36)	   0	  (0.29	  to	  3)	   Reference	   	  Factor	  II	  (84.3-­‐120.0	  iu/dL)	   90.33	  (14.28)	   95.71	  (20.88)	   101.67	  (26.41)	   0.056	  Difference	  (95%	  CI)	   -­‐11.33	  (-­‐25.22	  to	  2.55)	   -­‐5.95	  (-­‐24.36	  to	  12.46)	   Reference	   	  Factor	  V	  (63.85-­‐120.5	  iu/dL/ml)	   100.30	  (18.63)	   81.71	  (23.03)	   80.56	  (8.89)	   0.053	  Difference	  (95%	  CI)	   19.74	  (5.98	  to	  33.51)	   1.16	  (0.17	  to	  19.41)	   Reference	   	  Factor	  VII	  (77.5-­‐150.5	  iu/dL)	   92.40	  (22.70)	   86.89	  (24.80)	   83.14	  (21.11)	   0.915	  Difference	  (95%	  CI)	   5.51	  (-­‐12.04	  to	  23.06)	   -­‐3.75	  (-­‐27.02	  to	  19.52)	   Reference	   	  








(reference	  values)	  	  
SCD	  (n=30)	  
Mean	  	  (	  SD)	  
SCT	  (n=7)	  
Mean	  	  (	  SD)	  
Hb	  AA	  (n=9)	  
Mean	  	  (	  SD)	  
P	  	  
Factor	  IX	  (77.7-­‐130.0	  iu/dL)	   121.17	  (29.70)	   101.14	  (16.76)	   96.22	  (16.70)	   0.082	  Difference	  (95%	  CI)	   24.94	  (4.87	  to	  45.02)	   4.92	  (-­‐21.69	  to	  31.54)	   Reference	   	  Factor	  X	  (71.8-­‐130.0	  iu/dL)	   94.83	  (22.96)	   91.71	  (10.64)	   93.67	  (17.72)	   0.113	  Difference	  (95%	  CI)	   1.17	  (-­‐14.72	  to	  17.06)	   -­‐1.95	  (-­‐23.02	  to	  19.12)	   Reference	   	  Factor	  XI	  (68-­‐144	  iu/dL)	   92.37	  (20.84)	   91.43	  (21.46)	   94.44	  (9.55)	   0.066	  Difference	  (95%	  CI)	   -­‐2.08	  (-­‐16.9	  to	  12.75)	   -­‐3.02	  (-­‐22.68	  to	  16.64)	   Reference	   	  Factor	  XII	  (46.7-­‐181.0	  iu/dL)	   99.77	  (24.17)	   85.71	  (36.11)	   83.78	  (24.06)	   0.383	  Difference	  (95%	  CI)	   15.99	  (-­‐4.05	  to	  36.03)	   1.94	  (-­‐24.64	  to	  28.51)	   Reference	   	  Factor	  XIIIa	  (97.4-­‐179.0	  iu/dL)	   66.10	  (21.90)	   97.86	  (14.62)	   97.78	  (20.19)	   0.522	  Difference	  (95%	  CI)	   -­‐31.68	  (-­‐47.56	  to	  -­‐15.8)	   0.08	  (-­‐20.98	  to	  21.14)	   Reference	   	  
Table	  6-­‐36:	  Pro	  and	  anti-­‐	  coagulant	  markers	  in	  women	  not	  using	  HC	  (3)	  
Laboratory	  marker	  
(reference	  values)	  	  
SCD	  (n=30)	  
Mean	  	  (	  SD)	  
SCT	  (n=7)	  
Mean	  	  (	  SD)	  
Hb	  AA	  (n=9)	  
Mean	  	  (	  SD)	  
P	  	  Thrombin:anti-­‐thrombin	  III	  complex	  (2	  -­‐	  4.2	  mcg/l)	   19.70	  (40.28)	   3.13	  (0.58)	   4.90	  (1.91)	   <0.001	  Difference	  (95%	  CI)	   -­‐14.8	  (-­‐15.30	  to	  -­‐4.13)	   1.77	  (0.35	  to	  31.69)	   Reference	   	  Prothrombin	  fragment1	  +	  2	  (69	  –	  229	  pmol/L)	  	   492.72	  (380.72)	   142.71	  (109.00)	   144.11	  (78.38)	   <	  0.001	  Difference	  (95%	  CI)	   348.61	  (105.72	  to	  591.51)	   -­‐1.4	  (-­‐322.2	  to	  319.41)	   Reference	   	  D	  dimer	  (<130	  ng/ml)	   943.77	  (319.40)	   126.20	  (70.59)	   107.00	  (48.24)	   <0.001	  Difference	  (95%	  CI)	   836.77	  (90.01	  to	  1583.52)	   19.2	  (-­‐1022.5	  to	  1060.9)	   Reference	   	  




(reference	  values)	  	  
SCD	  (n=30)	  
Mean	  	  (	  SD)	  
SCT	  (n=7)	  
Mean	  	  (	  SD)	  
Hb	  AA	  
(n=9)	  Mean	  	  
(	  SD)	  
P	  	  
Soluble	  Platelet	  selectin(92-­‐212	  ng/ml)	   84.89	  (32.91)	   52.57	  1(4.05)	   53.55	  (12.99)	   0.004	  Difference	  (95%	  CI)	   31.34	  (9.8	  to	  52.89)	   -­‐0.98	  (-­‐1.44	  to	  -­‐0.27)	   Reference	   	  Soluble	  Cell	  Differentiation	  40	  ligand(0.03-­‐3.98	  ng/ml)	  
1.33	  (0.20)	   0.48	  (0.32)	   0.59(0.18)	   <0.001	  
Difference	  (95%	  CI)	   0.73	  (0.12	  to	  2.74)	   -­‐0.11	  (-­‐2.77	  to	  -­‐0.05)	   Reference	   	  Platelet	  factor	  4	  (<10I.U./ml)	   140.63	  (74.10)	   77.00	  (6.28)	   82.33	  (19.29)	   <0.001	  Difference	  (95%	  CI)	   58.29	  (24.77	  to	  141.35)	   -­‐5.33	  (-­‐10.5	  to	  -­‐0.94)	   Reference	   	  
Table	  6-­‐38:	  Platelet	  activation	  markers	  in	  women	  not	  using	  HC	  
Laboratory	  marker	  
(reference	  values)	  	  
SCD	  (n=30)	  
Mean	  	  (	  SD)	  
SCT	  (n=7)	  
Mean	  	  (	  SD)	  
Hb	  AA	  (n=9)	  
Mean	  	  (	  SD)	  
P	  	  
Soluble	  vascular	  cell	  adhesion	  molecule	  (ng/ml)	  (131-­‐1223)	   1095.11	  (563.90)	   486.43	  (207.00)	   507.67	  (260.05)	   0.005	  Difference	  (95%	  CI)	   587.44	  (217.35	  to	  957.53)	   -­‐21.24	  (-­‐510.03	  to	  -­‐4.65)	   Reference	   	  Soluble	  inter-­‐cellular	  adhesion	  molecule-­‐1(ng/ml)	  (41-­‐669)	   555.07	  (162.63)	   281.44	  (70.20)	   354.33	  (102.26)	   0.046	  Difference	  (95%	  CI)	   200.73	  (90.94	  to	  310.52)	   -­‐72.89	  (-­‐217.9	  to	  72.12)	   Reference	   	  Soluble	  endothelial-­‐leucocyte	  adhesion	  molecule-­‐1	  (ng/ml)	  (1.5	  –	  88.1)	  
68.86	  (38.49)	   51.14	  (22.98)	   66.55	  (13.15)	   0.006	  
Difference	  (95%	  CI)	   2.31	  (-­‐23.19	  to	  27.81)	   -­‐15.41	  (-­‐49.09	  to	  18.27)	   Reference	   	  




(reference	  values)	  	  
SCD	  (n=30)	  
Mean	  	  (	  SD)	  
SCT	  (n=7)	  
Mean	  	  (	  SD)	  
Hb	  AA	  (n=9)	  
Mean	  	  (	  SD)	  
P	  	  
Micro	  particles	  (<10nMol/ml)	  	   34.94	  (20.37)	   8.34	  (5.15)	   8.96	  (4.04)	   <0.001	  Difference	  (95%	  CI)	   25.99	  (13.03	  to	  38.95)	   -­‐0.61	  (-­‐17.73	  to	  0.02)	   Reference	   	  Tissue	  Factor(<2pMol/ml)	  	   12.08	  (5.96)	   5.49	  (7.55)	   5.60	  (5.90)	   0.734	  Difference	  (95%	  CI)	   6.47	  (1.67	  to	  11.28)	   -­‐0.11	  (-­‐6.43	  to	  6.21)	   Reference	   	  














(reference	  values)	  	  
SCD	  (n=30)	  
Mean	  	  (	  SD)	  
SCT	  (n=7)	  
Mean	  	  (	  SD)	  
Hb	  AA	  (n=9)	  
Mean	  	  (	  SD)	  
P	  	  
Lag	  Time	  (initiated	  with	  5pMol	  Tissue	  Factor)	  (2.0	  -­‐	  3.2	  minutes)	  
1.66	  (0.67)	   	  	  2.38	  (1.39)	   1.87	  (0.41)	   0.003	  
Difference	  (95%	  CI)	   -­‐0.21	  (-­‐0.8	  to	  0.03)	   0.51	  (0.27	  to	  1.3)	   Reference	   	  Endogenous	  Thrombin	  Potential	  (initiated	  with	  5pMol	  Tissue	  Factor)(1159	  –	  2168	  nM)	  
1345.43	  (245.32)	   1484.71	  (332.93)	   1637.89	  (284.27)	   0.581	  
Difference	  (95%	  CI)	   -­‐292.46	  (-­‐496.81	  to	  -­‐88.1)	   -­‐153.17	  (-­‐424.15	  to	  117.8)	   Reference	   	  Peak	  Height	  (initiated	  with	  5pMol	  Tissue	  Factor)(	  147	  –	  359	  nM)	  	  
305.65	  (58.93)	   283.86	  (59.42)	   322.00	  (37.81)	   0.363	  
Difference	  (95%	  CI)	   -­‐16.35	  (-­‐59.03	  to	  26.33)	   -­‐38.14	  (-­‐94.73	  to	  18.45)	   Reference	   	  Time	  to	  Peak	  (initiated	  with	  5pMol	  Tissue	  Factor)(4.6	  –	  7.4	  min)	  
3.90	  (	  0.96)	   4.93	  (1.64)	   4.28	  (0.48)	   0.010	  
Difference	  (95%	  CI)	   -­‐0.38	  (-­‐1.16	  to	  -­‐0.04)	   0.65	  (0.39	  to	  1.69)	   Reference	   	  Slope	  (33	  –	  142	  nM/min)	   142.72	  (40.36)	   114.90	  (33.83)	   134.62	  (17.37)	   0.048	  Difference	  (95%	  CI)	   8.1	  (-­‐19.69	  to	  35.89)	   -­‐19.72	  (-­‐56.57	  to	  17.12)	   Reference	   	  Start	  Time	  (initiated	  with	  5pMol	  Tissue	  Factor)(19	  -­‐28.3	  min)	   17.48	  (2.01)	   20.93	  (2.23)	   20.22	  (1.72)	   0.793	  Difference	  (95%	  CI)	   -­‐2.74	  (-­‐4.27	  to	  -­‐1.21)	   0.71	  (-­‐1.32	  to	  2.73)	   Reference	   	  





(reference	  values)	  	  
SCD	  (n=30)	  
Mean	  	  (	  SD)	  
SCT	  (n=7)	  
Mean	  	  (	  SD)	  
Hb	  AA	  (n=9)	  
Mean	  	  (	  SD)	  
P	  	  
Free	  Hb	  (11-­‐15.5mg/l)	   0.10	  (0.09)	   0.14	  (0.20)	   0.06	  (0.08)	   0.006	  Difference	  (95%	  CI)	   0.04	  (0.01	  to	  0.12)	   0.08	  (-­‐0.3	  to	  -­‐0.01)	   Reference	   	  Haptoglobin	  (<	  1.22	  g/l)	   1.54	  (0.47)	   1.12	  (0.43)	   1.28	  (0.69)	   0.299	  Difference	  (95%	  CI)	   0.26	  (-­‐0.13	  to	  0.66)	   -­‐0.16	  (-­‐0.69	  to	  0.36)	   Reference	   	  Lactate	  dehydrogenase	  (240-­‐480	  units/l)	   734.17	  (321.21)	   417.83	  (76.16)	   379.14	  (70.04)	   <0.001	  Difference	  (95%	  CI)	   355.03	  (120.87	  to	  589.19)	   38.69	  (-­‐270.67	  to	  348.05)	   Reference	   	  Bilirubin	  	  (<	  21	  μMol/l)	   39.74	  (27.72)	   5.29	  (1.70)	   6.38	  (2.13)	   <0.001	  Difference	  (95%	  CI)	   33.37	  (14.91	  to	  51.82)	   -­‐1.09	  (-­‐24.81	  to	  -­‐0.22)	   Reference	   	  
Table	  6-­‐42:	  Markers	  of	  haemolysis	  in	  women	  not	  using	  HC	  
Laboratory	  marker	  
(reference	  values)	  	  
SCD	  (n=30)	  
Mean	  	  (	  SD)	  
SCT	  (n=7)	  
Mean	  	  (	  SD)	  
Hb	  AA	  (n=9)	  
Mean	  	  (	  SD)	  
P	  	  
Alanine	  amino	  transferase	  (<33	  units/l)	  	   22.07	  (9.25)	   20.14	  (13.36)	   11.38	  (2.62)	   0.141	  Difference	  (95%	  CI)	   10.7	  (3.2	  to	  18.2)	   8.77	  (-­‐0.91	  to	  18.45)	   Reference	   	  Aspartate	  amino	  transferase	  (	  <31	  units/l)	   35.19	  (19.56)	   23.71	  (9.18)	   20.88	  (4.58)	   0.002	  Difference	  (95%	  CI)	   14.32	  (0.9	  to	  27.74)	   2.84	  (1.43	  to	  20.02)	   Reference	   	  Alkaline	  phosphatase	  (<	  129	  units/l)	  	   88.13	  (36.43)	   54.57	  (22.99)	   69.62	  (17.48)	   0.001	  Difference	  (95%	  CI)	   18.51	  (7.45	  to	  44.47)	   -­‐15.05	  (-­‐48.7	  to	  -­‐1.85)	   Reference	   	  Serum	  albumin	  (35-­‐50g/l)	   45.83	  (2.92)	   42.43	  (1.62)	   45.38	  (1.85)	   0.069	  Difference	  (95%	  CI)	   0.45	  (-­‐1.65	  to	  2.55)	   -­‐2.95	  (-­‐5.67	  to	  -­‐0.23)	   Reference	   	  




(reference	  values)	  	  
SCD	  (n=30)	  
Mean	  	  (	  SD)	  
SCT	  (n=7)	  
Mean	  	  (	  SD)	  
Hb	  AA	  (n=9)	  
Mean	  	  (	  SD)	  
P	  	  
Haemoglobin	  (11.5-­‐15-­‐5	  g/dl)	   9.07	  (1.44)	   11.55	  (0.55)	   12.19	  (0.49)	   0.002	  Difference	  (95%	  CI)	   -­‐3.12	  (-­‐4.06	  to	  -­‐0.21)	   -­‐0.64	  (-­‐1.95	  to	  -­‐0.07)	   Reference	   	  Platelet	  count	  (140-­‐400	  10^9/l)	   331.40	  (144.40)	   252.33	  (84.91)	   261.44	  (54.42)	   0.012	  Difference	  (95%	  CI)	   69.96	  (-­‐26.51	  to	  166.42)	   -­‐9.11	  (-­‐142.89	  to	  124.66)	   Reference	   	  Haematocrit	  (0.35-­‐0.47	  l/l)	   0.26(0.03)	   0.35	  (0.02)	   0.37	  (0.02)	   0.222	  Difference	  (95%	  CI)	   -­‐0.11	  (-­‐0.14	  to	  -­‐0.09)	   -­‐0.02	  (-­‐0.06	  to	  0.01)	   Reference	   	  













(reference	  values)	  	  
SCD	  (n=30)	  
Mean	  	  (	  SD)	  
SCT	  (n=7)	  
Mean	  	  (	  SD)	  
Hb	  AA	  (n=9)	  
Mean	  	  (	  SD)	  
P	  	  
Complement	  reactive	  protein	  (0.2-­‐10.0	  mcg/ml)	   35.39	  (22.07)	   13.29	  (10.80)	   17.67	  (20.64)	   	  0.04	  (0.03)	  Difference	  (95%	  CI)	   17.73	  (1.85	  to	  33.6)	   -­‐4.38	  (-­‐25.26	  to	  16.5)	   Reference	   	  White	  blood	  cells	  	  (3.5-­‐11.0	  10^9/l))	   8.23	  (2.69)	   5.78	  (2.59)	   5.33	  (0.93)	   0.013	  Difference	  (95%	  CI)	   2.9	  (1.02	  to	  4.77)	   0.45	  (-­‐2.15	  to	  3.05)	   Reference	   	  Neutrophils	  (1.7-­‐8.0	  10^9/l))	   4.22	  (1.71)	   3.21	  (1.62)	   2.50	  (0.45)	   0.002	  Difference	  (95%	  CI)	   1.73	  (0.54	  to	  2.91)	   0.71	  (-­‐0.91	  to	  2.34)	   Reference	   	  Lymphocytes	  (1.0-­‐3.510^9/l))	   2.57	  (1.04)	   3.21	  (1.62)	   2.23	  (0.48)	   0.050	  Difference	  (95%	  CI)	   0.34	  (-­‐0.44	  to	  1.11)	   -­‐0.29	  (-­‐1.35	  to	  0.77)	   Reference	   	  Monocytes	  (0.1-­‐1.010^9/l)	   0.71	  (0.38)	   0.31	  (0.15)	   0.45	  (0.10)	   0.001	  Difference	  (95%	  CI)	   0.26	  (0.01	  to	  0.51)	   -­‐0.14	  (-­‐0.48	  to	  0.2)	   Reference	   	  Eosinophils	  (0.0-­‐0.46	  10^9/l))	   0.231	  (0.22)	   0.22	  (0.17)	   0.13	  (0.07)	   0.015	  Difference	  (95%	  CI)	   0.1	  (-­‐0.06	  to	  0.25)	   0.09	  (-­‐0.12	  to	  0.3)	   Reference	   	  Basophils	  (0.0-­‐0.20	  10^9/l))	   0.04	  (0.03)	   0.03	  (0.02)	   0.02	  (0.01)	   0.001	  Difference	  (95%	  CI)	   0.02	  (0.01	  to	  0.04)	   0	  (0.03	  to	  3.2)	   Reference	   	  




6.10 SUMMARY	   OF	   RESULTS	   FOR	   THE	   WOMEN	   NOT	   USING	   HORMONAL	  
CONTRACEPTION	  
	  
There	  are	  no	  statistically	  significant	  differences	  between	  the	  three	  groups	  in	  terms	  of	  parity	  or	  duration	  of	  non-­‐use	  of	  HC.	  Women	  with	  SCD	  had	  more	  complications	  and	  one	  woman	  suffered	  an	  episode	  of	  VTE.	  
Pro	  and	  anti-­‐coagulant	  markers	  showed	  varying	  trends.	  Free	  Protein	  S	  levels	  were	  lower	   than	   the	   reference	   range	   in	   all	   three	   groups.	   Fibrinogen	   levels	   were	  statistically	  significantly	  higher	  in	  women	  with	  SCT.	  Women	  with	  SCD	  had	  higher	  levels	  of	  Factor	  VIII	  and	  VWF	  antigen.	  Activated	  Protein	  C	   resistance	   levels	  were	  again	   	   statistically	   significantly	   different	   between	   the	   three	   groups,	   the	   lowest	  mean	  value	  being	  in	  women	  with	  normal	  Hb.	  Factor	  XIII	  was	  lowest	  in	  women	  with	  SCD	  (ranging	  from	  66.10	  to	  97.78.).	  
	  
Coagulation	   activation	   markers	   (TAT	   complexes,	   D	   Dimers	   and	   Prothrombin	  F1+2)	  were	  all	  statistically	  significantly	  elevated	  in	  women	  with	  SCD.	  
	  




Endothelial	  activation	  markers	  were	  normal	  in	  all	  women	  not	  using	  HC.	  E	  elevated	  levels	   of	   TF	  were	   displayed	   by	   all	   the	   three	   groups	   but	   the	   difference	   between	  them	  did	  not	   reach	   statistical	   significance.	  Microparticle	   levels	  were	   statistically	  significantly	  higher	  in	  the	  SCD	  women.	  
	  
Thrombin	  generation	  markers	  were	  normal	  in	  all	  three	  groups.	  	  
	  
The	  free	  Haemoglobin	  levels	  were	  significantly	  higher	  in	  women	  with	  SCT,	  while	  LDH	  and	  Bilirubin	  were	  elevated	  in	  women	  with	  SCD.	  
	  
CRP	  levels	  were	  high	  in	  all	  women	  not	  using	  HC,	  however	  the	  differences	  between	  the	  groups	  did	  not	  reach	  statistical	  significance.	  
	  
Although	   it	   is	   to	   be	   expected	   that	   women	   with	   SCD	   will	   show,	   as	   they	   did,	  increased	   pro-­‐coagulant	   markers,	   increased	   coagulation	   activation	   markers	   and	  platelet	  activation	  markers,	  some	  of	  the	  findings	  in	  the	  SCT	  and	  normal	  Hb	  women	  have	   some	   unexpected	   features.	   	   All	   the	  women,	   regardless	   of	  Hb	   type,	   had	   low	  Protein	   S	   (a	   natural	   anticoagulant),	   raised	   endothelial	   activation	   markers	   and	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raised	  CRP,	  compared	  with	  general	  population	  reference	  ranges.	  All	  of	  these	  being	  adverse	   indicators	  of	  VTE	  risk.	   In	  addition,	   the	  SCT	  women,	  rather	  unexpectedly,	  had	   raised	   fibrinogen,	   and	   raised	   free	   Hb	   levels,	   a	   marker	   of	   haemolysis	   which	  predisposes	   to	   thrombosis.	   The	   implications	   of	   these	   findings	   being	   that	   some	  degree	   of	   VTE	   risk	   may	   be	   relevant	   to	   all	   women	   of	   black	   ethnicity,	   and	  additionally	   to	   women	   with	   SCT.	   Bearing	   in	   mind	   that	   the	   women	   described	   in	  Tables	  6.31	   to	  6.40	  are	  using	  no	  hormonal	   contraception,	   these	   features	  deserve	  further	  exploration.	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This	  research	  aims	  to	  answer	  the	  question	  whether	  hormonal	  contraception	  poses	  any	  additional	   clinical	  or	  haematological	   risks	   to	  women	  with	  SCD	  and	  SCT	  over	  and	   above	   the	   risks	   inherent	   in	   the	   disease	   itself.	   Although	   the	   UK	   Medical	  Eligibility	  Criteria	   (MEC)	   for	   contraceptive	  use,	   in	  2009,	   specified	   that	   the	  use	  of	  combined	  hormonal	  contraception	  in	  SCD	  is	  MEC	  “category	  2”	  (i.e.	  the	  benefits	  of	  use	  outweigh	  the	  risks)	  and	  the	  use	  of	  progestogen-­‐only	  contraception	  is	  “category	  1”	   (i.e.	   no	   restriction	   on	   their	   use),	   this	   was	   followed	   by	   the	   US	   MEC	  recommendation,	   in	   2010,	   that	   women	   with	   sickle	   cell	   disease	   should	   not	   be	  discouraged	   from	   the	   use	   of	   any	   particular	   contraceptive	   method,	   stating	   that	  combined	   hormonal	   contraceptive	   methods	   and	   copper	   IUDs	   are	   a	   US	   MEC	  “Category	   2”,	   while	   progestogen-­‐only	   methods	   are	   US	   MEC	   “Category	   1”	   (U	   S.	  Medical	   Eligibility	   Criteria	   for	   Contraceptive	   Use,	   2010).	   However,	   the	   first	  recommendation	  is	  based	  more	  on	  the	  fact	  that	  pregnancy	  carries	  many	  hazards	  to	  women	  with	  SCD	  and	  not	  on	  any	  evidence	  to	  support	  their	  complete	  safety,	  while	  the	  second	  recommendation,	  albeit	  very	  positive,	  is	  based	  also	  on	  limited	  evidence,	  as	  has	  been	  shown	  in	  Chapter	  1.	  	  
	  
7.2 IMPORTANCE	  OF	  THE	  STUDY	  
This	  study	  is	  important	  because	  it	  addresses	  an	  area,	  contraception	  in	  women	  with	  SCD,	  which	  at	  present	  is	  poorly	  understood.	  Advances	  in	  understanding	  in	  this	  area	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may	  help	  to	  reduce	  the	  high	  rate	  of	  unplanned	  pregnancies	  in	  this	  cohort	  of	  women	  and	  may	  assist	  medical	  practitioners	  and	  their	  patients	  in	  finding	  the	  right	  balance	  between	   the	   risks	   of	   VTE	   associated	   with	   the	   use	   of	   some	   types	   of	   hormonal	  contraception	   in	  women	  with	   SCD,	   and	   alternatively,	   the	  major	   complications	   of	  pregnancy.	  It	   is	  also	  the	  first	  study	  to	  combine	  clinical	  and	  laboratory	  markers	  in	  studying	   contraception	   in	   women	   with	   SCD	   using	   hormonal	   contraception.	   This	  study	  has	  also	  pioneered	  the	  assessment	  of	  contraception	  in	  women	  with	  SCT.	  
The	  number	  of	  unplanned	  pregnancies	  in	  SCD	  women	  is	  still	  unacceptably	  high.	  In	  a	  survey	  conducted	  by	  the	  Author	  in	  2010,	  53%	  of	  the	  pregnancies	  in	  SCD	  women	  were	  unplanned.	  This	  showed	  some	  improvement	  compared	  with	  a	  similar	  survey	  in	  1993	  (64.2%).	  These	  findings	  emphasise	  the	  continuing	  unmet	  need	  for	  effective	  contraceptive	  advice	  for	  SCD	  women	  (Appendix	  2).	  
	  
7.3 PRACTICALITIES	  AND	  DIFFICULTIES	  WITH	  THE	  RESEARCH	  
Clinically,	   this	   study	   covered	   vascular	   complications,	   such	   as	   VTE	   incidences,	  arterial	   thrombosis	   and	   strokes,	   sickle	   cell	   crises,	   the	  need	   for	  blood	   transfusion	  and	  hospital	   admissions	  as	  well	   as	   looking	  at	   side	  effects	   and	   failures	  associated	  with	   any	  particular	  method	  of	   contraception.	   In	   order	   for	   this	   information	   to	   be	  reliable	  I	  have	  only	  counted	  those	  events	  occurring	  prospectively	  during	  the	  study	  periods.	  However,	  at	  the	  interview,	  some	  women	  told	  me	  retrospectively	  that	  they	  had	   experienced	   complications	   and	   hence	   had	   changed	   their	   method	   of	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contraception.	  This	   inevitably	  raises	  the	  possibility	  of	  bias	  in	  these	  women	  at	  the	  time	  I	  was	  observing	  them.	  	  
I	  delayed	  taking	  blood	  samples	  until	  participants	  had	  been	  enrolled	  in	  the	  study	  for	  three	  months,	  to	  make	  sure	  that	  the	  participants	  have	  a	  plateau	  from	  exposure	  to	  their	  chosen	  contraception	  method	  because	  the	  risk	  of	  VTE	   is	  highest	   in	   the	   four	  months	   following	   initiation	   of	   combined	   hormonal	   contraception	   (WHO,	   1995).	  This	   three-­‐month	   period	   also	   helped	   me	   to	   organise	   the	   timings	   for	   blood	  collection	  in	  SCD	  women	  with	  regard	  to	  their	  crises,	  blood	  transfusions	  and	  their	  menstrual	  periods,	  where	  necessary.	  
	  




	  I	   have	   studied	   all	   the	   effects	   of	   the	   different	   COC	   preparations	   together	   as	   one	  group,	  as	  well	  as	  studied	  the	  POC	  preparations	  as	  a	  single	  group.	  While	  this	  helps	  to	  observe	  and	  identify	  any	  possible	  interactions	  of	  these	  hormones	  with	  SCD	  and	  SCT,	  it	  would	  not	  help	  in	  stratifying	  the	  risks	  with	  the	  different	  preparations.	  
	  
The	  small	  number	  of	  participants	  in	  some	  of	  the	  study	  arms	  arises	  partly	  from	  the	  major	   time	   delays	   with	   the	   ethics	   and	   R&D	   approval	   process	   and	   the	   failure	   to	  include	  some	  hospitals	  with	  SCD	  populations	  as	  discussed	   in	  chapter	  3.	   It	   is	  also	  due	   to	   fact	   that	   there	   are	   extremely	   few	   women	   with	   SCD	   who	   are	   using	   COC	  among	   the	   potential	   study	   population.	   This	   small	   number	   of	   COC	   users	   in	   the	  community	   reflects	   the	   fact	   that	   these	   women	   are	   not	   prescribed	   the	   COC	   as	  readily	  as	  POC.	  
	  
The	   study	   did	   involve	   looking	   at	  many	   facets	   of	   laboratory	  markers	   and	   clinical	  parameters,	   in	   the	   participants,	   in	   order	   to	   ensure	   good	   coverage	   to	   help	  answering	   the	   study	   question.	   However,	   I	   appreciate	   that	   studying	   many	  parameters	  could	  also	  be	  a	  source	  of	  bias,	  as	  the	  chance	  of	  identifying	  an	  adverse	  linkage	  with	   the	  use	  of	  hormonal	  contraception	  could	   increase.	  To	  deal	  with	   this	  potential	   source	   of	   bias	   additional	   analysis	   was	   done	   using	   logistic	   regression	  testing	   	   beside	   the	   main	   statiscal	   analysis	   by	   Linear	   regression	   (LR)in	   order	   to	  identify	   any	   true	   effects	   of	   contraception	   used	   by	   these	   women.	   As	   previously	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discussed	   (para	   3.9),	   however,	   unfortunately	   this	   did	   not	   prove	   useful,	   possibly	  because	  of	  the	  relatively	  small	  numbers	  involved.	  	  	  
	  
Of	  those	  women	  on	  any	  hormonal	  contraception,	  the	  duration	  of	  POC	  use	  is	  almost	  three	   times	   the	   COC	   use,	   and	   that	   probably	   results	   from	   the	   tendency	   of	  contraception	   prescribers	   to	   be	   influenced	   by	   anecdotal	   suggestions	   that	   POC	   is	  the	  better	  choice	  for	  women	  with	  SCD.	  Data	  obtained	  from	  the	  women’s	  interviews	  highlighted	  that	  sometimes	  SCD	  women	  accept	  POC	  use	  as	  their	  best	  choice	  even	  if	  they	  experience	  problems	  taking	  it.	  	  
	  
7.4 SIGINFICANCE	  OF	  SOME	  OF	  THE	  HAEMOSTATIC	  AND	  HAEMATOLOGICAL	  
TESTS	  USED	  
7.4.1 INTRODUCTION	  	  
Some	   of	   the	   haemostatic	   tests	   used	   in	   this	   study	   and	   their	   relevance	   to	   SCD	  pathogenesis	  or	  hormonal	  contraception	  were	  already	  discussed	  in	  chapters	  1	  and	  3.	  A	  further	  review	  of	  some	  of	  the	  other	  tests	  and	  their	  clinical	  value	  will	  be	  given	  in	  this	  section.	  
7.4.2 PRO	  AND	  ANTI-­‐COAGULANT	  MARKERS	  
In	   this	   paragraph	   I	   will	   explain	   further	   the	   relevance	   of	   activated	   Protein	   C	  resistance	  (APCR),	  Free	  Protein	  S	  (FPS)	  and	  the	  Dilute	  Russell’s	  Viper	  Venom	  Time	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(DRVVT)	  to	  this	  study.	  APCR	  is	  proven	  to	  occur	  in	  patients	  with	  SCD	  (Wright	  et	  al.,	  1997a)	  and	  in	  women	  using	  COC	  (Raps	  et	  al.,	  2013)	  and	  it	  can	  predict	  the	  risk	  of	  VTE	  (De	  Visser	  et	  al.,	  1999).	  	  
Protein	  S	  is	  one	  of	  the	  naturally	  occurring	  anticoagulants	  which	  together	  with	  PC	  and	  AT	   regulate	   c	   stimulates	   the	  Tissue	  Factor	   Inhibitor	  pathway,	   leading	   to	   the	  inhibition	   of	   coagulation	   (Castoldi	   et	   al.,	   2010).	   It	   is	   also	   known	   to	   be	   adversely	  affected	  by	  SCD,	  with	   low	  levels	  usually	  noted	  even	  in	  the	  steady	  state.	  However,	  there	   is	  a	  suggestion	  that	   low	  FPS	   levels	   in	  SCD	  patients	  may	  result	   from	  hepatic	  dysfunction	  rather	  than	  coagulation	  activation	  (Wright	  et	  al.,	  1997b)	  and	  may	  also	  be	   due	   to	   reduced	   endothelial	   production	   of	   PS,	   secondary	   to	   SCD-­‐related	  endothelial	   damage	   (Schnog	   et	   al.,	   2004).	   Acquired	   Protein	   S	   deficiency	   is	   also	  reported	  to	  be	  caused	  by	  COC	  use,	  as	  mentioned	  in	  chapter	  1	  
7.4.3 COAGULATION	  ACTIVATION	  MARKERS	  	  
Thrombin	  anti-­‐thrombin	  complexes	  (TAT)	  and	  Prothrombin	  Fragment	  1+	  2	  levels	  are	  well	   known	   to	   be	   raised	   in	   sickle	   cell	   disease	   (Peters	   et	   al.,	   1994),	   however	  there	   is	   evidence	   that	   these	   complexes	   could	   be	   also	   raised	   in	   other	   conditions	  such	  as	   inflammatory	  bowel	  disease	   (Souto	  et	  al.,	   1995).	  Elevated	   levels	  are	  also	  found	  in	  patients	  with	  VTE	  (Ota	  et	  al.,	  2008),	  malignancy	  (Tripodi	  et	  al.,	  1993)	  and	  in	   patients	  with	   thrombophilia	   (Simioni	   et	   al.,	   1996).	   Levels	  may	   be	   abnormally	  low	  in	  patients	  who	  are	  on	  anticoagulant	  therapy.	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7.4.4 	  PLATELET	  ACTIVATION	  MARKERS	  
The	   platelet	   activation	  markers	   studied	   in	   this	   project	   were:	   sPselectin,	   Platelet	  Factor	  4	  (PF4)	  and	  SCD40	  ligand.	  All	  these	  markers	  were	  shown	  to	  be	  relevant	  to	  thrombosis	   (Davis	  et	  al.,	  2003).	   sPselectin	   is	  an	  adhesion	  molecule	   that	   supports	  the	   binding	   of	  WBCs	   to	   activated	   platelets	   and	   the	   endothelium.	   	   It	   is	   normally	  present	  in	  granules	  in	  the	  membranes	  of	  unstimulated	  platelets	  and	  it	  is	  mobilised	  and	   migrates	   to	   the	   surface	   of	   platelets	   during	   activation.	   SP	   selectins	   are	   also	  present	  in	  endothelial	  cells	  and	  megakaryocyte	  membranes.	  The	  appearance	  of	  p-­‐selectin	   on	   the	   cell	   surface	   is	   usually	   very	   rapid.	   Excessive	   accumulation	   of	  neutrophilis,	  accompanied	  by	  high	  exposure	  of	  P-­‐selectin,	  has	  been	  implicated	  in	  a	  number	   of	   inflammatory	   disorders	   (Fijnheer	   et	   al.,	   1997).	   PF4	   is	   released	   from	  activated	  platelet	  α	  granules.	  It	  has	  a	  very	  short	  half	  life	  of	  less	  than	  five	  minutes,	  as	   it	   is	  quickly	  bound	   to	  endothelial	   cell	   glycos-­‐aminoglycans,	  where	   it	   is	   stored.	  	  PF4	  determination	  of	  platelet	  reactivity	  should	  be	  taken	  in	  conjunction	  with	  other	  markers	  of	  a	  hypercoagulable	  state	  including	  Fibrinopeptide	  A	  (FPA)	  and	  D-­‐dimer,	  because	   raised	   levels	   can	   be	   found	   in	   cardio-­‐vascular	   disease,	   diabetes,	   and	  malignancy	  (Kaplan	  and	  Owen,	  1986;	  Mosnier,	  2011).	  SCD40	   ligand	   is	  a	  platelet-­‐activation	  marker	   which	   could	   also	   signal	   T	   cell	   activation.	   Hence	   its	   levels	   can	  increase	   in	   pathological	   immune	   conditions	   such	   as	   Chronic	   Myeloid	   Leukemia	  (CLL),	   hyper	   IgM	   syndrome,	   B-­‐cell	   hybridisms	   and	   auto-­‐immune	   diseases.	   In	  conditions	  of	  pathological	  thrombosis	  the	  presence	  of	  high	  peripheral	  blood	  levels	  of	   sCD40	   ligand	   positively	   correlates	  with	   the	   amount	   of	   platelet	   content	   in	   the	  thrombus,	  giving	  an	  indication	  of	  the	  extent	  of	  thrombosis	  (Silvain	  et	  al.,	  2011).	  It	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has	   also	   been	   suggested	   that	   COC	   preparations	   containing	   spironolactione	  	  increase	  SCD40	  ligand	  release	  (Kebapcilar	  et	  al.,2010).	  
	  
7.4.5 	  ENDOTHELIAL	  CELL	  ACTIVATION	  	  
Selectins	   are	   adhesion	  molecules	   that	   guide	   non-­‐activated	   inflammatory	   cells	   to	  areas	   of	   inflammation	   and	   create	   loose	   contacts	  with	   endothelial	   cells	   (EC).	   The	  ones	   included	   in	   this	   study	   are	   sE-­‐selectin,	   sVCAM-­‐1,	   VWF:	   Ag	   and	   white	   cell	  activation	  slCAM-­‐1.	  	  
	  
SE	  selectin	  is	  a	  non-­‐specific	  disease	  marker	  expressed	  on	  many	  cells	  in	  the	  body.	  It	  is	   expressed	   when	   cytokines	   activate	   ECs	   and	   contributes	   to	   the	   adhesion	   of	  leukocytes	   to	   the	  endothelium.	  E-­‐selectin	   is	  maximally	  expressed	  2-­‐4	  hours	  after	  EC	  activation	  by	  exerting	  chemotactic	  signals	  on	  WBCs.	  Hence	  it	  is	  usually	  raised	  in	  many	   inflammatory	  conditions,	  septic	  shock,	  vascular	   infection	  and	   inflammation	  and	  inflammatory	  bowel	  disease	  (Azimi-­‐Nezhad	  et	  al.,	  2013).	  	  
	  
Soluble	  Intercellular	  adhesion	  molecule	  -­‐1	  (sICAM-­‐1)	  is	  produced	  by	  various	  cells	  including	   vascular	   endothelial	   cells	   (ECs),	   fibroblasts,	   epithelial	   cells	   and	   tissue	  macrophages.	  It	  is	  part	  of	  the	  immunoglobulin	  super-­‐gene	  family	  and	  functions	  as	  a	   ligand	   for	   the	   lymphocyte	   function-­‐associated	   antigen	   -­‐1	   (LFA-­‐1),	   an	   initial	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marker	  of	   the	   inflammatory	  reaction.	   	   Its	  role	   in	  predicting	  thrombosis	   is	   limited	  by	  the	  fact	  that	  it	  is	  raised	  in	  many	  medical	  and	  immunological	  conditions	  such	  as	  allergic	  airways	  inflammation,	  allergic	  contact	  dermatitis,	  cancers,	  acute	  transplant	  rejection,	   in	   insulin-­‐dependent	   diabetes	   mellitus,	   following	   acute	   myocardial	  infarction,	  glomerulonephritis,	  and	  asthma.	  
	  
Soluble	   Vascular	   cell	   adhesion	   molecule-­‐1	   (sVCAM-­‐1	   )	   supports	   adhesion	   of	  leukocytes	  to	  the	  endothelium.	  V-­‐CAM-­‐1	  is	  not	  usually	  expressed	  on	  endothelium,	  but	   can	   be	   upregulated	   by	   EC.	   It	   is	   present	   on	   tissue	   macrophages,	   and	   other	  immune	  system	  cells.	   Soluble	  VCAM-­‐1	   levels	   can	  be	   found	   in	  healthy	   individuals,	  however	   levels	   are	   elevated	   in	   malignancies,	   auto-­‐immune	   diseases,	   infections,	  inflammation,	  cirrhosis	  and	  impaired	  renal	  function	  (Jin	  et	  al.,	  2010).	  
	  
7.4.6 THROMBIN	  GENERATION	  
Thrombin	  generation	  (TG)	  has	  previously	  been	  shown	  to	  be	  increased	  in	  patients	  with	   high	   levels	   of	   FVIII	   C,	   FIX	   ,	   FXI	   and	   in	   women	   using	   COC	   or	   hormone	  replacement	  therapy	  (Chantarangkul	  et	  al.,	  2004;	  Dargaud	  et	  al.,	  2003;	  Eilertsen	  et	  
al.,	   2007;	   Mackie	   et	   al.,	   2001;	   Regnault	   et	   al.,	   2003;	   Siegemund	   et	   al.,	   2004;	  Tchaikovski	  and	  Rosing,	  2010;	  Tchaikovski	  et	  al.,	  2007;	  van	  Hylckama	  Vlieg	  et	  al.,	  2007).	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Thrombin-­‐generation	   (TG)	   assays	   are	   reported	   to	   be	   useful	   in	   detecting	  hypercoaguability	   in	   affected	   patients	   (Pereira	   et	   al.,	   2006).They	   have	   also	   been	  used	   to	   detect	   differences	   in	   clinical	   severity	   among	   	   patients	   with	   bleeding	  disorders,	   and	   to	  monitor	   patients	   on	   anticoagulants	   and	   	   those	  who	   are	   having	  anticoagulation	   reversed	   (Van	   Veen	   et	   al.,	   2008).However,	   TG	   tests	   measure	   a	  physiological	  process,	  	  and	  the	  usefulnes	  of	  this	  assay	  in	  pathological	  conditions	  is	  not	  	  straight	  forward.This	  could	  limit	  its	  clinical	  use	  at	  present,	  as	  people	  carrying	  similar	  TG	  defects	   could	   show	  different	   clinical	  manifestations	  depending	  on	   the	  presence	   of	   other	   confounding	   factors	   in	   haemostasis	   such	   as	   comorbidities,	  immobilisation,	  pregnancy	  and	  dehydration..	   Some	  studies	  have	   suggested	   that	   a	  high	   ETP	   in	   patients	   with	   thrombosis	   may	   indicate	   a	   higher	   risk	   of	   recurrence	  (Besser	  et	  al.,2008).	  TGA	   testing	  using	   the	  CAT	  analyser	   	  has	  been	   found	   to	  be	  a	  reliable	  and	  relatively	  easy	  way	  to	  measure	  TG	  (Brandts	  et	  al.,	  2007),	  however,	  it	  is	  still	  a	  research	  tool	  .	  
	  
7.5 COMPARISONS	  BY	  TYPE	  OF	  HAEMOGLOBIN	  
7.5.1 CLINICAL	   COMPLICATIONS	   AND	   CONTRACEPTION	   SIDE	   EFFECTS	   IN	  
WOMEN	  WITH	  SCD	  
Within	  the	   limits	  of	   the	  small	  numbers	  of	  participants,	  as	  mentioned	  already,	   the	  data	  do	  not	  support	  any	  excess	  of	  clinical	  complications	  in	  SCD	  women	  using	  COC,	  while	   women	   with	   SCD	   using	   POC	   had	   more	   complications.	   The	   statistically	  significant	  difference	  in	  age	  between	  women	  with	  SCD	  using	  COC	  and	  those	  using	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POC	  could	  have	  been	  a	  source	  of	  bias	  in	  the	  comparison	  between	  them.	  Generally	  COC	   are	   not	   prescribed	   for	   older	   women,	   even	   if	   they	   do	   not	   have	  haemoglobinopathies,	   as	   age	   alone	   puts	   women	   at	   higher	   risk	   of	   complications.	  COC	   should	   usually	   only	   be	   prescribed	   until	   the	   age	   of	   50	   years.	   Amongst	   all	  women	  using	  POC	  there	  was	  no	  age	  difference	  between	  those	  with	  SCD,	  SCT	  and	  normal	  haemoglobin	  and	  yet	  women	  with	  SCD	  fared	  worse	  than	  the	  other	  groups.	  However,	   this	   noticeable	   increase	   in	   clinical	   complications	   in	   women	   with	   SCD	  using	  POC	  could	  be	  attributed	  to	  their	  disease	  severity	  and	  not	  the	  contraception	  use,	  as	  there	  is	  a	  tendency	  for	  women	  with	  severe	  problems	  from	  the	  disease	  to	  be	  prescribed	  POC	  rather	  than	  COC.	  
	  
The	  increased	  incidence	  of	  clinical	  complications	  in	  SCD	  women	  who	  are	  not	  using	  any	  hormonal	   contraception	   could	  also	   result	   from	  a	   selection	  bias,	   as	   there	   is	   a	  chance	   that	   SCD	  women	  who	   are	   not	   on	   contraception	   could	   have	  more	   severe	  phenotypes	  of	  the	  disease.	  	  
	  
The	  occurrence	  of	  one	  episode	  of	  proven	  VTE	  in	  a	  cohort	  of	  68	  SCD	  women	  over	  a	  period	  of	   two	  years	  gives	  an	   incidence	  of	  0.7%,	  which	   is	   slightly	  higher	   than	   the	  one	   quoted	   in	   the	   literature	   (0.44	   risk	   of	   PE	   in	   Stein	   et	   al,	   2006	   study).	  Nonetheless,	  the	  literature	  about	  clinical	  VTEs	  in	  SCD	  patients	  is	   limited.	  The	  fact	  that	   the	  participants	   in	   this	  study	  are	  cared	   for	  at	  major	  referral	  centres	   for	  SCD	  could	  also	  be	  a	  possible	  source	  of	  bias	  here,	  as	  these	  patients	  may	  suffer	  from	  more	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disease	   complications	   than	   other	   SCD	   women	   who	   are	   not	   referred	   to	   these	  centres.	  
	  
The	  side	  effects	  from	  contraception,	  the	  occurrence	  of	  unplanned	  pregnancies	  and	  the	   discontinuation	   of	   contraception	   occurred	   in	   a	   very	   small	   amount	   of	  participants	  with	   little	  difference	  amongst	   the	   three	  groups.The	  small	  number	  of	  cases	  of	  menstrual	  irregularities	  noted	  in	  all	  SCD	  women	  using	  COC	  is	  an	  expected	  finding	  as	  well	  as	  the	  increased	  rate	  of	  menstrual	  irregularities	  and	  amenorrhoea	  in	  SCD	  women	  on	  POC,	  which	  is	  the	  same	  as	  observed	  in	  the	  general	  population,	  as	  discussed	  in	  chapter	  1.	  
	  
Despite,	  the	  study	  design	  not	  making	  any	  controlled	  assignment	  of	  the	  participants	  to	  any	  specific	  study	  group,	  there	  were,	  however,	  no	  significant	  differences	  in	  BMI,	  smoking	  and	  parity	  between	  them,	  which	  is	  a	  positive	  point	  in	  the	  study.	  
	  
7.5.2 CLINICAL	   COMPLICATIONS	   AND	   CONTRACEPTION	   SIDE	   EFFECTS	   IN	  
WOMEN	  WITH	  SCT	  
As	  expected,	   there	  were	  minimal	   serious	   clinical	   events	  during	   the	  period	  of	   the	  study	   in	  women	  with	  SCT	  using	  COC	  and	  POC.	  Contraceptive	  side	  effects	  are	  also	  few	  in	  this	  cohort.	  In	  women	  with	  SCT	  the	  prior	  contraceptive	  period	  use	  is	  more	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evenly	   distributed	   between	   the	   different	   contraceptive	  methods	   than	   in	   the	   SCD	  women.	   This	   is	   believed	   to	   be	   a	   true	   reflection	   of	   the	   situation	   in	   the	   SCT	  population,	  as	  there	  was	  no	  contraception	  method	  recruitment	  in	  the	  study,	  which	  could	   give	   such	  bias.	   Paradoxically,	   this	   also	  demonstrates	   that	   “pill”	   prescribers	  fail	  to	  recognise	  recent	  research	  evidence,	  which	  implies	  that	  there	  are	  increased	  risks	  of	  thrombosis	  in	  SCT	  women,	  as	  discussed	  in	  chapter	  1.	  
	  
7.5.3 CLINICAL	   COMPLICATIONS	   AND	   CONTRACEPTION	   SIDE	   EFFECTS	   IN	  
WOMEN	  WITH	  NORMAL	  HAEMOGLOBIN	  
There	  are	  also	  minimal	  clinical	  and	  contraceptive	  complications	   in	   these	  women.	  The	   different	   prior	   contraceptive-­‐use	   duration	   is	   not	   statistically	   significant	  between	  the	  women	  in	  this	  group.	  
7.5.4 HAEMOSTATIC	   AND	   HAEMATOLOGICAL	   RESULTS	   IN	   WOMEN	   WITH	  
SCD	  	  
Thelaboratory	  markers	  used	  did	  not	  support	  the	  theory	  that	  COC	  use	  increases	  the	  thrombotic	  risks	  in	  SCD	  women	  further.	  Activated	  protein	  C	  levels	  in	  this	  group	  are	  statistically	   significantly	   lower	   than	   in	   the	   other	   SCD	   women.	   However,	   the	  absolute	  value	  of	  APCR	  itself	  is	  within	  the	  normal	  range.	  Thus	  one	  can	  suggest	  that	  COC	  use	  has	  no	  clinically	  relevant	  additive	  or	  multiplicative	  effect	  on	  APCR	  in	  SCD	  women,	   because	  when	   SCD	  women	  using	  COC	   are	   compared	   to	   SCT	  women	   and	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women	  with	  normal	  Hb	  using	  the	  same	  methods	  the	  women	  with	  SCD	  have	  better	  values	  (see	  Table	  6.5).	  
	  
It	   is	  well	   known	   that	  COC	  use	   could	  decrease	  Protein	  S	   levels.	  However,	   the	   low	  levels	  of	  free	  Protein	  S	  in	  women	  with	  SCD	  using	  COC	  could	  be	  attributable	  to	  the	  disease	   activity,	   because	   all	   SCD	   women,	   regardless	   of	   their	   method	   of	  contraception,	  had	   low	  free	  Protein	  S	   levels	  (Table	  5.5)	  and	  because	  COC	  use	  did	  not	  alter	  the	  levels	  of	  free	  Protein	  S	  in	  SCT	  women	  and	  in	  women	  with	  normal	  Hb	  (see	  Table	  6.5).	  There	   is	  also	  no	   indication	   that	   this	  deficiency	   is	  made	  worse	  by	  COC	   use	   because	   the	   lowest	   levels	   were	   seen	   in	   women	   with	   SCD	   who	   are	   not	  using	  any	  hormonal	  contraception.	  
	  
Von	  willebrand	   factor	  antigen	   is	  higher	   than	   the	   reference	   range	   in	  women	  with	  SCD	  using	  COC;	  however	  this	  could	  also	  be	  a	  manifestation	  of	  the	  disease,	  as	  this	  is	  noticeable	   in	   all	   SCD	  women	   and	   is	  more	  marked	   in	   SCD	  women	   not	   using	   any	  hormonal	   contraception	   (see	   Table	   5.4).	   Von	  Willebrand	   factor	   is	   an	   endothelial	  biomarker	  which	  is	  a	  marker	  of	  risk	  for	  ischemic	  heart	  disease	  or	  stroke	  (Constans	  and	  Conri,	  2006)	  hence	  there	  is	  a	  chance	  that	  those	  women	  who	  have	  higher	  levels	  may	   be	   prone	   to	   such	   events.	   All	   the	   clotting	   factors	   studied	   were	   normal	   in	  women	   with	   SCD	   on	   COC	   which	   is	   unsurprising,	   as	   the	   multi	   factorial	  prothrombotic	   condition	  of	   SCD	  seems	  not	   to	   involve	   increased	   levels	  of	   clotting	  factors	  (Setty	  et	  al.,	  2001)	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Two	  of	  the	  coagulation	  activation	  markers	  studied	  showed	  levels	  higher	  than	  the	  reference	  range	  (TAT	  and	  D	  Dimer),	  though	  the	  levels	  of	  these	  markers	  levels	  were	  high	  in	  all	  the	  SCD	  women	  regardless	  of	  their	  method	  of	  contraception,	  and	  being	  worst	   in	   those	   on	   no	   HC	   (see	   Table	   5.7).	   TAT	   is	   reported	   to	   be	   elevated	   in	  thrombotic	   events	   and	   could	   predict	   a	   predisposition	   to	   thrombosis;	   however	   it	  can	   be	   raised	   in	   other	  medical	   conditions	   such	   as	   liver	   dysfunction,	   septicaemia	  and	  malignancy	  (Fidan	  et	  al.,	  2012).	  A	  multinomial	  logistic	  regression	  
	  
	  model	  found	  a	  Relative	  risk	  Ratio	  of	  1.02	  for	  D	  Dimer	  in	  SCD	  women	  regardless	  of	  their	  contraceptive	  method	  with	  a[95%	  CI:	  1.01	  to1.03)	   for	  and	  p	  value	  of	  0.001.	  There	   is	   evidence	   that	   high	   D	   Dimer	   levels	   signal	   micro-­‐thrombi	   which	   could	  predispose	  to	  the	  development	  of	  pulmonary	  hypertension,	  which	  is	  a	  recognised	  complication	   of	   SCD	   (Shitrit	   et	   al.,	   2002).	   In	   this	   study,	   women	   with	   known	  pulmonary	  hypertension	  were	  specifically	  excluded.	  As	  mentioned	  in	  chapter	  3,	  D	  dimer	  levels	  could	  also	  be	  raised	  in	  other	  inflammatory	  conditions	  and	  in	  cases	  of	  malignancy.	  
	  
Platelet	  activation	  factor	  4	  (PF4)	  is	  raised	  in	  all	  women	  with	  SCD	  (see	  Table	  5.8).	  As	  mentioned	  earlier,	  this	  marker	  is	  not	  very	  sensitive	  in	  predicting	  thrombosis.	  In	  the	   presence	   of	   high	   D	   dimer	   levels	   this	   could	   denote	   an	   increased	   risk	   of	  thrombosis	   in	   these	   women.	   However,	   the	   uniform	   rise	   in	   all	   the	   SCD	   women	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makes	   it	  more	   likely	   that	   this	   is	   a	   disease	  manifestation	  which	   is	   not	   influenced	  much	  by	  hormonal	  contraception.	  
	  
Endothelial	  activation	  markers	  are	  within	   the	  reference	  range	   in	  all	  women	  with	  SCD.	  This	  finding	  was	  unexpected	  because	  of	  published	  findings	  that	  these	  markers	  are	  elevated	  in	  patients	  with	  SCD,	  as	  mentioned	  in	  chapter	  1.	  
	  
The	   increased	   levels	   of	   microparticles	   seen	   in	   all	   SCD	   women	   is	   an	   expected	  finding	  (Tantawy	  et	  al.,	  2012).	  However,	  micorparticle	  levels	  are	  not	  increased	  by	  using	  COC,	  as	  there	  is	  a	  40-­‐60%	  reduction	  in	  the	  level	  in	  the	  group	  of	  women	  using	  COC.	  TF	   is	  also	  another	  marker	  which	   is	  expected	  to	  be	  high	   in	  women	  with	  SCD	  and	  yet	  again	   it	  was	  high	   in	  all	  women	  regardless	  of	   their	  contraceptive	  use	  (see	  Table	  5.10).	  The	  increased	  TF	  levels	  are	  strongly	  associated	  with	  an	  increased	  risk	  of	  thrombosis.	  	  
	  
The	  tests	  for	  TG	  using	  CAT	  showed	  normal	  results	  in	  all	  except	  the	  slope,	  which	  is	  higher	  than	  the	  reference	  range	  in	  SCD	  women	  using	  COC.	  Nonetheless,	  the	  normal	  TG	  test	  in	  these	  women,	  with	  a	  clear	  trend	  shift	  towards	  thrombosis	  could	  be	  due	  to	   the	   fact	   that	   this	   test	   fails	   to	  pick	  up	  ongoing	  prothrombotic	  changes.	  Though,	  Shah	  et	  al	  (2012)	  found	  that	  CAT	  measured	  TG	  markers	  were	  significantly	  higher	  in	  SCD	  crises	  compared	  to	  the	  steady	  state,	  however,	  they	  found	  that	  there	  were	  no	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differences	  in	  clinical	  outcomes	  studied	  simultaneously.	  It	  has	  been	  suggested	  that	  TG	  tests	  could	  be	  beneficial	  in	  assessing	  bleeding	  disorders	  (Van	  Veen	  et	  al.,	  2008).	  These	  results	  could	  indicate	  that	  TG	  tests	  fits	  less	  	  well	  with	  thrombosis.	  
	  
All	  markers	   of	   haemolysis	   are	   uniformly	   elevated	   in	   all	  women	  with	   SCD,	  which	  again	   fits	   with	   the	   pathology	   of	   SCD,	   but	   the	   levels	   of	   these	   markers	   did	   not	  indicate	   that	   hormonal	   contraception	   worsened	   their	   rate	   of	   haemolysis	   in	   the	  steady	  state.	  
SCD	  women	  on	  POC	  had	  a	  number	  of	  statistically	  significantly	  worse	  markers	  than	  other	  SCD	  women	  such	  as	  SCD	  40	  L,	  SVCAM	  and	  TP	  although	  the	  absolute	  values	  emained	  within	  the	  reference	  ranges..	  Again,	  this	  could	  be	  selection	  bias,	  with	  this	  group	  being	  more	  ill	  and	  hence	  being	  prescribed	  POC.	  Nonetheless,	  SCD40L	  has	  a	  stronger	  correlation	  with	  thrombosis,	  as	  mentioned	  in	  section	  7.4.4,	  and	  this	  could	  reflect	  an	  increased	  risk	  of	  thrombosis	  in	  these	  women.	  On	  the	  other	  hand,	  SVCAM	  can	  be	  raised	  in	  many	  diseases	  and	  it	  may	  not	  in	  itself	  indicate	  an	  increased	  risk	  of	  thrombosis.	  	  Amongst	  the	  TG	  tests	  done	  on	  SCD	  women	  on	  POC,	  time	  to	  peak	  (TP)	  is	  the	  only	  marker	  which	  is	  statistically	  significantly	  different	  between	  SCD	  women	  on	   differing	   forms	   of	   contraception.	  Women	   using	   POC	   have	   the	   highest	   values,	  however	   as	   mentioned	   earlier,	   the	   actual	   values	   themselves	   are	   within	   the	  reference	  range.	  	  
Women	  with	   SCD	  not	   using	  hormonal	   contraception	  had	   the	   greatest	   number	   of	  statistically	   significant	   adverse	   markers	   i.e	   DVVT,	   TAT,	   Prothrombin	   F1+2,	   D	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Dimer	  and	  AST.	  Again,	  this	  group	  of	  women	  could	  have	  more	  severe	  disease	  states,	  and	   the	   adverse	   results	   would	   be	   a	   manifestation	   of	   the	   disease	   itself	   which	   is	  known	  to	  be	  a	  prothrombotic	  condition,	  as	  discussed	  in	  chapter	  1.	  The	  fact	  that	  the	  woman	   who	   suffered	   VTE	   was	   in	   this	   group	   fits	   with	   this	   picture	   of	   adverse	  laboratory	  markers.	  As	  markers	  of	  haemolysis	  are	  uniformly	  elevated	  in	  all	  women	  with	   SCD,	   which	   again	   confirms	   the	   pathology	   of	   SCD,	   but	   does	   not	   imply	   that	  hormonal	   contraception	   has	   added	   further	   insult.	   This	   speculation	   (that	   the	  decision	  not	   to	  prescribe	  HC	   to	   these	   individuals	  was	  because	   they	  were	  already	  known	   to	   have	   a	  more	   severe	   SCD	  phenotype)	   cannot	   be	   explored	   by	   the	   data	   I	  have,	  since	  no	  comparison	  was	  made	  between	  them	  and	  the	  HC	  using	  SCD	  women	  before	  the	  latter	  started	  their	  HC.	  CRP	   levels	   are	   high	   in	   all	   women	   with	   SCD,	   and	   this	   is	   in	   agreement	   with	   the	  evidence	  that	  there	  is	  a	  high	  degree	  of	  endothelial	  activation	  and	  damage	  seen	  in	  these	  patients,	  even	  in	  the	  steady	  state.(Kanavaki	  et	  al.,	  2012).	  
7.5.5 HAEMOSTATIC	   AND	   HAEMATOLOGICAL	   RESULTS	   IN	   WOMEN	   WITH	  
SCT	  	  




On	  the	  other	  hand	  SCT	  women	  using	  POC	  had	  higher	  Factor	  VIIIC	  levels,	  which	  is	  statistically	  different	  from	  the	  other	  SCT	  women.	  They	  had	  also	  slightly	  lower	  free	  protein	   S	   levels.	   However,	   SCT	  women	   on	   no	   hormonal	   contraception	   had	   even	  lower	  levels	  of	  free	  Protein	  S.	  This	  deficiency	  of	  Protein	  S	  is	  most	  likely	  due	  to	  the	  condition	   itself,	   as	   it	   occurred	   in	  women	   not	   using	   any	   hormonal	   contraception.	  This	   finding	   is	   interesting,	  because	  while	   the	  association	  with	  SCD	  and	  protein	  S	  deficiency	  is	  well	  known,	  there	  is	  little	  information	  about	  this	  deficiency	  in	  the	  SCT	  population.	  A	  case	  report	   from	  2008	  described	  recurrent	  priapism	  in	  a	  man	  with	  SCT	  and	  Protein	  S	  deficiency,	  where	  the	  Protein	  S	  deficiency	  was	  found	  incidentally	  during	  the	  course	  of	  investigations	  (Rehman	  et	  al.,	  2008).SCT	  women	  not	  using	  any	  hormonal	  contraception	  have	  also	  significantly	  higher	  APTT	  and	  Fibrinogen	  levels	  compared	  to	  other	  SCT	  patients.	  
	  
SCT	  women	  on	  POC	  and	  on	  COC	  exhibited	  adversely	  higher	  levels	  of	  D	  Dimer,	  The	  logistic	  regression	  modeling	  found	  a	  Relative	  risk	  Ratio	  of	  1.01	  for	  D	  Dimer	  in	  SCT	  women	  regardless	  of	   their	   contraceptive	  method	  with	  a	   [95%	  CI:0.020	   to	  1.002)	  and	  a	  p	  value	  of	  0.020.	  This	  raises	   the	  question	  of	  SCT	   itself	  having	  an	   increased	  thrombotic	   risk	  and	  whether	  COC	   increases	   this	   risk	   further.SCT	  women	  on	  COC	  also	  exhibited	  adversely	  higher	   levels	  of	  TAT	  which	  were	   statistically	   significant.	  Another	  explanation	  is	  that	  this	  prothrombotic	  tendency	  is	  more	  related	  to	  the	  fact	  that	  these	  women	  are	  of	  black	  ethnicity.	  This	  agrees	  with	  a	  similar	  finding	  Lutsey	  
et	  al	  (2006)	  when	  they	  reported	  that	  people	  of	  black	  ethnic	  origin	  had	  the	  highest	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levels	   of	   factor	   VIII,	   D-­‐Dimer	   and	   von	  Willebrand	   factor,	   among	   all	   participants	  from	  four	  different	  ethnic	  groups	  
	  
Recent	   literature	   suggests	   that	   sickle	   cell	   trait	   is	   not	   a	   benign	   disease	   when	   it	  comes	  to	  thrombosis,	  as	  discussed	  in	  Chapter	  1,	  with	  a	  quoted	  doubling	  of	  risk	  for	  VTE,	  and	  a	  4	  four	  fold	  increase	  in	  PE.	  The	  levels	  of	  Prothrombin	  1+2-­‐fragment	  in	  women	  with	  SCT	  using	  COC	   is	   significantly	  higher	   (almost	  30	  %)	  compared	  with	  those	   women	   who	   are	   not	   using	   hormonal	   contraception,	   although	   the	   highest	  value	   is	   still	   within	   the	   reference	   range.	   In	   the	   published	   literature,	   Saleh	   et	   al,	  1993,	   found	   no	   increase	   in	   Prothrombin	   1+2-­‐fragment	   with	   conjugated	   equine	  estrogenuse,	  and	  Régine	  Sitruk-­‐Ware,	  2007,	  found	  no	  increased	  levels	  with	  E2	  use.	  
	  
Women	  with	  SCT	  using	  COC	  had	  high	   levels	  of	  PF4,	  more	   than	  10	   fold	  above	   the	  reference	  range,	  although	  PF4	  was	  also	  high	  in	  other	  women	  with	  SCT	  in	  the	  study,	  the	   difference	   was	   statistically	   significant.	   As	   mentioned	   in	   section	   7.4.4,	   this	  marker	  may	  not	  necessarily	  denote	  a	  higher	  risk	  of	  thrombosis.	  SCD40L,	  which	  is	  a	  more	  accurate	  predictor	  of	  platelet	  activation,	  was	  within	  the	  reference	  range	  in	  all	  women	   with	   SCT.	   However,	   there	   is	   still	   a	   statistically	   significant	   difference	  between	  the	  groups,	  with	  levels	  in	  those	  women	  on	  COC	  and	  those	  women	  on	  POC	  being	   2.5	   times	   the	   levels	   in	   women	   without	   hormonal	   contraception.	   This	  increase	   in	   SCD40L	   in	   COC	   users	   supports	   the	   current	   literature	   by	   Divani	   et	   al	  (2012).	   However,	   the	   increased	   level	   in	   women	   with	   SCT	   using	   POC	   is	   more	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puzzling.	   There	   is	   evidence	   that	   high	   levels	   of	   SCD40L	   may	   be	   a	   marker	   for	  atherosclerosis	  and	  cardiovascular	  disease,	  but	  whether	  these	  women	  are	  already	  affected,	  or	  will	  develop	  such	  changes	  in	  the	  future,	  is	  unknown.	  
P-­‐selectin	   is	   a	   marker	   for	   procoagulant	   properties	   and	   the	   prothrombotic	   state,	  and	   thus	   it	   is	   expected	   to	   be	   raised	   in	   subjects	   with	   conditions	   similar	   to	   SCD	  (Pabinger	  and	  Ay,	  2009).	  However,	  P-­‐selectin	  results	  showed	  levels	  lower	  than	  the	  reference	   range	   for	   participants	   of	   the	   three	   haemoglobin	   types	   studied.	   This	  result	   was	   unexpected,	   and	   will	   need	   further	   evaluation	   in	   future	   studies.	  However,	   whatever	   the	   reason	   behind	   these	   low	   levels	   of	   P-­‐selectin,	   this	   is	   a	  reassuring	   point	   in	   this	   study	   as	   it	   suggests	   that	   the	   platelets	   do	   not	   undergo	  activation	  at	   the	   time	  of	  blood	  collection,	  and	   thus	   the	  results	  of	   the	  haemostatic	  markers	  are	  valid	  and	  reliable.	  Endothelial	  activation	  markers	   in	  all	  women	  with	  SCT	   lie	  within	   the	   reference	   range,	   apart	   from	   the	   soluble	   endothelial-­‐leucocyte	  adhesion	  molecule-­‐1	  (sELAM),	  which	  was	  found	  to	  be	  higher	  in	  SCT	  women	  using	  COC.	  This	  increase	  was	  statistically	  significant,	  with	  levels	  being	  greater	  than	  twice	  those	   in	   the	  women	  not	  using	  any	  hormonal	   contraception.	  However	   sELAM	  can	  increase	  in	  inflammatory	  conditions,	  so	  the	  interpretation	  of	  this	  finding	  is	  as	  yet	  unclear.	  	  
	  
Tisssue	   factor	   is	   another	   haemostatic	   marker	   which	   was	   increased	   2-­‐fold	   in	  women	   with	   SCT	   who	   were	   using	   COC.	   	   This	   adverse	   result	   was	   statistically	  significantly	   different	   from	   the	   results	   in	   women	   with	   SCT	   not	   using	   hormonal	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contraception.	  The	  relevance	  of	  TF	  to	  thrombosis	  has	  already	  been	  highlighted	  in	  chapter	  1.	  This	  increase	  appears	  to	  be	  more	  related	  to	  the	  sickle	  carrier	  status	  that	  to	  the	  oral	  contraception	  use,	  as	  this	  increase	  was	  also	  seen	  in	  women	  with	  SCT	  not	  using	  any	  hormonal	  contraception.	  
	  
TG	  tests	  remained	  normal	  in	  all	  women	  with	  SCT,	  although	  the	  actual	  levels	  were	  statistically	  significantly	  different	  in	  two	  of	  these	  (LT	  and	  PH),	  with	  the	  levels	  being	  high	  in	  the	  group	  not	  using	  any	  hormonal	  contraception.	  Again,	  TG	  testing	  here	  did	  not	   suggest	   any	   thrombotic	   tendency,	   which	   raises	   the	   question	   about	   its	  usefulness	  in	  predicting	  prothrombotic	  conditions.	  
	  
All	  markers	  of	  haemolysis	  were	  normal	  in	  all	  women	  with	  SCT.	  This	  finding	  is	  to	  be	  expected	   as	   these	   women	   are	   not	   known	   to	   have	   un-­‐provoked	   haemolysis.	  However,	   the	  presence	  of	   elevated	   thrombotic	  markers	   in	   these	  women	   leads	   to	  the	   question	   as	   to	   whether	   the	   haemolysis	   contribution	   to	   thrombosis	   in	   SCD	  patients	   (discussed	   in	   section	  1.6.1.2)	   is	  only	  a	   small	   fraction	  of	  a	  very	  wide	  and	  complicated	  mechanism.	  	  	  
	  
The	  biochemical	  markers	  and	  full	  blood	  counts	  were	  normal	  in	  all	  SCT	  women.	  CRP	  was	  elevated	   in	  all	   those	  with	  SCT,	  although	   to	  a	   lesser	  extent	   than	  women	  with	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SCD,	  which	  may	   indicate	   that	   the	   SCT	  women	  were	   also	   undergoing	   a	   degree	   of	  chronic	  inflammatory	  changes.	  
	  
7.5.6 HAEMOSTATIC	   AND	   HAEMATOLOGICAL	   RESULTS	   IN	   WOMEN	   WITH	  
NORMAL	  HAEMOGLOBIN	  
With	   regard	   to	   the	   women	   with	   normal	   haemoglobin,	   women	   on	   COC	   had	  statistically	  significantly	  higher	  levels	  of	  DVVT,	  although	  the	  mean	  value	  was	  	  still	  within	   the	   reference	   range.	   Secondly,	   the	   mean	   level	   of	   APCR	   in	   women	   with	  normal	  Hb	  who	  were	   using	   COC	  was	   statistically	   significantly	   different	   from	   the	  rest.	   Again	   however,	   the	   value	   was	   still	   within	   the	   normal	   range.	   Women	   with	  normal	  Hb	  and	  using	  COC	  had	   levels	  of	  Factor	  VIIIC	  which	  were	  higher	   than	   the	  reference	  range,	  and	   this	   is	  also	  noticeable	   in	  women	  using	  POC.	  As	  discussed	   in	  section	  1.7.1.1.1,	  COC	  use	  may	  increase	  Factor	  VIII	  and	  these	  results	  support	  this.	  However,	  rather	  unexpectedly,	  the	  women	  with	  normal	  Hb	  on	  POC,	  and	  those	  not	  using	   any	   hormonal	   contraception,	   had	   Free	   Protein	   S	   levels	   which	   were	   lower	  than	   the	   reference	   range.	   This	   could	   be	   an	   ethnic	   characteristic,	   as	   low	   Free	  Protein	   S	   results	   are	   reported	   to	   be	   more	   prevalent	   in	   people	   of	   black	   African	  origin	  (Jerrard-­‐Dunne	  et	  al.,	  2003).	  
	  
TAT	   levels	   were	   significantly	   different	   between	   the	   women	   with	   normal	  haemoglobin,	   with	   the	   group	   not	   using	   any	   hormonal	   contraception	   showing	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results	  higher	  than	  the	  reference	  range,	  while	  the	  other	  groups	  had	  normal	  results.	  This	  again	  could	  be	  a	  feature	  of	  their	  ethnicity	  (Hagger	  et	  al.,	  1995).	  
	  
The	  adversely	  raised	  sCD40L	  levels	  in	  the	  women	  with	  normal	  Hb	  using	  COC	  was	  significantly	  different	   from	   the	  other	   two	  groups.	   	  As	  mentioned	   in	   section	  7.4.4,	  this	  could	  signal	  an	  increased	  risk	  of	  thrombosis.	  
	  
PF4	  was	  high	  in	  all	  the	  women	  with	  normal	  haemoglobin.	  The	  significance	  of	  this	  elevation	   is	   difficult	   to	   interpret,	   as	   mentioned	   in	   section	   7.4.4.	   Although	  microparticle	  levels	  were	  normal	  in	  all	  the	  women	  with	  normal	  haemoglobin,	  the	  levels	  in	  the	  group	  using	  COC	  was	  statistically	  significantly	  higher.	  
	  
Thrombin	  generation	  tests	  were	  normal	  in	  all	  the	  women	  with	  normal	  Hb,	  except	  the	  slope	  which	  was	  raised	  in	  women	  using	  POC.	  
The	   normal	   haemolysis	   markers	   seen	   in	   all	   the	   women	   with	   normal	   Hb	   is	   an	  expected	  result,	  as	  is	  the	  normal	  full	  blood	  count	  parameters.	  
	  
Some	   liver	   function	   markers	   (ALT,	   ALP	   and	   albumin)	   showed	   statistically	  significant	   adverse	   results	   in	   the	   group	   of	   women	   with	   normal	   Hb	   using	   POC.	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Whether	   there	   are	   some	   participants	   in	   this	   group	   with	   undiagnosed	   liver	  problems	  is	  unknown.	  
	  
CRP	  is	  elevated	  in	  all	  the	  women	  with	  normal	  Hb.	  The	  association	  of	  high	  CRP	  with	  future	  health	  risks	  is	  reported	  in	  the	  literature.	  Folsom	  et	  al	  (2009)	  and	  Divani	  et	  al	  (2009).	   suggested	   that	   elevated	   CRP	   is	   independently	   associated	  with	   increased	  risk	  of	  VTE	  .It	  has	  also	  been	  suggested	  that	  there	  is	  an	  association	  between	  minor	  CRP	  elevation	  and	  future	  major	  cardiovascular	  events	  (Black	  et	  al.,	  2004).	  (Folsom	  et	  al.,	  2009)	  
	  
7.6 COMPARISONS	  BY	  TYPE	  OF	  CONTRACEPTION	  
7.6.1 CLINICAL	  COMPLICATIONS	  
Within	  the	  limits	  of	  small	  numbers,	  the	  data	  do	  not	  support	  any	  excessive	  clinical	  problems	  in	  women	  with	  SCD	  or	  SCT,	  and	  there	  was	  no	  evidence	  that	  these	  women	  experienced	  more	  side	  effects	  with	  hormonal	  contraception.	  
7.6.2 HAEMOSTATIC	  AND	  HAEMATOLOGICAL	  RESULTS	  FOR	  WOMEN	  USING	  
COMBINED	  ORAL	  CONTRACEPTION	  (COC)	  	  
With	  regard	  to	  the	  findings	  on	  pro-­‐	  and	  anti-­‐coagulant	  markers,	  the	  results	  do	  not	  support	   the	   assumption	   that	   women	   with	   SCD	   and	   SCT	   using	   COC	   have	   an	  excessively	   high	   risk	   of	   VTE.	   	   Women	   with	   SCD	   using	   COC	   had	   two	   “adverse”	  
233 
 
results	   ie	   relatively	   high	   levels	   of	   von	  willebrand	   antigen	   and	   low	   levels	   of	   free	  Protein	  S.	  However,	   these	  parameters	  were	  not	  statistically	  significantly	  different	  	  from	  the	  results	  of	  COC	  women	  with	  SCT	  or	  normal	  Hb	  (see	  Tables	  6.4	  and	  6.5).	  While	  women	  with	  SCT	  showed	  no	  adverse	  values,	  women	  with	  normal	  Hb	  using	  COC	   had	   high	   Factor	   VIIIC	   levels,	   although	   the	   difference	   is	   not	   statistically	  significant.	   The	   only	   statistically	   significant	   difference	   among	  women	   using	   COC	  were	  the	  lower	  APCR	  values	  in	  SCT	  women,	  but	  the	  actual	  values	  remained	  within	  the	  reference	  range	  (Table	  6.5).	  
	  




With	   regard	   to	   platelet	   activation	   markers,	   the	   only	   statistically	   significantly	  different	  marker	  was	  SCD40L	  (see	  Table	  6.8).	  The	  actual	   levels	  were	  high	  only	  in	  women	  with	  normal	  Hb	  who	  were	  using	  COC	  .These	  levels	  were	  more	  than	  5	  fold	  higher	  than	  the	  levels	  in	  women	  with	  SCD.	  As	  discussed	  previously,	  this	  supports	  the	  known	  fact	  that	  COC	  use	  increases	  thrombotic	  risks.	  In	  addition,	  the	  tendency	  for	  women	  of	  black	  African	  ethnicity	  to	  have	  high	  levels	  of	  SCD40	  is	  significant	  and	  could	  be	  greater	  than	  the	  risk	  from	  SCD	  itself.	  
	  
Endothelial	   activation	  markers	   (Table	  6.9).	   are	   another	   area	  where	   the	   three	  Hb	  groups	  differ	  significantly	  in	  two	  of	  the	  three	  markers	  studied.	  Women	  in	  the	  SCD	  group	   had	   higher	   levels	   of	   sCVAM	   (but	   still	   within	   the	   reference	   range),	   while	  women	  with	  SCT	  had	  higher	  sE	  selectin-­‐1,	  which	  was	  outside	  the	  reference	  range.	  Again,	  these	  results	  indicate	  that	  SCD	  and	  SCT	  are	  conditions	  with	  a	  prothrombotic	  tendency,	  but	  COC	  use	  adds	   little	   to	   this	   risk,	   as	  demonstrated	   in	  Tables	  5.9	  and	  5.24.	  




Thrombin	   generation	   tests	  were	   all	   normal	   in	   all	  women	  who	  were	   taking	   COC,	  except	  for	  the	  slope,	  which	  was	  high	  in	  women	  with	  SCD,	  but	  the	  difference	  did	  not	  reach	  statistical	  significance.(Table	  6.11).	  	  
	  
Markers	  of	  haemolysis	  and	  liver	  function	  tests	  were	  raised	  in	  women	  with	  SCD,	  as	  expected.	  However,	  full	  blood	  count	  parametersin	  COC	  users	  were	  not	  statistically	  different	  from	  those	  with	  SCT	  and	  those	  with	  normal	  Hb.	  
	  
While	  CRP	  levels	  were	  high	  in	  all	  three	  groups,	  women	  with	  SCD	  showed	  levels	  3-­‐4	  times	  the	  levels	  of	  those	  in	  the	  other	  groups,	   indicating	  the	  chronic	  inflammatory	  nature	  of	  SCD	  even	  in	  when	  the	  woman	  is	  in	  steady	  state.	  
	  
7.6.3 HAEMOSTATIC	  AND	  HAEMATOLOGICAL	  RESULTS	  FOR	  WOMEN	  USING	  
PROGESTOGEN	  ONLY	  CONTRACEPTION	  (POC)	  
There	   are	   six	   prothrombotic	   and	   anti-­‐coagulant	   marker	   levels	   which	   are	  significantly	   different	   between	   the	   three	   groups	   of	   women	   who	   were	   using	  POC.(Tables	  6.19,	  6.20	  and	  6.21).	  Three	  of	  these	  markers	  were	  elevated	  in	  women	  with	   SCD	   (PT,	   INR	   and	   FX).	   and	   the	   other	   two	  were	   raised	   in	  women	  with	   SCT	  (APTT	  and	  DVVT).	  The	  last	  marker	  was	  APCR	  which	  showed	  the	  lowest	  levels	  (i.e	  adverse)	   in	   women	   with	   normal	   Hb.	   Nevertheless,	   within	   each	   group	   of	   these	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women	  there	  are	  markers	  which	  are	  outside	  the	  reference	  range,	  such	  as	  PT,	  FVIII	  and	  PS	  free	  in	  women	  with	  SCD	  using	  POC.	  However	  the	  data	  of	  Table	  	  5.4	  and	  5.5	  demonstrate	  that	  this	  derives	  from	  their	  SCD	  and	  not	  from	  their	  POC	  use.	  PS	  free	  levels	  were	  low	  in	  POC	  users,	  regardless	  of	  Hb	  type,	  with	  no	  statistically	  significant	  difference	  between	  them	  (Table	  6.20)	  
Factor	  XIIIa	  levels	  were	  low	  in	  all	  women	  taking	  POC,	  with	  the	  lowest	  results	  seen	  in	  women	  with	  SCD.	  The	  same	  finding	  was	  noticed	  with	  women	  using	  COC,	  when	  similarly	  the	  lowest	  levels	  were	  in	  women	  with	  SCD	  (Table	  5.6).	  There	  is	  reported	  evidence	   that	   Factor	   XIIIa	   has	   ethnic	   and	   genetic	   variation	   (Saha	   et	   al.,	   2000).	  However,	  no	  studies	  of	  factor	  XIIIa	  have	  been	  done	  in	  people	  of	  black	  ethnic	  origin,	  and	   the	   possibility	   that	   the	   reference	   range	   for	   them	   is	   different	   should	   be	  addressed	  in	  future	  studies.	  
All	  coagulation	  activation	  marker	  levels	  were	  raised	  in	  women	  with	  SCD;	  however,	  D	  Dimer	  was	  also	  raised	  in	  other	  women.	  The	  differences	  between	  SCD	  group	  and	  the	  other	  women	  who	  were	  using	  POC	  are	  statistically	  significant	  for	  D	  Dimer	  and	  P	  F1+2.	  The	  increase	  of	  D	  Dimer	  in	  women	  with	  normal	  Hb	  is	  minimal,	  however	  as	  mentioned	  previously	  this	  could	  signal	  future	  health	  risks.	  
Again,	  sP	  Selectin	  levels	  are	  low	  in	  all	  these	  women,	  while	  PF4	  levels	  are	  high	  in	  all.	  This	   consistent	   pattern	   is	   puzzling	   and	  needs	   further	   exploration,	   and	  may	   even	  represent	  a	  technical	  artifact.	  
SVCAM	  and	  sICAM-­‐1	  are	  statistically	  significantly	  higher	   in	  women	  with	  SCD,	  but	  all	  values	  were	  within	  the	  reference	  ranges	  (Table	  6.24).	   .This	  finding	  is	  expected	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as	   this	   shows	   disease	   activity.	   This	   is	   a	   similar	   phenomenon	   to	   the	   increase	   in	  microparticles	  and	  tissue	  factor	  (a	  4-­‐fold	  increase	  for	  both).	  
The	   Thrombin	   generation	   tests	   persistently	   failed	   to	   pick	   up	   any	   indication	   of	  thrombotic	   tendency	   in	   the	   different	   comparisons	   groups,	   and	   again	   showed	  normal	  results	  in	  all	  (Table	  6.26).	  However,	  the	  Start	  time	  and	  the	  Lag	  time	  were	  both	  highest	  in	  the	  women	  with	  normal	  Hb.	  
	  
Bilirubin	   and	   LDH	   are	   statistically	   significantly	   higher	   in	   women	   with	   SCD	   as	  expected,	  while	  free	  Hb	  and	  Haptoglobin	  show	  no	  such	  differences.	  ALT,	  AST,	  ALP	  and	   Platelets	   are	   also	   significantly	   higher	   in	   women	   with	   SCD,	   which	   is	   to	   be	  expected.	   However,	   the	   surprising	   result	   is	   that	   the	   difference	   in	   CRP	   levels	  between	  the	  three	  groups	  does	  not	  reach	  statistical	  significance.	  This	  stresses	  the	  fact	   that	   all	   the	   study	   participants,	   regardless	   of	   their	   contraception	   or	  haemoglobin,	   exhibit	   some	   degree	   of	   chronic	   inflammation	   which	   may	   be	   a	  manifestation	  of	  their	  shared	  ethnicity	  (Clark	  et	  al.,	  2007).	  
	  	  
7.6.4 HAEMOSTATIC	   AND	   HAEMATOLOGICAL	   RESULTS	   FOR	   WOMEN	   NOT	  
USING	  HORMONAL	  CONTRACEPTION	  
The	  comparison	  here	  followed	  most	  of	  the	  patterns	  already	  seen,	  	  Free	  Protein	  S	  is	  low	  in	  all	   the	  three	  groups,	  which	   is	   likely	  to	  reflect	   their	  shared	  ethnicity	  rather	  than	  any	  differences	  in	  Hb	  type.	  Women	  with	  SCT	  also	  had	  statistically	  significantly	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higher	   levels	   of	   Fibrinogen,	   while	   women	   with	   SCD	   had	   higher	   levels	   of	   Factor	  VIIIC	  and	  von	  Willebrand	  Factor.(Table	  6.34).	  At	  the	  same	  time	  activated	  Protein	  C	  resistance	   is	   statistically	   significantly	   different	   between	   the	   three	   groups,	   the	  lowest	  (adverse)	  mean	  values	  being	  in	  women	  with	  normal	  Hb	  and	  with	  SCT.	  
Again,	  Factor	  X111a	  is	   lowest	  in	  women	  with	  SCD	  and	  coagulation	  marker	  levels	  are	  significantly	  raised	  in	  the	  SCD	  women.	  Apart	  from	  PF4,	  all	  platelet	  activation	  markers	  are	  normal;	  however,	  these	  are	  statistically	  significantly	  higher	  in	  women	  with	  SCD	  (Table	  6.38).	  
Other	   unsurprising	   results	   are:-­‐the	   statistically	   significantly	   higher	   levels	   of	  endothelial	   activation	   markers	   and	   markers	   of	   tissue	   damage.	   However,	   all	  women,	  regardless	  of	  their	  haemoglobin	  type,	  had	  elevated	  levels	  of	  TF.	  Thrombin	  generation	  again	  did	  not	  reveal	  any	  differences	  between	  these	  women	  apart	  from	  in	   the	   Lag	   time.	   The	   free	  Haemoglobin	   levels	   are	   significantly	   higher	   in	  women	  with	  SCT,	  while	  LDH	  and	  Bilirubin	  are	  elevated	  in	  women	  with	  SCD.	  
	  
CRP	  was	  statistically	  significantly	  higher	   in	  women	  with	  SCD;	  however	   the	   levels	  are	  also	  elevated	  in	  the	  other	  two	  groups,	  as	  already	  discussed.	  
	  




7.7 LIMITATIONS	  OF	  THE	  STUDY	  AND	  POSSIBLE	  SOURCES	  OF	  ERROR	  	  
Some	   hospitals	   with	   large	   SCD	   populations	   were	   not	   included	   in	   this	   study	   for	  reasons	   mentioned	   in	   Chapter	   4.	   This	   gap	   in	   recruitment	   raises	   the	   issue	   of	  whether	  the	  women	  not	  included	  could	  have	  been	  different	  in	  some	  of	  the	  studied	  aspects,	  and	  this	  could	  have	  potentially	  influenced	  the	  study	  outcomes.	  
The	   observational	   design	   of	   the	   study	   carries	   some	   inherent	   problems	   eg,	   self	  selection.	  The	  contraceptive	  method	  used	  could	  also	  be	  a	  source	  of	  bias,	  especially	  in	   the	   SCD	   group,	   as	   the	   sicker	   women	   are	   prescribed	   a	   more	   limited	   range	   of	  contraception	   options	   and	   generally	   tend	   to	   be	   prescribed	   long	   acting	   POCs	   if	  anything.	   This	   also	   limits	   the	   ability	   to	   match	   comparable	   groups;	   in	   particular	  women	   with	   SCD	   on	   the	   COC	   were	   statistically	   significantly	   younger	   than	   their	  counterparts.	  
	  




All	   POC	   preparations	   were	   studied	   together	   (ie	   DMPA,	   POP,	   Contraceptive	  implants	   and	   Mirena	   IUS)	   due	   to	   the	   relatively	   small	   number	   of	   women	   on	  different	  progestogen	  preparations.	  	  
	  
The	  plan	  to	  include	  the	  SCT	  group	  arose	  at	  an	  advanced	  stage	  in	  the	  study,	  thus	  the	  participant	  number	  is	  smaller,	  compared	  with	  the	  SCD	  group.	  
Unfortunately,	   it	  was	  not	  possible	   to	  ascertain	   the	  cause	  of	  death	  of	   the	  woman	  who	   died	   in	   Nigeria.	   It	   is	   therefore	   difficult	   to	   speculate	   about	   any	   relevant	  complications	  in	  her	  case.	  
	  






My	  hypothesis	  was	  that	  there	  are	  no	  additional	  clinical	  or	  haematological	  risks	  to	  Sickle	  Cell	  Disease	  patients	  using	  hormonal	  contraceptive	  methods,	  over	  and	  above	  those	  inherent	  in	  their	  SCD.	  	  
	  
My	   further	  hypothesis	  was	   that	   there	  are	  no	  additional	   clinical	  or	  haematological	  risks	  to	  Sickle	  Cell	  Trait	  (SCT)	  women	  using	  hormonal	  contraceptive	  methods.	  With	  regard	   to	   women	   with	   SCT,	   there	   is	   no	   noticeable	   increase	   in	   the	   incidence	   of	  clinical	  complications,	  nor	  any	  increase	  in	  the	  contraception-­‐related	  complications	  in	  those	  women	  who	  are	  using	  COC	  or	  POC.	  	  
	  




Menstrual	   irregularities,	   contraceptive	   side	   effects,	   the	   discontinuation	   of	  contraception,	  accidental	  interruptions	  and	  the	  number	  of	  planned	  and	  unplanned	  pregnancies	  are	  not	  increased	  in	  women	  with	  SCD	  using	  COC.	  
	  
From	  the	  results	  of	  the	  laboratory	  markers	  researched	  in	  this	  study,	  I	  can	  conclude	  that	   the	   thrombotic	   tendency	   of	   COC	   has	   no	   or	   minimal	   additive	   effect	   to	   the	  disease’s	   known	   hypercoaguable	   state	   and	   hence	   COC	   use	   does	   not	   increase	   the	  thrombotic	  risks	  in	  SCD	  women,	  nor	  does	  it	  adversely	  affect	  their	  liver	  function	  or	  exacerbate	  any	  inflammatory	  changes.	  
	  
Progestogen	   only	   contraception	   is	   associated	   with	   an	   increased	   incidence	   of	  menstrual	  irregularities,	  however	  this	  is	  inherent	  to	  this	  type	  of	  contraception	  and	  these	  side	  effects	  are	  not	   significantly	  different	   from	  those	  noted	   in	  women	  with	  normal	  haemoglobin	  taking	  POC.	  
Thus,	   I	  hope	  that	  my	  findings	  will	  encourage	  clinicians	  looking	  after	  women	  with	  SCD	   to	   remember	   to	   discuss	   effective	   contraception	   with	   them	   on	   all	   relevant	  occasions.	   They	   should	   be	   aware	   that	   the	   hormonal	   methods	   are	   the	   most	  efficacious	  of	  the	  reversible	  options.	  My	  findings	  should	  reassure	  clinicians	  that	  the	  impact	  of	  hormonal	  contraceptives	  on	  coagulability	  is	  minimal	  in	  comparison	  with	  the	   inherent	  hypercoagulability	  of	   the	   sickle	   cell	   condition	   itself.	   In	  other	  words,	  any	  concerns	  about	  VTE	  risk	  should	  be	  sensibly	  balanced	  by	  an	  appreciation	  of	  the	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many	  advantages	  of	  effective	  hormonal	  contraception,	  not	   least,	   the	  avoidance	  of	  unplanned	  pregnancies,	  which	  are	  currently	  so	  prevalent	  in	  women	  with	  SCD,	  and	  which	  carry	  far	  greater	  risks	  for	  them.	  	  
	  
7.9 FUTURE	  RESEARCH	  
Future	  research	   involving	  a	  collaboration	  of	  all	   the	  Sickle	  Cell	  Centres,	   the	  Sickle	  Cell	  Society	  and	  the	  UK	  Forum	  for	  Haemogolobin	  Disorders	  will	  yield	  a	  wider	  data	  base	  and	  is	  greatly	  needed.	  Women	  from	  these	  sources	  could	  be	  recruited	  	  early	  in	  their	   reproductive	   life.	   These	   women	   could	   be	   encouraged	   to	   ask	   their	   doctors	  proactively	  to	  be	  put	  on	  hormonal	  contraception.	  Blood	  collections	  could	  be	  done	  before	  starting	  the	  HC,	  within	  the	  first	  three	  months	  of	  starting	  it	  and	  at	  6	  months.	  The	  clinical	  follow	  up	  could	  continue	  as	  long	  as	  the	  women	  are	  using	  HC.	  
My	   study	  of	   laboratory	  haemostatic	   and	  haematological	  markers	   in	  women	  with	  SCT	   showed	   significant	   increases	   in	   indicators	   of	   some	   of	   the	   pro	   and	   anti-­‐coagulant	   markers,	   coagulation	   activation	   markers,	   markers	   of	   tissue	   damage,	  platelet	   and	   endothelial	   activation	   markers.	   This	   phenomenon	   appears	   more	  marked	   in	  women	  with	  SCT	  using	  COC.	  However	  a	   larger	   randomised	   controlled	  study	  is	  needed	  to	  further	  assess	  this	  recently-­‐noted	  phenomenon.	  
	  
An	   incidental	   finding	   of	  my	   studies	   suggests	   that	  women	   of	   black	  African	   ethnic	  origin	   show	   increased	   inflammatory	   and	   endothelial	   activation	   markers	   and	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reduced	   anti-­‐coagulation	   factors,	   regardless	   of	   their	   method	   of	   contraception.	  Ironically,	  a	  study	  which	  set	  out	  to	  explore	  hormonal	  effects	  on	  women	  with	  SCD,	  has	  revealed	  equally	  interesting	  features	  of	  women	  with	  SCT	  and	  women	  of	  black	  African	  ethnicity	  who	  have	  normal	  Hb.	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Abstract	  






Sickle	  cell	  disease	  (SCD)	  is	  the	  most	  common	  genetically	  inherited	  disorder	  worldwide	  (1)	  its	   prevalence,	   albeit	   low,	   is	   increasing	   in	   the	  United	  Kingdom,	  with	   estimated	  numbers	  5,000	  in	  1986	  and	  	  12,000	  in	  2010	  (2–4).	  Recent	  advances	  in	  the	  medical	  management	  of	  SCD	   and	   the	   improvement	   in	   life	   expectancy	   for	   these	   patients,	   result	   in	   many	   more	  reaching	  reproductive	  age	  and	  becoming	  pregnant.	  The	  indications	  are	  that	  the	  fertility	  of	  women	  with	  SCD	  is	  normal	  (5).	  	  
Maternal	   sickle	   cell	   disease	   is	   associated	   with	   a	   higher	   rate	   of	   complications,	   than	  pregnant	  women	  without	  this	  disease	  	  (6–11).	  
It	   is	   estimated	   that	   there	   are	   currently	   between	   60	   and	   100	   pregnancies	   per	   year	   in	  women	  with	  SCD	  in	  the	  UK	  (9).	  
There	  have	  been	  a	  variety	  of	   changes	   in	  pregnancy	  outcome	  among	  women	  with	  SCD	   in	  the	  UK	  over	  the	  past	  few	  decades.	  Data	  from	  a	  multi-­‐centre	  survey	  carried	  out	  in	  the	  1990s	  suggest	   SCD	  pregnancies,	   in	   some	   respects,	   experienced	  worsening	   outcomes	   compared	  with	  a	  similar	  survey	  of	  pregnancies	  in	  the	  1970s	  (10)	  and	  1980s	  (11).	  
Similar	  deteriorations	  in	  pregnancy	  outcomes	  have	  been	  reported	  from	  the	  USA	  and	  from	  Jamaica	  (8,12–16).These	  impressions	  are	  also	  supported	  by	  the	  data	  from	  the	  Confidential	  Enquiries	   into	  Maternal	  Deaths	   in	   the	  UK	   relating	   to	   the	  1970’s,	   1980’s	   and	  1990’s	   (20,	  21).	   In	   the	   1970’s	   the	   maternal	   mortality	   rate	   nationally	   in	   women	   with	   SCD	   was	  approximately	  3%	  (with	  one	  death	  per	  year	  and	  an	  estimated	  30	  pregnancies	  per	  year).	  This	  was	  200-­‐times	  the	  overall	  contemporaneous	  maternal	  mortality	  rate	  in	  the	  UK,	  which	  then	  stood	  at	  15	  per	  100,000.	  In	  the	  1990s	  the	  maternal	  mortality	  rate	  in	  women	  with	  SCD	  was	   approximately	   2.2%	   (with	   one	   death	   in	   an	   estimated	   45	   pregnancies	   per	   year).	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However,	  by	  this	  time	  the	  overall	  maternal	  mortality	  rate	   in	  the	  UK	  had	  fallen	  to	  9.8	  per	  100,000	  births	  (21).	  The	  maternal	  mortality	  rate	  in	  SCD	  had	  thus	  risen,	  in	  relative	  terms,	  to	  224	   times	   the	  overall	   rate.	  The	  perinatal	  mortality	  rate	   (PMR)	  decreased	   from	  88	  per	  1000	   from	  1975	  –	  1982,	   to	  60	  per	  1000	  during	   the	  period	  1991	  –	  93.	   (The	  definition	  of	  stillbirth	   in	   the	   U.K.	   changed	   in	   1992,	   to	   include	   pregnancies	   delivered	   from	   24	   weeks	  gestation,	  rather	  than	  28	  weeks.	  The	  survey	  data	  have	  been	  adjusted	  accordingly	  in	  order	  to	  allow	  valid	  comparisons	  to	  be	  made).	  
It	   is	   possible	   that	   this	   continuing	   high	   mortality	   reflects	   the	   survival	   to	   adult	   life	   of	  individuals	   with	   more	   adverse	   disease	   states	   than	   in	   earlier	   decades.	   However,	   it	   is	  notable	   that	   there	   were	   no	   maternal	   deaths	   and	   only	   one	   perinatal	   loss	   in	   three	   more	  recent	  single	  hospital	  series	  from	  London	  teaching	  hospitals	  in	  25,	  62	  and	  71	  pregnancies,	  respectively,	  between	  2000	  and	  2007	  (17,18).	  This	  suggests	   that	  pregnancy	  outcomes	   in	  SCD	   can	   be	   significantly	   improved	   by	   the	   consistent	   delivery	   of	   care	   by	   experienced	  clinicians.	  	  




The	  study	  received	  ethical	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  on	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  of	  the	  National	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  Research	  Ethics	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Methods:	  	  
This	   study	   compares	   maternal	   and	   fetal	   outcomes	   in	   pregnancies	   complicated	   by	   SCD	  from	  three	  retrospective	  surveys	  in	  the	  UK,	  covering	  the	  periods	  1975	  to	  1981	  (survey	  1),	  1991	   to	   1993	   (survey	   2),	   and	   2000	   to	   2004	   (survey	   3).	   The	   numbers	   of	   pregnancies	   in	  each	   survey	   are	   125,	   82,	   and	   206,	   respectively.	   The	   same	   data	   collection	   proforma	  was	  used	  for	  all	  surveys.	   	  Data	  from	  the	  first	  two	  surveys	  were	  obtained	  from	  two	  MD	  theses	  (SMT	  and	  RJH).	  	  Data	  for	  the	  final	  survey	  was	  collected	  by	  the	  first	  author.	  
During	   each	   survey,	   women	   with	   SCD	   who	   had	   pregnancies	   during	   the	   relevant	   time	  periods	  were	  identified	  by	  their	  consultant	  haematologist	  from	  the	  following	  sources:	  SCD	  databases,	   laboratory	  registers,	  maternity	   records,	  and	   the	  network	  of	   the	  UK	  Forum	  on	  Haemoglobin	   Disorders.	   	   Eligible	   women	   were	   identified	   as	   those	   with	   the	   following	  haemoglobin	  types:	  SS,	  SC,	  and	  S-­‐beta°	  thalassaemia.	  
Data	   were	   extracted	   from	   the	   patient’s	   general	   and	   maternity	   hospital	   notes,	   if	   she	  consented	  to	  take	  part	  in	  the	  survey.	  Patient	  information	  was	  anonymised	  and	  handled	  in	  accordance	  with	  the	  Data	  Protection	  Act	  1998.	  
A	  total	  of	  23	  hospital	  in	  the	  UK	  with	  both	  maternity	  and	  haemoglobinopathy	  departments	  were	  invited	  to	  take	  part	  in	  the	  2000	  to	  2004	  survey.	  Ethical	  approval	  for	  data	  collection	  was	  obtained	  in	  78%	  (18/23),	  and	  61%	  (11/18)	  hospitals	  provided	  data.	   	  The	  remaining	  seven	   hospitals	   did	   not	   contribute	   to	   the	   data	   collection	   because,	   either	   there	   were	   no	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pregnancies	  in	  the	  relevant	  time	  period	  or	  there	  was	  no	  means	  of	  identifying	  pregnancies	  from	  their	  records	  system.	  
Data	  	  
No	  raw	  data	  from	  the	  first	  two	  surveys	  were	  available.	   	  Relevant	   information	  from	  these	  two	  surveys	  was	  extracted	  from	  the	  published	  tables.	  
Maternal	  and	  demographic	  characteristics	  included:	  maternal	  age,	  parity,	  sickle	  cell	  type,	  past	  medical	  history,	  socio-­‐demographic	  characteristics,	  past	  obstetric	  history.	  	  Pregnancy	  related	  information	  included:	  antenatal	  and	  pregnancy	  complications,	  labour	  and	  delivery,	  pregnancy	  management,	  and	  pregnancy	  outcome	  (maternal	  and	  fetal).	  	  
Analysis	  
Data	   were	   summarised	   using	   mean	   and	   standard	   deviation	   or	   median	   and	   range,	  depending	   on	   the	   distribution.	   Categorical	   data	   were	   summarised	   using	   count	   and	  percentages.	  	  95%	  confidence	  intervals	  are	  provided	  for	  all	  estimates.	  
A	  oneway	  analysis	  of	  variance	  (ANOVA)	  was	  performed	   for	  surveys	  1,	  2	  and	  3	  using	   the	  ‘‘aovsum’’	  Stata	  command,	  which	  can	  generate	  a	  statistical	  model	  from	  summary	  statistics.	  The	  “aovsum”	  generates	  synthetic	  data	  which	  enables	   the	  use	  of	  regression	  technique	  to	  assess	  trends	  across	  the	  three	  surveys	  for	  numerical	  variables.	  A	  non-­‐parametric	  method	  (nptrendi)	  was	  used	  to	  test	  for	  trend	  across	  categorical	  variables.	  	  






	   Survey	  1	  n=125	   Survey	  2	  n=82	  	   Survey	  3	  n=206	  	  Age	  in	  years	  	  	   mean	  (SD)	   22	  	  (3.9)	   28	  (5.2)	   28	  (6.5)	  	  	   Difference	  (95%	  CI)	   base	   6	  (4.4	  to	  7.5)	   6	  (4.7	  to	  7.2)	  	   Test	  for	  trend	   	  Smoker	   	   28	  (22%)	   	  	   23	  (11%)	  	   Difference	  (95%	  CI)	   -­‐11%	  (20%	  to	  -­‐3%)	  	  	   Test	  for	  trend	   0.006**	  Para	  0	   Count	  (%)	   64	  (51%)	   35	  (43%)	   112	  (54%)	  	   Difference	  (95%	  CI)	   base	   -­‐8%	  (-­‐22%	  to	  5%)	   3%	  (-­‐7%	  to	  14%)	  	   Test	  for	  trend	   0.456	  Para	  1	   count	  (%)	   39	  (31%)	   33	  (40%)	   60	  (29%)	  	   Difference	  (95%	  CI)	   base	   9%	  (-­‐4%	  to	  22%)	   -­‐2%	  (-­‐12%	  to	  8%)	  	   Test	  for	  trend	   0.555	  Para	  2	   count	  (%)	   14	  (11%)	   12	  (15%)	   29	  (14%)	  	   Difference	  (95%	  CI)	   base	   3%	  (-­‐6%	  to	  13%)	   3%	  (-­‐4%	  to	  10%)	  	   Test	  for	  trend	   0.485	  Para	  3+	   count	  (%)	   8	  (6%)	   2	  (2%)	   5	  (2%)	  	   Difference	  (95%	  CI)	   base	   -­‐4%	  (-­‐9%	  to	  15%)	   -­‐4%	  (-­‐9%	  to	  0.8%)	  	   Test	  for	  trend	   0.074	  
Haemoglobinopathy	  type	  SC	   Count	  (%)	   59	  (47%)	   34	  (41.5%)	   87	  (42.2%)	  	   Difference	  (95%	  CI)	   base	   -­‐6%	  (-­‐19%	  to	  8%)	   -­‐5%	  (-­‐16%	  to	  6%)	  	   Test	  for	  trend	   0.407	  SS	   Count	  (%)	   54	  (43%)	   43	  (52.4%)	   117	  (57%)	  	   Difference	  (95%	  CI)	   	   9%	  (-­‐5%	  to	  23%)	   14%	  (2%	  to	  25%)	  	   Test	  for	  trend	   0.018*	  Sβ°	  thal	   Count	  (%)	   12(9.6%)	   5(6.1%)	   2(0.97%)	  	   Difference	  (95%	  CI)	   base	   -­‐3%	  (-­‐11%	  to	  4%)	   -­‐9%	  (-­‐14%	  to	  -­‐3%)	  	   Test	  for	  trend	   0.002***	  
Comparison	  of	  the	  demographic	  characteristics	  of	  women	  from	  the	  three	  surveys	  	  
*p-­‐value	  significant	  at	  5%;	  ***	  p-­‐value	  significant	  at	  0.1%	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Mode	  of	  delivery	   	   Survey	  1	  n=125	   Survey	  2	  n=82	  	   Survey	  3	  n=206	  	  
Elective	  caesarean	  s	   Count	  (%)	   23	  (18%)	   12(15%)	   18(9%)	  	   Difference	  (95%	  CI)	   Base	  	   -­‐3%	  (-­‐14%	  to	  6%)	   -­‐9%	  (-­‐17%	  to	  -­‐2%)	  	   Test	  for	  trend	  	   0.010**	  Emergency	  caesarean	  S	   Count	  (%)	   20	  (16%)	   28	  (34%)	   69	  (33%)	  	   Difference	  (95%	  CI)	   Base	  	   18%	  (6%	  to	  30%)	   17%	  (8%	  to	  26%)	  	   Test	  for	  trend	   0.001**	  Operative	  vaginal	  delivery	   Count	  (%)	   21	  (16%)	   2	  (2%)	   11	  (5%)	  	   Difference	  (95%	  CI)	   base	   -­‐14%	   (-­‐22%	   to	   -­‐7%)	   -­‐11%	  (-­‐18%	  to	  -­‐4%)	  	   Test	  for	  trend	   0.001***	  Spontaneous	  normal	  vaginal	  delivery	   Count	  (%)	   56	  (45%)	   40	  (49%)	   84	  (41%)	  	   Difference	  (95%	  CI)	   	   4%	  (-­‐10%	  to	  18%)	  	   -­‐4%	  (-­‐15%	  to	  7%)	  	   Test	  for	  trend	   0.407	  
Comparison	  of	  mode	  of	  delivery	  across	  the	  three	  surveys	  
Complication	   	   Survey	  1	  n=125	   Survey	  2	  n=82	  	   Survey	  3	  n=206	  	  Pre-­‐eclampsia	   Count	  (%)	   17(13.6%)	   6	  (7.3%)	   19(9.2%)	  	   Difference	  (95%	  CI)	   Base	   -­‐6.3%(-­‐6.162	   to	   -­‐6.44)	   -­‐4.4%(-­‐4.26	  to	  -­‐4.54)	  	   Test	  for	  trend	  	   0.280	  UTI	   Count	  (%)	   35(28%)	   12(14.6%)	   20(9.7)%	  	   Difference	  (95%	  CI)	   Base	   -­‐13.4	  %(-­‐13.56	  to	  -­‐13.24)	   -­‐18.3	   (-­‐18.46	   to	  18.14)	  	   Test	  for	  trend	   <0.001	  Sickle	  crises	   Count	  (%)	   48(38.4%)	   33(40.2%)	   87(42.2%)	  	   Difference	  (95%	  CI)	   Base	   1.8%	  (1.623	  to	  1.976)	   3.83%(3.65	  to	  4)	  	   Test	  for	  trend	   0.051	  Chest	  complications	   Count	  (%)	   	   11(13%)	   24(12%)	  	   Difference	  (95%	  CI)	   	   Base	  	   -­‐1%	  (-­‐4.79	  to	  1.93)	  	   Test	  for	  trend	   0.786	   	  Blood	  transfusion	   Count	  (%)	   89(71.2%)	   43(52.4%)	   70(34%)	  	   Difference	  (95%	  CI)	   Base	   -­‐18.8	  %	  (-­‐18.93	  to	  -­‐18.64)	   -­‐37.2	   %(-­‐30	   35	   to	   -­‐37.04)	  	   Test	  for	  trend	   <0.001	  
Pregnancy	  Complications	   *Severe	  pre-­‐eclampsia	   is	   defined	  as	  blood	  pressure	   above	  140/90	  mm	  Hg,	  
with	  proteinuria,	  biochemical	  disturbance	  and	  clinical	  symptoms.	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Complication	   	   Survey	  1	  n=125	   Survey	  2	  n=82	  	   Survey	  3	  n=206	  	  
ITU	  admission	   Count	  (%)	   7(5.7%)	   6(7.3%)	   13(7%)	  	   Difference	  (95%	  CI)	   Base	   1.6%(1.4	  to	  1.74)	   1.3	   %(1.14	   to	  1.48)	  	   Test	  for	  trend	  	   0.897	  Sickle	  crises	   Count	  (%)	   17(13.7%)	   4(4.9%)	   29(15.5%)	  	   Difference	  (95%	  CI)	   Base	   -­‐8.8%	  (-­‐8.92	  to	  8.68)	   1.6%	  (1.2	  to	  2)	  	   Test	  for	  trend	   0.051	  Infection	   Count	  (%)	   77(62%)	   1(1.2%)	   6(3.2%)	  	   Difference	  (95%	  CI)	   Base	   -­‐60.8%	   (-­‐60.62	   to	   -­‐60.98)	   -­‐58.8%	   (-­‐59.9	   to	  -­‐58.21)	  	   Test	  for	  trend	   <0.000	  
Postnatal	  complications	  
Parameter	  	   	  	   Survey	  1	  n=125	   Survey	  2	  n=82	  	   Survey	   3	  
n=206	  	  	   	  	  	  Fetal	   Birth	   weight	  in	  grams	   Mean	  (SD)	   2883	  (822)	   2805	  (	  719)	   2772	  (656)	  	   Difference	  (95%CI)	   base	   -­‐78	  (-­‐291.5	  to	  135.5)	   -­‐111	   (-­‐286.6	   to	  59.6)	  	   Test	  for	  trend	   0.182	  Male	   Count	  (%)	   	  	   35	  (42%)	   79	  (38%)	  	   Difference	  (95%CI)	   	   -­‐4%	  (-­‐17%	  to	  8%)	  	   Test	  for	  trend	   0.497	  Female	   Count	  (%)	   	  	   47	  (57%)	   91	  (44%)	  	   Difference	  (95%CI)	   	   13%	  (-­‐26%	  to	  -­‐0.4%)	  	   Test	  for	  trend	   0.044*	  Gestational	   age	   at	  delivery	  in	  weeks	   Mean	  (SD)	  	   37.9	  (3.19)	   37.4	  (3.05)	   37.1	  (3.27)	  	   Difference	  (95%CI)	   base	   -­‐0.5	  (-­‐1.4	  to	  0.40)	   -­‐0.8	   (-­‐1.5	   to	   -­‐0.08)	  	   Test	  for	  trend	   0.029*	  Perinatal	  death	   Count	   (rate	   per	   1000	  births)	   11	  (88)*	   5	  (60)	   11	  (53)	  	   Difference	  (95%CI)	   	   	   	  	   Test	  for	  trend	   0.863	  Maternal	  death	   count	   (rate	   per	   1000	  pregnancies)	  	   0	   2	  (24)	   1(4.8)	  




The	   experience	   of	   any	   individual	   clinician	   or	   hospital	   department	   in	   the	   UK	   with	   SCD	  pregnancies	   will	   not	   necessarily	   reflect	   the	   general	   trend	   of	   outcomes	   for	   these	  pregnancies.	  Some	  pregnancy	  complications,	   such	  as	  severe	  sickle	  cell	   crises,	  pulmonary	  complications	   and	   severe	   pre-­‐eclampsia	   have	   remained	   the	   same	   over	   the	   past	   three	  decades,	   whilst	   urinary	   tract	   infections	   showed	   a	   significant	   reduction	   over	   the	   three	  decades,	  and	  this	  could	  be	  explained	  by	  the	  greater	  awareness	  of	  infection	  as	  an	  important	  issue.	  	  The	   finding	   of	   a	   persistently	   high	   incidence	   of	   severe	   pre	   eclampsia	   across	   all	   three	  surveys	  is	  notable.	  It	  is	  possible	  that	  there	  is	  an	  inherent	  association	  between	  severe	  pre	  eclampsia	   and	   SCD,	   which	   may	   be	   triggered	   by	   activation	   of	   the	   endothelium	   of	   blood	  vessels	   in	   SCD	   (19)	   However,	   not	   all	   researchers	   in	   this	   field	   have	   concurred	  with	   this	  observation	  (12).	  	  The	   last	   two	   decades	   have	   witnessed	   more	   selective	   practice	   in	   the	   use	   of	   blood	  transfusion	  in	  SCD	  patients	  generally,	  and	  our	  finding	  of	  a	  significant	  decline	  in	  the	  use	  of	  blood	  transfusions	  in	  pregnancy	  over	  this	  time	  is	  in	  keeping	  with	  this.	  	  The	   overall	   caesarean	   section	   rate	   has	   increased	   in	   the	   UK	   over	   this	   period,	   and	   is	  currently	   23.8%	   (24).	   However	   the	   rate	   for	   SCD	   women	   is	   almost	   double	   this.	   The	   UK	  perinatal	  mortality	  rate	  has	  fallen	  since	  the	  1970s,	  but	  that	  in	  SCD	  pregnancies	  has	  fallen	  to	   a	   much	   lesser	   extent.	   The	   rate	   is	   still	   seven	   times	   the	   overall	   national	   rate	   (which	  currently	   stands	   at	   7.6	   per	   1,000).	   The	   miscarriage	   rate	   in	   the	   last	   survey,	   conducted	  between	  2000	  –	  2004,	  was	  9.3%.	  However,	  no	  trend	  analysis	  was	  done,	  as	  this	  information	  was	  not	  included	  in	  the	  previous	  surveys.	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  Though	  our	  2000-­‐to-­‐2004	  survey	  reveals	  one	  maternal	  death,	  contemporaneous	  national	  data	  from	  the	  Centre	  for	  Maternal	  and	  Child	  Enquiries	  (CMACE)	  reported	  four	  pregnancy	  related	   deaths	   in	   SCD	   women	   during	   this	   period.	   CMACE	   uses	   different	   search	   and	  reporting	  methodology	  and	  collects	  deaths	  up	  to	  one	  year	  after	  birth.	  The	  unclear	  trend	  in	  maternal	  mortality	  shown	  by	  our	  data	  unfortunately	  includes	  an	  ascertainment	  bias.	  The	  most	  recent	  CMACE	  reports	  indicate	  continuing	  high	  national	  rates	  of	  maternal	  mortality	  for	  SCD	  women,	  with	  three	  deaths	  in	  the	  2000	  to	  2002	  triennium,	  two	  deaths	  in	  the	  2003	  to	  2005	  triennium,	  and	  three	  deaths	  in	  the	  2006	  to	  2008	  triennium.	  This	  would	  equate	  to	  a	  contemporary	  national	  mortality	  rate	  in	  SCD	  of	  approximately	  1.6%	  (with	  an	  estimated	  60	  pregnancies	   per	   year	   in	   the	   UK),	   compared	  with	   the	   current	   overall	  maternal	  mortality	  rate	  of	  11.4	  per	  100,000,	  which	  is	  140	  times	  lower	  than	  the	  rate	  in	  SCD	  women.	  
	  
Limitations	  of	  the	  study	  	  




Clinical	  data	  are	  likely	  to	  be	  unique	  to	  the	  population	  and	  health	  services	  being	  surveyed,	  and	   international	  extrapolations	  should	  not	  necessarily	  be	  made.	  The	   fluctuating	  natural	  course	  of	  sickle	  cell	  disease	  and	  the	  influence	  of	  other	  confounding	  factors	  on	  pregnancy	  mean	   that	   research	   in	   this	   field	   is	   challenging.	   Continuing	   data	   collection	   and	   shared	  clinical	  experience	  are	  essential	  to	  ensure	  future	  progress	  for	  the	  care	  of	  these	  patients.	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Trends	  in	  family	  planning	  and	  counselling	  for	  women	  with	  sickle	  
cell	  disease	  in	  the	  UK	  over	  two	  decades	  




Background	  Pregnancies	  in	  women	  with	  sickle	  cell	  disease	  (SCD)	  are	  known	  to	  have	  high	  rates	   of	   maternal	   and	   fetal	   mortality	   and	   morbidity.	   Given	   these	   pregnancy-­‐associated	  problems	  for	  women	  with	  SCD,	  advice	  both	  about	  pregnancy	  planning	  and	  about	  effective	  contraception	   are	   of	   paramount	   importance.	   This	   study	   sought	   to	   discover	   the	  contraception	  methods	   used	   by	  women	  with	   SCD,	  what	   complications	  women	  with	   SCD	  encounter	   with	   contraception,	   and	   their	   experiences	   of	   pre-­‐pregnancy	   counselling	   and	  pregnancy	  planning,	  and	  how	  such	  issues	  may	  have	  changed	  over	  the	  past	  two	  decades.	  	  
Method	  The	   study	  was	  a	  multicentre,	   interview-­‐based,	   cross-­‐sectional	   study.	   Interviews	  were	   carried	   out	  with	   102	  women	  with	   SCD,	   in	   north	   and	   central	   London	   during	   2010,	  concerning	   their	   current	   and	   previous	   contraceptive	   use,	   their	   pregnancy	   history,	   their	  menstrual	   history,	   and	   the	   advice	   they	   received	   concerning	   pregnancy	   planning	   and	  contraception.	   Patient	   information	   was	   anonymised	   and	   ethical	   approval	   was	   obtained.	  These	  data	  were	  compared	  with	  data	  from	  a	  similar	  study	  undertaken	  in	  1993.	  	  
Results	   There	   were	   significant	   differences	   in	   a	   number	   of	   key	   areas:	   the	   number	   of	  unplanned	   pregnancies	   decreased	   from	   64%	   in	   1993	   to	   53%	   in	   2010.	   The	   number	   of	  women	  with	  SCD	  who	  were	  advised	  not	  to	  become	  pregnant	  also	  fell,	   from	  36%	  to	  15%.	  The	  use	  of	  combined	  oral	  contraceptive	  pills	  declined,	  from	  45%	  of	  the	  women	  in	  1993	  to	  31%	   in	   2010.	   Conversely	   the	   use	   of	   depot	   medroxyprogesterone	   acetate	   contraception	  (DMPA)	  and	  the	  levonorgestrel	  intrauterine	  system	  (LNG-­‐IUS)	  both	  increased.	  	  
Conclusions	  Significant	  changes	   in	  the	  contraceptive	  methods	  used	  by	  women	  with	  SCD	  are	  demonstrated	  in	  the	  London	  population.	  LNG-­‐IUS	  use	  in	  SCD	  has	  not	  been	  investigated	  before.	  There	  has	  been	  an	  encouraging	  decrease	   in	  the	  number	  of	  women	  with	  SCD	  who	  are	  advised	  not	   to	  become	  pregnant,	  perhaps	   reflecting	  an	   improvement	   in	   their	  overall	  health.	   Although	   the	   number	   of	   unplanned	   pregnancies	   has	   fallen,	   it	   remains	   high	   –	  emphasising	  the	  continuing	  need	  for	  women	  with	  SCD	  to	  have	  access	  to	  informed	  advice	  about	  pregnancy-­‐associated	  issues	  and	  contraception.	  	  
	  
Method:	  The	   study	   is	   a	  multi-­‐centre,	   interview-­‐based,	   cross	   sectional	   study.	   Interviews	  were	   carried	   out	  with	   102	  women	  with	   SCD,	   in	   north	   and	   central	   London	   during	   2010,	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concerning	   their	   current	   and	   previous	   contraceptive	   use,	   their	   pregnancy	   history,	   their	  menstrual	   history,	   and	   the	   advice	   they	   received	   concerning	   pregnancy	   planning	   and	  contraception.	   Patient	   information	  was	   anonymised,	   and	   ethical	   approval	  was	   obtained.	  These	  data	  were	  compared	  with	  data	  from	  a	  similar	  study	  undertaken	  in	  1993.	  
Results:	   There	   were	   significant	   differences	   in	   a	   number	   of	   key	   areas:	   the	   number	   of	  pregnancies	  which	  were	  unplanned	  fell,	  from	  64.2%	  in	  1993	  to	  53%	  in	  2010.	  The	  number	  of	  women	  with	  SCD	  who	  are	  advised	  not	  to	  become	  pregnant	  has	  also	  fallen,	  from	  36%	  to	  15%.	   The	   use	   of	   Combined	   Oral	   Contraceptive	   Pills	   (COCPs)	   declined,	   from	   45%	   of	   the	  women	  in	  1993	  to	  31%	  in	  2010.	  The	  use	  of	  Depo-­‐Provera	  contraception,	  and	  the	  Mirena	  IUS	  meanwhile	  both	  increased.	  	  
Conclusions:	  Significant	  changes	  in	  the	  contraceptive	  methods	  used	  by	  women	  with	  SCD	  are	  demonstrated	  in	  the	  London	  population.	  Mirena	  IUS	  use	  in	  SCD	  has	  not	  be	  investigated	  before.	  There	  has	  been	  an	  encouraging	  decrease	   in	  the	  number	  of	  women	  with	  SCD	  who	  are	  advised	  not	   to	  become	  pregnant,	  perhaps	   reflecting	  an	   improvement	   in	   their	  overall	  health.	   Although	   the	   number	   of	   unplanned	   pregnancies	   has	   fallen,	   it	   remains	   high,	  emphasising	  the	  continuing	  need	  for	  women	  with	  SCD	  to	  have	  access	  to	  informed	  advice	  about	  pregnancy-­‐associated	  issues	  and	  contraception	  
Background	  
Sickle	   cell	   disease	   (SCD)	   is	   an	   inherited,	   incurable	   abnormality	   of	   haemoglobin,	   characterised	   by	  multiple	   acute	   episodes	   and	   chronic	   complications	   and	   a	   shorter-­‐than-­‐average	   life	   expectancy.	  There	  are	  an	  estimated	  12,500	  people	  with	  sickle	  cell	  disease	  in	  the	  UK	  (1).	  Pregnancies	  in	  women	  with	  SCD	  have	  a	  high	  rate	  of	  maternal	  and	  fetal	  mortality	  and	  morbidity	  (2–5).	  
The	  maternal	  death	   rate	   in	  women	  with	  SCD	   in	   the	  UK	   is	   approximately	  1.6%,	   in	   contrast	   to	   the	  overall	  national	  pregnancy-­‐related	  death	  rate	  in	  the	  UK	  which	  is	  0.01%.	  (6)	  The	  perinatal	  mortality	  rate	  (stillbirths	  and	  deaths	  in	  the	  first	  week	  after	  birth)	  in	  SCD	  is	  approximately	  60/1000	  compared	  with	  overall	  rate	  in	  the	  UK	  of	  7.9/1000.	  (4)	  .	  Serious	  complications	  such	  as	  sickling	  crises	  occur	  in	  40%	  of	  pregnancies	  (5).	  These	  significantly	  increased	  maternal	  and	  fetal	  risks	  necessitate	  effective	  family	  planning	  advice,	  so	  that	  women	  with	  SCD,	  recognising	  the	  problems	  in	  pregnancy	  associated	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with	  SCD,	  and	  are	  able	  to	  optimise	  the	  timing	  of,	  and	  preparation	  for,	  their	  pregnancies.	  However,	  this	   clear	   need	   is	   unfortunately	   handicapped	   by	   the	   extreme	   paucity	   of	   evidence-­‐based	  contraceptive	  advice	  for	  women	  with	  SCD(7),	  resulting	  in	  the	  family	  planning	  advice	  given	  to	  these	  women	  being	  generally	  negative	  and	  unhelpful.	  	  
Contraceptive	  choices	  for	  women	  with	  SCD	  are	  complicated	  by	  three	  main	  areas	  of	  concern:	  firstly,	  the	   combined	   oral	   contraceptive	   pill	   (COC)	   is	   associated	   with	   an	   increased	   risk	   of	   venous	  thromboembolism	   (VTE)	   (8–10).	   SCD	   is	   known	   to	   be	   a	   prothrombotic	   condition.	   Thrombosis	   is	  triggered	   by	   deformed	   red	   blood	   cells	   whose	   abnormal	   cell	   membrane	   has	   lost	   their	   natural	  phospholipid	  asymmetry,	  hence	  becoming	  stickier	  and	  adhering	  to	  the	  endothelium,	  forming	  a	  port	  to	  which	  prothrombotic	  enzymes	  dock.	  Thrombosis	  is	  also	  more	  likely	  with	  sickle	  cell	  disease	  due	  to	  the	  presence	  of	  free	  circulating	  haemoglobin	  (because	  of	  red	  cell	  breakdown),	  the	  occurrence	  of	  chronic	   inflammatory	   reactions,	   and	   the	   slow	   microcirculation	   (11,12).	   It	   has	   therefore	   been	  assumed	  that	  these	  two	  risks	  would	  be	  additive	  or	  indeed	  multiplicative.	  This	  presumed	  increased	  thrombosis	   risk	   is	   theoretical	   and	   has	   not	   been	   demonstrated	   in	   any	   well	   designed	   studies	   (7)	  	  Secondly,	  perhaps	  because	  of	  this	  concern	  over	  the	  thrombotic-­‐risk	  of	  COCs,	  there	  is	  a	  tendency	  to	  advise	   SCD	  women	   to	  use	  progestogen-­‐only	   forms	  of	   contraception,	   either	  oral	  progestogen-­‐only	  pills,	  (POPs),	  or	  long-­‐acting	  reversible	  contraceptives	  (LARCs),	  which	  have	  a	  lower	  VTE	  risk	  in	  the	  general	   population	   (13–16).	   Due	   to	   the	   need	   to	   adhere	   to	   a	   strict	   schedule	   for	   effective	   use,	   in	  practice	   the	   failure	   rate	   with	   traditional	   POPs	   is	   believed	   to	   be	   higher	   than	   with	   COC	   use	   (17),	  although,	   this	   is	   not	   a	   problem	   with	   desogestrel	   only	   pills.	   Despite	   the	   high	   efficacy	   of	   depot	  medroxyprogesterone	  acetate	  (DMPA),	  this	  commonly	  results	  in	  amenorrhoea,	  which	  some	  women	  find	   unacceptable,	   and	   also	   risks	   the	   problems	   of	   bone	   density	   loss	   (18).	   Both	   POPs	   and	   LARCs	  frequently	  cause	  irregular	  vaginal	  bleeding,	  which	  is	  the	  commonest	  cause	  of	  discontinuation	  (19–21).	   	   Thirdly,	   standard	   copper-­‐containing	   intrauterine	   contraceptive	   devices	   (IUDs)	   are	   often	  regarded	  as	  inappropriate	  for	  SCD	  women	  because	  of	  the	  increased	  menstrual	  blood	  loss	  associated	  with	  them,	  which	  would	  exacerbate	  the	  chronic	  anaemia	  of	  SCD,	  and	  because	  of	  anecdotal	  evidence	  of	   an	   increased	   risk	   of	   infection	   with	   IUD	   use	   (22,23),	   which	   could	   potentially	   provoke	   acute	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sickling	  episodes.	  However,	   	  more	  recent	  studies	  have	  found	  no	  association	  between	  IUD	  use	  and	  infection	  (24).	  	  
The	  UK	  Medical	  Eligibility	  Criteria	  (MEC)	  for	  contraceptive	  use,	  in	  2009,	  stated	  	  that	  the	  use	  of	  COC	  in	  SCD	  is	  MEC	  “category	  2”	  (i.e.	  the	  benefits	  of	  use	  outweigh	  the	  risks)	  and	  the	  use	  of	  progestogen-­‐only	   contraception	   (POC)	   is	   “category	   1”	   (i.e.	   no	   restriction	   on	   their	   use),	   However	   this	  recommendation	   is	  based	  on	  evidence	   that	  pregnancy	  carries	  many	  hazards	   in	  women	  with	  SCD,	  and	  not	  on	  evidence	  specifically	  supporting	  their	  	  safety	  (25).	  
This	  study	  aims	  to	  answer	  the	   following	  questions:	  what	   is	   the	  experience	  of	  pregnancy	  planning	  for	  women	  with	  SCD,	  what	  guidance	  do	  they	  receive,	  and	  what	  methods	  of	  contraception	  are	  they	  using?	  The	  study	  also	  aims	  to	  ascertain	  the	  proportion	  of	  their	  pregnancies	  which	  were	  unplanned.	  The	  survey	  provides	  some	  limited	  further	  data	  on	  what	  complications	  women	  with	  SCD	  experience	  with	   specific	   methods	   of	   contraception,	   and	   also	   looks	   at	   their	   menstrual	   histories	   and	   the	  counselling	  they	  receive	  about	  the	  reproductive	  health	  aspects	  of	  their	  disease.	  
These	   data	   were	   compared	  with	   data	   obtained	   from	   a	   similar	   survey	   conducted	   in	   1993(26)	   to	  explore	   how	   the	   knowledge	   and	   attitudes	   of	   women	   with	   SCD	   and	   that	   of	   their	   health	   care	  professionals	  might	  have	  changed	  over	  time.	  	  	  
Study	  Design:	  	  
This	   is	   a	  multi-­‐centre,	   interview	  based,	   cross-­‐sectional	   study	   involving	   four	  acute	  hospital	  Trusts	  and	  two	  Sickle	  Cell	  and	  Thalassaemia	  Centres	  in	  north	  and	  central	  London.	  The	  participants	  in	  the	  study	  were	   identified	   from	   lists	  of	  patients	   attending	   these	   services,	   over	   a	   twelve-­‐month	  period	  from	  2009	  to	  2010.	   	  The	  inclusion	  criteria	  were	  women	  with	  sickle	  cell	  disease	  (Haemoglobin	  SS,	  SC,	   and	   S-­‐beta	   thalassaemia),	   aged	   18	   years	   and	   over,	   and	   consenting	   to	   be	   interviewed.	  	  The	   participants	   were	   interviewed	   in	   confidence	   by	   the	   principal	   researcher	   (AE)	   using	   a	  structured	  validated	  questionnaire	  at	  their	  local	  hospital.	  Each	  interview	  lasted	  about	  30	  minutes.	  Patient	   information	   was	   anonymised	   to	   preserve	   confidentiality	   and	   to	   comply	   with	   the	   Data	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Protection	  Act	  1978.	  Data	  was	  obtained	  on	  demographic	  and	  clinical	  characteristics,	  contraceptive	  methods	   used,	   and	   side	   effects	   experienced.	   In	   addition,	   information	  was	   ascertained	   about	   past	  contraception,	   pregnancy	   history,	   and	   the	   health	   care	   advice	   they	   received	   regarding	   pregnancy	  planning.	  	  
The	   results	   are	   summarised	   using	   the	   mean	   and	   standard	   deviation,	   or	   median	   and	   range.	  Categorical	  data	  were	  summarised	  using	  count	  and	  percentages.	  The	  95%	  confidence	  intervals	  for	  the	   differences	   between	   proportions	   or	   means	   are	   presented,	   where	   appropriate.	   The	  contraceptive	  complications	  are	  reported	  as	  percentages	  in	  woman-­‐years	  of	  use	  (the	  summation	  of	  duration	  of	  use	  by	  individual	  women	  expressed	  in	  years).	  These	  data	  are	  compared	  with	  a	  similar	  survey	   conducted	   in	   1993	   from	   the	   same	   hospitals	   and	   Haemoglobinopathy	   Centres	   in	   north	  London,	  using	   the	  chi-­‐square	   test	  or	   logistic	   regression,	  as	  appropriate.	  All	  analyses	  were	  carried	  out	   in	   Stata	   Version.11	   (27).	   Consent	   to	   verify	   a	   reported	   serious	   illness,	   such	   as	   an	   episode	   of	  thrombosis	   requiring	   hospital	   admission,	   investigation	   and	   treatment,	   was	   sought	   and	   the	  researcher	   viewed	   the	   woman’s	   hospital	   records,	   in	   order	   to	   obtain	   clinical	   details	   of	   these	  complications.	  The	  inability	  to	  verify	  such	  details	  was	  a	  drawback	  to	  the	  1993	  survey.	  	  
The	  study	  received	  ethical	  approval	  from	  the	  Cambridge	  4	  Research	  Ethics	  Committee	  on	  behalf	  of	  the	   National	   Multi-­‐centre	   Research	   Ethics	   Committee.	   This	   survey	   was	   supported	   by	   the	   multi-­‐professional	  and	  multidisciplinary	  membership	  of	  the	  UK	  Forum	  for	  Haemoglobin	  Disorders	  which	  includes	  patient	  representatives	  from	  the	  Sickle	  Cell	  Society.	  
	  
Results	  
In	   total	   114	   women	   were	   invited	   to	   participate	   and	   102	   consented	   to	   do	   so,	   75	   of	   them	   carry	  haemoglobin	  SS	  type,	  19	  haemoglobin	  SC,	  and	  8	  have	  S	  beta	  thalassaemia.	  In	  the	  1993	  survey	  156	  consented	  to	  participate,	  of	  whom	  102	  had	  haemoglobin	  SS,	  42	  haemoglobin	  SC,	  and	  12	  had	  S	  beta	  thalassaemia.	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The	   mean	   age	   at	   interview	   was	   34.6	   (19-­‐65)	   years	   in	   the	   2010	   survey,	   while	   the	   mean	   age	   in	  the1993	  survey	  was	  28.7	  (17-­‐53)	  years.	  Age	  at	  menarche	  was	  14	  years	  in	  the	  2010	  survey	  and	  15	  years	  in	  the	  1993	  survey.	  	  
The	  102	  women	  surveyed	  in	  2010	  had	  had	  150	  pregnancies,	  and	  there	  had	  been	  207	  pregnancies	  in	  the	   156	   interviewed	   in	   1993.	   The	   unplanned	   pregnancy	   rate	   was	   53%	   in	   the	   2010	   survey,	  compared	  with	  64%	  in	   the	  1993	  survey.	  Sixteen	  women	  (15%)	   in	   the	  2010	  survey	  said	   they	  had	  received	   advice	   against	   pregnancy,	   compared	   with	   54	   women	   (36%)	   in	   the	   1993	   survey.	   The	  number	  of	  women	  understanding	  the	  mode	  of	  inheritance	  of	  SCD	  increased	  from	  28%	  in	  the	  1993	  survey	  to	  88	  %	  in	  the	  2010	  survey.	  
The	  COCs	  used	  by	  the	  women	  in	  the	  survey	  were	  standard	  formulations	  containing	  35	  micrograms,	  30	  micrograms	  or	  20	  micrograms	  of	  ethinylestradiol,	  with	  norethisterone	  acetate,	   levonorgestrel,	  noregestimate,	   or	   drospirenone	   progestogens.	   None	   of	   the	   participants	   reported	   use	   of	   “third	  generation”	  COCs	  containing	  desogestrel	  or	  gestodene	  as	  the	  progestogen.	  	  
The	  POPs	  used	  were	  levonorgestrel,	  norethisterone	  or	  desogestrel.	  
Trends	  in	  the	  use	  of	  contraceptive	  methods	  over	  a	  period	  of	  17	  years	  
Contraceptive	   1993	  Count	  (%)	  	   2010	  Count	  (%)	   p	  	  COC	   67	  (45%)	   29	  (31%)	   	  Difference	  in	  proportions	  (95%	  Confidence	  interval)	   14%	  (1%	  to	  26%)	   0.035	  	  DMPA	   26	  (17%)	   35	  (38%)	   	  Difference	  in	  proportions	  (95%	  Confidence	  interval)	   21%	  (10%	  to	  32%)	   <0.001	  POP	   	  30	  (20%)	   14	  (15%)	   	  Difference	  in	  proportions	  (95%	  Confidence	  interval)	   5%	  (4	  to15%)	   0.0325	  IUD	   28	  (19%)	   2	  (2%)	   	  Difference	  in	  proportions	  (95%	  Confidence	  interval)	   17%	  (10%	  to	  32%)	   <0.001	  








Percentages	   and	   trends	   of	   women	   reporting	   side	   effects	   with	   the	   use	   of	   different	   contraceptive	  
methods	  in	  the	  two	  surveys	  conducted	  in	  1993	  and	  2010	  
	  
	  
COC,	   combined	   oral	   contraceptive	   pill;	   POC,	   progestogen-­‐only	   contraceptives;	   Cu-­‐IUD,	   copper	   –containing	  intrauterine	  device,	  DMPA,	  depot	  medroxyprogesterone	  acetate;	  DVT,	  deep	  vein	   thrombosis;	  PE,	  pulmonary	  embolism	  
	  
	   COC	  (Number;	  %)	   p	  	   DMPA	  (Number;	  %)	   p	  	   POP	  (Number;	  %)	   p	  	   Copper	  IUD	  	  
(Number;	  %)	  
p	  	  
	   1993	  N=67	   2010	  N=	  29	   	   1993	  N=	  26	   2010	  N=35	   	   1993	  N=30	   2010	  N=	  14	   	   1993	  N=	  28	   2010	  N=	  2	   	  Woman	  years	  of	  use	   148	  	   98	   	   44	   77	   	   77	   53	   	   140	   7	   	  Irregular	  bleeding	   3	  (4.5)	   1	  (3.4)	   0.817	   8	  (30.8)	   6	  (20)	   0.009	   6	  (20)	   1	  (7.1)	   0.278	   0	   1(50)	   	  Forgetfulness	  depression.	   7	  (10.4)	   4	  (13.8)	   0.637	   1	  (3.8)	   1	  (3.3)	   0	   1	  (3.3)	   0	   	   0	   0	   	  Amenorrhoea	   0	   0	   	   5	  (19.2)	   1	  (3.3)	   0.634	   1	  (3.3)	   0	   	   0	   0	   	  Menorrhagia	   2	  (2.9)	   0	   	   4	  (15.4)	   0	   0.016	   0	   0	   	   11	  (39.2)	   0	   0.009	  Weight	  gain	   11	  (16.4)	   0	   0.020	   0	   3	  (10)	   0.074	   3	  (10)	   2	  (14.3)	   0.072	   0	   0	   	  DVT,	  PE	   2	  (2.9)	   0	   	   0	   0	   	   0	   0	   	   0	   0	   	  
Stroke	  	   0	   0	   	   0	   0	   	   0	   0	   	   0	   0	   	  
Failure	   15	  (22.4)	   1	  (3.4)	   0.022	   0	   6	  (21.4)	   	   6	  (21.4)	   0	   0.072	   6	  (21.4)	   0	   0.464	  Discontinuation	  due	  to	  side	  effects	  	   8	  (12)	   2	  (6.9)	   0.458	   3(11.6)	   2	  (6.7)	   0.039	   2	  (6.7)	   0	   0.323	   0	   0	   	  Increased	  crises	   4	  (5.9)	   1(3.4)	   0.610	   0	   0	   	   0	   0	   	   1	  (3.5)	   0	   0.786	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The	  intra	  uterine	  contraceptive	  devices	  (IUDs)	  used	  were	  all	  standard	  copper	  and	  plastic	  devices,	  but	  the	  specific	  design	  for	  each	  woman	  is	  not	  known.	  
In	  the	  2010	  survey	  eight	  women	  (8.7%)	  were	  using	  the	   levonorgestrel	   intrauterine	  system	  (LNG-­‐IUS),	   with	   a	   total	   of	   15	   years’	   use.	   Six	   women	   (6.5%)	   were	   using	   etonorgestrel	   subcutaneous	  implants	   with	   a	   total	   of	   14	   years’	   use.	   The	   side	   effects	   were	   minimal.	   Amenorrhoea	   was	  experienced	  by	  one	  woman	  in	  each	  group	  (12.5	  %	  and	  16.7%	  respectively).	  	  Irregular	  bleeding	  was	  reported	   by	   one	   woman	   in	   each	   group.	   There	   were	   no	   reports	   of	   VTE	   in	   either	   group,	   but	   one	  woman	  using	  an	  implant	  had	  a	  stroke,	  and	  there	  were	  no	  contraceptive	  failures	  with	  either	  of	  these	  methods.	  The	  LNG-­‐IUS,	  and	  the	  implant	  were	  not	  included	  in	  the	  trend	  analysis	  as	  these	  were	  not	  used	  by	  any	  of	  the	  women	  interviewed	  in	  the	  1993	  study.	  	  
Discussion:	  
The	  number	  of	  unplanned	  pregnancies	  in	  SCD	  women	  is	  still	  unacceptably	  high,	  albeit	  there	  is	  some	  improvement	  in	  2010	  compared	  with	  the	  1993	  survey	  (53%	  vs	  64.2%).	  That	  over	  fifty-­‐percent	  of	  SCD	  pregnancies	  are	  still	  unplanned	  in	  the	  2010	  survey	  confirms	  that	  there	  is	  a	  continuing	  unmet	  need	  for	  effective	  contraceptive	  advice	  for	  this	  patient	  group.	  Further	  efforts	  to	  educate	  healthcare	  professionals	  on	  this	  issue	  are	  clearly	  needed,	  as	  well	  as	  initiatives	  to	  include	  contraceptive	  advice	  in	  the	  routine	  medical	  care	  of	  young	  women	  with	  SCD.	  	  
There	   is	  a	   statistically	   significant	  declining	   trend	   in	   the	  use	  of	  COCs,	  which	  decreased	  by	  about	  a	  third	   from	   1993	   to	   2010,	   while	   the	   use	   of	   DMPA	   has	   more	   than	   doubled	   over	   this	   period.	   The	  authors	  believe	  that	  the	  studies	  conducted	  by	  de	  Ceular	  et	  al	  in	  1982	  and	  by	  de	  Aboud	  et	  al	  in	  1997,	  both	   of	   which	   concluded	   that	   DMPA	   decreases	   the	   incidence	   of	   painful	   sickling	   crises,	   led	   to	   a	  considerable	  change	  in	  the	  family	  planning	  practice	  of	  those	  looking	  after	  women	  with	  SCD,	  with	  a	  reversal	  of	  the	  rate	  of	  use	  between	  COCs	  and	  DMPA	  (28,29).	  This	  trend	  is	  opposite	  to	  that	  seen	  in	  the	  general	  population,	  where	  COC	  use	  is	  quoted	  to	  be	  ten	  times	  higher	  than	  the	  use	  of	  long	  acting	  reversible	   contraceptives	   (30).	  DMPA	  use	   in	   our	   2010	   study	   is	   reported	   by	   35%	  of	   SCD	  women,	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compared	   with	   3%	   for	   both	   DMPA	   and	   implants	   in	   the	   general	   population	   (30).	   However,	   this	  increased	  use	  of	  DMPA	  is	  supported	  only	  by	  the	  two	  small	  studies	  mentioned	  	  (28,	  29).	  
	  
Despite,	   the	  statistically	  significant	  decline	   in	   the	  use	  of	  POP	   in	  women	  with	  SCD,	   there	  were	  still	  15%	   of	   them	   using	   it	   compared	   with	   5%	   in	   the	   general	   population	   (30).	   This	   change	   occurred	  despite	   no	   evidence	   for	   an	   increased	   risk	   of	   thrombosis	   from	  progestogen	   only	   contraception	   in	  SCD	   (7)	   The	   2010	   survey	   has	   included	   the	   relatively	   newer	   methods,	   the	   LNG-­‐IUS	   and	  contraceptive	  implants.	  These	  methods	  together	  constitute	  15%	  of	  the	  methods	  used	  in	  2010	  and	  are	  associated	  with	  very	  few	  reported	  complications.	  This	  contrasts	  with	  a	  marked	  decrease	  in	  the	  use	  of	  copper	  IUDs.	  	  
With	   regard	   to	   serious	   complications	   with	   the	   use	   of	   the	   different	   methods,	   our	   data	   probably	  suggest	  a	  similar	  incidence	  of	  VTE	  with	  COC	  use	  in	  the	  two	  cohorts	  (2	  episodes	  during	  148	  women-­‐years	   in	  the	  1993	  survey,	  and	  no	  episodes	   in	  98	  women-­‐years	   in	  the	  2010	  survey).	  Taken	  at	   face	  value,	  this	  is	  higher	  than	  with	  hormonal	  contraceptive	  use	  in	  the	  general	  population,	  but	  in	  keeping	  with	  the	  usual	  incidence	  of	  VTE	  in	  women	  with	  SCD.	  Only	  one	  woman	  experienced	  a	  stroke,	  whilst	  using	  LARC,	  in	  the	  2010	  survey,	  and	  it	  is	  clearly	  not	  possible	  to	  deduce	  any	  comparisons	  from	  this.	  Four	  COC	  users	  in	  the	  1993	  survey	  reported	  an	  increased	  frequency	  of	  acute	  sickling	  crises,	  and	  one	  COC	  user	  had	  the	  same	  problem	  in	  the	  2010	  survey.	  The	  rate	  of	  contraceptive	  failure	  with	  COC	  use	  does	  seem	  to	  have	  reduced	  considerably	  (15	  failures	  in	  the	  1993	  survey	  compared	  with	  one	  failure	  in	  the	  2010	  survey).	  Anecdotally	   in	  the	  1993	  survey,	  the	  commonest	  reason	  for	  failure	  with	  COCs	  was	  an	  accidental	   interruption	  of	  medication	  during	  emergency	  hospital	  admissions.	  None	  of	  our	  data	   included	   any	   serious	   complications	   with	   POP	   use.	   However,	   it	   was	   associated	   with	   6	  contraceptive	   failures	   in	   the	   1993	   survey	   (during	   77	  woman-­‐years	   of	   use),	   although	  none	   in	   the	  2010	  survey,	  which	  hopefully	  reflects	  a	  better	  awareness	  of	   the	  potential	  reasons	   for	   failure	  with	  this	  method.	  The	  only	  serious	  complication	  in	  our	  data	  with	  DMPA	  use	  was	  one	  episode	  of	  VTE	  in	  the	  2010	   survey,	   and	   there	  were	  no	   contraceptive	   failures	  with	   this	  method,	  which	   is	   consistent	  with	  its	  performance	  in	  the	  general	  population.	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There	   appears	   also	   to	   be	   some	   progress	   in	   the	   number	   of	   women	   receiving	   advice	   against	  pregnancy	   (36%	   vs	   15%).	   This	   may	   reflect	   the	   improving	   medical	   care	   of	   this	   group,	   and	   an	  improvement	  in	  their	  overall	  health,	  such	  that	  pregnancy	  is	  thought	  to	  impose	  less	  of	  a	  risk	  to	  their	  well	   being.	   It	  may	  also	   reflect	   a	  more	  general	   shift	   away	   from	   issuing	  prescriptive	  or	  prohibitive	  advice.	  	  
The	   interpretation	   of	   these	   data	   faces	   the	   inevitable	   problems	   of	   relatively	   small	   numbers.	  Information	   derived	   from	   interviews	   with	   the	   SCD	   women	   themselves	   has	   potential	   flaws	   in	  accuracy	   of	   recall.	   In	   the	   1993	   survey,	   the	   terms	   of	   the	   consent	   given	   by	   women	   to	   participate	  precluded	   cross-­‐checking	   with	   their	   medical	   records,	   but	   this	   was	   permitted	   by	   the	   women	  participating	   in	   the	   2010	   survey.	   Another	   limitation	   of	   this	   study	   is	   that	   we	   do	   not	   have	   full	  demographic	   information	   for	   both	   groups	   for	   comparative	   analysis.	   	   However,	   the	   studies	   were	  conducted	  at	  the	  same	  centres	  in	  both	  1993	  and	  2010.	  All	  the	  women	  participating	  in	  both	  studies	  were	  from	  black	  African	  or	  Afro-­‐Carribbean	  ethnic	  groups.	  	  
All	   the	   women	   interviewed	   in	   both	   surveys	   felt	   strongly	   that	   the	   issues	   relating	   to	   pregnancy	  planning	  and	  contraceptive	  use	  were	  of	  high	  importance	  to	  them,	  and	  many	  of	  them	  encountered	  a	  lack	  of	  knowledge	  and	  of	  active	  discussion	  by	  their	  doctors	  of	  these	  matters.	  Without	  exception,	  the	  women	   were	   enthusiastic	   in	   their	   participation	   in	   this	   work,	   and	   took	   great	   trouble	   to	   provide	  answers	  to	  the	  structured	  questionnaire	  to	  the	  best	  of	  their	  ability.	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Reference	  range	  for	  haemostatic	  markers	  
Data	   derived	   from	   40	   normal	   adults	   presented	   as	   two	   standard	  
deviations	  below	  and	  above	  the	  mean.	  
Analysis	  conducted	  by	  Dr	  Anne	  Riddell,	  Chief	  Biomedical	  Scientist,	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Participants	  information	  sheet	  
The	  clinical	  and	  haematological	  effects	  of	  hormonal	  contraception	  (e.g.	  “the	  
pill”)	  on	  women	  with	  Sickle	  Cell	  Disease.	  
	  
You	   are	   being	   invited	   to	   take	   part	   in	   a	   research	   study.	   	   Before	   you	   decide	   it	   is	  important	  for	  you	  to	  understand	  why	  the	  research	  is	  being	  done	  and	  what	   it	  will	  involve.	   	   Please	   take	   time	   to	   read	   the	   following	   information	   carefully.	   Talk	   to	  others	  about	  the	  study	  if	  you	  wish.	  	  
Part	  1	  tells	  you	  the	  purpose	  of	  this	  study	  and	  what	  will	  happen	  to	  you	  if	  you	  take	  part.	  
Part	  2	  gives	  you	  more	  detailed	  information	  about	  the	  conduct	  of	  the	  study.	  	  






1.	   What	  is	  the	  purpose	  of	  the	  study?	  
The	  aim	  of	  this	  research	  is	  to	  test	  whether	  hormonal	  contraceptive	  methods	  pose	  any	   additional	   risk	   of	   complications	   for	   women	   with	   Sickle	   Cell	   Disease	   (SCD)	  compared	  with	  women	  with	  SCD	  not	  taking	  hormonal	  contraception.	  This	  mainly	  involves	   the	   combined	   pill	   and	   other	   “pills”	   like	   progesterone-­‐only	   tablets	   (“the	  mini-­‐pill”)	  and	  depot	  injections,	  as	  well	  as	  the	  Mirena	  (progesterone)	  coil.	  	  
	  
Whilst	  doing	  this,	   I	  will	  also	   look	  at	  what	  women	  with	  SCD	  experience	  with	  their	  menstrual	   cycles	   and	   reproductive	   health,	   i.e.	   use	   of	   different	   contraceptive	  methods,	   fertility	   issues	   and	   pregnancy	   planning.	   I	   realise	   that	   this	   information	  may	   be	   sensitive,	   but	   it	   forms	   an	   important	   part	   of	   understanding	   how	  women	  with	  SCD	  experience	  issues	  relating	  to	  pregnancy	  planning.	  	  
	  
2.	   Why	  have	  I	  been	  chosen?	  




Your	   Haematology	   Consultant	   has	   suggested	   your	   name	   to	  me	   as	   someone	  who	  might	  be	  interested	  in	  joining	  the	  project.	  
	  
3.	  Do	  I	  have	  to	  take	  part?	  
No.	   	   It	   is	  up	   to	  you	   to	  decide	  whether	  or	  not	   to	   take	  part.	   	   If	  you	  do,	  you	  will	  be	  given	  this	  information	  sheet	  to	  keep	  and	  be	  asked	  to	  sign	  a	  consent	  form.	  You	  are	  still	   free	   to	   withdraw	   at	   any	   time	   and	   without	   giving	   a	   reason.	   	   A	   decision	   to	  withdraw	  at	  any	  time,	  or	  a	  decision	  not	  to	  take	  part,	  will	  not	  affect	  the	  standard	  of	  care	  you	  receive.	  	  
	  
4.	   What	  will	  happen	  to	  me	  if	  I	  take	  part?	  
I	  am	  the	  Chief	  researcher,	  Dr	  Asma	  Eissa;	  I	  am	  a	  postgraduate	  trainee	  and	  member	  of	  the	  Royal	  College	  of	  Obstetricians	  &	  Gynaecologists	   in	  London;	  with	  over	  eight	  years	   of	   experience	   in	   Gynaecology.	   I	   am	   working	   with	   Miss	   Susan	   Tuck	  (Consultant	  Obstetrician	  &	  Gynaecologist	  at	  the	  Royal	  Free	  Hospital,	  London).	  
	  
I	  will	  see	  you	  throughout	  this	  project.	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In	   the	   first	  meeting	   I	   will	   check	   your	  medical	   history	   and	   spend	   30-­‐45	  minutes	  going	   through	   a	   set	   of	   questions	   about	   your	   SCD,	   your	  menstrual	   periods,	   your	  pregnancy	  plans	  and	  your	  experience	  of	  contraception	  methods.	  
	  
I	   will	   also	   check	   your	   blood	   pressure	   and	   your	   weight.	   Your	   name	   will	   not	   be	  written	   on	   the	   forms	   which	   I	   use	   to	   write	   your	   answers	   and	   the	   examination	  findings.	  Only	  a	  code	  number	  will	  be	  used.	  There	  will	  be	  only	  one	  copy	  of	  the	  list	  which	  matches	  women’s	  names	  and	  their	  project	  code	  number.	  I	  will	  keep	  this	  list	  securely	  in	  my	  office	  at	  the	  Royal	  Free	  Hospital,	  which	  is	  always	  locked	  if	  I	  am	  out	  of	   the	   office.	   This	   means	   that	   I	   will	   be	   the	   only	   person	   who	   can	   know	   which	  personal	  details	  are	  from	  which	  woman.	  
	  
Then	   I	   will	   take	   a	   blood	   sample	   to	   analyse	   for	   blood	   clotting	   tests	   and	   other	  investigations	  such	  as	  your	  haemoglobin	  concentration	  and	  the	  proportion	  of	  your	  red	  blood	  cells	  which	  have	  sickled.	  
	  




The	  amount	  of	  blood	  will	  be	  around	  30	  ml	  (about	  3	  dessert	  spoonfuls).	   I	  will	  see	  you	  again	  for	  the	  same	  checks	  and	  blood	  tests	  every	  3-­‐4	  months	  for	  the	  2	  years	  of	  the	  project.	  
5.	  What	  will	  happen	  to	  any	  samples	  I	  give?	  
There	   will	   be	   secure	   procedures	   for	   collecting,	   using	   and	   storing	   your	   blood	  samples	  The	  storage	  duration	  will	  be	  two	  years	  (till	  the	  end	  of	  the	  study).	  
There	   is	  no	   intention	   to	  use	   these	  samples	   in	   the	   future	   for	  research	   that	  cannot	  yet	  be	  specified.	  	  
I	  will	  have	  access	  to	  these	  samples	  as	  well	  as	  the	  senior	  biomedical	  scientist	  in	  the	  Haemophilia	   Centre	   at	   the	   Royal	   Free	   Hospital	   (where	   the	   tests	   will	   be	   carried	  out).	  	  
These	  tests	  are	  carried	  out	  three	  times	  a	  year,	  during	  the	  study.	  The	  inconvenience	  of	   the	  numerous	   venepunctures	  will	   be	   kept	   to	  minimum	  and	  you	   are	   obviously	  well	  used	  to	  having	  blood	  samples	  taken!	  All	  the	  usual	  hygiene	  precautions	  will	  be	  undertaken.	  However	  there	  is	  a	  small	  risk	  of	  infection	  and	  thrombosis	  from	  these	  procedures.	  Please	  report	  to	  your	  GP	  “as	  soon	  as	  possible”	  any	  swelling	  or	  unusual	  pain	  at	  the	  site	  of	  the	  needle	  insertion.	  
Your	  conversations	  with	  me,	  the	  physical	  examination	  and	  the	  blood	  tests	  will	  be	  private	  and	  confidential.	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The	  time	  will	  be	  arranged	  to	  suit	  you.	  The	  place	  of	  the	  meeting	  will	  be	  in	  your	  usual	  hospital,	   either	   in	   the	   Haematology	   Department	   or	   in	   the	   Gynaecology	   Clinic,	  whichever	  you	  prefer.	  
Your	  blood	  samples	  will	  have	  your	  name	  written	  on	   them	  when	   they	  are	  sent	   to	  the	  laboratory	  for	  testing.	  However	  the	  information	  from	  this	  is	  always	  treated	  as	  being	   confidential	   and	   they	   will	   be	   protected	   by	   the	   Data	   Protection	   Act	  procedures.	   The	   final	   analysis	   of	   these	   test	   results	   from	   all	   the	   women	   who	  participate	  will	  be	  totally	  anonymous.	  	  
In	  case	  the	  project	  finds	  an	  unexpected	  test	  result	  on	  you,	  you	  will	  need	  to	  let	  me	  know	  how	  you	  would	  like	  to	  be	  informed	  about	  this.	  For	  example,	  if	  a	  blood	  sample	  test	  shows	  that	  you	  have	  hepatitis	  and	  you	  need	  to	  be	  prescribed	  some	  treatment	  for	  this.	  I	  could	  either	  let	  you	  know	  about	  this	  myself,	  or	  ask	  your	  Haematologist	  to	  let	  you	  know,	  or	  your	  G.P.	   It	  will	  also	  be	  helpful	   for	  you	  to	   let	  me	  know	  how	  you	  would	  like	  to	  be	  contacted.	  This	  could	  be	  either	  by	  letter	  or	  by	  telephone.	  If	  you	  do	  need	   any	  particular	   treatment,	  which	  would	  obviously	   be	  discussed	  with	   you	  by	  your	  usual	  doctors.	  




This	  study	  is	  expected	  to	  run	  for	  two	  years,	  because	  we	  know	  that	  your	  health	  with	  SCD	  does	  vary	  from	  time	  to	  time.	  By	  looking	  over	  a	  reasonably	  long	  period	  of	  time	  I	  hope	  to	  get	  the	  most	  realistic	  picture	  of	  how	  these	  issues	  are.	  
6.What	  are	  the	  benefits	  of	  taking	  part?	  
We	  cannot	  promise	  the	  study	  will	  help	  you	  but	  the	  information	  we	  get	  might	  help	  improve	   the	   treatment	   of	  women	  with	   SCD	   for	   the	   future.	  However,	   you	  will	   be	  helping	   us	   to	   improve	   our	   understanding	   of	   important	   and	   effective	  methods	   of	  contraception	  and	  family	  planning	  for	  women	  with	  SCD.	  This	  will	  help	  doctors	  to	  provide	   women	   with	   SCD	   with	   the	   best	   possible	   family	   planning	   advice	   in	   the	  future.	  
Part	  2	  
Your	  own	  Haematology	  Consultant	  knows	  all	  about	  this	  project	  and	  is	  helping	  with	  the	  recruitment	  of	  appropriate	  women	  to	  participate	  in	  it.	  
This	  project	  is	  intended	  to	  be	  presented	  for	  a	  higher	  degree	  in	  medicine,	  (Medical	  Doctorate	   (MD	   Res)	   of	   University	   College,	   London)	   by	   the	   Chief	   researcher,	   Dr	  Asma	  Eissa.	  
1.	  Involvement	  of	  the	  General	  Practitioner/Family	  doctor	  (GP)	  	  




2.	  	  What	  if	  there	  is	  a	  problem?	  
If	  you	  have	  a	  concern	  about	  any	  aspect	  of	  this	  study,	  you	  should	  speak	  to	  me,	  and	  I	  will	  do	  my	  best	  to	  answer	  your	  questions.	  My	  mobile	  phone	  number	  is	  07717	  084	  861	  and	  my	  phone	  number	  at	   the	  Royal	  Free	  Hospital	   is	  020	  7	  830	  2565.	   	   If	  you	  remain	  unhappy	  and	  wish	  to	  complain	  formally,	  you	  can	  do	  this	  through	  the	  NHS	  Complaints	  Procedure.	   	  Details	  can	  be	  obtained	  from	  your	  usual	  hospital	  or	   from	  the	  Royal	  Free	  (www.royalfree.nhs.uk).	  	  
University	   College	   London	   has	   no-­‐fault	   indemnity	   (insurance)	   arrangements	   in	  place,	  in	  the	  event	  that	  something	  does	  go	  wrong	  and	  you	  are	  harmed	  during	  the	  research	   study.	   	   If	   you	  are	  harmed	  and	   this	   is	  due	   to	   someone’s	  negligence	   then	  you	  may	  have	  grounds	   for	   a	   legal	   action	   for	   compensation,	   but	   you	  may	  have	   to	  pay	  your	   legal	  costs.	  The	  normal	  National	  Health	  Service	  complaints	  mechanisms	  will	  still	  be	  available	  to	  you.	  
3.	  What	  will	  happen	  to	  the	  results	  of	  the	  study?	  
All	  the	  final	  information	  will	  be	  anonymous.	  Individual	  results	  will	  be	  put	  together	  for	   the	   two	   groups	   of	   women.	   These	   will	   be	   analysed	   and	   categorised	   without	  giving	   any	   personal	   details	   about	   individuals.	   I	   hope	   that	   our	   findings	   will	   be	  published	  in	  medical	  journals	  so	  that	  other	  doctors	  can	  read	  and	  learn	  from	  it.	  




4.	   Who	  is	  organising	  and	  funding	  this	  survey	  
The	  study	  has	  been	  organized	  by	  Miss	  Susan	  M	  Tuck,	  Consultant	  Gynecologist	  at	  the	   Royal	   Free	   Hampstead	   NHS	   Trust,	   North	   London	   &	   me,	   Dr	   Asma	   A.	   Eissa,	  Clinical	  Research	  Fellow	  in	  the	  Department	  of	  Obstetrics	  &	  Gynaecology.	  Both	  of	  us	  have	   experience	   of	   conducting	   various	   research	   projects	   concerning	   pregnancy	  and	  gynaecological	   issues	  affecting	  women	  with	  SCD.	   	  This	  study	   is	  being	   funded	  from	   in-­‐house	   funds	   of	   the	   Department	   of	   Obstetrics	   and	   Gynaecology	   at	  University	   College	   London.	   These	   funds	   cover	   all	   the	   hospitals	   involved	   in	   the	  study.	  
5.	   Who	  has	  reviewed	  the	  study	  project?	  	  
The	  study	  is	  reviewed	  by	  the	  researcher	  supervisor	  (Miss	  S	  M	  Tuck)	  &	  it	  has	  been	  externally	  reviewed	  by	  Miss	  Radhakrishnan	  (Consultant	  Gynaecologist	  at	  the	  Royal	  Free	  Hospital	  who	  is	  in	  charge	  of	  the	  family	  planning	  clinics).	  The	  ethical	  basis	  for	  this	  study	  was	  assessed	  independently	  by	  the	  Eastern	  Multicentre	  Research	  Ethics	  Committee,	  based	  in	  Cambridge.	  
6.Travel	  expenses	  
All	  your	  travel	  expenses	  will	  be	  paid	  for	  you.	  Please	  let	  me	  know	  what	  you	  need	  for	  these	  when	  you	  confirm	  your	  participation	  in	  the	  survey.	  If	  you	  are	  willing	  to	  take	  part	  in	  this	  study	  I	  will	  give	  you	  a	  consent	  form	  to	  sign	  and	  keep.	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Participants’	   information	   for	   Katherine	   Dormandy	   Coagulation	  




HAEMOPHILIA	  CENTRE	  &	  THROMBOSIS	  UNIT	  
Director:	  Professor	  Edward	  Tuddenham	  
Dr	  Pratima	  Chowdary,	  Dr	  Anja	  Drebes,	  Dr	  Keith	  Gomez,	  Dr	  Mary	  Mathias,	  Dr	  Thynn	  Thynn	  Yee	  
Telephone:	  020	  7830	  2068	   Fax:	  	  020	  7472	  6759	  
	  
Participant	  Information	  for	  the	  KD	  Coagulation	  Research	  Plasma	  Bank	  	  	  
You	   are	   being	   invited	   to	   contribute	   to	   research	   being	   co-­‐ordinated	   by	   the	   Haemophilia	  Centre	   and	   Thrombosis	   Unit	   by	   giving	   blood	   samples.	   Please	   take	   time	   to	   read	   the	  following	   information	  carefully	  before	  you	  decide.	  	  Ask	  us	   if	   there	   is	  anything	   that	   is	  not	  clear	  or	  if	  you	  would	  like	  more	  information.	  	  	  
What	  is	  blood	  coagulation?	  
Blood	  coagulation	  is	  a	  complex	  process	  by	  which	  blood	  forms	  clots,	  necessary	  to	  prevent	  excessive	  blood	  loss	  after	  injury.	  The	  bleeding	  and	  thrombotic	  disorders	  are	  due	  to	  under	  or	  over	  active	  coagulation	  factors	  and	  platelets.	  
	  
What	  is	  the	  purpose	  of	  the	  KD	  Coagulation	  Research	  Plasma	  Bank?	  	  	  
The	   purpose	   of	   the	   plasma	   bank	   is	   to	   enable	   research	   into	   the	   investigation	   and	  management	  of	  inherited	  and	  acquired	  coagulation	  disorders.	  The	  plasma	  bank	  will	  store	  samples	   from	  patients	  with	   a	   diagnosed	   or	   suspected	   inherited	   or	   acquired	   bleeding	   or	  
326 
 
thrombotic	  disorder	  for	  future	  research.	  Samples	  will	  be	  processed	  in	  the	  laboratory	  and	  either	  tested	  immediately	  or	  kept	  for	  long	  term	  storage	  at	  -­‐80°C.	  	  
The	  three	  research	  areas	  of	  interest	  for	  which	  the	  samples	  and	  data	  from	  plasma	  bank	  will	  be	  used	  are;	  	  
1. Developing	   tests	   to	   predict	   the	   effects	   of	   your	   condition	   -­‐	   Previous	   studies	   have	  shown	   that	   the	   severity	   of	   a	   clotting	   	   disorder	   cannot	   always	   be	   predicted	   by	  currently	  available	  	  tests.	  There	  are	  newer	  tests	  in	  development	  which	  may	  give	  a	  better	  indication	  of	  how	  a	  disease	  will	  affect	  patients.	  	  2. Tailoring	   treatment	   for	   individual	   patients	   -­‐	   Effective	   treatment	   is	   available	   for	  most	   coagulation	   disorders.	   but	   the	   response	   can	   vary	   between	   different	  individuals	   or	   in	   the	   same	   person	   over	   time.	   A	   better	   understanding	   of	   how	  treatment	  responses	  vary	  may	  lead	  to	  better	  treatment	  for	  individual	  patients	  	  3. Validation	  of	  new	  tests.	  When	  new	  tests	  are	  developed	  they	  need	  to	  be	  tested	  on	  samples	  from	  patients	  who	  are	  known	  to	  have	  a	  particular	  clotting	  disorder.	  This	  will	   show	  whether	   they	   are	  better,	   or	   offer	   further	   information,	  when	   compared	  with	  existing	  tests.	  	  
	  
Why	  have	  I	  been	  chosen?	  	  	  





Do	  I	  have	  to	  take	  part?	  	  	  
It	  is	  up	  to	  you	  to	  decide	  whether	  or	  not	  to	  take	  part.	  	  If	  you	  decide	  to	  take	  part,	  you	  will	  be	  given	   this	   information	  sheet	   to	  keep	  and	  be	  asked	   to	   sign	  a	   consent	   form.	  	  Whether	  you	  decide	   to	   partake	   or	   not	   it	   will	   not	   affect	   the	   number	   of	   hospital	   visits	   you	   make,	   the	  duration	  of	  an	  inpatient	  stay	  or	  the	  treatment	  of	  your	  medical	  condition.	  
What	  if	  I	  change	  my	  mind	  ?	  
Your	  participation	  is	  entirely	  voluntary	  and	  you	  are	  	  free	  to	  withdraw	  at	  any	  time,	  without	  giving	  any	  reason,	  without	  your	  medical	  care	  or	  legal	  rights	  being	  affected.	  If	  you	  decide	  to	  withdraw	  we	  will	   dispose	   of	   the	   blood	   samples	   and	   delete	   the	   information	   collected	   on	  you.	  Where	   your	   sample	   has	   already	   been	   used,	   that	   data	   cannot	   be	   destroyed,	   but	   no	  further	  use	  will	  be	  permitted	  
What	  will	  happen	  to	  me	  if	  I	  take	  part?	  	  	  




What	  do	  I	  have	  to	  do?	  	  	  
No	  lifestyle	  or	  dietary	  changes	  are	  required	  for	  participation	  in	  this	  trial.	  	  Any	  changes	  that	  are	  made	  have	  been	  done	  as	  a	  part	  of	  your	  routine	  care.	  
Is	  there	  any	  Financial	  Compensation?	  	  
No,	  There	  is	  no	  financial	  compensation	  if	  you	  decide	  to	  donate	  a	  	  sample	  for	  this	  research	  programme.	  	  
What	  are	  the	  possible	  disadvantages,	  risks	  and	  possible	  benefits	  of	  taking	  part?	  	  	  
If	   you	   agree	   to	   take	   part	  we	   do	   not	   anticipate	   any	   disadvantages	   to	   you	   and	  we	   cannot	  promise	   that	   donating	   blood	   samples	   will	   help	   you	   directly.	   It	   is	   entirely	   possible	   that	  investigations	  done	  on	   the	   samples	   at	   a	   later	   date	  might	   reveal	   new	   information,	  which	  might	  be	  useful	  in	  the	  	  management	  of	  your	  underlying	  condition.	  	  In	  such	  situations	  you	  will	  be	  written	  to	  by	  one	  of	  the	  doctors	  taking	  care	  of	  you	  and	  offered	  an	  appointment	  for	  further	   discussion.	  We	   hope	   that	   the	   research	   co-­‐ordinated	   by	   us	  will	   help	   advance	   the	  treatment	  of	  people,	  including	  yourself,	  with	  bleeding	  or	  thrombotic	  conditions.	  
Will	  my	  taking	  part	  in	  this	  study	  be	  kept	  confidential?	  	  	  
All	  information	  which	  is	  collected	  about	  you	  during	  the	  course	  of	  the	  research	  will	  be	  kept	  strictly	  confidential.	  	  If	  you	  consent	  to	  take	  part	  in	  the	  research,	  your	  data	  will	  be	  handled	  in	   a	   manner	   in	   accordance	   with	   the	   Data	   Protection	   Act	   1998	   and	   the	   rights	   you	   have	  	  under	  this	  Act.	  For	  interpreting	  the	  information	  obtained	  from	  the	  plasma	  sample	  we	  will	  need	   information	   on	   your	   medical	   conditions	   The	   information	   that	   is	   used	   will	   be	   the	  information	   collected	   at	   the	   time	  of	   the	   blood	   sampling.	   	   It	   is	   our	   intention	   to	   store	   the	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samples	  for	  a	  maximum	  of	  10	  years.	  The	  results	  will	  be	  published	  in	  various	  journals	  and	  international	  meetings	  in	  a	  way	  that	  you	  will	  not	  be	  identified.	  
Where	  samples	  are	  sent	  outside	  of	  the	  trust,	  to	  other	  researchers	  in	  the	  United	  Kingdom	  and	   European	   Union	   accompanied	   by	   clinical	   information,	   all	   personal	   identifiable	  information	  such	  as	  your	  name,	  and	  date	  of	  birth,	  will	  be	  removed	  so	  that	  you	  will	  not	  be	  recognised	  from	  that	  information.	  
Representatives	   of	   regulatory	   authorities,	   research	   and	   development	   team	   at	   the	   Royal	  Free	  Hampstead	  NHS	  Trust	  or	  ethics	  committee	  will	  be	  allowed	  to	  see	  your	  medical	  notes	  as	  required	  to	  ensure	  the	  research	  is	  being	  properly	  conducted	  and	  that	  the	  data	  collected	  is	  accurate.	  Your	  privacy	  will	  be	  respected	  at	  all	  times.	  	  	  
You	  have	  the	  right	  to	  ask	  and	  see	  the	  data	  that	  has	  been	  collected	  about	  your	  health	  and	  if	  you	  think	  anything	  is	  incorrect,	  to	  have	  it	  corrected.	  The	  only	  person	  outside	  the	  trust	  able	  to	  view	  any	  identifiable	  data	  will	  be	  your	  GP	  to	  help	  with	  your	  ongoing	  care.	  	  
Who	  has	  reviewed	  the	  study?	  
This	   research	   programme	   has	   been	   reviewed	   by	   Sheffield	   Ethics	   Committee,	   and	   the	  reference	  number	  is	  09/H1308/115	  
What	  happens	  if	  there	  is	  a	  problem?	  
We	  would	  not	  expect	  you	  to	  suffer	  any	  harm	  or	  injury	  by	  donating	  samples	  for	  the	  plasma	  bank.	  If	  you	  are	  harmed	  by	  taking	  part	  there	  is	  no	  special	  compensation	  arrangement.	  	   If	  you	  are	  harmed	  due	  to	  someone's	  negligence	  then	  you	  may	  have	  grounds	  for	  legal	  action,	  but	  you	  may	  have	  to	  pay	  your	  legal	  cost.	  Regardless	  of	  this,	  if	  you	  wish	  to	  complain	  or	  have	  any	  concerns	  about	  any	  aspect	  of	  the	  way	  you	  have	  been	  approached	  or	  treated	  during	  the	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course	  of	  this	  consent	  process,	  the	  normal	  National	  Health	  Service	  Complaints	  mechanism	  is	  available	  to	  you.	  If	  you	  have	  any	  concerns	  regarding	  the	  care	  you	  have	  received	  or	  as	  an	  initial	   point	   of	   contact	   if	   you	   have	   a	  complaint,	   please	   contact	   the	   Patient	   Advice	   and	  Liaison	  Service	  (PALS)	  at	  the	  address	  given	  below;	  	  
PALS	  office:	  020	  7830	  2174	  pals@royalfree.nhs.uk	  PALS	  Royal	  Free	  Hospital,	  	  Pond	  Street,	  London,	  NW3	  2QG	  	  
	  
Contact	  for	  further	  information?	  	  
If	   you	   require	   any	   further	   information	  please	  do	  not	   hesitate	   to	   discuss	  with	   any	   of	   the	  nurses	  or	  clinicians	  looking	  after	  you.	  	  





Donor	   consent	   form	   for	   the	   Katherine	   Dormandy	   Coagulation	  
Research	  Plasma	  Bank.	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  HAEMOPHILIA	  CENTRE	  &	  THROMBOSIS	  UNIT	  
Director: Professor Edward Tuddenham 
Dr Pratima Chowdary, Dr Anja Drebes, Dr Keith Gomez, Dr Mary Mathias, Dr Thynn Thynn Yee 
Telephone: 020 7830 2068 Fax:  020 7472 6759 
Donor	  Consent	  Form	  for	  the	  KD	  Coagulation	  Research	  Plasma	  Bank	  
(KDCRPB) 
Patient details (or affix pre-printed label)     
Patient’s Full Name: 
Date of Birth:  
Hospital Number:  
Research Ethics committee Ref:  09/H1308/115    Patient 
Initials 
I confirm that I have read and understood the information sheet, version 2, 
dated 17 Nov. 2009   for the above plasma bank and have had the 
opportunity to ask questions.  
 
 
I understand that additional blood may be taken during the investigation 
and / or treatment of my condition for the purposes of the plasma bank, 
and there is no need for extra needle sticks  
 
 
I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care 
or legal rights being affected.  
 
 
Medical information collected about myself at the time of blood samples 
will be treated as confidential.  
 
 
I understand that sections of my medical notes may be looked at by  
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authorised individuals from regulatory authorities or by the ethics 
committee, where it is relevant to my participation in this study.  All my 
medical information will be treated as confidential. 
 
I have the right to ask to see the data collected about me and if anything is 
incorrect, I can ask for it to be corrected.  
 
 
If you have any preferences or exclusions for use of the donated plasma 





Name	  of	  Patient	   Date	   Signature	  
_________________________	  




Participants’	   consent	   form	   for	   project:	   The	   clinical	   and	  
haematological	  effects	  of	  hormonal	  contraception	  on	  women	  with	  




The	  clinical	  and	  haematological	  effects	  of	  hormonal	  contraception	  on	  women	  with	  sickle	  cell	  
disease	  Name	  of	  Researcher:	  Dr	  Asma	  A	  .Eissa	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Please	  initial	  box	  
1.	   I	  confirm	  that	  I	  have	  read	  and	  understand	  the	  information	  sheet	  dated…01/09/2006	   	  
	   for	  the	  above	  study	  and	  have	  had	  the	  opportunity	  to	  ask	  questions	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
2.	   I	  understand	  that	  Dr	  Asma	  A.	  Eissa	  will	  spend	  around	  30-­‐45	  minutes	  to	  ask	  me	  questions	  relating	  to	  my	  medical	  history,	  examine	  me	  and	  take	  blood	  samples.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3.	   I	  understand	  that	  my	  participation	  is	  voluntary	  and	  that	  I	  am	  free	  to	  withdraw	  at	  any	  time,	  without	  giving	  any	  reason,	  without	  my	  medical	  care	  or	  legal	  rights	  being	  affected.	  	  	  	   	  
4.	   I	  understand	  that	  sections	  of	  any	  of	  my	  medical	  notes	  may	  be	  looked	  at	  by	  Dr	  Asma	  Eissa	  	  	  	  
	  	  	  	  	  	  	  With	  my	  consent,	  if	  that	  would	  help	  the	  accuracy	  of	  the	  survey	  .	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
5.	   I	  understand	  that	  sections	  of	  any	  of	  my	  medical	  notes	  may	  be	  looked	  at	  by	  responsible	   individuals	  from	  Royal	  Free	  Hospital,	  London	  or	  from	  regulatory	  authorities	  where	  it	  is	  	   relevant	  to	  my	  taking	  part	  in	  research.	  	  I	  give	  permission	  for	  these	  individuals	  to	  have	  access	  to	  my	  records.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
6.	   I	  agree	  to	  take	  part	  in	  the	  above	  study.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
7.	  	  	  I	  agree	  for	  my	  GP	  being	  informed	  about	  my	  participation	  in	  this	  study.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Name	  of	  Patient	  
336 
 
Signature	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Date	  
	  
	  _________________________	  
Name	  of	  Patient	   Date	   Signature	  
_________________________	  
Name	  of	  Person	  taking	  consent	   Date	   Signature	  
	  
When	  completed:	  1	  for	  patient;	  1	  for	  researcher;	  1	  to	  be	  kept	  with	  hospital	  notes	  
	  
	  
